Note: Descriptions are shown in the official language in which they were submitted.
CA 02936408 2016-06-29
SPECIFICATION
Title of the Invention: TRIAZINE COMPOUNDS AND PHARMACEUTICAL
USE THEREOF
TECHNICAL FIELD OF THE INVENTION
[0001]
The present invention relates to a triazine compound
having a microsomal prostaglandin E2 synthase-1 (mPGES-1)
inhibitory activity or a pharmaceutically acceptable salt
thereof, a pharmaceutical composition containing same,
/0 pharmaceutical use thereof and the like.
BACKGROUND OF THE INVENTION
[0002]
Non-steroidal anti-inflammatory drugs (NSAIDs) are often
used for the treatment of diseases accompanying inflammation,
/5 fever and pain, for example, rheumatism, osteoarthritis,
headache and the like. NSAIDs show an anti-inflammatory action,
an antipyretic action and an analgesic action by preventing
production of prostanoids by inhibiting cyclooxygenase (COX).
[0003]
20 COX includes two isoforms of COX-1 which is ubiquitously
distributed and constitutively expressed, and COX-2 which
expression is induced by various pro-inflammatory stimulations,
for example, cytokines such as interleukin-113 (IL-1p) and the
like. COX-1 and COX-2 are enzymes that convert arachidonic
25 acid derived from cell membrane phospholipids to prostaglandin
H2 (PGH2) which is a prostanoid precursor. Specific prostanoid
synthases are responsible for the conversion of PGH2 to
respective prostanoids (prostaglandin E2 (PGE2), prostaglandin
F2a (PGF2a), prostaglandin 12 (PGI2), prostaglandin D2 (PGD2),
30 thromboxane A2 (TXA2) etc.). These prostanoids have various
physiological activities, for example, induction/suppression of
inflammation, vasodilation/vasoconstriction,
bronchodilation/bronchoconstriction, induction of/awakening
from sleep, development of fever and the like. PGE2 is the
35 most commonly existing prostaglandin in living organisms, and
1
CA 02936408 2016-06-29
is known to be deeply involved in inflammation, pain and fever.
Therefore, suppression of PGE2 production is considered the
main action mechanism of NSAIDs.
[0004]
Inhibition of COX-1 or COX-2 suppresses all prostanoids
production in the downstream thereof. This is considered to
cause side effects of NSAIDs. Since NSAIDs that non-
selectively inhibit COX also suppress production of PGE2 by
COX-1 and PGE2 protectively acts on stomach mucosal injury,
/0 NSAIDs are considered to suppress secretion of gastric mucus
and gastric mucosal blood flow, thereby increasing the risk of
stomach perforations, bleeding and the like. While COX-2
selective inhibitors suppress production of PGI2 having a
vasodilation action and a platelet aggregation inhibitory
/5 action in vascular endothelial cells, they do not suppress
production of TXA2 which is a blood coagulation factor produced
by platelet COX-1. Therefore, they are considered to disrupt
the balance of the blood coagulation system to increase the
risk of cardiovascular disorder.
20 [0005]
Microsomal prostaglandin E2 synthase-1 (mPGES-1) is an
enzyme that catalyzes the final step of PGE2 biosynthesis, and
belongs to the membrane-associated proteins in eicosanoid and
glutathione metabolism family (MAPEG family). The human mPGES-
25 1 gene was cloned in 1999, and indicated to be constitutively
expressed in placenta, prostate, testis and mammary gland (non-
patent document 1). In other organs, human mPGES-1 gene
expression is induced by various pro-inflammatory stimulations,
conjugated with COX-2. For example, inflammatory cytokine IL-
30 13 and Tumor Necrosis Factor-a (TNF a) induce mPGES-1
expression in synovial cell, osteoblast, endothelial cell,
orbital fibroblast, gingival cell, chondrocyte, endothelial
cell, myocardial cell and the like. For example,
Lipopolysaccharide (LPS), which is a bacterial endotoxin,
35 induces mPGES-1 expression in macrophage, smooth muscle and the
2
CA 02936408 2016-06-29
like.
[0006]
mPGES-1 inhibitor is considered to selectively suppress
PGE2 production only in the topical site of inflammation or
tissues where mPGES-1 is expressed, and does not suppress
production of prostanoids (PGI2, PGD2, PGF2a, TXA2 etc.) other
than PGE2 (non-patent documents 2, 3). Therefore, mPGES-1
inhibitor is considered to be a medicament having an efficacy
equivalent to that of NSAIDs but free of side effects of NSAIDs
derived from a decreased production of prostanoids other than
PGE2.
[0007]
It is also known that when one of the metabolism pathways
downstream from PGH2 is shut off in the arachidonic acid
cascade, PGH2 is converted to prostanoids other than the shut-
off pathway, or shunt occurs. That is, it is known that while
the production amount of PGE2 in macrophage derived from mPGES-
1 knockout mice stimulated with LPS becomes lower than the PGE2
production amount in macrophage derived from wild-type (WT)
mice stimulated with LPS, the production amounts of TXB2, PGI2,
PGD2 and PGF2a in macrophage derived from mPGES-1 knockout mice
stimulated with LPS increase beyond the production amounts
thereof in macrophage derived from WT mice stimulated with LPS
(non-patent document 4). Since mPGES-1 inhibitor increases
production of other prostanoids while suppressing the PGE2
production, it is considered to be effective even for diseases
different from those treated by NSAIDs.
[0008]
Use of mPGES-1 inhibitor is described below.
(1) pain
In mPGES-1 knockout mice, intraperitoneal PGE2 production
amount and nociceptive response per unit time significantly
decrease as compared to WT mice, in the evaluation of
nociceptive response by LPS stimulation which is an acute
inflammatory pain model. Therefore, mPGES-1 inhibitor is
3
CA 02936408 2016-06-29
considered to be an analgesic for acute inflammatory pain (non-
patent documents 3, 6).
(2) rheumatism
mPGES-1 gene of Swedish females contains some single
s nucleotide polymorphisms that increase the onset risk and
severity of rheumatism. An increase in the mPGES-1 expression
is immunohistologically confirmed in the synovium of rheumatism
patients showing single nucleotide polymorphism (Reference SNP
ID number: rs23202821) that increases severity, as compared to
/0 patients free of mutation (non-patent document 5). In mPGES-1
knockout mice, intraarticular infiltration of inflammatory
cells, articular destruction and tumentia of the four limbs are
markedly suppressed in a collagen-induced arthritis model,
which is an animal model of rheumatism, as compared to WT mice
15 (non-patent document 6). Therefore, mPGES-1 inhibitor is
considered to be a therapeutic drug for rheumatism.
(3) osteoarthritis
mRNA expression of mPGES-1 increases in meniscus cells of
osteoarthritis patients (non-patent document 7). mPGES-1
20 inhibitor reduces nociceptive responses in osteoarthritis model
using monoiodoacetic acid, as compared to WT mice (patent
document 1). Therefore, mPGES-1 inhibitor is considered to be
a therapeutic drug for osteoarthritis.
(4) fever
25 In mPGES-1 knockout mice, body temperature elevation due
to LPS stimulation is suppressed as compared to WT mice (non-
patent document 8). Therefore, mPGES-1 inhibitor is considered
to be an antipyretic drug.
(5) Alzheimer's disease
30 Long-term use of NSAIDs mitigates the onset and
progression of Alzheimer's disease. Under amyloid p peptide
treatment, PGE2 production in the primary culture brain neuron
of mPGES-1 knockout mice is suppressed, compared to the brain
neuron of WT mice, and nerve cell death does not occur (non-
35 patent document 9). Therefore, mPGES-1 inhibitor is considered
4
CA 02936408 2016-06-29
to be a therapeutic drug for Alzheimer's disease.
(6) multiple sclerosis
EP4 gene of multiple sclerosis patients contains some
single nucleotide polymorphisms that increase the onset risk
(Reference SNP ID numbers: rs9292777, rs4613763, rs1044063,
rs6896969). In macrophage present in the periventricular
demyelinating lesion of multiple sclerosis patients, expression
of mPGES-1 protein is confirmed. In mPGES-1 knockout mice,
PGE2 production in the spinal cord of experimental autoimmune
/o encephalomyelitis model mice, which is an animal model of
multiple sclerosis, is suppressed, and progression of paralysis
is suppressed, as compared to WT mice, (non-patent document 10).
Therefore, mPGES-1 inhibitor is considered to be a therapeutic
drug for multiple sclerosis.
/5 (7) arteriosclerosis
In mPGES-1 knockout mice, PGE2 production in vascular
endothelial cells of high-fat fed low density lipoprotein (LDL)
receptor deficient mice, which is an atherosclerosis model,
decreases, and atheroma formation is delayed as compared to WT
20 mice. In vascular endothelial cells, production of PGI2, which
is known to have a platelet function suppressive action,
increases (non-patent document 11). Therefore, mPGES-1
inhibitor is considered to be a prophylactic or therapeutic
drug for arteriosclerosis.
25 (8) glaucoma, ocular hypertension
Glaucoma is a disease showing a characteristic change in
the optic nerve and the field of vision. Optic nerve disorder
can be generally improved or suppressed by sufficiently
decreasing the intraocular pressure. Glaucoma can be
30 categorized into open angle glaucoma and closed angle glaucoma.
mPGES-1 gene is constitutively highly expressed in human
conjunctiva (GEO accession No: GSE2513 (Gene Expression
Omnibus:http://www.ncbi.nlm.nih.gov/geo/)). In the retina of
glaucoma patients, expression of mPGES-1 increases as compared
35 to healthy individuals. In the retina of high intraocular
5
CA 02936408 2016-06-29
pressure dogs and high intraocular pressure mice, which are
glaucoma models, expression of mPGES-1 increases as compared to
normal animals (GEO accession No: human GSE2378, dog GSE21879,
mouse GSE3554).
When PGE2 is instilled into the eyes of healthy
individuals, the intraocular pressure increases, along with the
expansion of blood vessels, for 2 hours after instillation
(non-patent document 12). When PGE2 is administered to rabbits
subconjunctivally, the intraocular pressure increases due to
/0 dilatation of ciliary body and increase in the aqueous humor
production (non-patent document 13). PGF2a and PGD2, which are
prostaglandins that may increase when mPGES-1 is inhibited,
decrease the intraocular pressure of rabbit (non-patent
document 14). PGF2a formulations increase outflow of aqueous
/5 humor and are used as therapeutic drugs for glaucoma that
decrease the intraocular pressure. PGI2 does not show a clear
action on the intraocular pressure of rabbits. That is, the
intraocular pressure is considered to decrease since decrease
of PGE2 suppresses aqueous humor production by mPGES-1
20 inhibition, and/or since increased PGD2 and PGF2a promote
outflow of aqueous humor due to shunt. Also, PGE2 promotes
expression of vascular endothelial growth factor (VEGF) from
retina (non-patent document 15). Since VEGF produced in retina
transfers to the anterior ocular segment to cause angiogenesis
25 glaucoma, which is increase of the intraocular pressure that is
caused by obstruction of corner angle due to angiogenesis in
iris, mPGES-1 inhibitor is considered to show an improvement or
prophylactic effect on angiogenesis glaucoma as well.
Furthermore, considering an anti-inflammatory action by the
30 inhibition of PGE2 production, mPGES-1 inhibitor is applicable
to patients having intraocular inflammation, who require
careful administration of the existing prostaglandin
formulations (latanoprost etc.). Therefore, mPGES-1 inhibitor
is considered to be a therapeutic drug also effective for
35 glaucoma having various background diseases.
6
CA 02936408 2016-06-29
(9) ischemic retinal disease
Excessive secretion of VEGF plays a key role in ischemic
retinal diseases such as diabetic retinopathy, diabetic macular
edema, retinal vein occlusion and the like. Since PGE2
promotes expression of VEGF (non-patent document 15), mPGES-1
inhibitor is considered to improve these diseases.
(10) systemic scleroderma
Expression of mPGES-1 increases in the skin of systemic
scleroderma patients, as compared to healthy individuals.
/0 Similarly, expression of mPGES-1 increases in the skin of
bleomycin induced scleroderma model mice, which is a systemic
scleroderma model, as compared to the skin of normal mice. As
compared to WT mice, mPGES-1 knockout mice showed a decrease in
the accumulation of macrophage in the dermal lesion of
bleomycin induced scleroderma model mice, and mitigation of
cutaneous thickening, deposition of extracellular matrix and
increase in the collagen content (non-patent document 16).
Therefore, mPGES-1 inhibitor is considered to be a therapeutic
drug for systemic scleroderma.
(11) cancer
In mPGES-1 knockout mice, the polyp number and size were
markedly suppressed in azoxymethane-induced colorectal cancer
model mice, which are animal model of colorectal cancer, as
compared to WT mice. In mPGES-1 knockout mice, PGE2 production
in large intestinal tumor tissue decreased and production
amount of PGI2 that inhibits adhesion of cancer cells and PGD2
that induces cell death via peroxisome proliferator-activated
receptor y (PPARy) increased, as compared to WT mice. When
colorectal cancer or lung cancer cells were transplanted into
the spleen of mPGES-1 knockout mice, the post-transplantation
weight of spleen tumor and the rate of metastasis to the liver
decreased as compared to WT mice. Growth of lung cancer cells
was decreased when they ware co-cultured in vitro with mPGES-1
knockout mice-derived bone marrow macrophages compared to when
they ware co-cultured with WT mice-derived bone marrow
7
CA 02936408 2016-06-29
macrophages, which indicates that host macrophage-derived PGE2
is involved in cancer cell growth (non-patent document 17).
Therefore, mPGES-1 inhibitor is considered to be an anticancer
drug that suppresses the growth and metastasis of cancer
including colorectal cancer.
(12) disease for which suppression of PGE2 production is
effective
As inflammatory symptoms and/or pain relating to the
conditions thereof, for which NSATDs are effective, for example,
/0 arthritis, gout, nephrolithiasis, urolithiasis, headache,
menstrual pain, toothache, lumbago, muscular pain,
periarthritis scapulohumeralis, cervical syndrome,
temporomandibular disorder, and postoperative or posttraumatic
inflammation and pain, and inflammation and pain after tooth
/5 extraction can be mentioned. Besides these, acute and chronic
non-bacterial inflammation of eye can be mentioned and, for
example, uveitis, allergic conjunctivitis and postoperative
inflammation and ophthalmalgia in intraocular operation can be
mentioned.
20 The main mechanism for the efficacy of NSAIDs is
considered to be the suppression of PGE2 production, which is
an inflammation promoting substance. Since mPGES-1 inhibitor
also has a suppressive action on the PGE2 production, it is
considered to be a therapeutic drug for these diseases.
25 [0009]
The mPGES-1 inhibitor is considered to be beneficial for
the prophylaxis or treatment of pain, rheumatism,
osteoarthritis, fever, Alzheimer's disease, multiple sclerosis,
arteriosclerosis, glaucoma, ocular hypertension, ischemic
30 retinal disease, systemic scleroderma, cancer including
colorectal cancer and diseases for which suppression of PGE2
production is effective.
[Document List]
patent document
35 [0010]
8
CA 02936408 2016-06-29
patent document 1: WO 2012/161965
non-patent documents
[0011]
non-patent document 1: JAKOBSSON, PJ et al. Identification of
human prostaglandin E synthase: a microsomal, glutathione-
dependent, inducible enzyme, constituting a potential novel
drug target. Proc Natl Acad Sci U S A. Jun 22 1999, Vol.96,
No.13, pages 7220-7225.
non-patent document 2: SAMUELSSON, B et al. Membrane '
/0 prostaglandin E synthase-1: a novel therapeutic target.
Pharmacol Rev. Sep 2007, Vol.59, No.3, pages 207-224.
non-patent document 3: KAMEI, D et al. Reduced pain
hypersensitivity and inflammation in mice lacking microsomal
prostaglandin e synthase-1. J Biol Chem. Aug 6 2004, Vol.279,
/5 No.32, pages 33684-33695.
non-patent document 4: TREBINO, CE et al. Redirection of
eicosanoid metabolism in mPGES-1-deficient macrophages. J Biol
Chem. Apr 29 2005, Vol.280, No.17, pages 16579-16585.
non-patent document 5: KOROTKOVA, M et al. Variants of gene for
20 microsomal prostaglandin E2 synthase show association with
disease and severe inflammation in rheumatoid arthritis. Eur J
Hum Genet. Aug 2011, Vol.19, No.8, pages 908-914.
non-patent document 6: TREBINO, CE et al. Impaired inflammatory
and pain responses in mice lacking an inducible prostaglandin E
25 synthase. Proc Natl Acad Sci U S A. Jul 22 2003, Vol.100, No.15,
pages 9044-9049.
non-patent document 7: SUN, Y et al. Analysis of meniscal
degeneration and meniscal gene expression. EMC Musculoskelet
Disord. 2010, Vol.11, pages 19.
30 non-patent document 8: ENGBLCM, D et al. Microsomal
= prostaglandin E synthase-1 is the central switch during immune-
induced pyresis. Nat Neurosci. Nov 2003, Vol.6, No.11, pages
1137-1138.
non-patent document 9: KUROKI, Y et al. Deletion of microsomal
35 prostaglandin E synthase-1 protects neuronal cells from
9
CA 02936408 2016-06-29
cytotoxic effects of beta-amyloid peptide fragment 31-35.
Biochem Biophys Res Commun. Aug 3 2012, Vol.424, No.3, pages
409-413.
non-patent document 10: KIHARA, Y et al. Targeted lipidomics
reveals mPGES-1-PGE2 as a therapeutic target for multiple
sclerosis. Proc Natl Acad Sci U S A. Dec 22 2009, Vol.106,
No.51, pages 21807-21812.
non-patent document 11: WANG, M et al. Deletion of microsomal
prostaglandin E synthase-1 augments prostacyclin and retards
/0 atherogenesis. Proc Natl Acad Sci U S A. Sep 26 2006, Vol.103,
No.39, pages 14507-14512.
non-patent document 12: FLACH, AJ et al. Topical prostaglandin
E2 effects on normal human intraocular pressure. J Ocul
Pharmacol. Spring 1988, Vol.4, No.1, pages 13-18.
/5 non-patent document 13: NAKAJIMA, T et al. [Effects of
prostaglandin E2 on intraocular pressure, anterior chamber
depth and blood flow volume of the iris and the ciliary body in
rabbit eyes]. Nihon Ganka Gakkai Zasshi. Apr 1992, Vol.96, No.4,
pages 455-461.
20 non-patent document 14: GOB, Y et al. Prostaglandin D2 reduces
intraocular pressure. Br J Ophthalmol. Jun 1988, Vol.72, No.6,
pages 461-464.
non-patent document 15: YANNI, SE et al. The role of PGE2
receptor EP4 in pathologic ocular angiogenesis. Invest
25 Ophthalmo1 Via sci. Nov 2009, Vol.50, No.11, pages 5479-5486.
non-patent document 16: MCCANN, MR et al. mPGES-1 null mice are
resistant to bleomycin-induced skin fibrosis. Arthritis Res
Ther. 2011, Vol.13, No.1, pages R6.
non-patent document 17: SASAKI, Y et al. Microsomal
30 prostaglandin E synthase-1 is involved in multiple steps of
colon carcinogenesis. Oncogene. Jun 14 2012, Vol.31, No.24,
pages 2943-2952.
SUMMARY OF THE INVENTION =
[0012]
35 The present
invention aims to provide a triazine compound
85406584
having an mPGES-1 inhibitory activity or a pharmaceutically
acceptable salt thereof, a pharmaceutical composition
containing same, and pharmaceutical use thereof and the like.
As the target disease, for example, pain, rheumatism,
osteoarthritis, fever, Alzheimer's disease, multiple sclerosis,
arteriosclerosis, glaucoma, ocular hypertension, ischemic
retinal disease, systemic scleroderma, cancer including
colorectal cancer and diseases for which suppression of PGE2
production is effective can be mentioned.
119 [0013]
The present inventors have found a triazine compound
having an mPGES-1 inhibitory activity, which is represented by
the following formula [I], and completed the present invention.
Accordingly, the present invention is as follows.
[0014]
[01]
A compound represented by the formula [I] or a
pharmaceutically acceptable salt thereof:
[0015]
(R5) m
Ni N
H
[I]
[0016]
wherein
X is CH or N,and,in particular embodiments, X is CH,
ring Cy is
the formula:
[0017]
11
Date Recue/Date Received 2021-08-05
CA 02936408 2016-06-29
R4
R1
,s R2
[0018]
or
the formula:
[0019]
=
R1
R4
.3
[0020]
{wherein R1 is
(1) halogen,
(2) C1_6 alkyl,
(3) cyano or
(4) haloCI_A alkyl,
R2 is
(1) halogen,
(2) hydroxy,
(3) carboxy,
(4) C1_6 alkyl,
(5) C1-6 alkoxy,
(6) ha1o01_4 alkoxy,
(7) haloC1-4 alkyl,
(8) C1-6 alkyl-carbonyl,
(9) ¨C(0)NR0lRa2 (Ral and R02 are each independently
hydrogen or C1-6 alkyl) or
(10) ¨(CnH2n)¨Rb
(n is 1, 2, 3 or 4, -(CõH211)- may be straight or branched
chain, and
12
CA 02936408 2016-06-29
Rb is
(a) hydroxy,
(b) carboxy,
(c) C1-6 alkoxY,
(d) 01-6 alkyl-carbonyloxy,
(e) -C(0)NRblRb2 (Rbl and Rb2 are each independently
hydrogen or C1-6 alkyl),
(f) -0C(0)NRb3Rb4 (Rb3 and Rb4 are each independently
hydrogen or 01-6 alkyl),
(g) -NRb5C (0) NRb6Rb7 (Rb5, Rb6 and Rb7 are each
independently hydrogen or 01-6 alkyl),
(h) _NRID8Rb9 (Rb8 and Rb9 are each independently hydrogen,
01-6 alkyl or haloC1_4 alkyl),
(i) _NRbios (0) 2Rbil (Rm. and Rbll are each independently
/5 hydrogen, C1-6 alkyl or 03-7 cycloalkyl),
( j ) _NR1l2C (0) ORb13 (Rb12
is hydrogen or 01-6 alkyl, and Rb13
is 01-6 alkyl),
(k) _NRbi4c (0) Rbis (Rb3.4 is hydrogen or 01-6 alkyl, and
Rbis is
(i) 06-bo aryl,
(11) 01-6 alkyl (said 01-6 alkyl is optionally
substituted by 1, 2 or 3 substituents selected from the group
consisting of hydroxy, haloC1_4 alkyl, 01-6 alkoxy and 06-10 aryl),
(iii) adamantyl or
(iv) C3-7 cycloalkyl (said 03-7 cycloalkyl is optionally
substituted by 1, 2, 3 or 4 substituents selected from the
group consisting of 01-6 alkyl, halogen, hydroxyl C1-6 alkyl and
halo C1-4 alkyl, and/or optionally form a fused ring with a
benzene ring), or
Rbi4 and R115 optionally form a 4-, 5- or 6-membered
lactam together with the nitrogen atom the nitrogen atom that
R1314 is bonded to and the carbon atom that Rb15 is bonded to
(said lactam is optionally substituted by 1, 2 or 3 C1-6 alkyls,
and/or optionally form a fused ring with a benzene ring),
(1) the formula:
13
CA 02936408 2016-06-29
[0021]
(Rb 1 6)
im4
2
N
m3
[0022]
wherein m2 and m3 are each independently 1, 2 or 3, m4 is 0, 1,
2, 3 or 4, Rb16 is C1-6 alkyl or 01-6 alkoxy, and when m4 is 2, 3
or 4, each Rb16 is selected independently, or
(m) the formula:
[0023]
5
N
m6 Db17
.70 [0024]
wherein m5 and m6 are each independently 1, 2 or 3, and Rba7 iS
C1_6 alkyl or Ci_6 alkoxy)),
R3 is
(1) halogen,
(2) hydroxy,
(3) C1-6 alkyl or
(4) -OR' fRc is C1_6 alkyl optionally substituted by 1, 2
or 3 substituents selected from the group consisting of the
following (a) to (f);
(a) halogen,
(b) hydroxy,
(C) 01-6 alkoxy,
(d) -C (0) NRciRc2 (Rdi and Rc2 are each independently
hydrogen or C1-6 alkyl),
(e) 06-10 aryl (said C6_10 aryl is optionally substituted
by 1, 2 or 3 substituents selected from the group consisting of
14
CA 02936408 2016-06-29
(i) halogen,
(ii) hydroxy,
(iii) 01-6 alkyl,
(iv) 01-6 alkoxy, and
(v) ha1o01-4 alkyl), and
(f) 5- or 6-membered heteroaryl containing 1, 2 or 3
nitrogen atoms, oxygen atoms or sulfur atoms (said heteroaryl
is optionally substituted by 1, 2 or 3 substituents selected
from the group consisting of
(i) halogen,
(ii) hydroxy,
(iii) 01_6 alkyl,
(iv) C1-6 alkoxy, and
(v) haloC1-1 alkyl)}, and
/5 R4 is
(1) hydrogen,
(2) halogen,
(3) 01-6 alkyl or
(4) 01-6 alkoxy},
R5 is
(1) halogen,
(2) hydroxy,
(3) C1_6 alkylsulfanYl,
(4) 01-6 alkyl (said 01-6 alkyl is optionally substituted
by 1, 2 or 3 substituents selected from the group consisting of
halogen, 06-10 aryl and 01-6 alkoxy),
(5) 03-7 cycloalkyl,
(6) -ORd {Rd is
(a) 02-6 alkYnYir
(b) 03_7 cycloalkyl optionally substituted by 1, 2 or 3
01-6 alkyls or
(c) 01-6 alkyl (said C1-6 alkyl is optionally substituted
by 1, 2 or 3 substituents selected from the group consisting of
the following (i) to (v);
(i) halogen,
CA 02936408 2016-06-29
(ii) C6_10 aryl,
(iii) C1-6 alkoxy,
(iv) C3-7 cycloalkyl (said C3-7 cycloalkyl is optionally
substituted by 1, 2 or 3 substituents selected from the group
consisting of C1-6 alkyl and haloC1-4 alkyl), and
(v) 4-, 5- or 6-membered saturated heterocyclyl
containing 1, 2 or 3 nitrogen atoms, oxygen atoms or sulfur
atoms (said saturated heterocyclyl is optionally substituted by
1, 2 or 3 substituents selected from the group consisting of
/o C1-6 alkyl and haloC1-4 alkyl))} or
(7) the formula:
[0025]
Re
[0026]
/5 wherein Re is
(a) C1-6 alkyl,
(b) C3_7 cycloalkyl,
(c) 5- or 6-membered heteroaryl containing 1, 2 or 3
nitrogen atoms, oxygen atoms or sulfur atoms, or
20 (d) C6_10 aryl (said C6_10 aryl is optionally substituted
by 1, 2 or 3 substituents selected from the group consisting of
(i) halogen,
(ii) C1-6 alkyl,
(iii) haloC1-1 alkyl,
25 (1V) C1-6 alkoxy, and
(v) haloC1_4 alkoxy), and
ml is 0, 1, 2 or 3 and, when ml is 2 or 3, each R5 is selected
independently,
excluding 4,6-bis-(2,5-dimethyl-pheny1)-1,3,5-triazin-2-ol.
30 [0027]
[02]
The compound of [01] or a pharmaceutically acceptable
salt thereof, wherein ring Cy is the formula:
16
CA 02936408 2016-06-29
[0028]
R4
R1
R2
[0029]
wherein Rl, R2 and R4 are as defined in [01].
[0030]
[03]
The compound of [01] or a pharmaceutically acceptable
salt thereof, wherein ring Cy is the formula:
[0031]
R1
R4
3
/o
[0032]
wherein Rl, R3 and R4 are as defined in [01].
[0033]
[04]
The compound of any of [01] to [03] or a pharmaceutically
acceptable salt thereof, wherein X is CH.
[0034]
[05]
The compound of any of [01] to [03] or a pharmaceutically
acceptable salt thereof, wherein X is N.
[0035]
[06]
The compound of any of [01] to [05] or a pharmaceutically
acceptable salt thereof, wherein RI. is
(1) chloro,
(2) methyl,
17
CA 02936408 2016-06-29
(3) cyano or
(4) trifluoromethyl.
[0036]
[07]
The compound of any of [01] to [06] or a pharmaceutically
acceptable salt thereof, wherein R4 is hydrogen.
[0037]
[08]
The compound of any of [01], [02] and [04] to [07] or a
20 pharmaceutically acceptable salt thereof, wherein R2 is
-(CnH2n)-Rb (n is 1 or 2, -(CnH2n)- may be straight or branched
chain, and Rb is
( a ) -C ( 0) NRblRb2
(b) -NR"C (0) NR"Rb7,
(c) _NR110 s (0) 2Rb11 or
(d) _NRbit (0) Rbi5
(Rbi, Rb2, Rb5, Rb6, Rb7, Rbio, Rbn, Rba4, and Rb15 are as defined in
[01])).
[0038]
[09]
The compound of [08] or a pharmaceutically acceptable
salt thereof, wherein R2 is -CH2-Rb (Rb is as defined in [081)=
[0039]
[10]
The compound of any of [Cl] and [03] to [09] or a
pharmaceutically acceptable salt thereof, wherein R3 is
(1) halogen,
(2) hydroxy,
(3) C1-6 alkyl or
(4) -OR' {RC is 01-6 alkyl optionally substituted by 1, 2
or 3 substituents selected from the group consisting of the
following (a) to (f)
(a) halogen,
(b) hydroxy,
(C) C1-6 alkoxy,
18
CA 02936408 2016-06-29
(d) -C(0)NRclRc2 (Rd l and Rc2 are each independently
hydrogen or C1-6 alkyl),
(e) phenyl (said phenyl is optionally substituted by 1,
2 or 3 substituents selected from the group consisting of
(i) halogen,
(ii) hydroxy,
(iii) C1-6 alkyl,
(iv) 01-6 alkoxy, and
(v) haloC1_21 alkyl), and
/o (f) pyridyl (said pyridyl is optionally substituted by 1,
2 or 3 substituents selected from the group consisting of
(i) halogen,
(ii) hydroxy,
(iii) 01-6 alkyl,
(iv) C1_6 alkoxy, and
(v) haloC1-1 alkyl)}.
[0040]
[11]
The compound of any of [01] to [10] or a pharmaceutically
acceptable salt thereof, wherein ml is 1, and
R5 is the formula:
[0041]
¨ __________ Re
[0042]
wherein Re is as defined in [01].
[0043]
[12]
A compound selected from the following formulas:
[0044]
19
CA 02936408 2016-06-29
H3C
H3C
CI
/
)=-N
HO N CH,
(CH,,
0 CH,
[0045]
CI III H
N_ 0 F
H,C \ H ,C __ F 4 H3
\OH
[0046]
H,C CH, CI
F
\ H3C _____ F
H3
\OH
[0 0 4 7]
CH3
H3C
CI
/ \
FIC;= F F
CH,
H3
[0 0 4 8]
H3C Cu-'
H C __________________________ F
\ 4 3
H3
\OH
= 20
CA 02936408 2016-06-29
[00 4 9]
CH3
0
CI
/ \
H0)-= CH3
0
[0 0 50]
FI3C-1c
CI
N
)-N
HO N CHCH
0 F
F F
[0051]
H3C
CI
/ \
0)õ FFHF3
ci H3
[0052]
21
CA 02936408 2016-06-29
=
H3C
H3 CI
/ \
F 11? FEF3
.1
H3
[0 0 5 3]
1-0
H3C
CI
/
N
)=-N
HO N CH3
0 F
F F
[0054]
CI
N)-/
HO N CH3
_________________________________ E_I-13
0 F
F F
[0 0 5 5 ]
CI
H3C
CI
N/
)=N H p H3
HO N>7.
F
F F
22
CA 02936408 2016-06-29
00 56 I
113C-r
CI
N
)=N
HO
CH
0
F F
[0057]
HG
H3C
CI
N
)-=N
HO N CH,
Oh-F
F F
[00581
<LO
CI
N
HO
0 ___________________________ F
F F
[0059]
23
CA 02936408 2016-06-29
CH3
H3C¨c_
0
CI
¨N
N
HO
ONF
F F
[0 0 6 0 ]
H3C
CI
/
N=
)=N
HO N CH
________________________ CH
OF
F F
[0 0 61]
H3O
CI
N
)=N
HO N CH3
F F
[ 0062 ]
and
[0063]
24
CA 02936408 2016-06-29
N N
C H 3
[0064]
or a pharmaceutically acceptable salt thereof.
[0065]
[13]
A pharmaceutical composition comprising the compound of
any of [01] to [12] or a pharmaceutically acceptable salt
thereof, and a pharmaceutically acceptable carrier.
[0066]
/o [14]
An mPGES-1 inhibitor comprising the compound of any of
[01] to [12] or a pharmaceutically acceptable salt thereof.
[0067]
[15]
A therapeutic or prophylactic agent for pain, rheumatism,
fever, osteoarthritis, arteriosclerosis, Alzheimer's disease,
multiple sclerosis, glaucoma, ocular hypertension, ischemic
retinal disease, systemic scleroderma, cancer or a disease for
which suppression of PGE2 production is effective, comprising
the compound of any of [01] to [12] or a pharmaceutically
acceptable salt thereof.
[0068]
[16]
A therapeutic or prophylactic agent for glaucoma or
ocular hypertension, comprising the compound of any of [01] to
[12] or a pharmaceutically acceptable salt thereof, and one or
more kinds of other therapeutic agents for glaucoma in
combination.
[0069]
CA 02936408 2016-06-29
[17]
A method of inhibiting mPGES-1, comprising administering
a pharmaceutically effective amount of the compound of any of
[01] to [12] or a pharmaceutically acceptable salt thereof to a
human.
[0070]
[18]
A method of treating or preventing pain, rheumatism,
fever, osteoarthritis, arteriosclerosis, Alzheimer's disease,
/0 multiple sclerosis, glaucoma, ocular hypertension, ischemic
retinal disease, systemic scleroderma, cancer or a disease for
which suppression of PGE2 production is effective, which method
comprising administering a pharmaceutically effective amount of
the compound of any of [01] to [12] or a pharmaceutically
/5 acceptable salt thereof to a human.
[0071]
[19]
The method of [18] for treating or preventing glaucoma or
ocular hypertension, further comprising administering a
20 pharmaceutically effective amount of one or more kinds of other
therapeutic agents for glaucoma to the human.
[0072]
[20]
Use of the compound of any of [01] to [12] or a
25 pharmaceutically acceptable salt thereof for the production of
an mPGES-1 inhibitor.
[0073]
[21]
Use of the compound of any of [01] to [12] or a
30 pharmaceutically acceptable salt thereof for the production of
a therapeutic or prophylactic agent for pain, rheumatism, fever,
osteoarthritis, arteriosclerosis, Alzheimer's disease, multiple
sclerosis, glaucoma, ocular hypertension, ischemic retinal
disease, systemic scleroderma, cancer or a disease for which
35 suppression of PGE2 production is effective.
26
CA 02936408 2016-06-29
EFFECT OF THE INVENTION
[0074]
The compound of the present invention is effective as a
therapeutic or prophylactic agent for pain, rheumatism, fever,
osteoarthritis, arteriosclerosis, Alzheimer's disease, multiple
sclerosis, glaucoma, ocular hypertension, ischemic retinal
disease, systemic scleroderma, cancer including colorectal
cancer, a disease for which suppression of PGE2 production is
/o effective and the like.
BRIEF DESCRIPTION OF THE DRAWINGS
[0075]
Fig. 1 shows effect of a test article (compounds of
Example 2-98), a reference article (Xalatan (registered
trademark)) or a vehicle (methylcellulose, MC) on the
intraocular pressure immediately before and after
administration in Macaca fascicularis.
DESCRIPTION OF EMBODIMENTS
[0076]
The definitions of the terms used in the present
invention are as follows.
[0077]
The "halogen" is fluoro, chloro, bromo or iodo.
[0078]
The "C16 alkyl" means straight chain or branched chain
alkyl haying 1 to 6 carbon atoms. Examples thereof include
methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl,
tert-butyl, pentyl, isopentyl, neopentyl, 1-ethylpropyl, hexyl,
isohexyl, 1,1-dimethylbutyl, 2,2-dimethylbutyl, 3,3-
dimethylbutyl, 2-ethylbutyl and the like.
[0079]
The "Cl_El alkyl" means straight chain or branched chain
alkyl having 1 to 8 carbon atoms. Examples thereof include
27
CA 02936408 2016-06-29
methyl, ethyl, propyl, isopropyl, 1,1-dimethylpropyl, 1-ethyl-
propyl, 1-methyl-1-ethyl-propyl, butyl, isobutyl, sec-butyl,
tert-butyl, 1-methyl-l-propyl-butyl, pentyl, isopentyl,
neopentyl, 1-ethylpropyl, hexyl, isohexyl, 1,1-dimethylbutyl,
2,2-dimethylbutyl, 3,3-dimethylbutyl, 2-ethylbutyl and the like.
[0080]
The "C1..6 alkoxy" means alkoxy wherein the alkyl moiety is
the above-defined "01_6 alkyl". Examples thereof include
methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec-
butoxy, tert-butoxy, pentyloxy, isopentyloxy, neopentyloxy,
1,2-dimethylpropyloxy, 1-ethylpropyloxy, hexyloxy, isohexyloxy,
1,2,2-trimethylpropyloxy, 1,1-dimethylbutyloxy, 2,2-
dimethylbutyloxy, 3,3-dimethylbutyloxy, 2-ethylbutyloxy and the
like.
[0081]
The "ha1oC1-4 alkyl" means straight chain or branched
chain alkyl having 1-4 carbon atoms, which is substituted by 1
to 9 the above-defined "halogens". When it is substituted by
plural halogens, respective halogens may be the same or
different. Examples thereof include 2-fluoroethyl, 2-
chloroethyl, 2-bromoethyl, 3-fluoropropyl, 3-chloropropyl, 4-
fluorobutyl, 4-chlorobutyl, 1,1-difluoroethyl, 1,1-
difluoropropyl, 1,1-difluoro-2-methylpropyl, trifluoromethyl,
2,2,2-trifluoroethyl, 3,3,3-trifluoropropyl, 4,4,4-
trifluorobutyl, pentafluoroethyl, 2,2,2-trifluoro-1-
trifluoromethyl-ethyl and the like.
[0082]
The "haloC1-4 alkoxy" means alkoxy wherein the alkyl
moiety is the above-defined "ha1o01_4 alkyl". Examples thereof
include fluoromethoxy, chloromethoxy, bromomethoxy, 2-
fluoroethoxy, 2-chloroethoxy, 2-bromoethoxy, 3-fluoropropoxy,
3-chloropropoxy, 4-fluorobutoxy, 4-chlorobutoxy, 1,1-
difluoroethoxy, 2,2-difluoroethoxy, 1,1-difluoropropoxy, 2,2-
difluoropropoxy, 3,3-difluoropropoxy, 1,1-difluoro-2-
methylpropoxy, trifluoromethoxy, 2,2,2-trifluoroethoxy, 3,3,3-
28
CA 02936408 2016-06-29
trifluoropropoxy, 4,4,4-trifluorobutoxy, pentafluoroethoxy,
2,2,2-trifluoro-l-trifluoromethyl-ethoxy and the like.
[0083]
The "hydroxy01_6 alkyl" means the above-defined "01-6
alkyl" substituted by 1 or 2 hydroxy. Examples thereof include
hydroxymethyl, 2-hydroxyethyl, 1-hydroxy-l-methylethyl, 1,2-
dihydroxyethyl, 3-hydroxypropyl, 1-hydroxy-2,2-dimethylpropyl,
4-hydroxybutyl, 1-hydroxy-2,2-dimethylbutyl, 5-hydroxypentyl,
6-hydroxyhexyl and the like.
/o [0084]
The "01_6 alkyl-carbonyl" means carbonyl bonded to the
above-defined "01-6 alkyl". Examples thereof include acetyl,
propionyl, 2,2-dimethylpropionyl, butyryl, 3-methylbutyryl,
2,2-dimethylbutyryl, pentanoyl, 4-methylpentanoyl, hexanoyl and
/5 the like.
[0085]
The "01_6 alkyl-carbonyloxy" means carbonyloxy bonded to
the above-defined "01_6 alkyl". Examples thereof include
methylcarbonyloxy, ethylcarbonyloxy, propylcarbonyloxy,
20 isopropylcarbonyloxy, butylcarbonyloxy, isobutylcarbonyloxy,
sec-butylcarbonyloxy, tert-butylcarbonyloxy, pentylcarbonyloxy,
isopentylcarbonyloxy, 2-methylbutylcarbonyloxy, 1,1-
dimethylpropylcarbonyloxy, neopentylcarbonyloxy, 3,3-
dimethylbutylcarbonyloxy, 1-ethylpropylcarbonyloxy,
25 hexylcarbonyloxy and the like.
[0086]
The "03_7 cycloalkyl" means 3- to 7-membered monocyclic
cycloalkyl. Examples thereof include cyclopropyl, cyclobutyl,
cyclopentyl, cyclohexyl and cycloheptyl.
30 [0087]
The "C6_10 aryl" means 6- to 10-membered aryl. Examples
thereof include phenyl, 1-naphthyl, 2-naphthyl and the like.
Of these, preferred is phenyl.
[0088]
35 The "5- or 6-membered heteroaryl containing 1, 2 or 3
29
CA 02936408 2016-06-29
nitrogen atoms, oxygen atoms or sulfur atoms" means 5- or 6-
membered monocyclic heteroaryl containing, besides carbon atoms,
1, 2 or 3 hetero atoms selected from a nitrogen atom, an oxygen
atom and a sulfur atom. Examples thereof include furyl,
thienyl, pyrrolyl, oxazolyl, isoxazolyl, thiazolyl,
isothiazolyl, imidazolyl, pyrazolyl, oxadiazoly1(1,2,5-
oxadiazolyl, 1,3,4-oxadiazolyl, 1,2,4-oxadiazoly1),
thiadiazoly1(1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl, 1,2,4-
thiadiazolyl), triazoly1(1,2,3-triazolyl, 1,2,4-triazoly1),
/0 pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl, 1,3,5-triazinyl
and the like. Of these, preferred is pyridyl.
[0089]
The "4-, 5- or 6-membered saturated heterocyclyl
containing 1, 2 or 3 nitrogen atoms, oxygen atoms or sulfur
/5 atoms" means 4-, 5- or 6-membered monocyclic saturated
heterocyclyl containing, besides carbon atoms, 1, 2 or 3 hetero
atoms selected from a nitrogen atom, an oxygen atom and a
sulfur atom. The carbon atom of the heterocycle is optionally
substituted by oxo. When a sulfur atom is contained as a
20 hetero atom, the sulfur atom is optionally monooxidized or
dioxidized. Examples thereof include oxetanyl, azetidinyl,
tetrahydrofuryl, tetrahydropyranyl, tetrahydrothienyl,
tetrahydrothiopyranyl, oxazolidinyl, isoxazolidinyl,
thiazolidinyl, isothiazolidinyl, imidazolidinyl, pyrazolidinyl,
25 pyrrolidinyl, piperidyl (including piperidino), morpholinyl
(including morpholino), thiomorpholinyl (including
thiomorpholino), piperazinyl, 1,1-dioxidoisothiazolidinyl, 1,1-
dioxidotetrahydrothienyl, 1,1-dioxidotetrahydrothiopyranyl,
1,1-dioxidothiomorpholinyl (including 1,1-
30 dioxidothiomorpholino) and the like. In addition, the
saturated heterocyclyl may be partially saturated. Examples
thereof include imidazolinyl, oxazolinyl, pyrazolinyl,
thiazolinyl and the like. Of these, preferred is oxetanyl.
[0090]
35 The "C1_6 alkylsulfanyl" means sulfanyl bonded to the
CA 02936408 2016-06-29
above-defined "C1-6 alkyl". Examples thereof include
methylsulfanyl, ethylsulfanyl, propylsulfanyl,
isopropylsulfanyl, n-butylsulfanyl, isobutylsulfanyl, sec-
butylsulfanyl, tert-butylsulfanyl, pentylsulfanyl, 1,1-
dimethylpropylsulfanyl, 2,2-dimethylpropylsulfanyl,
hexylsulfanyl and the like.
[0091]
The "02-6 alkynyl" means straight chain or branched chain
hydrocarbon having 2 to 6 carbon atoms and at least one triple
/0 bond. Examples thereof include ethynyl, 1-propynyl, 2-propynyl,
1-butynyl, 2-butynyl, 3-butynyl, 1-methyl-2-propynyl, 3,3-
dimethylbutynyl (that is, 3,3-dimethylbut-l-ynyl) and the like.
[0092]
The "-(CnH2,i)-" means straight chain or branched chain
alkylene having n carbon atoms and 2n hydrogen atoms. Examples
thereof include -CH2-, -0H20H2-, -CH(0E2)-, -0H20R20H2-, -C(0H3)2-,
-OH(CH2)C1-12- and the like.
[0093]
When R2 is (10) -(CnH2n)-Rb and Rb is (k) _NRbizic (0) Rbn,
"(ii) 01-8 alkyl (said al-8 alkyl is optionally substituted by 1,
2 or 3 substituents selected from the group consisting of
hydroxy, ha1o01_4 alkyl, C1-6 alkoxy and 06-10 aryl)" for Rb15
means the above-defined "C1_8 alkyl" substituted or not
substituted by the same or different, 1, 2 or 3 substituents
selected from the group consisting of hydroxy, the above-
defined "ha1o01_4 alkyl", the above-defined "01_6 alkoxy" and the
above-defined "C6_10 aryl", at the substitutable position(s)
thereof. Examples of Rb include 2-ethoxy-3-
methoxypropylcarbonylamino, 1-methyl-l-methoxy-2,2,2-
trifluoroethylcarbonylamino and the like.
[0094]
When R2 is (10) - (Cril-12n) -Rb and Rb is (k) -NRb1-4C (0) Rb15,
"(iv) 03-7 cycloalkyl (said 03-7 cycloalkyl is optionally
substituted by 1, 2, 3 or 4 substituents selected from the
group consisting of 01_6 alkyl, halogen, hydroxyC1..6 alkyl and
31
CA 02936408 2016-06-29
haloC1_4 alkyl, and/or optionally form a fused ring with a
benzene ring)" for Rb15 means (1) the above-defined "C3-7
cycloalkyl" substituted by the same or different, 1, 2, 3 or 4
substituents selected from the group consisting of the above-
defined "01_6 alkyl", the above-defined "halogen", the above-
defined "hydroxyC1_6 alkyl" and the above-defined "haloC1-4
alkyl", at the substitutable position(s) thereof, (2)
unsubstituted C3-7 cycloalkyl, or (3) C3-7 cycloalkyl of (1) or
(2), fused with one benzene ring at a fusible position.
/o Examples of Rb include 1,2,3,4-tetrahydro-naphthalen-2-
ylcarbonylamino, 2-methyl-indan-2-ylcarbonylamino and the like.
[00951
When R2 is (10) -(CnH2n.)-Rb and Fe' is (k) -NRbi.4c (0) Rbis,
µNRb14 and Rb15 optionally form a 4-, 5- or 6-membered lactam
together with the nitrogen atom that Rb14 is bonded to and the
carbon atom that Rb15 is bonded to" means that RI' is 2-oxo-
azetidin-l-yl, 2-oxo-pyrrolidin-l-yl, 2-oxo-piperidin-l-y1 or
the like.
[0096]
In addition, in this case, "said lactam is optionally
substituted by 1, 2 or 3 C1-6 alkyls, and/or optionally form a
fused ring with a benzene ring" means that, in addition to the
above-mentioned "lactam", (1) the same or different 1, 2 or 3
01-6 alkyls defined above are present at the substitutable
position(s) of the lactam, (2) one benzene ring is fused at the
fusible position of the lactam, and (3) one benzene ring is
fused at the fusible position of the lactam substituted by 01-6
alkyl(s). Examples of Rb include 3,4-dimethy1-2-oxo-
pyrrolidin-1-yl, 1-oxo-1,3-dihydro-isoindo1-2-yl, 3,3-dimethyl-
2-oxo-2,3-dihydro-indo1-1-y1 and the like.
[0097]
In the compound represented by the formula [I],
preferable embodiments of respective groups are as described
below.
[0098]
32
CA 02936408 2016-06-29
R1 is preferably chloro, methyl, cyano or trifluoromethyl,
more preferably chloro or trifluoromethyl, and further
preferably chloro.
[0099]
R2 is preferably
(1) halogen,
(2) hydroxy,
(3) carboxy,
(5) C1-6 alkoxy,
(6) haloC1_4 alkoxy,
(7) haloC1_4 alkyl,
(8) C1-6 alkyl-carbonyl,
(9) ¨C(0)NRalRa2 (Ral and Ra2 are as defined above) or
(10) -(C.1-12b)-Rb (Rb is as defined above),
/5 more preferably
(10) - (C.1-12.) -Rb (Rb is as defined above) .
Rb is preferably
(g) -NR"C (0) NRb6Rb7 (Rb5, Rb6 and Rb7 are as defined
above),
(h) _NRbeRb5 (Rbe
and Rb9 are as defined above),
(i) _NRbios (0) 2Rbli (Rbio and Rml are as defined above),
(j) _NRbi2C (0) ORb13 (Rb12 and Rm3 are as defined above),
or
( k) _NRbizic (0) Rb15 (Rbi4 and Rb15 are as defined above,
more preferably
( k) _NRbiac (0) Rbis (Rbi4 and RI315 are as defined above).
n is preferably 1 or 2, more preferably 1.
Rbi4 is preferably hydrogen or methyl, more preferably
hydrogen.
Rb15 is preferably
(ii) C1-4 alkyl (said C1-4 alkyl is optionally
substituted by 1 or 2 substituents selected from the group
consisting of hydroxy, trifluoromethyl, C1-4 alkoxy and phenyl)
Or
(iv) C3_7 cycloalkyl (said C3_7 cycloalkyl is optionally
33
CA 02936408 2016-06-29
substituted by 1, 2, 3 or 4 substituents selected from the
group consisting of C1_4 alkyl, halogen, hydroxyC1_4 alkyl and
trifluoromethyl),
more preferably C1-4 alkyl optionally substituted by 1 or 2
s trifluoromethyls and C1-4 alkoxy, or C3-7 cycloalkyl optionally
substituted by one trifluoromethyl, further preferably tert-
butyl, 3,3,3-trifluoro-2,2-dimethylpropyl, 3,3,3-trifluoro-2-
methoxy-2-methylpropyl, 3,3,3-trifluoro-2-methy1-2-
trifluoromethylpropyl, or 1-trifluoromethylcyclopropyl.
/o [0100]
R3 is preferably
(3) C1-6 alkyl or
(4) -OR' {RC is C1-6 alkyl optionally substituted by 1, 2
or 3 substituents selected from the group consisting of the
/5 following (a) to (f);
(a) halogen,
(b) hydroxy,
(c) C1-6 alkoxy,
(d) -C(0)NRclRc2 (Rcl and Rc2 are as defined above),
20 (e) C6-10 aryl (said C6-10 aryl is optionally substituted
by 1, 2 or 3 substituents selected from the group consisting of
(i) halogen,
(ii) hydroxy,
(iii) C1-6 alkyl,
25 (iv) 01-6 alkoxy, and
(v) haloC1-4 alkyl), and
(f) 5- or 6-membered heteroaryl containing 1, 2 or 3
nitrogen atoms, oxygen atoms or sulfur atoms (said heteroaryl
is optionally substituted by 1, 2 or 3 substituents selected
30 from the group consisting of
(i) halogen,
(ii) hydroxy,
(iii) C1_6 alkyl,
(iv) 01-6 alkoxy, and
35 (v) ha1o01..4 alkyl)}.
34
CA 02936408 2016-06-29
12' is preferably methyl optionally substituted by 1 or 2
substituents selected from the following (e) and (f);
(e) C6-10 aryl (said C6_10 aryl is optionally substituted
by 1, 2 or 3 substituents selected from the group consisting of
(i) halogen,
(ii) hydroxy,
(iii) C1-6 alkyl,
(iv) C1-6 alkoxy, and
(v) haloC1_4 alkyl), and
(f) 5- or 6-membered heteroaryl containing 1, 2 or 3
nitrogen atoms, oxygen atoms or sulfur atoms (said heteroaryl
is optionally substituted by 1, 2 or 3 substituents selected
from the group consisting of
(i) halogen,
(ii) hydroxy,
(iii) C1_6 alkyl,
(iv) C1-6 alkoxy, and
(v) haloC1_4 alkyl),
more preferably methyl optionally substituted by 1 or 2
substituents selected from the following (el) and (fl);
(el) phenyl (said phenyl is optionally substituted by 1
or 2 substituents selected from the group consisting of
(i) halogen,
(ii) hydroxy,
(iii) C1_6 alkyl,
(iv) C1-6 alkoxy, and
(v) haloC1_4 alkyl), and
(fl) pyridyl (said pyridyl is optionally substituted by
1 or 2 substituents selected from the group consisting of
(i) halogen,
(ii) hydroxy,
(iii) C1-6 alkyl,
(iv) C1-6 alkoxy, and
(v) haloC1_4 alkyl).
[0101]
CA 02936408 2016-06-29
R4 is preferably hydrogen, fluoro, chloro, or methyl,
more preferably hydrogen.
101021
R5 is preferably
(1) halogen,
(4) 01-6 alkyl (said 01-6 alkyl is optionally substituted
by 1, 2 or 3 substituents selected from the group consisting of
halogen, 06-13 aryl and C1-6 alkoxy),
(5) 03-7 cycloalkyl,
(6) -OR' {Rd is
(a) 02-6 alkynyl,
(b) 03-7 cycloalkyl optionally substituted by 1, 2 or 3
01-6 alkyls or
(c) 01-8 alkyl (said 01-8 alkyl is optionally substituted
/5 by 1, 2 or 3 substituents selected from the group consisting of
the following (i) to (v);
(i) halogen,
(ii) 06-10 aryl,
(Hi) 0I-6 alkOXY,
(iv) 03-7 cycloalkyl (said 03-7 cycloalkyl is optionally
substituted by 1, 2 or 3 substituents selected from the group
consisting of 01-6 alkyl and haloC1_4 alkyl), and
(v) 4-, 5- or 6-membered saturated heterocyclyl
containing one oxygen atom (said saturated heterocyclyl is
optionally substituted by 1, 2 or 3 substituents selected from
the group consisting of 01-6 alkyl and haloC1..4 alkyl))}, or
(7) the formula:
[0103]
[0104]
wherein Re is
(a) 01-6 alkyl,
(b) 03_7 cycloalkyl,
36
CA 02936408 2016-06-29
(c) 5- or 6-membered heteroaryl containing 1, 2 or 3
nitrogen atoms, oxygen atoms or sulfur atoms, or
(d) C6-10 aryl (said 06-10 aryl is optionally substituted
by 1, 2 or 3 substituents selected from the group consisting of
(i) halogen,
(ii) C1-6 alkyl,
(iii) ha1o01_4 alkyl,
(iv) 01-6 alkoxy, and
(v) ha1o01_4 alkoxy).
Rd is preferably Cl..8 alkyl (said 01-8 alkyl is optionally
substituted by 1, 2 or 3 substituents selected from the group
consisting of the following (i) to (v);
(i) halogen,
(ii) 06-10 aryl,
(iii) 01-6 alkoxy,
(iv) 03_7 cycloalkyl (said 03-7 cycloalkyl is optionally
substituted by 1, 2 or 3 substituents selected from the group
consisting of C1-6 alkyl and haloC1_4 alkyl), and
(v) 4-, 5- or 6-membered saturated heterocyclyl
containing one oxygen atom (said saturated heterocyclyl is
optionally substituted by 1, 2 or 3 substituents selected from
the group consisting of C1-6 alkyl and haloCI..4 alkyl)).
Re is preferably
(b) 03-7 cycloalkyl,
(c) 5- or 6-membered heteroaryl containing 1, 2 or 3
nitrogen atoms, oxygen atoms or sulfur atoms, or
(d) 06-10 aryl (said 06-10 aryl is optionally substituted
by 1, 2 or 3 substituents selected from the group consisting of
(i) halogen,
(ii) C1-6 alkyl,
(iii) haloCi_i alkyl,
(iv) C1-6 alkoxy, and
(v) ha1o01-4 alkoxy)=
[0105]
ml is preferably 0, 1 or 2, more preferably 1 or 2.
37
CA 02936408 2016-06-29
[0106]
In the compound represented by the formula [I], one of
preferable embodiments is a compound represented by the
following formula [I-A]:
[0107]
R 5 ) H R1 R4 H
X 1V,
R2
N
011 H
[I-A]
[0108]
wherein
a carbon atom with a hydrogen atom is not substituted by R4 and
/0 R5,
X, Rl, R2 and R4 are as defined in the aforementioned formula
[I],
R5 is
(1) halogen,
(4) C1-6 alkyl (said C1-6 alkyl is optionally substituted
by 1, 2 or 3 substituents selected from the group consisting of
halogen, C6-10 aryl and C1-6 alkoxy),
(5) C3_7 cycloalkyl, or
(6) _oRd {Rd is
(a) C2-6 alkynyl or
(c) C1-8 alkyl (said C1-6 alkyl is optionally substituted
by 1, 2 or 3 substituents selected from the group consisting of
the following (i) to (v);
(i) halogen,
(ii) C6_10 aryl,
(iii) 01_6 alkoxy,
(iv) 03-7 cycloalkyl (said 03-7 cycloalkyl is optionally
38
CA 02936408 2016-06-29
substituted by 1, 2 or 3 substituents selected from the group
consisting of 01-6 alkyl and ha1o01-1 alkyl), and
(v) 4-, 5- or 6-membered saturated heterocyclyl
containing 1, 2 or 3 nitrogen atoms, oxygen atoms or sulfur
atoms (said saturated heterocyclyl is optionally substituted by
1, 2 or 3 substituents selected from the group consisting of
01-6 alkyl and haloC1-4 alkyl))}, and
m7 is 0, 1 or 2 and, when m7 is 2, each R5 is selected
independently.
lo [01091
In a compound represented by the formula [I], one of the
preferable other embodiments is a compound represented by the
following formula [I-B]:
[0110]
(R5)m7 R1 R4 H
3
H
D-13]
[0111]
wherein
a carbon atom with a hydrogen atom is not substituted by R4 and
R5,
X, R3 and R4 are as defined in the aforementioned formula [I],
Rl is chloro or trifiuoromethyl,
R5 is
(4) C1_6 alkyl (said Ci_6 alkyl is optionally substituted
by 1, 2 or 3 substituents selected from the group consisting of
halogen, 06-10 aryl and 01-6 alkOXY),
(6) -ORd {Rd is
39
CA 02936408 2016-06-29
C1-8 alkyl (said C1-8 alkyl is optionally substituted by 1, 2 or
3 substituents selected from the group consisting of the
following (i) to (iv);
(i) halogen,
(ii) 06-10 aryl,
(iii) 01-6 alkoxy, and
(iv) 03_7 cycloalkyl (said 03_7 cycloalkyl is optionally
substituted by 1, 2 or 3 substituents selected from the group
consisting of 01-6 alkyl and ha1o01-4 alkyl))}, or
(7) the formula:
[0112]
________ Re
[0113]
wherein Re is
(b) 03-7 cycloalkyl, or
(d) 06-10 aryl (said 06-10 aryl is optionally substituted
by 1, 2 or 3 substituents selected from the group consisting of
(i) halogen,
(ii) 01-6 alkyl,
(iii) haloC1-4 alkyl,
(iv) 01-6 alkoxy, and
(v) ha1oC1-4 alkoxy), and
m7 is 0, 1 or 2 and, when m7 is 2, each R5 is selected
independently.
[0114]
In a compound represented by the formula [I], one of the
preferable other embodiments is a compound represented by the
following formula [I-C]:
[0115]
CA 02936408 2016-06-29
(R5b)m8
R5a CI
X N
N N HNO
*I 5
H
[I-Cl
[0116]
wherein
X is CH or N,
Rb15 s
(11) C1_4 alkyl (said C1_4 alkyl is optionally
substituted by 1 or 2 substituents selected from
trifluoromethyl and methoxy) or
(iv) 02-7 cycloalkyl optionally substituted by
/o trifluoromethyl,
5a
R is
(1) fluoro,
(4) methyl (said methyl is optionally substituted by 3
fluoros), or
(6) -ORd {Rd is
(a) C2-4 alkynyl or
(c) C1-4 alkyl optionally substituted by one 03-7
cycloalkyl (said 02-7 cycloalkyl is optionally substituted by
trifluoromethyl) 1,
R5b iS
(1) halogen,
(4) Ci_4 alkyl, or
(5) cyclopropyl, and
m8 is 0 or 1.
[0117]
41
CA 02936408 2016-06-29
A pharmaceutically acceptable salt of a compound
represented by the formula [I] (hereinafter to be also referred
to as the compound of the present invention) may be any salt as
long as it forms a nontoxic salt with the compound of the
present invention, and examples thereof include salts with
inorganic acid, salts with organic acid, salts with inorganic
base, salts with organic base, salts with amino acid and the
like.
Various forms of pharmaceutically acceptable salts are
/o well known in this field and, for example, they are described
in the following documents.
(a) Berge et al., J. Pharm. Sc., 66, p 1-19 (1977),
(b) Stahl et al., "Handbook of Pharmaceutical Salt: Properties,
Selection, and Use" (Wiley-VCH, Weinheim, Germany, 2002),
(c) Paulekuhn et al., J. Med. Chem., 50, p 6665-6672 (2007)
Examples of the salts with inorganic acid include salts
with hydrochloric acid, nitric acid, sulfuric acid, phosphoric
acid, hydrobromic acid and the like.
Examples of the salts with organic acid include salts
with oxalic acid, maleic acid, citric acid, fumaric acid,
lactic acid, malic acid, succinic acid, tartaric acid, acetic
acid, trifluoroacetic acid, gluconic acid, ascorbic acid,
methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic
acid and the like.
Examples of the salts with organic acid include salts
with adipic acid, alginic acid, 4-aminosalicylic acid,
anhydromethylenecitric acid, benzoic acid, calcium edetate,
camphoric acid, camphor-10-sulfonic acid, carbonic acid, edetic
acid, ethane-1,2-disulfonic acid, dodecylsulfuric acid,
ethanesulfonic acid, glucoheptonic acid, glucuronic acid,
glucoheptonic acid, glycollyarsanilic acid, hexylresorcinic
acid, hydrofluoric acid, hydroiodic acid, hydroxy-naphtoic acid,
2-hydroxy-1-ethanesulfonic acid, lactobionic acid, mandelic
acid, methylsulfuric acid, methylnitric acid,
methylenebis(salicylic acid), galactaric acid, naphthalene-2-
42
CA 02936408 2016-06-29
sulfonic acid, 2-naphtoic acid, 1,5-naphthalenedisultonic acid,
oleic acid, pamoic acid, pantothenic acid, pectin acid, picric
acid, propionic acid, polygalacturonic acid, salicylic acid,
stearic acid, tannic acid, teoclic acid, thiocyanic acid,
undecanoic acid and the like.
Examples of the salts with inorganic base include sodium
salt, potassium salt, calcium salt, magnesium salt, ammonium
salt and the like.
Furthermore, examples of the salts with inorganic base
/o include salts with aluminum, barium, bismuth, lithium, or zinc.
Examples of the salts with organic base include salts
with methylamine, diethylamine, trimethylamine, triethylamine,
ethanolamine, diethanolamine, triethanolamine, ethylenediamine,
tris(hydroxymethyl)methylamine, dicyclohexylamine, N,N'-
/5 dibenzylethylenediamine, guanidine, pyridine, picoline, choline,
cinchonine, meglumine and the like.
Furthermore, examples of the salts with organic base
include salts with arecoline, betaine, clemizole, N-
methylglucamine, N-benzylphenethylamine or
20 tris(hydroxymethyl)methylamine.
Examples of the salts with amino acid include salts with
lysine, arginine, aspartic acid, glutamic acid and the like.
Among the above-mentioned salts, preferred are salts with
hydrochloric acid, sulfuric acid or p-toluenesulfonic acid.
25 Various salts can be obtained by reacting a compound
represented by the formula [I] with inorganic base, organic
base, inorganic acid, organic acid or amino acid according to a
known method.
[0118]
30 A compound represented by the formula [I] or a
pharmaceutically acceptable salt thereof may be present as a
solvate. The "solvate" is a compound represented by the
formula [I] or a pharmaceutically acceptable salt thereof,
which is coordinated with a solvent molecule, and also
35 encompasses hydrates. The solvate is preferably a
43
CA 02936408 2016-06-29
pharmaceutically acceptable solvate, examples thereof include a
hydrate, ethanolate, dimethyl sulfoxidate and the like of a
compound represented by the formula [I] or a pharmaceutically
acceptable salt thereof. Specific examples include semihydrate,
monohydrate, dihydrate or monoethanolate of a compound
represented by the formula [I], monohydrate of sodium salt or
2/3 ethanolate of dihydrochloride of a compound represented by
the formula [I], and the like.
The solvates can be obtained by a known method.
/o [0119]
In addition, a compound represented by the formula [I]
may be labeled with isotope (e.g., 2H, 3H, 14-, 35S etc.).
[0120]
The compound of the present invention may exist as a
/5 tautomer. In this case, the compound of the present invention
can be a single tautomer or a mixture of individual tautomers.
For example, a compound represented by the formula [I] may
contain a tautomer shown below
[0121]
(R\5)m1
rN(
NN
20 0
[0122]
Such tautomer is also encompassed in the compound represented
by the formula [I].
The compound of the present invention may have a carbon
25 double bond. In this case, the compound of the present
invention can be present as E form, Z form, or a mixture of E
form and Z form.
The compound of the present invention may contain a
stereoisomer that should be recognized as a cis/trans isomer.
44
CA 02936408 2016-06-29
In this case, the compound of the present invention can be
present as a cis form, a trans form, or mixture of a cis form
and a trans form.
The compound of the present invention may contain one or
more asymmetric carbons. In this case, the compound of the
present invention may be present as a single enantiomer, a
single diastereomer, a mixture of enantiomers or a mixture of
diastereomers.
The compound of the present invention may be present as
/0 an atropisomer. In this case, the compound of the present
invention may be present as an individual atropisomer or a
mixture of atropisomers.
The compound of the present invention may simultaneously
contain plural structural characteristics that produce the
/5 above-mentioned isomers. Moreover, the compound of the present
invention may contain the above-mentioned isomers at any ratio.
[0123]
In the absence of other reference such as annotation and
the like, the formulae, chemical structures and compound names
20 indicated in the present specification without specifying the
stereochemistry thereof encompass all the above-mentioned
isomers that may exist.
[0124]
A diastereomeric mixture can be separated into each
25 diastereomer by conventional methods such as chromatography,
crystallization and the like. In addition, each diastereomer
can also be formed by using a stereochemically single starting
material, or by a synthesis method using a stereoselective
reaction.
30 [0125]
An enantiomeric mixture can be separated into each single
enantiomer by a method well known in the pertinent field.
For example, enantiomeric mixture can be prepared by
reacting the enantiomeric mixture with a substantially pure
35 enantiomer that is known as a chiral auxiliary. The
CA 02936408 2016-06-29
diastereomeric mixture can be separated into each diastereomer
mentioned above. The diastereomer mixture can be separated
into each diastereomer as mentioned above. The separated
diastereomer can be converted to a desired enantiomer by
removing the added chiral auxiliary by cleavage.
In addition, a mixture of enantiomers of a compound can
also be directly separated by a chromatography method using a
chiral solid phase well known in the pertinent field.
Alternatively, one of the enantiomers of a compound can
/0 also be obtained by using a substantially pure optically active
starting material or stereoselective synthesis (asymmetric
induction) of a prochiral intermediate using a chiral auxiliary
and an asymmetric catalyst.
[0126]
The absolute steric configuration can be determined based
on the X-ray crystal analysis of the resultant crystalline
product or intermediate. In this case, a resultant crystalline
product or intermediate derivatized with a reagent having an
asymmetric center with a known steric configuration may be used
where necessary.
[0127]
As a compound represented by the formula [I] or a
pharmaceutically acceptable salt thereof, a substantially
purified compound represented by the formula [I] or a
pharmaceutically acceptable salt thereof is preferable. More
preferred is a compound represented by the formula [I] or a
pharmaceutically acceptable salt thereof or a solvate thereof,
which is purified to have a purity of more than 80%.
[0128]
Examples of the "pharmaceutical composition" include oral
preparations such as tablet, capsule, granule, powder, troche,
syrup, emulsion, suspension and the like, and parenteral agents
such as external preparation, suppository, injection, eye drop,
nasal preparations, pulmonary preparation and the like.
46
CA 02936408 2016-06-29
[0129]
The pharmaceutical composition of the present invention is
produced according to a method known per se in the art of
pharmaceutical preparations, by mixing etc. a compound
represented by the formula [I] or a pharmaceutically acceptable
salt thereof, or a solvate thereof with a suitable amount of at
least one kind of phaimaceutically acceptable carrier and the
like as appropriate. While the content of the compound
represented by the formula [I] or a pharmaceutically acceptable
lo salt thereof, or a solvate thereof in the pharmaceutical
composition varies depending on the dosage form, dose and the
like, it is, for example, 0.00001 to 100 wt% of the whole
composition.
[0130]
Examples of the "pharmaceutically acceptable carrier"
include various organic or inorganic carrier substances
conventionally used as preparation materials, for example,
excipient, disintegrant, binder, glidant, lubricant and the like
for solid preparations, and solvent, solubilizing agent,
suspending agent, isotonicity agent, buffering agent, soothing
agent, surfactant, pH adjuster, thickening agent and the like
for liquid preparations. Where necessary, moreover, additives
such as preservative, antioxidant, colorant, sweetening agent
and the like are used.
[0131]
Examples of the "excipient" include lactose, sucrose, D-
mannitol, D-sorbitol, cornstarch, dextrin, microcrystalline
cellulose, crystalline cellulose, carmellose, carmellose
calcium, sodium carboxymethyl starch, low-substituted
hydroxypropylcellulose, gum arabic and the like.
[0132]
Examples of the "disintegrant" include carmellose,
carmellose calcium, carmellose sodium, sodium carboxymethyl
starch, croscarmellose sodium, crospovidone, low-substituted
47
CA 02936408 2016-06-29
hydroxypropylcellulose, hydroxypropylmethylcellulose,
crystalline cellulose and the like.
[0133]
Examples of the "binder" include hydroxypropylcellulose,
hydroxypropylmethylcellulose, povidone, crystalline cellulose,
sucrose, dextrin, starch, gelatin, carmellose sodium, gum arabic
and the like.
[0134]
Examples of the "glidant" include light anhydrous silicic
/o acid, magnesium stearate and the like.
[0135]
Examples of the "lubricant" include magnesium stearate,
calcium stearate, talc and the like.
[0136]
Examples of the "solvent" include purified water, ethanol,
propylene glycol, macrogol, sesame oil, corn oil, olive oil and
the like.
[0137]
Examples of the "solubilizing agent" include propylene
glycol, D-mannitol, benzyl benzoate, ethanol, triethanolamine,
sodium carbonate, sodium citrate and the like.
[0138]
Examples of the "suspending agent" include benzalkonium
chloride, carmellose, hydroxypropylcellulose, propylene glycol,
povidone, methylcellulose, glycerol monostearate and the like.
[0139]
Examples of the "isotonicity agent" include glucose, D-
sorbitol, sodium chloride, D-mannitol and the like.
[0140]
Examples of the "buffering agent" include sodium
hydrogenphosphate, sodium acetate, sodium carbonate, sodium
citrate and the like.
[0141]
Examples of the "soothing agent" include benzyl alcohol
and the like.
48
CA 02936408 2016-06-29
[0142]
Examples of the "surfactant" include polyoxyethylene
hydrogenated castor oil, polyethylene glycol monostearate,
polyoxyethylene sorbitan fatty acid ester,
alkyldiaminoethylglycine, alkylbenzenesulfonate, benzethonium
chloride and the like.
[0143]
Examples of the "pH adjuster" include hydrochloric acid,
sulfuric acid, phosphoric acid, citric acid, acetic acid,
/o sodium hydrogen carbonate, sodium carbonate, potassium
hydroxide, sodium hydroxide, monoethanolamine, triethanolamine
and the like.
[0144]
Examples of the "thickening agent" include polyvinyl
/5 alcohol, carboxyvinyl polymer, methylcellulose,
hydroxyethylcellulose, polyethylene glycol, dextran and the
like.
[0145]
Examples of the "preservative" include ethyl
20 parahydroxybenzoate, chlorobutanol, benzyl alcohol, sodium
dehydroacetate, sorbic acid and the like.
[0146]
Examples of the "antioxidant" include sodium sulfite,
ascorbic acid and the like.
25 [0147]
Examples of the "colorant" include food colors (e.g., Food
Color Red No. 2 or 3, Food Color Yellow No. 4 or 5 etc.), p-
carotene and the like.
[0148]
30 Examples of the "sweetening agent" include saccharin
sodium, dipotassium glycyrrhizinate, aspartame and the like.
[0149]
The pharmaceutical composition of the present invention
can be administered orally or parenterally (e.g., topical,
35 rectal, intravenous administration etc.) to human as well as
49
CA 02936408 2016-06-29
mammals other than human (e.g., hamster, guinea pig, cat, dog,
swine, bovine, horse, sheep, monkey etc.). The dose varies
depending on the subject of administration, disease, symptom,
dosage form, administration route and the like. For example, the
daily dose for oral administration to an adult patient (body
weight: about 60 kg) is generally within the range of about 0.1
g to 10 g, based on the compound of the present invention as
the active ingredient. This amount can be administered in one to
several portions.
/o [0150]
The above-mentioned compound represented by the formula
[I] or a pharmaceutically acceptable salt thereof, or a solvate
thereof can be used in combination with one or a plurality of
other medicaments (hereinafter to be also referred to as a
/5 concomitant drug) according to a method generally employed in
the medical field (hereinafter to be referred to as combined
use).
[0151]
The administration period of the above-mentioned compound
20 represented by the formula [I] or a pharmaceutically acceptable
salt thereof, and a concomitant drug is not limited, and they
may be administered to an administration subject as combination
preparation, or the both preparations may be administered
simultaneously or at given intervals as individual preparations.
25 In addition, the pharmaceutical composition of the present
invention and a concomitant drug may be used in the form of a
kit. The dose of the concomitant drug is similar to the
clinically-employed dose and can be appropriately selected
according to the subject of administration, disease, symptom,
30 dosage form, administration route, administration time,
combination and the like. The administration form of the
concomitant drug is not particularly limited, and it is only
required that the compound represented by the formula [I] or a
pharmaceutically acceptable salt thereof, or a solvate thereof
35 is combined with a concomitant drug.
CA 02936408 2016-06-29
[0152]
Examples of the concomitant drug include therapeutic
agents for glaucoma such as prostaglandin preparation, p
blocker, a receptor agonist, sympathetic nerve stimulation
agent, a blocker, carbonic anhydrase inhibitor,
anticholinesterase agent, Rho kinase inhibitor and the like.
[0153]
Examples of the prostaglandin preparation include
isopropyl unoprostone, latanoprost, travoprost, tafluprost,
lo bimatoprost and the like.
Examples of the p blocker include timolol maleate,
Befunolol hydrochloride, carteolol hydrochloride, betaxolol
hydrochloride, nipradilol, levobunolol hydrochloride and the
like.
[0154]
Examples of the a receptor agonist include brimonidine
tartrate and the like.
[0155]
Examples of the sympathetic nerve stimulation agent
include dipivefrin hydrochloride, pilocarpine hydrochloride and
the like.
[0156]
Examples of the a blocker include bunazosin hydrochloride
and the like.
[0157]
Examples of the carbonic anhydrase inhibitor include
dorzolamide hydrochloride, brinzolamide and the like.
[0158]
Examples of the anticholinesterase agent include
distigmine bromide and the like.
[0159]
Examples of the Rho kinase inhibitor include ripasudil
hydrochloride hydrate and the like.
[0160]
An example of the specific combination of medicaments is
51
CA 02936408 2016-06-29
a combination of one medicament selected from latanoprost,
travoprost, tafluprost, timolol maleate, dorzolamide
hydrochloride and brinzolamide, and the above-mentioned
compound represented by the formula [I] or a pharmaceutically
acceptable salt thereof, or a solvate thereof.
[0161]
Next, one example of the production methods of the
compound to practice the present invention is explained below.
However, the production method of the compound of the present
_to invention or a pharmaceutically acceptable salt thereof is not
limited thereto.
Even when no directly corresponding disclosure is found in
the following Production Methods, the steps may be modified for
efficient production of the compound, such as introduction of a
protecting group into a functional group with deprotection in a
subsequent step, changing the order of Production Methods and
steps, appropriate use of reagents other than the exemplified
reagents to promote progress of the reactions, and the like.
The treatment after reaction in each step may be
conventional ones, where isolation and purification can be
performed as necessary according to a method appropriately
selected from conventional methods such as crystallization,
recrystallization, distillation, partitioning, silica gel
chromatography, preparative HPLC and the like, or a combination
of those methods. In some cases, the next step may be conducted
without isolation and purification.
An intermediate capable of forming a salt may also be
obtained as a salt, or used as a salt for reactions. Examples
of such salt include hydrochloride of an intermediate having an
amino group.
[0162]
[Production Method 1-1]
[0163]
52
CA 02936408 2016-06-29
( R5 ) 1
Hall (1R5).
Hall
Hall
[2]
N
IL6 Step 1-1-1
Suzuki coupling
[1] [3]
(R5)
ZoXI
[4]
N
Step 1-1-2
Suzuki coupling
11R6
[5]
(1=0)
X
Step 1-1-3
N
hydrolysis
[0164]
wherein Hall is chloro or bromo;
6 =
R is C1-6 alkyl such as methyl, ethyl and the like or benzyl;
Z is a boron substituent used for the Suzuki coupling reaction
such as -B(OH)2, -B(0R7)2 (wherein R7 is C1-4 alkyl or one R7 may
be bonded to the other R7 to form a ring), -BF3, the formula
[0165]
0 __
________________ OH3
. \fp
[01661
and the like; and
53
CA 02936408 2016-06-29
X, Cy, R5 and ml are as defined in the aforementioned formula
[I].
[0167]
(Step 1-1-1)
Compound [3] can be obtained by the Suzuki coupling
reaction of compound [1] and compound [2]. For example,
compound [3] can be obtained by reacting compound [1] with
compound [2] under heating in a solvent in the presence of a
base and a palladium catalyst. Where necessary, a ligand may
/o be added. Not less than 1.5 equivalents of compound [1] are
preferably used relative to compound [2] to prevent the Suzuki
coupling reaction from progressing twice.
Examples of the palladium catalyst to be used for the
reaction include palladium acetate,
/5 tetrakistriphenylphosphinepalladium,
bis(triphenylphosphine)palladium dichloride,
(bis(diphenylphosphino)ferrocene)palladium dichloride-methylene
chloride complex and the like.
Examples of the base to be used for the reaction include
20 inorganic bases such as alkali metal salts (e.g., potassium
phosphate, sodium carbonate, sodium hydrogen carbonate,
potassium carbonate, potassium acetate, sodium acetate, cesium
fluoride etc.) and the like, and organic bases such as
triethylamine and the like.
25 Examples of the ligand to be used for the reaction
include organic phosphine ligands (e.g., triphenylphosphine,
tricyclohexylphosphine, 2,2'-bis(diphenylphosphino)-1,1'-
binaphthalene, 2-dicyclohexylphosphino-2',6'-dimethoxybiphenyl
etc.) and the like.
30 Examples of the solvent to be used for the reaction
include ether solvents such as 1,4-dioxane, tetrahydrofuran,
diethyl ether, 1,2-dimethoxyethane, cyclopentyl methyl ether
and the like; alcohol solvents such as methanol, ethanol, 1-
propanol, 2-propanol and the like; hydrocarbon solvents such as
35 toluene, xylene, hexane and the like; polar solvents such as
54
CA 02936408 2016-06-29
N,N-dimethylformamide, N,N-dimethylacetamide, dimethyl
sulfoxide, acetonitrile and the like; a mixed solvent thereof,
and a mixed solvent thereof with water.
Compound [1] may be a commercially available product such
as 2,4-dichloro-6-methoxy-1,3,5-triazine, or may be obtained by
converting a commercially available product as appropriate by a
method well known to those of ordinary skill in the art.
As for the Suzuki coupling reaction, for example, the
following review article is known (SUZUKI, A et al. Palladium-
/0 Catalyzed Cross-Coupling Reactions of Organoboron Compounds.
Chem Rev. 1995, Vol.95, pages 2457-2483).
[0168]
(Step 1-1-2)
Compound [5] can be obtained by the Suzuki coupling
/5 reaction of compound [3] and compound [4]. For example,
compound [5] can be obtained by reacting compound [3] with
compound [4] under heating in a solvent in the presence of a
base and a palladium catalyst. Where necessary, a ligand may
be added.
20 Examples of the palladium catalyst to be used for the
reaction include palladium acetate,
tetrakistriphenylphosphinepalladium,
bis(triphenylphosphine)palladium dichloride,
(bis(diphenylphosphino)ferrocene)palladium dichloride-methylene
25 chloride complex and the like.
Examples of the base to be used for the reaction include
inorganic bases such as alkali metal salts (e.g., potassium
phosphate, sodium carbonate, sodium hydrogen carbonate,
potassium carbonate, potassium acetate, sodium acetate, cesium
30 fluoride etc.) and the like, and organic bases such as
triethylamine and the like.
Examples of the ligand to be used for the reaction
include organic phosphine ligands such as triphenylphosphine,
tricyclohexylphosphine, 2,2'-bis(diphenylphosphino)-1,1'-
35 binaphthalene, 2-dicyclohexylphosphino-2',6'-dimethoxybiphenyl
CA 02936408 2016-06-29
and the like, and the like.
Examples of the solvent to be used for the reaction
include ether solvents such as 1,4-dioxane, tetrahydrofuran,
diethyl ether, 1,2-dimethoxyethane, cyclopentyl methyl ether
and the like; alcohol solvents such as methanol, ethanol, 1-
propanol, 2-propanol and the like; hydrocarbon solvents such as
toluene, xylene, hexane and the like; polar solvents such as
N,N-dimethylformamide, N,N-dimethylacetamide, dimethyl
sulfoxide, acetonitrile and the like; a mixed solvent thereof,
/o and a mixed solvent thereof with water.
[0169]
(Step 1-1-3)
Compound [I] can be obtained by converting the alkoxy of
compound [5] to hydroxy by hydrolysis. For example, when R6 is
/5 C1-6 alkyl, compound [I] can be obtained by reacting compound
[5] in a solvent in the presence of a base at room temperature
to under heating, and neutralizing the obtained solution.
Examples of the base to be used for the reaction include
lithium hydroxide, sodium hydroxide, potassium hydroxide,
20 sodium methoxide and the like.
Examples of the solvent to be used for the reaction
include a mixed solvent of water and alcohol solvents such as
methanol, ethanol, 1-propanol, 2-propanol and the like; and a
mixed solvent thereof with ether solvents such as 1,4-dioxane,
25 tetrahydrofuran, diethyl ether, 1,2-dimethoxyethane,
cyclopentyl methyl ether and the like.
[0170]
[Production Method 1-2]
Compound [2] can be obtained by, for example, Production
30 Method 1-2.
[0171]
[Production Method 1-2]
[0172]
56
CA 02936408 2016-06-29
(R5)m1 (R5)m1
Step 1-2
[6] [2]
[0173]
wherein L1 is a leaving group such as bromo, iodo,
trifluoromethanesulfonyloxy and the like, X, R5 and ml are as
defined in the aforementioned formula [I], and Z is as defined
in the aforementioned Production Method 1-1.
[0174]
(Step 1-2)
Compound [2] can be obtained by borating compound [6].
For example, compound [2] can be obtained by reacting compound
[6] with a boron reagent under heating in the presence of a
base and a palladium catalyst. Where necessary, a ligand may
be added
Examples of the boron reagent to be used for the reaction
/5 include 4,4,4',4',5,5,5',5'-octamethy1-2,2'-bi-1,3,2-
dioxaborolane, 5,5,5',5'-tetramethy1-2,2'-bi-1,3,2-
dioxaborinane, tetrahydroxydiboron, 4,4,5,5-tetramethy1-1,3,2-
dioxaborolane and the like.
Examples of the palladium catalyst to be used for the
reaction include palladium acetate,
tetrakistriphenylphosphinepalladium,
bis(triphenylphosphine)palladium dichloride,
(bis(diphenylphosphino)ferrocene)palladium dichloride-methylene
chloride complex and the like.
Examples of the base to be used for the reaction include
inorganic bases such as alkali metal salts (e.g., potassium
phosphate, sodium carbonate, sodium hydrogen carbonate,
potassium carbonate, potassium acetate, sodium acetate, cesium
fluoride etc.) and the like, and organic bases such as
triethylamine and the like.
57
CA 02936408 2016-06-29
Examples of the ligand to be used for the reaction
include organic phosphorus ligands (e.g., triphenylphosphine,
tricyclohexylphosphine, 2,2'-bis(diphenylphosphino)-1,1'-
binaphthalene, 2-dicyclohexylphosphino-2',6'-dimethoxybiphenyl
etc.) and the like.
Examples of the solvent to be used for the reaction
include ether solvents such as 1,4-dioxane, tetrahydrofuran,
diethyl ether, 1,2-dimethoxyethane, cyclopentyl methyl ether
and the like; alcohol solvents such as methanol, ethanol, 1-
propanol, 2-propanol and the like; hydrocarbon solvents such as
toluene, xylene, hexane and the like; polar solvents such as
N,N-dimethylformamide, N,N-dimethylacetamide, dimethyl
sulfoxide, acetonitrile and the like; a mixed solvent thereof,
and a mixed solvent thereof with water.
Compound [2] can also be obtained by adding an organic
metal reagent to compound [6] in a solvent at -78 C to room
temperature, and reacting the product with a boron compound at
-78 C to room temperature.
Examples of the organic metal reagent to be used for the
reaction include n-butyllithium, tert-butyllithium,
isopropylmagnesium chloride and the like.
Examples of the boron reagent to be used for the reaction
include trimethyl borate, triisopropyl borate, 2-isopropoxy-
4,4,5,5-tetramethy1-1,3,2-dioxaborolane and the like.
Examples of the solvent to be used for the reaction
include ether solvents such as 1,4-dioxane, tetrahydrofuran,
diethyl ether, 1,2-dimethoxyethane, cyclopentyl methyl ether
and the like; hydrocarbon solvents such as toluene, xylene,
hexane and the like, and a mixed solvent thereof.
In one embodiment, compound [6] may be a commercially
available product such as those shown below, or may be obtained
by converting a commercially available product as appropriate
by a method well known to those of ordinary skill in the art.
[0175]
58
CA 02936408 2016-06-29
CI
F3C CI F3C F3C
161 Nyk
111 111.1%.".
Br Br Br
Br Br
[0176]
In one embodiment, compound [2] may be a commercially
available product such as those shown below, or may be obtained
by converting a commercially available product as appropriate
by a method well known to those of ordinary skill in the art.
[0177]
59
CA 02936408 2016-06-29
F,C
0
0 F,C'0 0
F
0 *
Z Z Z Z Z
CI y-,,,,, 0 0 0
0 Z Z /"'"' \ / 0
0 Z F,C,,,,0
0 Z ,=" 0
Z
F
F
0
* 2 Z
F,C = Z I Z ...,o 0
Z Z
Z 0 Z F $ Z 0 Z
F,C 0 Z
S V
0 0Z
Z * Z
0 Z
0 z
F a CI
F . Z CI Z = Z 0 Z
0 Z 0 S Z
F 0
F C F,C F,C F ''`=-=
1111 Z CI = Z 3 0
Z 0 * 0 Z
Z Z
CI
0 0 * Z
0 0 * Z y--- 0 0 Z F3C,
0 0 Z
õT,0
* z 0 z * z ,- $ z * z
SO
,,,, 41 0 0
NI ,,,, z 0 0
Ni ,--
Z Z Z
HO S
0 0
0 Z 0 z 0'-e-() 0
Z '\../'''\/ 0
Z
CI 0 ,.,0
/ \ _ /
_ \ Z ,, j , 0
0 Z HO Z 0 0Z Z
F
CI or
* 0
N...,.. N ,..- Z
Z Z Z
[ 0 17 8 ]
CA 02936408 2016-06-29
wherein Z is as defined in the aforementioned Production Method
1-1.
[0179]
[Production Method 1-3]
Compound [4] can be obtained by, for example, Production
Method 1-3.
[0180]
[Production Method 1-3]
[0181]
RI R4
RI R4
Step 1-3
R Z R2
[7a] [8a]
RI
Step 1-3 R4
R4 ______________________ xo-
Li
3 3
{7b] [813]
[0182]
wherein R1, R2, R3 and R4 are as defined in the aforementioned
formula [I], L1 is as defined in the aforementioned Production
Method 1-2, and Z is as defined in the aforementioned
/5 Production Method 1-1.
[0183]
(Step 1-3)
Compound [4] is compound [8a] or [8b]. Compound [8a] or
[8b], i.e., compound [4], can be obtained by borating compound
[7a] or [7b] in the same manner as in Production Method 1-2,
Step 1-2.
Compounds [7a] and [7h] may be commercially available
products such as 2-bromo-4-methylbenzonitrile and 2-bromo-3-
methylphenol, or may be obtained by converting a commercially
available product as appropriate by a method well known to
those of ordinary skill in the art.
61
CA 02936408 2016-06-29
[0184]
In one embodiment, compound [4] may be a commercially
available product such as those shown below, or may be obtained
by converting a commercially available product as appropriate
by a method well known to those of ordinary skill in the art.
[0185]
CI
Z F Z CI Z (11101 Z 11101 ' CF3
0
CI
CI CI
Z CF3 1110 OH Z
Z 0 Z OH
CI CI
Z Z z (16 OH F3:5 OH
01-1
OMe
CI CI CI CI
1110 0 0 0 0
Z
NH2
[0186]
wherein Z is as defined in the aforementioned Production Method
lo 1-1.
[0187]
[Production Method 2-1] or [Production Method 2-3]
For example, compound [I-al] which is a compound
represented by the formula [I] wherein ring Cy is the formula
[0188]
R1
R4
(CnH2n)
HN 0
T15
62
CA 02936408 2016-06-29
[0189]
wherein RI, R4, Rip's and n are as defined in the aforementioned
formula [I], can be obtained by appropriately converting the
substituent of ring Cy.
When C,-,H2n is a straight chain, Production Method 2-1 is
preferable, and when CõH2õ is a branched chain, Production
Method 2-3 is preferable.
[0190]
[Production Method 2-1]
lo -- [0191]
63
CA 02936408 2016-06-29
R4 R4 R4
RI R1 R1
Step 2-1-1 Step 2-1-2
hydrolysis reduction
___________________ s __________________ a
Hal2 (C,F1õ) Hal2 (ctitd Hal2 (CtHõ)
0-:>.....'"001_6Alkyl 0 OH (--..OH
[9] [10] [11]
R4
R'
Step 2-1-3 Step 2-1-4 RI R4 Step 2-1-5
protection boration Suzuki coupling
_... ________________________ k. ____________________ pi-
Hal2 (c,H2)
z (cAd
D4 .......
OP' [13]
Step 2-1-7
RI R4 R4
Step 2-1-6 RI introduction of
deprotection leaving group
-as. -------10.
Y (Ct.H2t)
Y (OtH2t)
[14] L=opv Li-...OH
[15]
R4 R4
RI Step 2-1-8 R1 Step 2-1-9
amination
deprotection
___,...
HNPi" ___....
Y (CtH2d Y (CtH2t)
-
L.L2 IL' , I"
"--
Ds] N
D7] [18]
ft-
R4
Ri
R4
Ri Step 2-1-10
.
amidation
Y (Ctl-12)
Y (Ctilla) OH
L.NH
[19] I..õ....N H2
[21]
[20] ORb15
(R5)
RI
õ...\"..,
R4
xI R4 Step 2-1-11
X,......õ,........,,,N,,..._
deprotection
..,.......õ.....5.,.........õ...,N,, ()
(0õ1-12) ________________________ si
I
I
I
HN,......,
N......i.......õ.... OH N H N.........0 v
kiu5
46 [22] Ilt1315 [I-al]
[0192]
wherein Y is the formula
[0193]
64
CA 02936408 2016-06-29
(R5)1
066
[0194]
wherein R5, R6 and ml are as defined in the aforementioned
formula [I];
C1-6 Alkyl is C1-6 alkyl;
t is 0, 1, 2 or 3, -(CtH2t)- may be a straight or branched
chain;
Hal2 is bromo or iodo;
Pv is a hydroxy-protecting group such as methoxymethyl and the
lo like;
Pw is an amino-protecting group such as tert-butoxycarbonyl and
the like;
L2 is a leaving group such as halogen (e.g., chloro, bromo and
the like), methanesulfonyloxy, p-toluenesulfonyloxy and the
like;
R1, R4, R6, Rb15 and n are as defined in the aforementioned
formula [I], and Z is as defined in the aforementioned
Production Method 1-1.
[0195]
(Step 2-1-1)
Compound [10] can be obtained by converting the ester of
compound [9] to carboxy by hydrolysis. For example, compound
[10] can be obtained by reacting compound [9] in a solvent in
the presence of a base at room temperature to under heating,
and neutralizing the obtained solution.
Examples of the base to be used for the reaction include
lithium hydroxide, sodium hydroxide, potassium hydroxide,
sodium methoxide and the like.
Examples of the solvent to be used for the reaction
CA 02936408 2016-06-29
include a mixed solvent of water and alcohol solvents such as
methanol, ethanol, 1-propanol, 2-propanol and the like; and a
mixed solvent thereof with ether solvents such as 1,4-dioxane,
tetrahydrofuran, diethyl ether, 1,2-dimethoxyethane,
cyclopentyl methyl ether and the like.
Compound [9] may be a commercially available product such
as those shown below, or may be obtained by converting a
commercially available product as appropriate by a method well
known to those of ordinary skill in the art.
io [0196]
Br
OMe
OMe OMe OMe OMe OMe
Br Br Br
[0197]
(Step 2-1-2)
Compound [11] can be obtained by converting the carboxy
of compound [10] to hydroxy by reduction. For example,
compound [11] can be obtained by reacting compound [10] with a
reducing agent in a solvent under ice-cooling to room
temperature.
Examples of the reducing agent to be used for the
reaction include lithium aluminum hydride, diisobutylaluminum
hydride, sodium bis(2-methoxyethoxy)aluminum hydride, borane-
tetrahydrofuran complex and the like.
Examples of the solvent to be used for the reaction
include tetrahydrofuran, diethyl ether, 1,2-dimethoxyethane,
cyclopentyl methyl ether, toluene, xylene, hexane and the like
and a mixed solvent thereof.
[0198]
(Step 2-1-3)
Compound [12] can be obtained by protecting the hydroxy
group of compound [11]. The protection reaction can be
performed by a known method according to the protecting group
to be employed.
66
CA 02936408 2016-06-29
For example, when Pv is methoxymethyl, compound [12] can
be obtained by reacting compound [11] with chloromethyl methyl
ether in a solvent such as tetrahydrofuran, 1,2-dimethoxyethane,
cyclopentyl methyl ether, N,N-dimethylformamide and the like in
the presence of a base such as sodium hydride and the like from
ice-cooling to room temperature.
[0199]
(Step 2-1-4)
Compound [13] can be obtained by borating compound [12]
lo in the same manner as in Production Method 1-2, Step 1-2.
[0200]
(Step 2-1-5)
Compound [14] can be obtained by the Suzuki coupling
reaction of compound [3] and compound [13] in the same manner
/5 as in Production Method 1-1, Step 1-1-2.
[0201]
(Step 2-1-6)
Compound [15] can be obtained by removing Pv of compound
[14] by hydroxy-deprotection by a conventional method. The
20 deprotection reaction can be performed by a known method
according to the protecting group to be employed.
For example, when Pv is methoxymethyl, a treatment with
an acid such as hydrochloric acid, trifluoroacetic acid,
methanesulfonic acid and the like only needs to be performed in
25 a single or mixed solvent of chloroform, 1,4-dioxane,
tetrahydrofuran, diethyl ether, 1,2-dimethoxyethane,
cyclopentyl methyl ether, ethyl acetate, ethanol, methanol,
water and the like.
Compound [15] can also be obtained by the Suzuki coupling
30 reaction of compound [3] and compound [23] represented by the
formula
[0202]
67
CA 02936408 2016-06-29
R4
R1
(C H )
t 2t
H
[0203]
wherein RI- and R4 are as defined in the aforementioned formula
[I], Z is as defined in the aforementioned Production Method 1-
1, and t is as defined in the aforementioned Production Method
2-1,
in the same manner as in Production Method 1-1, Step 1-1-2.
[0204]
(Step 2-1-7)
Compound [16] can be obtained by converting the hydroxy
of compound [15] to the leaving group L2. For example, when L2
is methanesulfonyloxy, compound [16] can be obtained by
reacting compound [15] with methanesulfonyl chloride in a
solvent in the presence of a base at room temperature. When L2
is bromo, compound [16] can be obtained by reacting compound
[15] with carbon tetrabromide in a solvent in the presence of
triphenylphosphine from ice-cooling to room temperature.
Examples of the base to be used for the reaction include
triethylamine, pyridine and the like.
Examples of the solvent to be used for the reaction
include ether solvents such as 1,4-dioxane, tetrahydrofuran,
diethyl ether, 1,2-dimethoxyethane, cyclopentyl methyl ether
and the like; hydrocarbon solvents such as toluene, hexane,
xylene and the like; halogenated solvents such as
dichloromethane, chloroform and the like; and polar solvents
such as N,N-dimethylformamide, N,N-dimethylacetamide, dimethyl
sulfoxide, acetonitrile and the like.
It is possible to use dimethylsulfide instead of the
above-mentioned triphenylphosphine, and N-bromosuccinimide can
68
CA 02936408 2016-06-29
be used instead of the above-mentioned carbon tetrabromide.
p-Toluenesulfonyl chloride and benzenesulfonyl chloride
can be used instead of the above-mentioned methanesulfonyl
chloride.
[0205]
(Step 2-1-8)
Compound [18] can be obtained by reacting compound [16]
in a solvent in the presence of a base at room temperature to
under heating compound [17]. Examples of the protecting group
/o Pw include tert-butoxycarbonyl.
Examples of the base to be used for the reaction include
inorganic bases such as alkali metal salts (e.g., cesium
carbonate, potassium phosphate, sodium carbonate, potassium
carbonate etc.) and the like.
Examples of the solvent to be used for the reaction
include polar solvents such as N,N-dimethylformamide, N,N-
dimethylacetamide, dimethyl sulfoxide, acetonitrile and the
like.
10206]
(Step 2-1-9)
Compound [19] can be obtained by removing Pw of compound
[18] by amine-deprotection by a conventional method. The
deprotection reaction can be performed by a known method
according to the protecting group to be employed.
For example, when Pw is tert-butoxycarbonyl, a treatment
with an acid such as hydrochloric acid, trifluoroacetic acid,
methanesulfonic acid and the like only needs to be performed in
a solvent.
Examples of the solvent to be used for the reaction
include ether solvents such as 1,4-dioxane, tetrahydrofuran,
diethyl ether, 1,2-dimethoxyethane, cyclopentyl methyl ether
and the like; hydrocarbon solvents such as toluene, hexane,
xylene and the like; halogenated solvents such as
dichloromethane, chloroform and the like; ester solvents such
as ethyl acetate and the like; and alcohol solvents such as
69
CA 02936408 2016-06-29
methanol, ethanol, 1-propanol, 2-propanol and the like.
[0207]
(Step 2-1-10)
Compound [21] can be obtained by a conventional amide
bond forming reaction, for example, by reacting compound [19]
with compound [20] in a solvent in the presence of a condensing
agent and an additive. A base may be added as necessary.
Examples of the condensing agent to be used for the
reaction include dicyclohexylcarbodiimide (DCC), 1-ethy1-3-(3-
dimethylaminopropyl)carbodiimide hydrochloride (WSC-HC1),
diisopropylcarbodiimide, 1,1'-carbonyldiimidazole (CDI), 0-(7-
azabenzotriazol-1-y1)-N,N,N',N'-tetramethyluronium
hexafluorophosphate (HATU), (benzotriazol-1-
yloxy)tris(pyrrolidino)phosphonium hexafluorophosphate (PyBOP),
/5 diphenylphosphoryl azide and the like.
Examples of the additive to be used for the reaction
include 1-hydroxybenzotriazole (HOBt), 1-hydroxy-7-
azabenzotriazole (HOAt), N-hydroxysuccinimide (HOSu), 4-
dimethylaminopyridine and the like.
Examples of the base to be used for the reaction include
organic bases such as pyridine, triethylamine and the like.
Examples of the solvent to be used for the reaction
include ether solvents such as 1,4-dioxane, tetrahydrofuran,
diethyl ether, 1,2-dimethoxyethane, cyclopentyl methyl ether
and the like; hydrocarbon solvents such as toluene, hexane,
xylene and the like; halogenated solvents such as
dichloromethane, chloroform and the like; and polar solvents
such as N,N-dimethylformamide, N,N-dimethylacetamide, dimethyl
sulfoxide, acetonitrile, pyridine and the like. These may be
used singly or as a mixture of two or more kinds thereof.
Compound [20] may be a commercially available product
such as cyclopentanecarboxylic acid and 1-
(trifluoromethyl)cyclopropane-1-carboxylic acid, or may be
obtained by converting a commercially available product as
appropriate by a method well known to those of ordinary skill
CA 02936408 2016-06-29
in the art.
[0208]
(Step 2-1-11)
Compound [21] can be indicated as compound [22].
Compound [I-al] can be obtained by converting the alkoxy of
compound [22] to hydroxy by hydrolysis in the same manner as in
Production Method 1-1, Step 1-1-3.
[0209]
[Production Method 2-2]
Compound [10a] which is compound [10] wherein Rl is C1-6
alkyl or chloro can be obtained by [Production Method 2-2].
[0210]
[Production Method 2-2]
[0211]
R4 R4
Step 2-2 13'
halogenation
(CtF12t) H a I2 (CtH 2t
OOH 0 H
[24] [10a]
[0212]
wherein Rx is C1-6 alkyl or chloro;
R4 is as defined in the aforementioned formula [I], and Hal2
and t are as defined in the aforementioned Production Method 2-
1.
[0213]
(Step 2-2)
Compound [10a] can be obtained by halogenating compound
[24]. For example, when Hal2 is iodo, compound [10a] can be
obtained by reacting compound [24] with N-iodosuccinimide in an
acid at room temperature.
Examples of the acid to be used for the reaction include
concentrated sulfuric acid and the like.
Compound [24] may be a commercially available product
such as 4-chlorophenylacetic acid, 3-(4-chlorophenyl)propionic
71
CA 02936408 2016-06-29
acid, 4-(4-chlorophenyl)butanoic acid, 4-methylphenylacetic
acid and 2-(4-methylphenyl)propionic acid, or may be obtained
by converting a commercially available product as appropriate
by a method well known to those of ordinary skill in the art.
s [0214]
[Production Method 2-31
[0215]
72
CA 02936408 2016-06-29
R4
Ri
R4
R4
RI 1 Step 2-3-2
boration
Ha 12 Step 2-3-1 R
(C H )
j 2,
j
______________________ 3 ______________________ N.-
Z (CI-1 Suzuki coupling
2) Y (CjI-l2i)
(C,F12k)0
II _."...
(CkH2k)'0 (CkEli 2k)
-1
[261 [26] Hi [27] lil
Step 2-3-4
R4 Step 2-3-3
R4
Ri
introduction of RI
reduction leaving group
________ C
(OH, ) ______________________________ a
Y Y (C H3)
(CkH2k)OH (O,H2k)L2
HI III
[28] [29]
R4 R4
Step 2-3-5 RI Step 2-3-6 R 1
amination Tildeprotection
________ o.. _______________________ a
w Y (C, Hz, )
H N.P Y (CiH2j)
It'
(CkH2k)/\.N..-1" (O,H,k)*NH,
[171
Ili w
[30] [31] II
-1
R4 (R5),,,,
Ri Ri
r'
Step 2-3-7 R4
amidation X N
Y (C JH, j)
(CnH,n)
__________ ) =
OH Ni N H NI 0
(C H )NH
k 1 2k
0Rb15
I OW T:15
[20] [32] H 0Rb15 [22]
(R5) R'
Step 2-3-8
i ...r R4
deprotection X N
\ (O.H2õ)
__________ 1
I
H NI 0
N N
bil T:15
[1-a1]
[0216]
wherein j and k are each 0, 1, 2 or 3, j+k=n-1;
R1, R4, R5, Rb15 and n are as defined in the aforementioned
formula [I],
Z is as defined in the aforementioned Production Method 1-1,
73
CA 02936408 2016-06-29
and
Hal2, Y, Pw and L2 are as defined in the aforementioned
Production Method 2-1.
[0217]
(Step 2-3-1)
Compound [26] can be obtained by borating compound [25]
in the same manner as in Production Method 1-2, Step 1-2.
Compound [25] may be a commercially available product
such as 1-(3-bromo-4-chlorophenyl)propan-1-one and 1-(3-bromo-
/0 4-chlorophenyl)butan-l-one, or may be obtained by converting a
commercially available product as appropriate by a method well
known to those of ordinary skill in the art.
[0218]
(Step 2-3-2)
Compound [27] can be obtained by the Suzuki coupling
reaction of compound [3] and compound [26] in the same manner
as in Production Method 1-1, Step 1-1-2.
[0219]
(Step 2-3-3)
Compound [28] can be obtained by converting the carboxy
of compound [27] to hydroxy by reduction. For example,
compound [28] can be obtained by reacting compound [27] with a
reducing agent in a solvent under ice-cooling to room
temperature.
Examples of the reducing agent to be used for the
reaction include sodium borohydride and the like.
Examples of the solvent to be used for the reaction
include methanol, ethanol, 2-propanol, 1,4-dioxane,
tetrahydrofuran, diethyl ether, 1,2-dimethoxyethane,
cyclopentyl methyl ether and the like.
[0220]
(Step 2-3-4)
Compound [29] can be obtained by converting the hydroxy
of compound [28] to the leaving group L2 in the same manner as
in Production Method 2-1, Step 2-1-7.
74
CA 02936408 2016-06-29
[0221]
(Step 2-3-5)
Compound [30] can be obtained by reacting compound [29]
with compound [17] in the same manner as in Production Method
2-1, Step 2-1-8.
[0222]
(Step 2-3-6)
Compound [31] can be obtained by removing Pw of compound
[30] in the same manner as in Production Method 2-1, Step 2-1-9.
/o [0223]
(Step 2-3-7)
Compound [32] can be obtained by reacting compound [31]
with compound [20] in the same manner as in Production Method
2-1, Step 2-1-10.
[0224]
(Step 2-3-8)
Compound [32] can be indicated as compound [22].
Compound [I-a1] can be obtained by converting alkoxy of
compound [22] to hydroxy by hydrolysis in the same manner as in
Production Method 1-1, Step 1-1-3.
[0225]
In Production Method 2-1, compound [I-a2] which is a
compound represented by the formula [I] wherein ring Cy is the
formula
[0 22 6]
Ri
R4
=
= (0n H 2n)
H
[0227]
wherein R1, R4 and n are as defined in the aforementioned
formula [I], can be obtained by subjecting compound [9] to the
CA 02936408 2016-06-29
reactions of Step 2-1-4, Step 2-1-5 and Step 2-1-11.
[0228]
In Production Method 2-1, the amide bond forming reaction
is performed by using compound [10] and HNRbi Rb2 such as
dimethylamine, tert-butylamine and the like and in the same
manner as in Step 2-1-10. Thereafter, the resultant product is
subjected to the reactions of Step 2-1-4, Step 2-1-5 and Step
2-1-11, whereby compound [I-a3] which is a compound represented
by the formula [I] wherein ring Cy is the formula
lo [0229]
R1
R4
=,
(CnH2n)
Rb2
?131
[0230]
wherein RI, R4, Rbi, h-b2
and n are as defined in the
aforementioned formula [I], can be obtained.
[0231]
In Production Method 2-1, compound [I-a4] which is a
compound represented by the formula [I] wherein ring Cy is the
formula
[0232]
Ri
R4
(C H )
n 2n
61-1
[0233]
wherein R1, R4 and n are as defined in the aforementioned
formula [I] can be obtained by subjecting compound [15] to the
reaction of Step 2-1-11.
76
CA 02936408 2016-06-29
[0234]
In Production Method 2-1, the reaction of Step 2-1-11 is
performed by using compound [15]. Thereafter, the resultant
product is reacted with a C1-6 alkyl-carboxylic anhydride such
as acetic anhydride, propionic anhydride and the like, whereby
compound [I-a5] which is a compound represented by the formula
[I] wherein ring Cy is the formula
[0235]
Ri
R4
ss
(C H )
s, ni2n
0 6
C1-6Alkyl
lo [0236]
wherein R1, R4 and n are as defined in the aforementioned
formula [I] and C1-6 Alkyl is as defined in the aforementioned
Production Method 2-1, can be obtained.
[0237]
In Production Method 2-1, compound [15] is reacted with
C1C(0)NRb' Rb4 such as dimethylcarbamoyl chloride,
diethylcarbamoyl chloride and the like in the presence of a
base. Thereafter, the resultant product is subjected to the
reaction of Step 2-1-11, whereby compound [I-a6] which is a
compound represented by the formula [I] wherein ring Cy is the
formula
[0238]
77
CA 02936408 2016-06-29
W
R4
=
= (C H)
n 2n
0 6
[0239]
wherein RI, R4, Rb3, E¨b4
and n are as defined in the
aforementioned formula [I], can be obtained.
[0240]
In Production Method 2-1, compound [15] is subjected to
an alkylation reaction by using sodium hydride and a C1-6 alkyl
halide. Thereafter, the resultant product is subjected to the
reaction of Step 2-1-11, whereby compound [I-a7] which is a
compound represented by the formula [I] wherein ring Cy is the
formula
[0241]
RI
R4
(Cn1-12)
1-6Alkyl
[0242]
wherein R1, R4 and n are as defined in the aforementioned
formula [I] and C1_6 Alkyl is as defined in the aforementioned
Production Method 2-1, can be obtained.
[0243]
In Production Method 2-1, compound [16] is subjected to
an amination reaction by using HNRb8Rb9 such as dimethylamine,
diethylamine and the like. Thereafter, the resultant product
is subjected to the reaction of Step 2-1-11, whereby compound
[I-a8] which is a compound represented by the formula [I]
78
CA 02936408 2016-06-29
wherein ring Cy is the formula
[0244]
R4
(CnI-i2n)
NI
Rb8 1=tb9
[0245]
wherein RI, R4, Rb8, Rb9 and n are as defined in the
aforementioned formula [I], can be obtained.
[0246]
In Production Method 2-1, compound [16] is reacted by
using sodium hydride, and HNRbl4C(0) Rb15 such as N-
/o methylacetamide, 2-pyrrolidinone and the like. Thereafter, the
resultant product is subjected to the reaction of Step 2-1-11,
whereby compound [I-a9] which is a compound represented by the
formula [I] wherein ring Cy is the formula
[0247]
W
R4
(CnH,n)
Rbi5
/5
[0248]
wherein RI, R4, Rb14, Rb15 and n are as defined in the
aforementioned formula [I], can be obtained.
[0249]
20 In Production Method 2-1, compound [16] is reacted by
using sodium hydride and compound [33] represented by the
formula
[0250]
79
CA 02936408 2016-06729
H N
0176
[0251]
wherein Rb17, m5 and m6 are as defined in the aforementioned
formula [I]. Thereafter, the resultant product is subjected to
5 the reaction of Step 2-1-11, whereby compound [I-a10] which is
a compound represented by the formula [I] wherein ring Cy is
the formula
[0252]
Rbu
R1
( m5
R4 m6
(Cn H 2n)
0
[0253]
wherein RI, R4, Rbi7, n, m5 and m6 are as defined in the
aforementioned formula [I], can be obtained.
[0254]
In Production Method 2-1, compound [19] is reacted with
C1C(0)NRb6Rb7 such as dimethylcarbamoyl chloride,
diethylcarbamoyl chloride and the like in the presence of a
base. Thereafter, the resultant product is subjected to the
reaction of Step 2-1-11, whereby compound [I-all] which is a
compound represented by the formula [I] wherein ring Cy is the
formula
[0255]
CA 02936408 2016-06-29
Ri
R4
=
= (C H )
n 2n
H N 0
N Rb7
[0256]
wherein RI, R4, Rb6 x¨b7
and n are as defined in the
aforementioned formula [I], can be obtained.
[0257]
In Production Method 2-1, compound [19] is reacted with
RbilS(0)201 such as methanesulfonyl chloride and the like in the
presence of a base. Thereafter, the resultant product is
subjected to the reaction of Step 2-1-11, whereby compound [I-
a12] which is a compound represented by the formula [I] wherein
ring Cy is the formula
[0258]
JZIR1
R4
(C H)
µ, n 2n
0
H N
S
f!?bl P
[0259]
wherein R1, R4, Rbll and n are as defined in the aforementioned
formula [I], can be obtained.
[0260]
In Production Method 2-1, compound [19] is reacted with
R1130C(0)C1 such as ethyl chloroformate and the like in the
presence of a base. Thereafter, the resultant product is
subjected to the reaction of Step 2-1-11, whereby compound [I-
81
CA 02936408 2016-06-.29
a13] which is a compound represented by the formula [I] wherein
ring Cy is the formula
[0261]
R4
(C H )
ni2n
HO
[0262]
wherein R1., R4, Rion and n are as defined in the aforementioned
formula [I], can be obtained.
[0263]
In Production Method 2-3, compound [I-a14] which is a
lo compound represented by the formula [I] wherein ring Cy is the
formula
[0264]
R1 R4
s, (CjH2j)
(CkH2k) 0
[0265]
wherein R1 and R4 are as defined in the aforementioned formula
[I], j and k are as defined in the aforementioned Production
Method 2-2, can be obtained by subjecting compound [27] to the
reaction of Step 2-3-8.
[0266]
By Production Method 2-4, compound [I-a15] which is a
compound represented by the formula [I] wherein ring Cy is the
formula
82
CA 02936408 2016-06-29
[0267]
R1 R4
(C H )
m2
m3
(Rb")m4
[0268]
wherein RI, R4, Rb16, m2, m3 and m4 are as defined in the
aforementioned Production Method 2-1, can be obtained.
[0269]
[Production Method 2-4]
[0270]
( R616) m4 (R616)m4
Step 2-4-1
L2
alkylation
m3
) rn3 OP' ______________ 0
m2 m2
0 0 pv
[34] [35] [36]
(R616)4 (Rb16)4 Step 2-4-4
r7,
'm
Step 2-4-2 Step 2-4-3 compound [19]
deprotection
) m3 ) amidation
hydrolysis HO
m3
C1-6AlkylII .
m2
[37] [38]
R4 R4
W W
Step 2-4-5
cyclization
(CtH,t) (CtH2t)
N LNH OH
3
m2 r112
0 (Rb16)
m3 [40] = m4
[39] (IR")
.
[0271]
83
CA 02936408 2016-06-29
wherein RI, R4, RI:A.6, m2, m3 and m4 are as defined in the
aforementioned formula [I] and C1-6 Alkyl, L2, Pv, t and Y are
as defined in the above-mentioned Production Method 2-1.
[0272]
(Step 2-4-1)
Compound [36] can be obtained by reacting compound [34]
with compound [35] in a solvent in the presence of a base.
Examples of the base to be used for the reaction include,
lithium diisopropylamide, lithium bis(trimethylsilyl)amide and
lo the like base.
Examples of the solvent to be used for the reaction
include ether solvents such as tetrahydrofuran, diethyl ether,
1,2-dimethoxyethane, cyclopentyl methyl ether and the like;
hydrocarbon solvents such as toluene, hexane, xylene and the
like, and a mixed solvent thereof.
Compound [35] may be a commercially available product
such as benzyl chloromethyl ether, or may be obtained by
converting a commercially available product as appropriate by a
method well known to those of ordinary skill in the art.
[0273]
(Step 2-4-2)
Compound [37] can be obtained by removing Pv of compound
[36] in the same manner as in Production Method 2-1, Step 2-1-6.
[0274]
(Step 2-4-3)
Compound [38] can be obtained by converting the ester of
compound [37] to carboxy by hydrolysis in the same manner as in
Production Method 2-1, Step 2-1-1.
[0275]
(Step 2-4-4)
Compound [39] can be obtained by reacting compound [38]
with compound [19] in a solvent in the presence of a condensing
agent and an additive in the same manner as in Production
Method 2-1, Step 2-1-10.
[0276]
84
CA 02936408 2016-06-29
(Step 2-4-5)
Compound [40] can be obtained by cyclization of compound
[39] by intramolecular Mitsunobu reaction. For example,
compound [40] can be obtained by reacting compound [39] with an
azodicarboxylic acid diester (e.g., diethyl azodicarboxylate,
diisopropyl azodicarboxylate, bis(2-methoxyethyl)
azodicarboxylate etc.) in a solvent in the presence of a
phosphine such as triphenylphosphine, tributylphosphine and the
like.
Examples of the solvent to be used for the reaction
include dichloromethane, chloroform, 1,4-dioxane,
tetrahydrofuran, diethyl ether, 1,2-dimethoxyethane,
cyclopentyl methyl ether, toluene, N,N-dimethylformamide and
the like. These may be used singly or as a mixture of two or
more kinds thereof.
[0277]
[Production Method 3-1]
Another method of appropriately converting the
substituent of ring Cy is, for example, Production Method 3-1
for obtaining compound [I-bl] which is a compound represented
by the formula [I] wherein ring Cy is the formula
[0278]
RI
R4
fRc
[0279]
wherein RI, R4 and Rc are as defined in the aforementioned
formula [I].
[Production Method 3-1]
[0280]
CA 02936408 2016-06-29
Step 3-1-1 R1 Step 3-1-2 R1 Step 3-1-3
R4 protection R4 boration R4 Suzuki coupling
Hal2 Hal2
Pv
[41] [42] [43]
1
(R5))(\.
rn
RI (R5)mi
RI Step 3-1-5
R4 Step 3-1-4 4FR4
Mitsunobu
deprotection reactionX
1\) N N N
WOH
[46]
OW OW
[44] [45]
(W)m1 RI
)(=-kN.
frR4 Step 3-1-6 R4
deprotection
NI N
I68 OH
[47]
[0281]
wherein RI, R4, R5, -c,
ml and X are as defined in the
aforementioned formula [I], Z is as defined in the above-
mentioned Production Method 1-1, and Hal2 and Pv are as defined
in the above-mentioned Production Method 2-1.
[0282]
(Step 3-1-1)
Compound [42] can be obtained by protecting the hydroxy
lo group of compound [41] in the same manner as in Production
Method 2-1, Step 2-1-3.
Compound [41] may be a commercially available product
such as 2-bromo-3-methylphenol, or may be obtained by
converting a commercially available product as appropriate by a
method well known to those of ordinary skill in the art.
[0283]
(Step 3-1-2)
Compound [43] can be obtained by borating compound [42]
in the same manner as in Production Method 1-3, Step 1-3.
[0284]
86
CA 02936408 2016-06-29
(Step 3-1-3)
Compound [44] can be obtained by the Suzuki coupling
reaction of compound [3] and compound [43] in the same manner
as in Production Method 1-1, Step 1-1-2.
[0285]
(Step 3-1-4)
Compound [45] can be obtained by removing Pv of compound
[44] in the same manner as in Production Method 2-1, Step 2-1-6.
[0286]
(Step 3-1-5)
Compound [47] can be obtained by the Mitsunobu reaction
of compound [45] and compound [46]. For example, compound [47]
can be obtained by reacting compound [45] with compound [46] in
a solvent in the presence of an azodicarboxylic acid diester
(e.g., diethyl azodicarboxylate, diisopropyl azodicarboxylate,
bis(2-methoxyethyl) azodicarboxylate etc.) and a phosphine such
as triphenylphosphine, tributylphosphine and the like.
Examples of the solvent to be used for the reaction
include dichloromethane, chloroform, 1,4-dioxane,
tetrahydrofuran, diethyl ether, 1,2-dimethoxyethane,
cyclopentyl methyl ether, toluene, N,N-dimethylformamide and
the like. These may be used singly or as a mixture of two or
more kinds thereof.
Compound [46] may be a commercially available product
such as benzyl alcohol, 2-pyridinemethanol and the like, or may
be obtained by converting a commercially available product as
appropriate by a method well known to those of ordinary skill
in the art.
[0287]
(Step 3-1-6)
Compound [I-bl] can be obtained by converting the alkoxy
of compound [47] to hydroxy by hydrolysis in the same manner as
in Production Method 1-1, Step 1-1-3.
[0288]
In Production Method 3-1, for example, compound [I-b2]
87
CA 02936408 2016-06-29
which is a compound represented by the formula [I] wherein ring
Cy is the formula
[0289]
RI
R4
[0290]
wherein R1 and R4 are as defined in the aforementioned formula
[I], can be obtained by subjecting compound [45] to the
reaction of Step 3-1-6.
[0291]
[Production Method 3-2]
Compound [43a] which is compound [43] wherein Rl is
chloro or trifluoromethyl can also be obtained by [Production
Method 3-2].
[0292]
[Production Method 3-2]
[0293]
Step 3-2-2
RY Step 3-2-1 RY lithiation/ RY
R4 protection R4 boraticm R4
pv pv
[48] [49] [43a]
[0294]
wherein RY is chloro or trifluoromethyl;
R4 is as defined in the aforementioned formula [I], Z is as
defined in the aforementioned Production Method 1-1, and Pv is
as defined in the aforementioned Production Method 2-1.
[0295]
(Step 3-2-1)
Compound [49] can be obtained by protecting the hydroxy
group of compound [48] in the same manner as in Production
88
CA 02936408 2016-06-29
Method 2-1, Step 2-1-3.
In one embodiment, compound [48] may be a commercially
available product such as those shown below, or may be obtained
by converting a commercially available product as appropriate
by a method well known to those of ordinary skill in the art.
[0296]
OMe
11, F3C 110 F2C a CI
C 1111 1111 OMe
=
IPH 011 IH 8H
[0297]
(Step 3-2-2)
Compound [43a] can be obtained by reacting compound [49]
with a boron compound in a solvent in the presence of a base.
For example, compound [43a] can be obtained by adding a base to
compound [49] in a solvent at -78 C to room temperature, and
reacting the resultant product with a boron reagent at -78 C to
room temperature.
Examples of the base to be used for the reaction include
n-butyllithium, sec-butyllithium and the like.
Examples of the boron reagent to be used for the reaction
include 2-isopropoxy-4,4,5,5-tetramethy1-1,3,2-dioxaborolane,
trimethyl borate and the like.
Examples of the solvent to be used for the reaction
include tetrahydrofuran, diethyl ether, 1,2-dimethoxyethane,
cyclopentyl methyl ether and the like.
[0298]
[Production Method 4]
For example, compound [I-cl] of the formula
[0299]
89
CA 02936408 2016-06-29
Re
XN
N,
NN
[0300]
wherein R5, Re, X and Cy are as defined in the aforementioned
formula [I], m7 is 0, 1 or 2, and when m7 is 2, each R5 is
selected independently, can be obtained by appropriately
converting the substituent of compound [2].
[Production Method 4]
[0301]
CA 02936408 2016-06-29
Px-0 (1:26),,,7
Px-0 (R6),7 Step 4-1 Step 4-2
Suzuki coupling X Suzuki coupling
11\-
X N
[50]
[51]
Step 4-3
Px¨O (R5),,7 HO (R5)7
Step 4-4
iik XIN introduction
of
deprotection leaving group
NI N
N
TR6 [52] IIR6 [53]
Step 4-5
Step 4-6
Sonogashira
XIN
reaction X deprotection
NI N RC __
N N
TR6 [54]
R [56]
[55]
Re
(R6)m7
NIT
[I-ci]
[0302]
wherein L3 is a leaving group such as
trifluoromethanesulfonyloxy and the like;
Px is a hydroxy-protecting group such as benzyl and the like;
Rs, R6 -e õ
K X and Cy are as defined in the aforementioned
formula [I], Hall and Z are as defined in the aforementioned
Production Method 1-1, and m7 is as defined in the
/o aforementioned formula [I-A].
91
CA 02936408 2016-06-29
[0303]
(Step 4-1)
Compound [51] can be obtained by the Suzuki coupling
reaction of compound [1] and compound [50] in the same manner
as in Production Method 1-1, Step 1-1-1.
Compound [50] may be a commercially available product
such as 4-(benzyloxy)phenylboronic acid, or may be obtained by
converting a commercially available product as appropriate by a
method well known to those of ordinary skill in the art.
[0304]
(Step 4-2)
Compound [52] can be obtained by the Suzuki coupling
reaction of compound [4] and compound [51] in the same manner
as in Production Method 1-1, Step 1-1-2.
/5 [0305]
(Step 4-3)
Compound [53] can be obtained by removing the phenol
protecting group Px of compound [52]. The deprotection can be
performed by a known method according to the protecting group
to be employed.
For example, when Px is benzyl, compound [52] only needs
to be subjected to a hydrogenation reaction in a single or
mixed solvent of tetrahydrofuran, ethyl acetate, ethanol,
methanol, water and the like in the presence of a catalyst such
as palladium carbon, platinum carbon and the like.
[0306]
(Step 4-4)
Compound [54] can be obtained by converting the hydroxy
to a leaving group L3. For example, when the leaving group is
trifluoromethanesulfonyloxy, compound [54] can be obtained by
reacting compound [53] with trifluoromethanesulfonic anhydride,
N-phenyl bis(trifluoromethanesulfonimide) and the like in a
solvent in the presence of a base from ice-cooling to room
temperature.
Examples of the base to be used for the reaction include
92
CA 02936408 2016-06-29
organic bases such as pyridine, 2,6-lutidine, triethylamine and
the like; inorganic bases such as alkali metal salts (e.g.,
cesium carbonate, sodium hydride etc.) and the like.
Examples of the solvent to be used for the reaction
include ether solvents such as 1,4-dioxane, tetrahydrofuran,
diethyl ether, 1,2-dimethoxyethane, cyclopentyl methyl ether
and the like; hydrocarbon solvents such as toluene, hexane,
xylene and the like; halogenated solvents such as
dichloromethane, chloroform and the like; polar solvents such
as N,N-dimethylformamide, N,N-dimethylacetamide, dimethyl
sulfoxide, acetonitrile, pyridine and the like, and the like.
These may be used singly or as a mixture of two or more kinds
thereof.
[0307]
(Step 4-5)
Compound [56] can be obtained by the Sonogashira reaction
of compound [54] and compound [55]. For example, compound [56]
can be obtained by reacting compound [54] with compound [55] in
a solvent preferably under heating in the presence of a base, a
palladium catalyst and a copper catalyst.
Examples of the palladium catalyst to be used for the
reaction include palladium acetate,
tetrakistriphenylphosphinepalladium,
bis(triphenylphosphine)palladium dichloride,
(bis(diphenylphosphino)ferrocene)palladium dichloride-methylene
chloride complex and the like.
Examples of the copper catalyst to be used for the
reaction include copper iodide, copper bromide and the like.
Examples of the base to be used for the reaction include
diethylamine, dicyclohexylamine, triethylamine, N-
ethyldiisopropylamine and the like.
Examples of the solvent to be used for the reaction
include ether solvents such as 1,4-dioxane, tetrahydrofuran,
diethyl ether, 1,2-dimethoxyethane, cyclopentyl methyl ether
and the like; hydrocarbon solvents such as toluene, hexane,
93
CA 02936408 2016-06-29
xylene and the like; and polar solvents such as N,N-
dimethylformamide, N,N-dimethylacetamide, dimethyl sulfoxide,
acetonitrile, pyridine and the like. These may be used singly
or as a mixture of two or more kinds thereof.
Compound [55] may be a commercially available product
such as cyclohexylacetylene, 2-ethynylpyridine and the like, or
may be obtained by converting a commercially available product
as appropriate by a method well known to those of ordinary
skill in the art.
As for the Sonogashira coupling reaction, for example,
the following review article is known (NAJERA, C et al. The
Sonogashira Reaction: A Booming Methodology in Synthetic
Organic Chemistry. Chem Rev. 2007, Vol.107, pages 874-922.).
[0308]
/5 (Step 4-6)
Compound [I-cl] can be obtained by converting the alkoxy
of compound [56] to hydroxy by hydrolysis in the same manner as
in Production Method 1-1, Step 1-1-3.
[0309]
In Production Method 4, compound [I-c2] of the formula
[0310]
HO (R5)
m 7
N
N
[0311]
wherein R5, X and Cy are as defined in the aforementioned
formula [I], and m7 is as defined in the aforementioned formula
[I-A], can be obtained by subjecting compound [53] to the
reaction of Step 4-6.
[0312]
In Production Method 4, compound [I-c3] of the formula
[0313]
94
CA 02936408 2016-06-29
Rd 0 ( R5 )
X
N
[0314]
wherein R5, Rd, X and Cy are as defined in the aforementioned
formula [I], and m7 is as defined in the aforementioned formula
[I-A], can be obtained by the Mitsunobu reaction of compound
[53] and Rd0H such as cyclohexylmethanol and the like in the
same manner as in Production Method 3-1, Step 3-1-5, and
subjecting the resultant product to the reaction of Step 4-6.
[0315]
In Production Method 4, the Suzuki coupling reaction of
compound [54] and compound [57] of the formula
[0316]
[0317]
/5 wherein Z is as defined in the aforementioned Production Method
1-1, is performed in the same manner as in Production Method 1-
1, Step 1-1-2. The resultant product is subjected to the
reaction of Step 4-6, whereby compound [I-c4] of the formula
[0318]
(R5)7
X
1µ11,N
95
CA 02936408 2016-06-29
[0319]
wherein R5, X and Cy are as defined in the aforementioned
formula [I] and m7 is as defined in the aforementioned formula
[I-A], can be obtained.
[0320]
In Production Method 4, the Suzuki coupling reaction of
compound [54] and compound [58] of the formula
[0321]
ilk m9
[0322]
wherein m9 is 1, 2, 3, or 4, and Z is as defined in the
aforementioned Production Method 1-1, is performed in the same
manner as in Production Method 1-1, Step 1-1-2. After
reduction of the olefin of the resultant product, the obtained
product is subjected to the reaction of Step 4-6, whereby
compound [I-c5] of the formula
[0323]
m9
R5)m7
X
[0324]
wherein m9 is as defined above, m7 is as defined in the
aforementioned formula [I-A], and R5, X and Cy are as defined
in the aforementioned formula [I], can be obtained. For
reduction reaction of the olefin, for example, a hydrogenation
reaction only needs to be performed in a single or mixed
solvent of tetrahydrofuran, ethyl acetate, ethanol, methanol,
water and the like in the presence of a catalyst such as
96
CA 02936408 2016-06-29
palladium carbon or platinum carbon and the like.
Examples
[0325] =
The present invention is explained in more detail in the
following by referring to Examples and Experimental Examples,
which are not to be construed as limitative.
The abbreviations in the Examples are as follows.
WS0.HC1: 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide
lo hydrochloride
HOBt.H20: 1-hydroxy-1H-benzotriazole monohydrate
DMSO: dimethyl sulfoxide
M: mol/L
[0326]
[Production Example 1]
Synthesis of N-(4-chloro-3-{4-[4-(2,2-dimethylpropoxy)pheny1]-
6-hydroxy-1,3,5-triazin-2-yllbenzy1)-3,3,3-trifluoro-2,2-
dimethylpropionamide (Example No. 1-86)
[0327]
40 ci H.XF
N,
0
O
H
[0328]
(1) 2-chloro-4-[4-(2,2-dimethylpropoxy)pheny1]-6-methoxy-1,3,5-
triazine
[0329]
Ck
11 T
110 , N CI
NN r
,OH
NN
OH
[0330]
Under an argon atmosphere, a suspension of 4-(2,2-
97
CA 02936408 2016-06-29
dimethylpropoxy)phenylboronic acid (2.0 g, 9.6 mmol), 2,4-
dichloro-6-methoxy-1,3,5-triazine (3.5 g, 19 mmol), [1,1'-
bis(diphenylphosphino)ferrocene]palladium(II)dichloride
dichloromethane adduct (1.1 g, 0.96 mmol) and 2M aqueous sodium
carbonate solution (14 ml, 29 mmol) in toluene (20 ml) was
stirred at 100 C for 3.5 hr. At room temperature, to the
reaction mixture were added water and ethyl acetate and the
mixture was partitioned. The organic layer was washed with
saturated aqueous sodium hydrogen carbonate, washed with
lo saturated brine, dried over sodium sulfate, filtered to remove
sodium sulfate, and concentrated under reduced pressure. The
residue was purified by silica gel column chromatography
(eluent: n-hexane/ethyl acetate=19/1 - 4/1) to give the title
compound (2.3 g, yield 77%).
111-NMR (400MHz, CDC13) 15: 1.06 (9H, s), 3.68 (2H, s), 4.14 (3H,
s), 6.94-7.02 (2H, m), 8.42-8.46 (2H, m).
[0331]
(2) (4-chloro-3-{4-[4-(2,2-dimethylpropoxy)pheny1]-6-methoxy-
1,3,5-triazin-2-yllphenyl)methanol
[0332]
dati
N HO
õCl N 1141 OH
, a OH 00
B
NN
OH NN
,0 ,0
[03331
Under an argon atmosphere, a suspension of 2-chloro-4-[4-
(2,2-dimethylpropoxy)pheny1]-6-methoxy-1,3,5-triazine (2.3 g,
7.4 mmol) obtained in the above-mentioned (1), 2-chloro-5-
hydroxymethylphenylboronic acid (1.7 g, 8.9 mmol), [1,1'-
bis(diphenylphosphino)ferrocene]palladium(II)dichloride
dichloromethane adduct (0.61 g, 0.74 mmol) and 2M aqueous
sodium carbonate solution (15 ml, 30 mmol) in 1,4-dioxane (23
ml) was stirred at 100 C for 1.5 hr. At room temperature, to
the reaction mixture were added water and ethyl acetate and the
98
CA 02936408 2016-06-29
mixture was partitioned. The organic layer was washed with
saturated aqueous sodium hydrogen carbonate, washed with
saturated brine, dried over sodium sulfate, filtered to remove
sodium sulfate, and concentrated under reduced pressure. The
residue was purified by silica gel column chromatography
(eluent: n-hexane/ethyl acetate=4/1 - 1/1) to give the title
compound (1.3 g, yield 43%).
1H-NMR (400MHz, CDO13) 6: 1.06 (9H, s), 1.75 (1H, t, J = 5.9
Hz), 3.69 (2H, s), 4.19 (3H, s), 4.77 (2H, d, J = 5.9 Hz),
lo 6.98-7.03 (2H, m), 7.46 (1H, dd, J = 8.2, 2.2 Hz), 7.53 (1H, d,
J = 8.2 Hz), 8.00 (1H, d, J = 2.2 Hz), 8.52-8.58 (2H, m).
[0334]
(3) tert-butyl N-(4-chloro-3-{4-[4-(2,2-
dimethylpropoxy)pheny1]-6-methoxy-1,3,5-triazin-2-yllbenzy1)-N-
(tert-butoxycarbonyl)carbamate
[0335]
X0 N 0 *I
, -1 ____________________________ Ny0)7
NN NN 0
=
[0336]
Under an argon atmosphere, to a solution of (4-chloro-3-
{4-[4-(2,2-dimethylpropoxy)pheny1]-6-methoxy-1,3,5-triazin-2-
yllphenyl)methanol (1.3 g, 3.2 mmol) obtained in the above-
mentioned (2) and triethylamine (0.58 ml, 4.2 mmol) in
tetrahydrofuran (13 ml) was added methanesulfonyl chloride
(0.29 ml, 3.8 mmol) under ice-cooling, and the mixture was
warmed to room temperature. After stirring for 0.5 hr, the
reaction mixture was filtered, and the filtrate was
concentrated under reduced pressure. To a solution of the
residue in N,N-dimethylformamide (13 ml) were added cesium
carbonate (3.1 g, 9.5 mmol) and di-tert-butyl
iminodicarboxylate (0.83 g, 3.8 mmol), and the mixture was
stirred for 3 hr. To the reaction mixture were added water and
99
CA 02936408 2016-06-29
ethyl acetate and the mixture was partitioned. The organic
layer was washed with saturated aqueous sodium hydrogen
carbonate, washed with saturated brine, dried over sodium
sulfate, filtered to remove sodium sulfate, and concentrated
under reduced pressure. The residue was purified by silica gel
column chromatography (eluent: n-hexane/ethyl acetate=9/1 -7/3)
to give the title compound (1.6 g, yield 82%).
1H-NMR (400MHz, CDC13) 5: 1.06 (9H, s), 1.48 (18H, s), 3.69 (2H,
s), 4.18 (3H, s), 4.83 (2H, s), 6.96-7.01 (2H, m), 7.39 (1H, dd,
lo J = 8.2, 2.2 Hz), 7.48 (1H, d, J = 8.2 Hz), 7.98 (1H, d, J =
2.2 Hz), 8.51-8.57 (2H, m).
[0337]
(4) 4-chloro-3-{4-[4-(2,2-dimethylpropoxy)pheny1]-6-methoxy-
1,3,5-triazin-2-yl)benzylamine hydrochloride
[0338]
CI
CI Aki Oy,0
-4P Ny0)7 _____________________________________________________ N, 41t H2
+ICI
0
NN NyN
,0 ,/0
[0339]
Under an argon atmosphere, to a solution of tert-butyl N-
(4-chloro-3-{4-[4-(2,2-dimethylpropoxy)pheny1]-6-methoxy-1,3,5-
triazin-2-yllbenzy1)-N-(tert-butoxycarbonyl)carbamate (1.3 g,
2.2 mmol) obtained in the above-mentioned (3) in 1,4-dioxane
(2.8 ml) was added 4M hydrogen chloride/1,4-dioxane solution
(11 ml) at room temperature, and the mixture was stirred for 3
hr. The solid was collected by filtration from the suspension,
and dried under reduced pressure to give the title compound
(0.97 g, yield 99%).
11-1-NMR (400MHz, DMSO-d6) 5: 1.03 (9H, s), 3.76 (2H, s), 4.10-
4.18 (2H, m), 4.14 (3H, s), 7.11-7.17 (2H, m), 7.72 (2H, d, J =
0.9 Hz), 8.13 (1H, br s), 8.40-8.58 (5H, m).
[0340]
(5) N-(4-chloro-3-(4-[4-(2,2-dimethylpropoxy)pheny1]-6-methoxy-
100
CA 02936408 2016-06-29
1,3,5-triazin-2-yllbenzy1)-3,3,3-trifluoro-2,2-
dimethylpropionamide
[0341]
X,0 0/0 CI am X...o 110 ci aam
N, NH2 -HCI ___________________ N, N
NoN NN 0
,0 ,0
[0342]
Under an argon atmosphere, to a solution of 4-chloro-3-
{4-[4-(2,2-dimethylpropoxy)pheny1]-6-methoxy-1,3,5-triazin-2-
yllbenzylamine hydrochloride (0.97 g, 2.2 mmol) obtained in the
above-mentioned (4) and 3,3,3-trifluoro-2,2-dimethylpropionic
lo acid (0.41 g, 2.6 mmol) in N,N-dimethylformamide (10 ml) were
added HOBt-H20 (0.43 g, 2.8 mmol), WSC-HC1 (2.8 g, 2.8 mmol)
and triethylamine (0.91 ml, 6.5 mmol) at room temperature, and
the mixture was stirred for 3.5 hr. 3,3,3-Trifluoro-2,2-
dimethylpropionic acid (0.067 g, 0.43 mmol), HOBt=H20 (0.066 g,
0.43 mmol) and WSC=HC1 (0.082 g, 0.43 mmol) were added, and the
mixture was stirred for 1.5 hr. To the reaction mixture were
added water and ethyl acetate and the mixture was partitioned.
The organic layer was washed with saturated aqueous sodium
hydrogen carbonate, washed with saturated brine, dried over
sodium sulfate, filtered to remove sodium sulfate, and
concentrated under reduced pressure. The residue was purified
by silica gel column chromatography (eluent: n-hexane/ethyl
acetate=9/1 - 7/3) to give the title compound (0.97 g, yield
81%).
1H-NMR (400MHz, ODC13) 6: 1.07 (9H, s), 1.44 (6H, s), 3.69 (2H,
s), 4.19 (3H, s), 4.55 (2H, d, J = 5.8 Hz), 6.22 (1H, br s),
6.96-7.03 (2H, m), 7.34 (IH, dd, J = 8.3, 2.3 Hz), 7.51 (1H, d,
J = 8.3 Hz), 7.91 (1H, d, J = 2.3 Hz), 8.50-8.57 (2H, m).
[0343]
(6) N-(4-chloro-3-{4-[4-(2,2-dimethylpropoxy)pheny1]-6-hydroxy-
1,3,5-triazin-2-yl}benzy1)-3,3,3-trifluoro-2,2-
101
CA 02936408 2016-06-29
dimethylpropionamide (Example No. 1-86)
[0344]
,,k,0 00 CI 4HF1';(! Xo ci aim HF1!
N, N N, N
NyN 0 NN 0
,0 OH
[0345]
Under an argon atmosphere, to a solution of N-(4-chloro-
3-{4-[4-(2,2-dimethylpropoxy)pheny1]-6-methoxy-1,3,5-triazin-2-
yllbenzy1)-3,3,3-trifluoro-2,2-dimethylpropionamide (0.97 g,
1.76 mmol) obtained in the above-mentioned (3) in methanol (10
ml) was added 4M aqueous sodium hydroxide solution (3.5 ml, 14
/o mmol) at room temperature, and the mixture was stirred at 65 C
for 1.5 hr. To the reaction mixture were added 2M hydrochloric
acid (7.0 ml, 14 mmol) and water at room temperature, and the
mixture was stirred. The precipitated solid was collected by
filtration, washed with water, and dried under reduced pressure
to give the title compound (0.87 g, yield 92%).
1H-NMR (400MHz, DMSO-d6) 5: 1.02 (9H, s), 1.37 (6H, s), 3.73
(2H, s), 4.35 (2E, d, J = 5.8 Hz), 7.08 (2H, d, J = 9.1 Hz),
7.40 (1H, dd, J = 8.3, 2.2 Hz), 7.58 (1H, d, J = 8.3 Hz), 7.62
(1H, d, J = 1.9 Hz), 8.29 (2H, d, J = 9.1 Hz), 8.62 (1H, t, J =
5.8 Hz), 13.13 (1H, s).
[0346]
[Production Example 2]
Synthesis of 1-[4-chloro-3-(4-hydroxy-6-pheny1-1,3,5-triazin-2-
y1)-benzy1]-3,3-dimethy1-1,3-dihydroindol-2-one (Example No.1-
258)
[0347]
CI 010 4110
N N
`
N N 0
OH
102
CA 02936408 2016-06-.29
[0348]
(1) 2-(5-bromomethy1-2-chloropheny1)-4-methoxy-6-phenyl-1,3,5-
triazine
[0349]
CI
N 411 OH CI
1401 N 101 Br
NN NN
0 0
[0350]
By a method similar to that in Production Example 1 (1)
and (2), and using 2,4-dichloro-6-methoxy-1,3,5-triazine, 2-
chloro-5-hydroxymethylphenylboronic acid, and phenylboronic
lo acid instead of 4-(2,2-dimethylpropoxy)phenylboronic acid, [4-
chloro-3-(4-methoxy-6-pheny1-1,3,5-triazin-2-yl)phenyl]methanol
was obtained.
Under an argon atmosphere, to a solution of the obtained
[4-chloro-3-(4-methoxy-6-phenyl-1,3,5-triazin-27
yl)phenyl]methanol (0.47 g, 1.4 mmol) and triphenylphosphine
(0.56 g, 2.1 mmol) in chloroform (4.5 ml) was added carbon
tetrabromide (0.71 g, 2.1 mmol) under ice-cooling. The
reaction mixture was stirred at room temperature for 10 min,
and concentrated under reduced pressure. The residue was
purified by silica gel column chromatography (eluent: n-
hexane/ethyl acetate=30/1 - 9/1) to give the title compound
(0.49 g, yield 87%).
1H-NMR (400MHz, CDC13) 6: 4.22 (3H, s), 4.53 (2H, s), 7.45-7.64
(5H, m), 8.06 (1H, hr s), 8.57-8.63 (2H, m).
[0351]
(2) 1-[4-chloro-3-(4-methoxy-6-pheny1-1,3,5-triazin-2-
yl)benzy1]-3,3-dimethy1-1,3-dihydroindo1-2-one
[0352]
103
CA 02936408 2016-06-29
CI
N Br = 4/0 a aam
N N
HN
1 0
0
,0
[0353]
Under an argon atmosphere, to a solution of 3,3-
dimethylindolin-2-one (0.050 g, 0.31 mmol) in N,N-
dimethylformamide (1.0 ml) was added sodium hydride (0.012 g,
60 wt% oil dispersion) under ice-cooling. After stirring for
30 min, 2-(5-bromomethy1-2-chloropheny1)-4-methoxy-6-phenyl-
1,3,5-triazine (0.10 g, 0.26 mmol) obtained in the above-
mentioned (1) was added, and the mixture was stirred at room
lo temperature for 30 min. To the reaction mixture were added
saturated aqueous ammonium chloride solution and ethyl acetate
and the mixture was partitioned. The organic layer was washed
with saturated aqueous sodium hydrogen carbonate, washed with
saturated brine, dried over sodium sulfate, filtered to remove
sodium sulfate, and concentrated under reduced pressure. The
residue was purified by silica gel column chromatography
(eluent: n-hexane/ethyl acetate=7/2) to give the title compound
(0.11 g, yield 89%).
1H-NMR (400MHz, CDC13) 6: 1.44 (6H, s), 4.18 (3H, s), 4.98 (2H,
s), 6.72-6.76 (1H, m), 7.02-7.08 (1H, m), 7.13-7.19 (1H, m),
7.21-7.25 (1H, m), 7.31-7.36 (1H, m), 7.46-7.53 (3H, m), 7.55-
7.61 (1H, m), 8.00 (1H, br s), 8.51-8.58 (2H, m).
[0354]
(3) 1-[4-chloro-3-(4-hydroxy-6-pheny1-1,3,5-triazin-2-
yl)benzy1]-3,3-dimethy1-1,3-dihydroindol-2-one (Example No.1-
258)
[0355]
104
CA 02936408 2016-06-29
010 NCI fiN NCI *N
0 0
NN
OH
[0356]
Under an argon atmosphere, to a solution of 1-[4-chloro-
3-(4-methoxy-6-pheny1-1,3,5-triazin-2-yl)benzyl]-3,3-dimethyl-
1,3-dihydroindo1-2-one (0.11 g, 0.23 mmol) obtained in the
above-mentioned (2) in methanol (10 ml) was added 4M aqueous
sodium hydroxide solution (0.34 ml, 1.4 mmol) at room
temperature, and the mixture was stirred at 65 C for 2 hr. To
the reaction mixture were added 10 wt% aqueous citric acid
lo solution (1.4 ml) and water (7.0 ml) at room temperature, and
the mixture was stirred for 30 min. The precipitated solid was
collected by filtration, washed with water, and dried under
reduced pressure to give the title compound (0.10 g, yield 96%).
1H-NMR (400MHz, DMSO-d0 5: 1.34 (6H, s), 4.99 (2H, s), 6.97
(1H, d, J = 7.6 Hz), 7.05 (1H, t, J = 7.6 Hz), 7.20 (1H, t, J =
7.6 Hz), 7.39 (1H, d, J = 7.6 Hz), 7.48 (1H, dd, J = 8.3, 1.8
Hz), 7.55 (2H, t, J = 7.6 Hz), 7.59-7.68 (2H, m), 7.75 (1H, d,
J = 1.8 Hz), 8.29 (2H, d, J = 7.6 Hz), 13.32 (1H, br s).
[0357]
[Production Example 3]
Synthesis of N-[4-chloro-3-(4-hydroxy-6-pheny1-1,3,5-triazin-2-
yl)benzyl]-N-ethyl-3,3,3-trifluoro-2,2-dimethylpropionamide
(Example No.1-263)
[0358]
CI
141) 1401 N F
1
0 F F
OH
[0359]
105
CA 02936408 2016-06-29
(1) [4-chloro-3-(4-methoxy-6-pheny1-1,3,5-triazin-2-
yl)benzyllethylamine
10360]
CI
N Br CI
14111 N 1010 NH
N yN NyN
[0361]
Under an argon atmosphere, to 2-(5-bromomethy1-2-
chloropheny1)-4-methoxy-6-phenyl-1,3,5-triazine (0.20 g, 0.51
mmol) obtained in the same manner as in Production Example 2
(1) was added a solution of 2M ethylamine tetrahydrofuran (2.5
lo ml) at room temperature, and the mixture was stirred for 1 hr.
To the reaction mixture were added saturated aqueous sodium
hydrogen carbonate and ethyl acetate and the mixture was
partitioned. The organic layer was washed with saturated brine,
dried over sodium sulfate, filtered to remove sodium sulfate,
and concentrated under reduced pressure to give the title
compound (0.28 g) as a crude product.
1H-NMR (400MHz, CDC13) 5: 1.14 (3H, t, J = 7.2 Hz), 2.70 (2H, q,
J = 7.2 Hz), 3.86 (2H, s), 4.22 (3H, s), 7.44 (1H, dd, J = 8.2,
2.2 Hz), 7.48-7.55 (3H, m), 7.57-7.62 (1H, m), 7.97 (1H, d, J
2.2 Hz), 8.58-8.64 (2H, m).
[0362]
(2) N-[4-chloro-3-(4-methoxy-6-pheny1-1,3,5-triazin-2-
yl)benzy1]-N-ethy1-3,3,3-trifluoro-2,2-dimethylpropionamide
[0363]
011 a r,
N e.P NH N, 1(.1<i F
0 FE NN
HO
0 F
õO ,0
[0364]
Under an argon atmosphere, to a solution of [4-chloro-3-
(4-methoxy-6-pheny1-1,3,5-triazin-2-yl)benzyl]ethylamine (0.18
106
CA 02936408 2016-06-29
g, 0.38 mmol) obtained in the above-mentioned (1) and 3,3,3-
trifluoro-2,2-dimethylpropionic acid (0.12 g, 0.76 mmol) in
chloroform (2.0 ml) were added WSC.HC1 (0.15 g, 0.76 mmol) and
4-dimethylaminopyridine (0.93 mg, 0.76 mmol) at room
temperature, and the mixture was stirred for 16 hr. The
residue was purified by silica gel column chromatography
(eluent: n-hexane/ethyl acetate=8/3) to give the title compound
(0.086 g, yield 46%).
1H-NMR (400MHz, CDC13) 6: 1.20 (3H, t, J = 6.9 Hz), 1.55 (6H,
/o s), 3.47 (2H, q, J = 6.9 Hz), 4.21 (3H, s), 4.71 (2H, s),
7.24-7.30 (1H, m), 7.45-7.63 (4H, m), 7.88 (1H,br s), 8.56-8.64
(2H, m).
[0365]
(3) N-[4-chloro-3-(4-hydroxy-6-pheny1-1,3,5-triazin-2-
.
yl)benzy1]-N-ethyl-3,3,3-trifluoro-2,2-dimethylpropionamide
(Example No.1-263)
[0366]
CI
N NF N Nr'lf<.F
F I
0 F N.fN 0 F
OH
[0367]
Under an argon atmosphere, to a solution of N-[4-chloro-
3-(4-methoxy-6-pheny1-1,3,5-triazin-2-yl)benzyl]-N-ethyl-3,3,3-
trifluoro-2,2-dimethylpropionamide (0.086 g, 0.17 mmol)
obtained in the above-mentioned (2) in methanol (1.5 ml) was
added 4M aqueous sodium hydroxide solution (0.26 ml, 1.0 mmol)
at room temperature, and the mixture was stirred at 65 C for 2
hr. At room temperature, 10 wt% aqueous citric acid solution
(1.2 ml) and water (6 ml) were added, and the mixture was
stirred for 30 min. The precipitated solid was collected by
filtration, washed with water, and dried under reduced pressure
to give a crude product. To a suspension of the crude product
in ethyl acetate (1.5 ml) was added n-hexane (1.5 ml), and the
mixture was stirred for 30 min. The solid was collected by
107
CA 02936408 2016-06-29
filtration, dried under reduced pressure to give the title
compound (0.067 g, yield 80%).
1H-NMR (400MHz, DMSO-d6) 6:1.13 (3H, t, J = 6.9 Hz), 1.50 (6H,
s), 3.42 (2H, br s), 4.66 (2H, s), 7.41 (1H, dd, J = 8.3, 1.8
Hz), 7.56 (2H, t, J = 7.9 Hz), 7.61-7.69 (3H, m), 8.34 (2H, d,
J = 7.9 Hz), 13.33 (1H, br s).
[0368]
[Production Example 4]
Synthesis of 7-tert-buty1-2-[4-chloro-3-(4-hydroxy-6-phenyl-
1,3,5-triazin-2-yl)benzy1]-2-azaspiro[3.5]nonan-1-one (Example
No. 1-266)
[0369]
op NS
Nrgi<
0
N N
OH
[0370]
(1) methyl 1-benzyloxymethy1-4-tert-butyl-
cyclohexanecarboxylate
[0371]
0 116.,.. 0
-0 0 0
[0372]
Under an argon atmosphere, to a solution of methyl 4-
tert-butyl-cyclohexanecarboxylate (0.46 g, 2.3 mmol) in
tetrahydrofuran (2.5 ml) was added dropwise 2M
heptane/tetrahydrofuran/ethylbenzene solution (1.4 ml, 2.8
mmol) of lithium diisopropylamide at -78 C over 5 min. After
stirring for 1 hr, benzyl chloromethyl ether (0.38 ml, 2.8
mmol) was added dropwise over 1 min. Under ice-cooling, the
mixture was stirred for 1 hr. To the reaction mixture were
added 10 wt% aqueous citric acid solution (3.0 ml) and ethyl
acetate, and the mixture was partitioned. The organic layer
108
CA 02936408 2016-06-29
was washed with saturated aqueous sodium hydrogen carbonate,
washed with saturated brine, dried over sodium sulfate,
filtered to remove sodium sulfate, and concentrated under
reduced pressure. The residue was purified by silica gel
column chromatography (eluent: n-hexane/ethyl acetate=30/1) to
give the title compound (0.49 g, yield 66%). While the title
compound was obtained as a single stereoisomer, the relative
configuration thereof is undetermined. Specifically, whether
the methoxycarbonyl group is cis/trans relative to the tert-
lo butyl group is undetermined.
1H-NMR (400MHz, CDC13) 6: 0.81 (9H, s), 0.88-0.99 (1H, m),
1.00-1.21 (4H, m), 1.68 (2H, d, J = 12.0 Hz), 2.29 (2H, d, J =
12.0 Hz), 3.36 (2H, s), 3.69 (3H, s), 4.48 (2H, br s), 7.22-
7.38 (5H, m).
[0373]
(2) methyl 4-tert-butyl-1-hydroxymethyl-cyclohexanecarboxylate
[0374]
,c)..õ,c) 40 ,01:60H
0 0
[0375]
Under an argon atmosphere, to a solution of methyl 1-
benzyloxymethyl-4-tert-butyl-cyclohexanecarboxylate (0.49 g,
1.5 mmol) obtained in the above-mentioned (1) in methanol (5.5
ml) was added ASCA-2 (4.5% palladium of activated carbon
support-0.5% platinum catalyst (see N.E. CHEMCAT, Fine chemical
October 1, 2002, pages 5-14), 0.20 g) at room temperature.
Under 1 atm hydrogen, the mixture was stirred for 4 hr. Under
an argon atmosphere, the reaction mixture was filtered through
celite, and the filtrate was eluted with ethyl acetate. The
filtrate was concentrated under reduced pressure to give the
title compound (0.27 g, yield 75%). While the title compound
is a single stereoisomer, the relative configuration thereof is
undetermined.
109
CA 02936408 2016-06-29
1H-NMR (400MHz, CD013) 6: 0.83 (9H, s), 0.91-1.17 (5H, m),
1.64-1.78 (3H, m), 2.20-2.31 (2H, m), 3.53 (2H, d, J = 6.0 Hz),
3.73 (3H, s).
[0376]
(3) 4-tert-butyl-1-hydroxymethyl-cyclohexanecarboxylic acid
[0377]
,0 õ116õOH HO .1.1õOH
[0378]
Under an argon atmosphere, to a solution of methyl 4-
tert-butyl-l-hydroxymethyl-cyclohexanecarboxylate (0.27 g, 1.2
mmol) obtained in the above-mentioned (2) in methanol (1.7 ml)
were added tetrahydrofuran (1.7 ml) and 4M aqueous sodium
hydroxide solution (1.7 ml, 7.0 mmol) at room temperature, and
the mixture was stirred at 65 C for 1.5 hr. Methanol (1.7 ml),
tetrahydrofuran (1.7 ml) and 4M aqueous sodium hydroxide
solution (1.7 ml, 7.0 mmol) were added, and the mixture was
stirred at 65 C for 2 hr. To the reaction mixture were added
2M hydrochloric acid (7.5 ml, 15 mmol) and water at room
temperature, and the mixture was stirred. Ethyl acetate was
added and the mixture was partitioned. The organic layer was
washed with saturated brine, dried over sodium sulfate,
filtered to remove sodium sulfate, and concentrated under
reduced pressure. The residue was purified by silica gel
column chromatography (eluent: n-hexane/ethyl acetate=12/1) to
give the title compound (0.24 g, yield 94%). While the title
compound is a single stereoisomer, the relative configuration
thereof is undetermined.
11-1-NMR (400MHz, DMSO-d6) 5: 0.80 (9H, s), 0.86-1.12 (5H, m),
1.53-1.66 (2H, m), 2.00-2.13 (2H, m), 3.31 (2H, s).
[0379]
(4) 4-tert-butyl-1-hydroxymethyl-cyclohexanecarboxylic acid 4-
chloro-3-(4-methoxy-6-pheny1-1,3,5-triazin-2-yl)benzylamide
110
CA 02936408 2016-06-29
[0380]
CI 5N NH, OH
N N -Ha HO OH
N N 0
,0 0
,0
[0381]
By a method similar to that in Production Example 1 (1) -
.5 (4), and using 2,4-dichloro-6-methoxy-1,3,5-triazine, 2-chloro-
5-hydroxymethylphenylboronic acid, and phenylboronic acid
instead of 4-(2,2-dimethylpropoxy)phenylboronic acid, 4-chloro-
3-(4-methoxy-6-pheny1-1,3,5-triazin-2-yl)benzylamine
hydrochloride was obtained.
Under an argon atmosphere, to a solution of the obtained
4-chloro-3-(4-methoxy-6-phenyl-1,3,5-triazin-2-yl)benzylamine
hydrochloride (0.90 g, 0.25 mmol) and 4-tert-buty1-1-
hydroxymethy1-cyclohexanecarboxylic acid (0.080 g, 0.37 mmol)
obtained in the above-mentioned (3) in N,N-dimethylformamide
(2.0 ml) were added HOBt.H20 (0.057 g, 0.37 mmol), WSC-HC1
(0.071 g, 0.37 mmol) and triethylamine (0.10 ml, 0.74 mmol) at
room temperature, and the mixture was stirred for 13 hr. To
the reaction mixture were added saturated aqueous sodium
hydrogen carbonate and ethyl acetate, and the mixture was
partitioned. The organic layer was washed with saturated
aqueous sodium hydrogen carbonate, washed with saturated brine,
dried over sodium sulfate, filtered to remove sodium sulfate,
and concentrated under reduced pressure. The residue was
purified by silica gel column chromatography (eluent: n-
hexane/ethyl acetate=1/2 - 1/3) to give the title compound
(0.11 g, yield 81%). While the title compound is a single
stereoisomer, the relative configuration thereof is
undetermined.
1H-NMR (400MHz, CDC13) 6: 0.78 (9H, s), 0.94-1.22 (5H, m),
1.66-1.75 (2H, m), 2.22-2.30 (2H, m), 2.42 (1H, t, J - 5.0 Hz),
3.52 (2H, d, J = 5.0 Hz), 4.21 (3H, a), 4.57 (2H, d, J = 5.8
111
CA 02936408 2016-06-29
Hz), 6.46 (1H, t, J- = 5.8 Hz), 7.38 (1H, dd, J = 8.3, 2.3 Hz),
7.47-7.55 (3H, m), 7.57-7.62 (1H, m), 7.97 (1H, d, J = 2.3 Hz),
8.57-8.62 (2H, m).
[0382]
(5) 7-tert-buty1-2-[4-chloro-3-(4-methoxy-6-pheny1-1,3,5-
triazin-2-yl)benzyl]-2-azaspiro[3.5]nonan-1-one
[0383]
rsi 100 OH CIN ahn
N NI-121k
0
N
0
NY-
,0
,0
[0384]
io Under an argon atmosphere, to a solution of 4-tert-butyl-
1-hydroxymethyl-cyclohexanecarboxylic acid 4-chloro-3-(4-
methoxy-6-phenyl-1,3,5-triazin-2-yl)benzylamide (0.11 g, 0.20
mmol) obtained in the above-mentioned (4) and
triphenylphosphine (0.080 g, 0.30 mmol) in tetrahydrofuran (1.0
ml) was added bis(2-methoxyethyl) azodicarboxylate (0.071 g,
0.30 mmol) at room temperature, and the mixture was stirred for
1.5 hr. To the reaction mixture were added water and ethyl
acetate, and the mixture was partitioned. The organic layer
was washed with saturated aqueous sodium hydrogen carbonate,
washed with saturated brine, dried over sodium sulfate,
filtered to remove sodium sulfate, and concentrated under
reduced pressure. The residue was purified by preparative thin
layer chromatography (eluent: n-hexane/ethyl acetate=4/1) to
give the title compound (0.068 g, yield 66%). While the title
compound is a single stereoisomer, the relative configuration
of the tert-butyl group is undetermined.
1H-NMR (400MHz, CDC13) 5: 0.81-1.77 (7H, m), 0.87 (9H, s),
2.03-2.12 (2H, m), 2.87 (2H, br s), 4.21 (3H, s), 4.40 (2H, br
s), 7.30-7.37 (1H, m), 7.48-7.64 (4H, m), 7.90 (1H, br s),
8.57-8.63 (2H, m).
[0385]
112
CA 02936408 2016-06-29
(6) 7-tert-buty1-2-[4-chloro-3-(4-hydroxy-6-pheny1-1,3,5-
triazin-2-yl)benzyl]-2-azaspiro[3.5]nonan-l-one (Example No.1-
266)
[0386]
5' 544:1-5-j<
ci 001 Ni3j<
0 0
N N
NN
,0 OH
[0387]
Under an argon atmosphere, to a solution of 7-tert-buty1-
2-[4-chloro-3-(4-methoxy-6-pheny1-1,3,5-triazin-2-yl)benzy1]-2-
azaspiro[3.5]nonan-l-one (0.068 g, 0.13 mmol) obtained in the
above-mentioned (5) in methanol (1.2 ml) was added 4M aqueous
sodium hydroxide solution (0.20 ml, 0.81 mmol) at room
temperature, and the mixture was stirred at 65 C for 1.5 hr.
At room temperature, to the reaction mixture were added 10 wt%
aqueous citric acid solution (0.82 ml) and water (4.0 ml), and
the mixture was stirred for 30 min. The precipitated solid was
collected by filtration, washed with water, and dried under
reduced pressure to give the title compound (0.062 g, yield
94%). While the title compound is a single stereoisomer, the
relative configuration of the tert-butyl group is undetermined.
1H-NMR (400MHz, DMSO-d0 5: 0.83 (9H, s), 0.90-0.99 (1H, m),
1.41-1.67 (6H, m), 1.96-2.03 (2H, m), 2.92 (2H, s), 4.38 (2H,
s), 7.47 (1H, dd, J = 8.3, 1.8 Hz), 7.56 (2H, t, J = 7.6 Hz),
7.63-7.69 (3H, m), 8.34 (2H, d, J = 7.6 Hz), 13.34 (1H, br s).
[0388]
[Production Example 5]
Synthesis of 4-[2-(6-methylpyridin-2-ylmethoxy)-6-
trifluoromethylpheny1]-6-(4-phenylethynylpheny1)-1,3,5-triazin-
2-ol hydrochloride (Example No.2-98)
[0389]
113
CA 02936408 2016-06-29
F F
F
N 0 ci I
OH HCI
[0390]
(1) 2-bromo-l-methoxymethoxy-3-trifluoromethyl-benzene
[0391]
F F
F
F
Br Br
0 0,
[0392]
Under an argon atmosphere, to a solution of 2-bromo-3-
fluorobenzotrifluoride (6.0 g, 25 mmol) and 2-
(methylsulfonyl)ethanol (4.3 g, 35 mmol) in N,N-
/o dimethylformamide (10 ml) was added sodium hydride (2.8 g, 60
wt% oil dispersion) in 3 portions under ice-cooling. After
stirring at room temperature for 10 min, chloromethyl methyl
ether (5.3 ml, 69 mmol) was added dropwise under ice-cooling.
After stirring for 30 min, the mixture was stirred at room
temperature for 15 min. Under ice-cooling, to the reaction
mixture were added water and ethyl acetate, and the mixture was
partitioned. The organic layer was washed with saturated
aqueous sodium hydrogen carbonate, washed with saturated brine,
dried over sodium sulfate, filtered to remove sodium sulfate,
and concentrated under reduced pressure. The residue was
purified by silica gel column chromatography (eluent: n-
hexane/ethyl acetate=12/1) to give the title compound (5.0 g,
yield 70%).
1H-NMR (400MHz, CDC13) 6: 3.53 (3H, s), 5.29 (2H, s), 7.31-7.38
(3H, m).
[0393]
(2) 2-(2-methoxymethoxy-6-trifluoromethylphenyl)-4,4,5,5-
tetramethy1-1,3,2-dioxaborolane
[0394]
114
CA 02936408 2016-06-29
FF F
oF,
F
Br
o o, o o,
[0395]
Under an argon atmosphere, to a solution of 2-bromo-1-
methoxymethoxy-3-trifluoromethyl-benzene (4.9 g, 17 mmol)
obtained in the above-mentioned (1) in tetrahydrofuran (90 ml)
was added dropwise n-butyllithium (1.6M n-hexane solution, 11
ml, 17 mmol) at -78 C over 30 min. 2-Isopropoxy-4,4,5,5-
tetramethy1-1,3,2-dioxaborolane (3.5 ml, 17 mmol) was added
dropwise over 15 min, and the mixture was warmed to room
lo temperature and stirred for 2 hr. To the reaction mixture were
added saturated ammonium chloride aqueous solution and ethyl
acetate, and the mixture was partitioned. The organic layer
was washed with saturated aqueous sodium hydrogen carbonate,
washed with saturated brine, dried over sodium sulfate,
is filtered to remove sodium sulfate, and concentrated under
reduced pressure. The residue was purified by silica gel
column chromatography (eluent: n-hexane/ethyl acetate=9/1) to
give the title compound (2.8 g, yield 48%).
1H-NMR (40011Hz, CDC13) 6: 1.39 (12H, s), 3.47 (3H, s), 5.18 (211,
20 s) 7.20 (1H, d, J = 8.4 Hz), 7.24-7.28 (111, m), 7.36-7.42 (1H,
m).
[0396]
(3) 2-(4-benzyloxypheny1)-4-methoxy-6-(2-methoxymethoxy-6-
trifluoromethylpheny1)-1,3,5-triazine
25 [0397]
FF 4 FF 111 41 0 os F
)
0-B
NCI __________________________________
NY N 01
Ny
,0 ,0 0,
[0398]
By a method similar to that in Production Example 1 (1),
and using 2,4-dichloro-6-methoxy-1,3,5-triazine, and 4-
115
CA 02936408 2016-06-29
(benzyloxy)phenylboronic acid instead of 4-(2,2-
dimethylpropoxy)phenylboronic acid, 2-(4-benzyloxypheny1)-4-
chloro-6-methoxy-1,3,5-triazine was obtained.
Under an argon atmosphere, to a solution of the obtained
2-(4-benzyloxypheny1)-4-chloro-6-methoxy-1,3,5-triazine (3.0 g,
9.2 mmol) and 2-(2-methoxymethoxy-6-trifluoromethylpheny1)-
4,4,5,5-tetramethy1-1,3,2-dioxaborolane (2.8 g, 8.4 mmol)
obtained in the above-mentioned (2) in N,N-dimethylformamide
(25 ml) were added [1,1f-
bis(diphenylphosphino)ferrocene]palladium(II)dichloride
dichloromethane adduct (1.4 g, 1.7 mmol), copper(I) iodide
(0.48 g, 2.5 mmol) and 2M aqueous sodium carbonate solution (13
ml, 25 mmol), and the mixture was stirred at 115 C for 45 min.
To the reaction mixture were added water and ethyl acetate.
After stirring, the insoluble material was removed by celite
filtration, and the filtrate was eluted with ethyl acetate.
The filtrate was partitioned, and the organic layer was washed
with saturated aqueous sodium hydrogen carbonate, washed with
saturated brine, dried over sodium sulfate, filtered to remove
sodium sulfate, and concentrated under reduced pressure. The
residue was purified by silica gel column chromatography
(eluent: n-hexane/ethyl acetate=7/2) to give the title compound
(2.0 g, yield 47%).
1H-NMR (400MHz, DMSO-d0 6: 3.39 (3H, s), 4.14 (3H, s), 5.13
(2H, s), 5.15 (2H, s), 7.02-7.08 (2H, m), 7.30-7.46 (7H, m),
7.48-7.55 (1H, m), 8.47-8.52 (2H, m).
[0399]
(4) 4-[4-methoxy-6-(2-methoxymethoxy-6-trifluoromethylpheny1)-
1,3,5-triazin-2-yl]phenol
[0400]
FF
0 F HO
F
N
N. 140)
NYY
N 0 N Asi 0
,o o, ,o o,
[0401]
116
CA 02936408 2016-06-29
Under an argon atmosphere, to a solution of 2-(4-
benzyloxypheny1)-4-methoxy-6-(2-methoxymethoxy-6-
trifluoromethylpheny1)-1,3,5-triazine (2.0 g, 4.0 mmol)
obtained in the above-mentioned (3) in ethyl acetate (10 ml)
were added methanol (10 ml) and 10 wt% palladium carbon (0.49
g) at room temperature. Under 1 atm hydrogen, the mixture was
stirred for 2 hr. Under an argon atmosphere, the reaction
mixture was filtered through celite, and the filtrate was
eluted with ethyl acetate. The filtrate was concentrated under
reduced pressure to give the title compound (1.6 g, yield 97%).
1H-NMR(400MHz, 0D013)6:3.39 (3H, s), 4.14 (4H, s), 5.13 (2H, s),
5.39 (1H, br s), 6.87-6.93 (2H, m), 7.40-7.45 (2H, m), 7.48-
7.55 (1H, m), 8.43-8.48 (2H, m).
[0402]
(5) trifluoromethanesulfonic acid 4-[4-methoxy-6-(2-
methoxymethoxy-6-trifluoromethylpheny1)-1,3,5-triazin-2-
yllphenyl ester
[0403]
HO 0 FF
õO
F
NN
N
0, NN 0,
1 1
[0404]
Under an argon atmosphere, to a solution of 4-[4-methoxy-
6-(2-methoxymethoxy-6-trifluoromethylpheny1)-1,3,5-triazin-2-
yl]phenol (1.6 g, 3.9 mmol) obtained in the above-mentioned (4)
in pyridine (15 ml) was added dropwise trifluoromethanesulfonic
anhydride (13 ml, 7.7 mmol) under ice-cooling, and the mixture
was stirred at room temperature for 30 min. To the reaction
mixture were added water and ethyl acetate, and the mixture was
partitioned. The organic layer was washed with saturated
aqueous sodium hydrogen carbonate, washed with saturated brine,
dried over sodium sulfate, filtered to remove sodium sulfate,
and concentrated under reduced pressure. The residue was
117
CA 02936408 2016-06-29
purified by silica gel column chromatography (eluent: n-
hexane/ethyl acetate=3/1) to give the title compound (2.0 g,
yield 95%).
1H-NMR (400MHz, CDC13) 6: 3.39 (3H, s), 4.17 (3H, s), 5.13 (2H,
s), 7.37-7.48 (4H, m), 7.51-7.58 (1H, m), 8.61-8.67 (2H, m).
[0405]
(6) 2-methoxy-4-(2-methoxymethoxy-6-trifluoromethylpheny1)-6-
(4-phenylethynylpheny1)-1,3,5-triazine
[0406]
q. 0 1.46
FF
FYS'
F FN F
N 0
Y N 0
,o 0,
[0407]
Under an argon atmosphere, to a solution of
trifluoromethanesulfonic acid 4-[4-methoxy-6-(2-methoxymethoxy-
6-trifluoromethylpheny1)-1,3,5-triazin-2-yl]phenyl ester (0.50
g, 0.93 mmol) obtained in the above-mentioned (5),
bis(triphenylphosphine)palladium(II)dichloride (0.098 g, 0.139
mmol) and copper(I) iodide (0.053 g, 0.28 mmol) in N,N-
dimethylformamide (5.0 ml) were added triethylamine (0.39 ml,
2.8 mmol) and ethynylbenzene (0.51 ml, 4.6 mmol), and the
mixture was stirred at 65 C for 2.5 hr. To the reaction
mixture were added water and ethyl acetate. After stirring for
1 hr, the insoluble material was removed by celite filtration,
and the filtrate was eluted with ethyl acetate. The filtrate
was partitioned, and the organic layer was washed with
saturated aqueous sodium hydrogen carbonate, washed with
saturated brine, dried over sodium sulfate, filtered to remove
sodium sulfate, and concentrated under reduced pressure. The
residue was purified by silica gel column chromatography
(eluent: n-hexane/ethyl acetate=5/1 - 4/1) to give the title
compound (0.45 g, yield 98%).
1H-NMR (400MHz, DMSO-d6) 6: 3.40 (3H, s), 4.17 (3H, s), 5.14
118
CA 02936408 2016-06-29
(2H, s), 7.34-7.39 (31-1, m), 7.42-7.47 (2H, m), 7.50-7.59 (3H,
m), 7.62-7.67 (2H, m), 8.50-8.55 (2H, m).
[0408]
(7) 2-[4-methoxy-6-(4-phenylethynylpheny1)-1,3,5-triazin-2-y1]-
3-trifluoromethylphenol
[0409]
FF
FF
NS OL1F
NN N N OH
Y
õO
[0410]
Under an argon atmosphere, to a solution of 2-methoxy-4-
/0 (2-methoxymethoxy-6-trifluoromethylpheny1)-6-(4-
phenylethynylpheny1)-1,3,5-triazine (0.45 g, 0.92 mmol)
obtained in the above-mentioned (6) in methanol (4.5 ml) were
added 1,4-dioxane (4.5 ml) and methanesulfonic acid (0.030 ml,
0.46 mmol) at room temperature. The mixture was stirred at
70 C for 5 hr, and triethylamine (0.13 ml, 0.92 mmol) was added
to the reaction mixture at room temperature. To the reaction
mixture was added water (45 ml), and the mixture was stirred
for 30 min. The precipitated solid was collected by filtration
and dried to give the title compound (0.38 g, yield 93%).
1H-NMR (400MHz, CDC13) 6: 4.23 (3H, s), 7.25-7.30 (1H, m),
7.36-7.40 (3H, m), 7.43-7.47 (1H, m), 7.50-7.60 (3H, m), 7.67-
7.72 (2H, m), 8.48-8.52 (2E, m), 12.43 (1H, br s)
[0411]
(8) 2-methoxy-4-[2-(6-methylpyridin-2-ylmethoxy)-6-
trifluoromethylpheny1]-6-(4-phenylethynylpheny1)-1,3,5-triazine
[0412]
FF
FF
Oçk 411 1-10'AN
N OH
NN
N Y
,0 ,0
119
CA 02936408 2016-06-29
[0413]
Under an argon atmosphere, to a solution of 2-[4-methoxy-
6-(4-phenylethynylpheny1)-1,3,5-triazin-2-y1]-3-
trifluoromethylphenol (0.24 g, 0.54 mmol) obtained in the
above-mentioned (7), 6-methyl-2-pyridinemethanol (0.099 g, 0.80
mmol) and triphenylphosphine (0.21 g, 0.80 mmol) in
tetrahydrofuran (6.0 ml) was added bis(2-methoxyethyl)
azodicarboxylate (0.19 g, 0.80 mmol) in 3 portions under ice-
cooling. The reaction mixture was stirred for 20 min and at
room temperature for 20 hr. Thereafter, to the reaction
mixture were added 6-methyl-2-pyridinemethanol (0.099 g, 0.80
mmol) and triphenylphosphine (0.21 g, 0.80 mmol), and bis(2-
methoxyethyl) azodicarboxylate (0.19 g, 0.80 mmol) in 2
portions under ice-cooling. After stirring for 20 min, the
/5 reaction mixture was stirred for 10 min at room temperature.
To the reaction mixture were added water and ethyl acetate, and
the mixture was partitioned. The organic layer was washed with
saturated aqueous sodium hydrogen carbonate, washed with
saturated brine, dried over sodium sulfate, filtered to remove
sodium sulfate, and concentrated under reduced pressure. The
residue was purified by silica gel column chromatography
(eluent: n-hexane/ethyl acetate=4/3) to give the title compound
(0.28 g, yield 95%).
1H-NMR (400MHz, CDC13) 6: 2.51 (3H, s), 4.17 (3H, s), 5.21 (2H,
s), 6.96-7.01 (1H, m), 7.02-7.07 (1H, m), 7.20-7.25 (1H, m),
7.33-7.42 (5H, m), 7.47-7.59 (3H, m), 7.62-7.68 (2H, m), 8.52-
8.57 (2H, m).
[0414]
(9) 4-[2-(6-methylpyridin-2-ylmethoxy)-6-
trifluoromethylpheny1]-6-(4-phenylethynylpheny1)-1,3,5-triazin-
2-ol
[0415]
120
CA 02936408 2016-06-29
F F
Nõ. 4111
F 0
,0 OH
[0416]
Under an argon atmosphere, to a suspension of 2-methoxy-
4-[2-(6-methylpyridin-2-ylmethoxy)-6-trifluoromethylpheny1]-6-
(4-phenylethynylpheny1)-1,3,5-triazine (0.28 g, 0.52 mmol)
obtained in the above-mentioned (8) in methanol (4.6 ml) were
added 4M aqueous sodium hydroxide solution (0.77 ml, 3.1 mmol)
and tetrahydrofuran (0.46 ml) at room temperature. At 65 C,
the reaction mixture was stirred for 3.5 hr. To the reaction
/o mixture were added 10 wt% aqueous citric acid solution (3.2 ml)
and water (16 ml) at room temperature, and the mixture was
stirred for 30 min. The precipitated solid was collected by
filtration, washed with water, and dried under reduced pressure
to give the title compound (0.27 g, yield 95%).
1H-NMR (400MHz, DMSO-d6) 5: 2.43 (3H, s), 5.31 (2H, s), 7.07-
7.17 (2H, m), 7.43-7.49 (3H, m), 7.50-7.68 (5H, m), 7.69-7.82
(3H, m), 8.32-8.38 (2H, m), 13.63 (1H, br s).
[0417]
(10) 4-[2-(6-methylpyridin-2-ylmethoxy)-6-
trifluoromethylpheny1]-6-(4-phenylethynylpheny1)-1,3,5-triazin-
2-ol hydrochloride (Example No.2-98)
[0418]
FF
Cl F
=
N... imp N, 4k
N N N 0,XL.
y
OH OH -NCI
[0419]
Under an argon atmosphere, to a solution of 4-[2-(6-
methylpyridin-2-ylmethoxy)-6-trifluoromethylpheny1]-6-(4-
phenylethynylpheny1)-1,3,5-triazin-2-ol (0.27 g, 0.49 mmol)
121
CA 02936408 2016-06-29
obtained in the above-mentioned (9) in 1,4-dioxane (5.3 ml) was
added 4M hydrogen chloride/1,4-dioxane solution (0.37 ml, 1.5
mmol) at room temperature. To the reaction mixture was added
n-hexane (21 ml), and the mixture was stirred for 30 min. The
precipitated solid was collected by filtration, washed with n-
hexane, and dried under reduced pressure to give the title
compound (0.26 g, yield 91%).
1H-NMR (400MHz, DMSO-d6) 6: 2.48 (3H, s), 5.37 (2H, s), 7.23
(1H, d, J = 7.3 Hz), 7.28 (1H, d, J = 7.3 Hz), 7.48-7.45 (3H,
lo m), 7.56 (1H, d, J = 7.9 Hz), 7.64-7.59 (2H, m), 7.67 (1H, d, J
= 8.6 Hz), 7.82-7.72 (4H, m), 8.35 (2H, dd, J = 6.8, 2.0 Hz).
[0420]
[Production Example 6]
Synthesis of 2-[4-chloro-2-methyl-5-(4,4,5,5-
Is tetramethyl[1,3,2]dioxaborolan-2-yl)benzyloxy]tetrahydropyran
[0421]
(1) 4-chloro-5-iodo-2-methylbenzoic acid
[0422]
ri& CI Al
Lir OH _______________ I W. OH
0 0
20 [0423]
Under an argon atmosphere, to 4-chloro-2-methylbenzoic
acid (1.9 g, 11 mmol) were added concentrated sulfuric acid (16
ml) and N-iodosuccinimide (2.7 g, 12 mmol) under ice-cooling,
and the mixture was stirred at room temperature for 4 hr. The
25 reaction mixture was carefully poured into ice water and the
mixture was stirred. The precipitated solid was collected by
filtration, washed with water, and dried under reduced pressure
to give the title compound (3.3 g, yield 99%).
1H-NMR (CDC13) 6: 2.58 (3H, s), 7.38 (1H, br s), 8.50 (1H, s).
30 [0424]
(2) (4-chloro-5-iodo-2-methylphenyl)methanol
[0425]
122
CA 02936408 2016-06-29
CI AI
CI AI
H SH
IW / 41P
[0426]
Under an argon atmosphere, to a solution of 4-chloro-5-
iodo-2-methylbenzoic acid (2.4 g, 8.1 mmol) in tetrahydrofuran
(12 ml) were added triethylamine (1.2 ml, 8.9 mmol) and
isobutyl chloroformate (1.2 ml, 8.9 mmol) under ice-cooling,
and the mixture was stirred for 30 min. At room temperature,
the insoluble material was removed by filtration, and washed
with tetrahydrofuran (36 ml). The filtrate was added dropwise
lo to a solution of prepared sodium borohydride (0.92 g, 24 mmol)
in water (4.5 ml) over 10 min under ice-cooling. After
stirring at room temperature for 2 hr, to the reaction mixture
was added sodium borohydride (0.30 g, 8.1 mmol), and the
mixture was stirred for 1 hr. To the reaction mixture were
added saturated aqueous ammonium chloride solution and ethyl
acetate, and the mixture was partitioned. The organic layer
was washed with saturated aqueous sodium hydrogen carbonate,
washed with saturated brine, dried over sodium sulfate,
filtered to remove sodium sulfate, and concentrated under
reduced pressure. The residue was purified by silica gel
column chromatography (eluent: chloroform /ethyl acetate=100/0
- 95/5) to give the title compound (2.0 g, yield 88%).
1H-NMR (400MHz, CDC13) 5: 1.60 (1H, t, J = 5.7 Hz), 2.26 (3H,
s), 4.63 (2H, d, J = 5.6 Hz), 7.25-7.26 (1H, m), 7.84 (1H, br
s) .
[0427]
(3) 2-(4-chloro-5-iodo-2-methylbenzyloxy)tetrahydropyran
[0428]
CI
101
a Ai,
SH I 'W
I 4V
[0429]
Under an argon atmosphere, to a solution of (4-chloro-5-
123
CA 02936408 2016-06-29
iodo-2-methylphenyl)methanol (2.0 g, 7.1 mmol) obtained in the
above-mentioned (1) In chloroform (20 ml) were added pyridinium
p-toluenesulfonate (0.27 mg, 1.1 mmol) and 3,4-dihydro-2H-pyran
(0.97 ml, 11 mmol) at room temperature, and the mixture was
stirred for 16 hr. The reaction mixture was concentrated under
reduced pressure, and the residue was purified by silica gel
column chromatography (eluent: n-hexane/ethyl acetate=9/1) to
give the title compound (2.6 g, yield 99%).
1H-NMR (400MHz, CDC13) 8: 1.51-1.92 (6H, m), 2.26 (3H, s),
lo 3.52-3.59 (1H, m), 3.85-3.91 (1H, m), 4.38 (1H, d, J - 12.6 Hz),
4.67-4.72 (2H, m), 7.25 (1H, br s), 7.82 (1H, br s).
[0430]
(4) 2-[4-chloro-2-methy1-5-(4,4,5,5-
tetramethyl[1,3,2]dioxaborolan-2-yl)benzyloxy]tetrahydropyran
/5 [0431]
0-B
0
[0432]
Under an argon atmosphere, to a solution of 2-(4-chloro-
5-iodo-2-methylbenzyloxy)tetrahydropyran (2.3 g, 6.2 mmol)
20 obtained in the above-mentioned (2) in 1,4-dioxane (23 ml) were
added biphenyl-2-yl-dicyclohexylphosphine (0.43 g, 1.2 mmol),
palladium(II) acetate (0.070 g, 0.31 mmol), triethylamine (3.4
m1, 25 mmol) and 4,4,5,5-tetramethy1-1,3,2-dioxaborolane (2.7
ml, 18 mmol) at room temperature, and the mixture was stirred
25 at 80 C for 5 hr. Under ice-cooling, to the reaction mixture
was added dropwise water, and ethyl acetate was added. After
partitioning, the organic layer was washed with saturated
aqueous sodium hydrogen carbonate, washed with saturated brine,
dried over sodium sulfate, filtered to remove sodium sulfate,
30 and concentrated under reduced pressure. The residue was
purified by silica gel column chromatography (eluent: n-
hexane/ethyl acetate-98/2 - 80/20) to give the title compound
(1.3 g, yield 60%).
124
CA 02936408 2016-06-29
1H-NMR (400MHz, CDC13) 5: 1.36 (12H, s), 1.47-1.90 (6H, m),
2.34 (3H, s), 3.52-3.59 (1H, m), 3.88-3.95 (1H, m), 4.42 (1H, d,
J = 11.6 Hz), 4.67 (1H, t, J = 3.5 Hz), 4.74 (1H, d, J = 11.6
Hz), 7.18 (1H, br s), 7.63 (1H, br s).
[0433]
[Production Example 7]
Synthesis of tert-butyl-(4-chloro-3-iodo-2-
methylbenzyloxy)dimethylsilane
[0434]
119 (1) 3-(tert-butyl-dimethylsilanyloxymethyl)-6-chloro-2-
methylphenylamine
[0435]
CI Ai
0,1 0 '
FI214
/Sir(
[0436]
Under an argon atmosphere, to a solution of 3-(tert-
butyldimethylsilanyloxymethyl)-2-methyl-phenylamine (0.91 g,
3.6 mmol) in tetrahydrofuran (5.0 m1) was added N-
chlorosuccinimide (0.48 g, 3.6 mmol) at room temperature.
After stirring for 22 hr, to the reaction mixture was added n-
hexane (10 ml), and the insoluble material was filtered off.
The filtrate was concentrated, and purified by silica gel .
column chromatography (eluent: n-hexane/ethyl acetate=20/1) to
give the title compound (0.18 g, yield 17%).
1H-NMR(400MHz, CDC13)6:0.08 (6H, s), 0.92 (9H, s), 2.11 (3H, s),
4.01 (2H, br s), 4.60-4.69 (2H, m), 6.77 (1H, d, J = 8.4 Hz),
7.11 (1H, d, J = 8.4 Hz).
[0437]
(2) tert-butyl-(4-chloro-3-iodo-2-
methylbenzyloxy)dimethylsilane
[0436]
CI Ai CI i6
FI2N 0'Si I WI
125
CA 02936408 2016-06-.29
[0439]
Under an argon atmosphere, to a solution of 3-(tert-
butyl-dimethylsilanyloxymethyl)-6-chloro-2-methylphenylamine
(0.18 g, 0.63 mmol) obtained in the above-mentioned (1) in
acetonitrile (2.0 ml) were added iodine (0.19 g, 0.76 mmol) and
tert-butyl nitrite (0.11 ml, 0.94 mmol) at room temperature,
and the mixture was stirred at 65 C for 30 min. At room
temperature, to the reaction mixture were added water and ethyl
acetate. After partitioning, the organic layer was washed with
lo saturated aqueous sodium hydrogen carbonate, 10 wt% aqueous
sodium thiosulfate solution, washed with saturated brine, dried
over sodium sulfate, filtered to remove sodium sulfate, and
concentrated under reduced pressure. The residue was purified
by silica gel column chromatography (eluent: n-hexane/ethyl
acetate=40/1) to give the title compound (0.099 g, yield 40%).
1H-NMR(400MHz, CDC13)6:0.10 (6H, s), 0.93 (9H, s), 2.47 (3H, s),
4.68 (2H, s), 7.30 (11-1, d, J - 8.4 Hz), 7.35 (1H, d, J - 8.1
Hz).
[0440]
[Production Example 8]
Synthesis of 2-(6-chloro-2-methoxymethoxy-3-methylpheny1)-
4,4,5,5-tetramethyl[1,3,2]dioxaborolane
[0441]
(1) 4-chloro-2-methoxymethoxy-l-methylbenzene
[0442]
CI, _______________________ 0
OH 0
0
[0443]
Under an argon atmosphere, to a solution of 5-chloro-2-
methylphenol (1.0 g, 7.0 mmol) in N,N-dimethylformamide (20 ml)
was added sodium hydride (0.34 g, 60 wt% oil dispersion) under
ice-cooling. After stirring for 15 min, the mixture was
stirred at room temperature for 30 min. Under ice-cooling,
126
CA 02936408 2016-06-29
chloromethyl methyl ether (0.64 ml, 8.4 mmol) was added, and
the mixture was stirred for 30 min. To the reaction mixture
were added water and diethyl ether, and the mixture was
partitioned at room temperature. The organic layer was washed
with water, washed with saturated brine, dried over sodium
sulfate, filtered to remove sodium sulfate, and concentrated
under reduced pressure. The residue was purified by silica gel
column chromatography (eluent: n-hexane/diethyl ether=25/1) to
give the title compound (1.3 g, yield 96%).
lo 1H-NMR(400MHz, CDC13)6:2.20 (3H, s), 3.48 (3H, s), 5.18 (2H, s),
6.89 (1H, dd, J = 7.9, 2.0 Hz), 7.03-7.07 (2H, m).
[0444]
(2) 2-(6-chloro-2-methoxymethoxy-3-methylpheny1)-4,4,5,5-
tetramethyl[1,3,2]dioxaborolane
[0445]
4" a
0 0-B 0
0 /)c 0 (0
[0446]
Under an argon atmosphere, to a solution of 4-chloro-2-
methoxymethoxy-1-methylbenzene (0.75 g, 4.0 mmol) obtained in
the above-mentioned (1) in tetrahydrofuran (20 ml) was added
dropwise n-butyllithium (1.6M n-hexane solution, 2.5 ml, 4.0
mmo1) at -78 C over 5 min. After stirring for 30 min, 2-
isopropoxy-4,4,5,5-tetramethy1-1,3,2-dioxaborolane (0.81 ml,
4.0 mmol) was added. After stirring for 2 hr, the stirring was
discontinued, and the mixture was warmed to room temperature.
After 13 hr, to the reaction mixture were added saturated
aqueous ammonium chloride solution and ethyl acetate, and the
mixture was partitioned. Thereafter, the organic layer was
washed with water, washed with saturated brine, dried over
magnesium sulfate, filtered to remove magnesium sulfate, and
concentrated under reduced pressure. The residue was purified
by silica gel column chromatography (eluent: n-hexane/ethyl
127
CA 02936408 2016-06-29
acetate=12/1) to give the title compound (0.20 g, yield 15%).
1H-NMR (400MHz, CDC13) 5: 1.40 (12H, s), 2.27 (3H, s), 3.55 (3H,
s), 5.03 (2H, s), 7.01 (1H, d, J = 8.2 Hz), 7.07-7.11 (1H, m).
[0447]
[Production Example 9]
Synthesis of N-{4-chloro-3-[4-(4-isobutylpheny1)-6-hydroxy-
1,3,5-triazin-2-yl]benzy11-2,2-dimethylpropionamide (Example
No.1-51)
[0448]
Ny-N 0
O
H
[0449]
(1) 2-chloro-4-(4-isobutylpheny1)-6-methoxy-1,3,5-triazine
[0450]
ayvya
,OH yCI
,0 11.0
OH
[0451]
Under an argon atmosphere, a suspension of 4-(2-
methylpropyl)phenylboronic acid (35 g, 200 mmol), 2,4-dichloro-
6-methoxy-1,3,5-triazine (46 g, 260 mmol),
tetrakis(triphenylphosphine)palladium(0) (2.3 g, 2.0 mmol) and
sodium carbonate (63 g, 590 mmol) in toluene (280 ml) and
distilled water (280 ml) was stirred at 70 C for 3.5 hr. At
room temperature, to the reaction mixture were added water,
ethyl acetate, and n-hexane, and the mixture was partitioned.
The organic layer was washed with saturated brine, dried over
sodium sulfate, filtered to remove sodium sulfate, and
concentrated under reduced pressure to give the title compound
(60 g) as a crude product.
[0452]
(2) f4-chloro-3-[4-(4-isobutylpheny1)-6-methoxy-1,3,5-triazin-
2-yl]phenyllmethanol
[0453]
128
CA 02936408 2016-06-29
N CI CI * CI
1.1 N, 1.1 *1-1
9 H -------a
NyN
OH IVyN
/0
[0454]
Under an argon atmosphere, a suspension of a crude
product (60 g) of 2-chloro-4-(4-isobutylpheny1)-6-methoxy-
1,3,5-triazine obtained in the above-mentioned (1), 2-chloro-5-
hydroxymethylphenylboronic acid (44 g, 240 mmol), [1,1'-
bis(diphenylphosphino)ferrocene]palladium(II)dichloride
dichloromethane adduct (3.2 g, 3.9 mmol) and cesium fluoride
(90 g, 590 mmol) in acetonitrile (440 ml) and distilled water
/0 (130 ml) was stirred at 67 C for 2 hr. At room temperature, to
the reaction mixture were added water and ethyl acetate, and
the mixture was partitioned. The organic layer was washed with
water, and the organic layer was washed with saturated brine,
dried over sodium sulfate, filtered to remove sodium sulfate,
15 and concentrated under reduced pressure. The residue was
purified by silica gel column chromatography (eluent: n-
hexane/ethyl acetate=7/3 - 6/4) to give the title compound (57
g).
1H-NMR (CDC13) 6: 0.93 (6H, d, J = 6.6 Hz), 1.77 (1H, t, J =
20 6.1 Hz), 1.90-1.97 (1H, m), 2.57 (2H, d, J = 7.3 Hz), 4.21 (3H,
s), 4.77 (2H, d, J = 6.1 Hz), 7.29 (2H, d, J = 8.3 Hz), 7.47
(1H, dd, J = 8.3, 2.1 Hz), 7.54 (1H, d, J = 8.3 Hz), 8.01 (1H,
d, J = 2.1 Hz), 8.51 (2H, d, J = 8.3 Hz).
[0455]
25 (3) tert-butyl N-14-chloro-3-[4-(4-isobutylpheny1)-6-methoxy-
1,3,5-triazin-2-yl]benzyll-N-(tert-butoxycarbonyl)carbamate
[0456]
40 a 00 =11 _____________________ = CI soNN 0...r0
y0A,
0 I
Ny N
[0457]
30 Under an argon atmosphere, to a solution of 14-chloro-3-
129
CA 02936408 2016-06-29
[4-(4-isobutylpheny1)-6-methoxy-1,3,5-triazin-2-
yllphenyllmethanol (0.25 g, 0.64 mmol) obtained in the above-
mentioned (2) and triphenylphosphine (0.25 g, 0.96 mmol) in
chloroform (2.4 ml) was added carbon tetrabromide (0.32 g, 0.96
mmol) under ice-cooling. The reaction mixture was stirred at
room temperature for 10 min. The reaction mixture was subject
to silica gel column chromatography (eluent: n-hexane/ethyl
acetate=30/1 - 10/1), and concentrated under reduced pressure.
A solution of the residue in N,N-dimethylformamide (2.0 ml) was
added to a solution of di-tert-butyl iminodicarboxylate (0.140
g, 0.64 mmol) and sodium hydride (0.026 g, 60 wt% oil
dispersion) in N,N-dimethylformamide (1.0 ml) under ice-cooling,
and the mixture was stirred at room temperature for 15 min.
The reaction mixture were added water and ethyl acetate, and
is the mixture was partitioned. The organic layer was washed with
water, and the organic layer was washed with saturated brine,
dried over sodium sulfate, filtered to remove sodium sulfate,
and concentrated under reduced pressure. The residue was
purified by silica gel column chromatography (eluent: n-
hexane/ethyl acetate=6/1) to give the title compound (0.27 g,
yield 72%).
1H-NMR (CDC13) 5: 0.93 (6H, d, J = 6.6 Hz), 1.47 (18H, s),
1.88-1.98 (1H, m), 2.57 (2E, d, J = 7.3 Hz), 4.19 (3H, s), 4.83
(2H, s), 7.28 (2E, d, J = 8.4 Hz), 7.39 (1H, dd, J = 8.4, 2.3
Hz), 7.48 (1H, d, J - 8.4 Hz), 8.00 (1H, d, J = 2.3 Hz), 8.50
(2H, dt, J = 8.4, 1.8 Hz).
[0458]
(4) 4-chloro-3-[4-(4-isobutylpheny1)-6-methoxy-1,3,5-triazin-2-
yl]benzylamine hydrochloride
[0459]
a op 0.yo
_______,. 40 a op
NH2 =HCI
Ny-11 0 I NN
.0
[0460]
130
CA 02936408 2016-06-29
Under an argon atmosphere, to tert-butyl N-{4-chloro-3-
[4-(4-isobutylpheny1)-6-methoxy-1,3,5-triazin-2-yl]benzyll-N-
(tert-butoxycarbonyl)carbamate (0.27 g, 0.46 mmol) obtained in
the above-mentioned (3) was added 4M hydrogen chloride/1,4-
dioxane solution (2.0 ml) at room temperature, and the mixture
was stirred for 30 min. The solid was collected by filtration
from the suspension, and dried under reduced pressure to give
the title compound as a crude product (0.16 g).
[0461]
lo (5) N-{4-chloro-3-[4-(4-isobutylpheny1)-6-methoxy-1,3,5-
triazin-2-yl]benzy1}-2,2-dimethylpropionamide
[0462]
1101N 0111 NI-12 = HCI _______ )== 1$1 I NC: ENlyi.
W 0NN
,0 20
[0463]
/5 Under an argon atmosphere, to a solution of a crude
product (0.035 g) of 4-chloro-3-[4-(4-isobutylpheny1)-6-
methoxy-1,3,5-triazin-2-yl]benzylamine hydrochloride obtained
in the above-mentioned (4), HOBt.H20 (0.019 g, 0.12 mmol) and
WSC-HC1 (0.024 g, 0.13 mmol) in N,N-dimethylformamide (1.0 ml)
20 were added 2,2-dimethylpropionic acid (0.014 ml, 0.12 mmol) and
triethylamine (0.035 ml, 0.25 mmol) at room temperature, and
the mixture was stirred for 3 hr. To the reaction mixture were
added saturated aqueous sodium hydrogen carbonate and ethyl
acetate, and the mixture was partitioned. The organic layer
25 was washed with saturated aqueous sodium hydrogen carbonate,
washed with saturated brine, dried over sodium sulfate,
filtered to remove sodium sulfate, and concentrated under
reduced pressure. The residue was purified by silica gel
column chromatography (eluent: n-hexane/ethyl acetate=3/2) to
30 give the title compound (0.030 g).
1H-NMR (CDC13) 6: 0.93 (6H, d, J = 6.6 Hz), 1.24 (9H, s), 1.88-
1.99 (1H, m), 2.57 (2H, d, J - 7.1 Hz), 4.20 (3H, s), 4.50 (2H,
d, J = 6.0 Hz), 5.98 (1H, br s), 7.29 (2H, d, J = 8.3 Hz), 7.36
131
CA 02936408 2016-06-29
(1H, dd, J = 8.2, 2.3 Hz), 7.51 (1H, d, J = 8.2 Hz), 7.92 (1H,
d, J = 2.3 Hz), 8.50 (2H, d, J = 8.3 Hz).
[0464]
(6) N-{4-chloro-3-[4-hydroxy-6-(4-isobutylpheny1)-1,3,5-
triazin-2-yl]benzy1}-2,2-dimethylpropionamide (Example No.1-51)
[0465]
ci [11,Aõ, c
40 i 40 y,
igr W
0 0
NY41
I\1YN
OH
[0466]
Under an argon atmosphere, to a solution of N-{4-chloro-
3-[4-(4-isobuty1pheny1)-6-methoxy-1,3,5-triazin-2-yl]benzyll-
2,2-dimethylpropionamide (0.030 g, 0.064 mmol) obtained in the
above-mentioned (5) in methanol (10 ml) was added 4M aqueous
sodium hydroxide solution (0.096 ml) at room temperature, and
the mixture was stirred at room temperature for 16 hr. To the
reaction mixture were added 10% aqueous citric acid solution
(0.38 ml) and water (2.3 ml) at room temperature, and the
mixture was stirred. The precipitated solid was collected by
filtration, washed with water, and dried under reduced pressure
to give the title compound (0.026 g, yield 90%). A suspension
of the title compound (0.030 g) in DME (0.60 ml) was stirred at
room temperature, and the solid was collected by filtration and
dried to give the title compound as crystals (0.026 g).
[0467]
[Production Example 10]
Synthesis of N-{4-chloro-3-[4-(3-fluoro-4-methylpheny1)-6-
hydroxy-1,3,5-triazin-2-yl]benzyll-3,3,3-trifluoro-2,2-
dimethylpropionamide (Example No.1-81)
[0468]
CI
F 011 NyV.1<F
NN 0 F F
OH
[0469]
132
CA 02936408 2016-06-29
(1) 2-chloro-4-(3-fluoro-4-methylpheny1)-6-methoxy-1,3,5-
triazine
[0470]
CI N CI
N CI B4OH NYN
,0 NN
OH ,0
5 [0471]
Under an argon atmosphere, to a suspension of 3-fluoro-4-
methylphenylboronic acid (0.43 g, 2.8 mmol), 2,4-dichloro-6-
methoxy-1,3,5-triazine (1.0 g, 5.6 mmol) and
tetrakis(triphenylphosphine)palladium(0) (0.16 g, 0.14 mmol) in
lo toluene (8 ml) was added 2M aqueous tripotassium phosphate
solution (4.0 ml) at room temperature, and the mixture was
stirred at 100 C for 3 hr. At room temperature, to the
reaction mixture were added water and ethyl acetate, and the
mixture was partitioned. The organic layer was washed with
water, partitioned, washed with saturated brine, dried over
magnesium sulfate, filtered to remove magnesium sulfate, and
concentrated under reduced pressure. The residue was purified
by silica gel column chromatography (eluent: n-
hexane/chloroform =2/3 - 1/2) to give the title compound (0.58
g, yield 81%).
1H-NMR (CDC13) 5: 2.37 (3H, d, J - 2.1 Hz), 4.17 (3H, s), 7.32
(1H, t, J = 7.9 Hz), 8.12 (1H, dd, J - 10.7, 1.7 Hz), 8.19 (1H,
dd, J = 7.9, 1.7 Hz).
[0472]
(2) 14-chloro-3-[4-(3-fluoro-4-methylpheny1)-6-methoxy-1,3,5-
triazin-2-yl]phenyllmethanol
[0473]
F ArCI + HOB 41 OH _______________ F NCI os
OH
NY OH N,eN -N
,0 ,0
[0474]
133
CA 02936408 2016-06-29
Under an argon atmosphere, to a solution of 2-chloro-4-
(3-fluoro-4-methylpheny1)-6-methoxy-1,3,5-triazine (0.58 g, 2.3
mmol) obtained in the above-mentioned (1), 2-chloro-5-
hydroxymethylphenylboronic acid (0.51 g, 2.7 mmol) and [1,1'-
bis(diphenylphosphino)ferrocene]palladium(II)dichloride
dichloromethane adduct (0.18 g, 0.23 mmol) in 1,4-dioxane (9.0
ml) was added 2M aqueous sodium carbonate solution (4.5 ml),
and the mixture was stirred at 100 C for 2 hr. At room
temperature, to the reaction mixture were added water and ethyl
/0 acetate, and the mixture was partitioned. The organic layer
was washed with saturated brine, dried over magnesium sulfate,
filtered to remove magnesium sulfate, and concentrated under
reduced pressure. The residue was purified by silica gel
column chromatography (eluent: n-hexane/ethyl acetate=4/3) to
give the title compound (0.44 g, yield 53%).
1H-NMR (CDC13) 6: 1.76 (1H, t, J = 5.8 Hz), 2.37 (3H, d, J =
1.9 Hz), 4.21 (3H, s), 4.78 (2H, d, J = 5.8 Hz), 7.33 (1H, t, J
= 7.9 Hz), 7.47 (1H, dd, J = 8.1, 2.2 Hz), 7.54 (1H, d, J = 8.1
Hz), 8.02 (1H, d, J = 2.2 Hz), 8.23 (1H, dd, J = 10.7, 1.6 Hz),
8.29 (1H, dd, J = 7.9, 1.6 Hz).
(0475]
(3) tert-butyl N-{4-chloro-3-[4-(3-fluoro-4-methylpheny1)-6-
methoxy-1,3,5-triazin-2-yl]benzyll-N-(tert-
butoxycarbonyl)carbamate
[0476]
F .N,
CI OH rdN
NY' NN 0
,0 ,0
[0477]
Under an argon atmosphere, to a solution of {4-chloro-3-
[4-(3-fluoro-4-methylpheny1)-6-methoxy-1,3,5-triazin-2-
yl]phenyllmethanol (0.44 g, 1.2 mmol) obtained in the above-
mentioned (2) in tetrahydrofuran (13 ml) were added
triethylamine (0.22 ml, 1.6 mmol) and methanesulfonyl chloride
134
CA 02936408 2016-06-29
(0.10 ml, 1.3 mmol) under ice-cooling, and the mixture was
stirred for 0.5 hr. The reaction mixture was added to a
solution of di-tert-butyl iminodicarboxylate (0.32 g, 1.5 mmol)
and cesium carbonate (1.2 g, 3.6 mmol) in N,N-dimethylformamide
(3.0 ml) at room temperature, and the mixture was stirred for 1
hr. To the reaction mixture were added water and ethyl acetate,
and the mixture was partitioned. The organic layer was washed
with saturated brine, dried over magnesium sulfate, filtered to
remove magnesium sulfate, and concentrated under reduced
io pressure. The residue was purified by silica gel column
chromatography (eluent: n-hexane/ethyl acetate-6/1) to give the
title compound (0.64 g, yield 94%).
1H-NMR (CDC13) 5: 1.48 (18H, s), 2.37 (3H, d, J = 1.6 Hz), 4.19
(3H, s), 4.83 (2H, s), 7.31 (1H, t, J = 7.9 Hz), 7.40 (1H, dd,
J = 8.4, 2.3 Hz), 7.49 (1H, d, J = 8.4 Hz), 8.00 (1H, d, J -
2.3 Hz), 8.22 (1H, dd, J = 10.7, 1.6 Hz), 8.28 (1H, dd, J = 7.9,
1.6 Hz).
[0478]
(4) 4-chloro-3-[4-(3-fluoro-4-methylpheny1)-6-methoxy-1,3,5-
triazin-2-yl]benzylamine hydrochloride
[0479]
FCW ak0,e0 4111
YL W NY9'' F Nõ NH2- HCI
NY
0 NyN '
[0480]
Under an argon atmosphere, to a solution of tert-butyl N-
{4-chloro-3-[4-(3-fluoro-4-methylpheny1)-6-methoxy-1,3,5-
triazin-2-yl]benzyll-N-(tert-butoxycarbonyl)carbamate (0.64 g,
1.1 mmol) obtained in the above-mentioned (3) in 1,4-dioxane
(2.0 ml) was added 4M hydrogen chloride/1,4-dioxane solution
(6.0 ml) at room temperature, and the mixture was stirred for 2
hr. To the reaction mixture was added n-hexane (32 ml), and
the mixture was stirred for 45 min. The solid was collected by
filtration from the suspension, and dried under reduced
135
CA 02936408 2016-06-29
pressure to give the title compound (0.45 g, yield 99%).
1H-NMR (DMSO-DO 6: 2.36 (3H, d, J = 1.4 Hz), 4.13-4.19 (2H, m),
4.17 (3H, s), 7.55 (1H, t, J = 8.0 Hz), 7.71 (1H, dd, J = 8.1,
2.1 Hz), 7.75 (1H, d, J = 8.1 Hz), 8.16-8.20 (2H, m), 8.27 (1H,
dd, J = 7.9, 1.6 Hz), 8.38 (3H, br s).
[0481]
(5) N-14-chloro-3-[4-(3-fluoro-4-methylpheny1)-6-methoxy-1,3,5-
triazin-2-yl]benzy11-3,3,3-trifluoro-2,2-dimethylpropionamide
[0482]
CI CI
F 141. M-12=HN _________ F* N
Ny;F
N, 0 F F
?111
[0483]
Under an argon atmosphere, to a solution of 4-chloro-3-
[4-(3-fluoro-4-methylpheny1)-6-methoxy-1,3,5-triazin-2-
yllbenzylamine hydrochloride (0.070 g, 0.18 mmol) obtained in
/5 the above-mentioned (4), HOBt=H20 (0.041 g, 0.27 mmol) and
3,3,3-trifluoro-2,2-dimethylpropionic acid (0.042 g, 0.27 mmol)
in N,N-dimethylformamide (1.0 ml) were added WSC=HC1 (0.051 g,
0.27 mmol) and triethylamine (0.037 ml, 0.027 mmol) at room
temperature, and the mixture was stirred for 1.5 hr. To the
reaction mixture were added water and ethyl acetate, and the
mixture was partitioned. The organic layer was washed with
saturated aqueous sodium hydrogen carbonate, washed with
saturated brine, dried over magnesium sulfate, filtered to
remove magnesium sulfate, and concentrated under reduced
pressure. The residue was purified by silica gel column
chromatography (eluent: n-hexane/ethyl acetate=2/1) to give the
title compound (0.080 g, yield 90%).
1H-NMR (CDC12) 6: 1.45 (6H, s), 2.37 (3H, d, J = 1.9 Hz), 4.20
(3H, s), 4.55 (2H, d, J = 5.8 Hz), 6.23 (1H, br s), 7.30-7.37
(2H, m), 7.52 (1H, d, J = 8.4 Hz), 7.93 (1H, d, J = 2.3 Hz),
8.22 (1H, dd, J = 10.7, 1.6 Hz), 8.28 (1H, dd, J = 7.9, 1.6 Hz).
[0484]
136
CA 02936408 2016-06-29
(6) N-14-chloro-3-[4-(3-fluoro-4-methyl-pheny1)-6-hydroxy-
1,3,5-triazin-2-yl]benzy1}-3,3,3-trifluoro-2,2-
dimethylpropionamide (Example No.1-81)
[0485]
F *CI is NC,IA,H
.N= Hlf.;F
0 FF F
N.fN 0 F F
,0
OH
[0486]
Under an argon atmosphere, to a solution of N-{4-chloro-
3-[4-(3-fluoro-4-methylpheny1)-6-methoxy-1,3,5-triazin-2-
yl]benzy11-3,3,3-trifluoro-2,2-dimethylpropionamide (0.077 g,
/o 0.16 mmol) obtained in the above-mentioned (5) in methanol (1.4
ml) was added 4M aqueous sodium hydroxide solution (0.23 ml) at
room temperature, and the mixture was stirred at 60 C for 2 hr.
To the reaction mixture were added 10% aqueous citric acid
solution (0.070 ml) and water at room temperature, and the
mixture was stirred. The precipitated solid was collected by
filtration, washed with water, and dried under reduced pressure
to give the title compound (0.070 g, yield 92%).
[0487]
[Production Example 11]
Synthesis of N-(4-chloro-3-[4-hydroxy-6-(4-isopropylpheny1)-
1,3,5-triazin-2-yl]benzy1}-3,3,3-trifluoro-2,2-
dimethylpropionamide (Example No. 1-98)
[0488]
40 00 V F
-1 N Irl<F
0 F
OH
[0489]
(1) 2-chloro-4-(4-isopropylpheny1)-6-methoxy-1,3,5-triazine
[0490]
137
CA 02936408 2016-06-29
Cly
110 ,OH NN 1101 YCI
,0 NN
OH
[0491]
Under an argon atmosphere, to a suspension of 4-
isopropylphenylboronic acid (0.30 g, 1.7 mmol), 2,4-dichloro-6-
methoxy-1,3,5-triazine (0.23 g, 1.4 mmol) and [1,1'-
bis(diphenylphosphino)ferrocene]palladium(II)dichloride
dichloromethane adduct (0.11 g, 0.14 mmol) in 1,4-dioxane (4.0
ml) was added 2M aqueous sodium carbonate solution (2.0 ml) at
room temperature, and the mixture was stirred at 100 C for 1.5
hr. At room temperature, to the reaction mixture were added
water and ethyl acetate, and the mixture was partitioned. The
organic layer was washed with saturated brine, dried over
sodium sulfate, filtered to remove sodium sulfate, and
concentrated under reduced pressure. The residue was purified
by silica gel column chromatography (eluent: n-hexane/ethyl
acetate=20/1) to give the title compound (0.21 g, yield 57%).
1H-NMR (CDC13) 6: 1.29 (6H, d, J = 7.1 Hz), 2.99-3.02 (1H, m),
4.16 (3H, s), 7.34-7.38 (2H, m), 8.39-8.43 (2H, m).
[0492]
(2) 14-chloro-3-[4-(4-isopropylpheny1)-6-methoxy-1,3,5-triazin-
2-yl]phenyllmethanol
[0493]
1101NyCI + HOB 40 oH ci oH
NI-..N
OH NN
[0494]
Under an argon atmosphere, to a suspension of 2-chloro-4-
(4-isopropylpheny1)-6-methoxy-1,3,5-triazine (0.21 g) obtained
in the above-mentioned (1), 2-chloro-5-
hydroxymethylphenylboronic acid (0.15 g, 0.80 mmol) and [1,1'-
bis(diphenylphosphino)ferrocene]palladium(II)dichloride
138
CA 02936408 2016-06-29
dichloromethane adduct (0.066 g, 0.080 mmol) in 1,4-dioxane
(2.4 ml) was added 2M aqueous sodium carbonate solution (1.2
ml) at room temperature, and the mixture was stirred at 100 C
for 2 hr. At room temperature, to the reaction mixture were
added water and ethyl acetate, and the mixture was partitioned.
The organic layer was washed with water, washed with saturated
brine, dried over sodium sulfate, filtered to remove sodium
sulfate, and concentrated under reduced pressure. The residue
was purified by silica gel column chromatography (eluent: n-
/o hexane/ethyl acetate=5/3) to give the title compound (0.15 g,
yield 51%).
1H-NMR (CDC13) 5: 1.30 (6H, d, J = 7.1 Hz), 1.77 (1H, t, J =
6.1 Hz), 2.95-3.07 (1H, m), 4.20 (3H, s), 4.77 (2H, d, J = 6.1
Hz), 7.35-7.39 (2H, m), 7.46 (1H, dd, J = 8.2, 2.2 Hz), 7.54
is (1H, d, J = 8.2 Hz), 8.01 (1H, dd, J = 2.2, 0.4 Hz), 8.50-8.54
(2H, m).
[0495]
(3) tert-butyl N-14-chloro-3-[4-(4-isopropylpheny1)-6-methoxy-
1,3,5-triazin-2-yl]benzy1}-N-(tert-butoxycarbonyl)carbamate
20 [0496]
-2(
ci
1110 N, 00 =
ci 0 y0
Ny0,y
I
0
N1YN NyN
[0497]
Under an argon atmosphere, to a solution of {4-chloro-3-
[4-(4-isopropylpheny1)-6-methoxy-1,3,5-triazin-2-
25 yllphenyllmethanol (0.15 g, 0.41 mmol) obtained in the above-
mentioned (2) and triphenylphosphine (0.16 g, 0.62 mmol) in
chloroform (1.5 ml) was added carbon tetrabromide (0.20 g, 0.62
mmol) under ice-cooling, and the mixture was stirred at room
temperature for 10 min. The reaction mixture was applied to
30 silica gel column chromatography (eluent: n-hexane/ethyl
acetate=30/1 - 10/1) and concentrated under reduced pressure.
A solution of the residue in N,N-dimethylformamide (1.5
139
CA 02936408 2016-06-29
ml) was added to a solution of di-tert-butyl iminodicarboxylate
(0.089 g, 0.41 mmol) and sodium hydride (0.016 g, 60 wt% oil
dispersion) in N,N-dimethylformamide (0.70 ml) under ice-
cooling, and the mixture was stirred at room temperature for 15
min. To the reaction mixture were added water and ethyl
acetate, and the mixture was partitioned. The organic layer
was washed with water, washed with saturated brine, dried over
sodium sulfate, filtered to remove sodium sulfate, and
concentrated under reduced pressure. The residue was purified
/0 by silica gel column chromatography (eluent: n-hexane/ethyl
acetate=5/1) to give the title compound (0.20 g, yield 85%).
1H-NMR (CDC13) 6: 1.30 (6H, d, J = 7.0 Hz), 1.47 (18H, s),
2.94-3.05 (1H, m), 4.19 (3H, s), 4.83 (2H, s), 7.34-7.41 (31-I,
m), 7.48 (1H, d, J = 8.4 Hz), 8.00 (1H, d, J = 2.3 Hz), 8.49-
/5 8.53 (2H, m).
[0498]
(4) 4-chloro-3-[4-(4-isopropylpheny1)-6-methoxy-1,3,5-triazin-
2-yl]benzylamine hydrochloride
[0499]
a 0
40 NI , 40 40 00 Id, = HCI
Ny0)
NN 0 NoN
A2I
[0500]
Under an argon atmosphere, to tert-butyl N-{4-chloro-3-
[4-(4-isopropylpheny1)-6-methoxy-1,3,5-triazin-2-yl]benzyll-N-
(tert-butoxycarbonyl)carbamate (0.20 g, 0.35 mmol) obtained in
the above-mentioned (3) was added 4M hydrogen chloride/1,4-
dioxane solution (2.0 ml) at room temperature, and the mixture
was stirred for 1 hr. The suspension was concentrated under
reduced pressure, and azeotropically distilled with ethyl
acetate (twice) to give the title compound as a crude product
(0.14 g).
[0501]
(5) N-{4-chloro-3-[4-(4-isopropylpheny1)-6-methoxy-1,3,5-
140
CA 02936408 2016-06-29
triazin-2-yl]benzyll-3,3,3-trifluoro-2,2-dimethylpropionamide
[0502]
* .N,
NH2 = HC N N.XF
F
NyN NLeN 0 F
,0 ,0
[0503]
Under an argon atmosphere, to a solution of a crude
product (0.10 g) of 4-chloro-3-[4-(4-isopropylpheny1)-6-
methoxy-1,3,5-triazin-2-yl]benzylamine hydrochloride obtained
in the above-mentioned (4), HOBt=H20 (0.052 g, 0.34 mmol) and
WSC-HC1 (0.066 g, 0.34 mmol) in N,N-dimethylformamide (1.0 ml)
/o were added 3,3,3-trifluoro-2,2-dimethylpropionic acid (0.042 g,
0.27 mmol) and triethylamine (0.069 ml, 0.49 mmol) at room
temperature, and the mixture was stirred for 4 hr. To the
reaction mixture were added water and ethyl acetate, and the
mixture was partitioned. The organic layer was washed with
/5 saturated brine, dried over sodium sulfate, filtered to remove
sodium sulfate, and concentrated under reduced pressure. The
residue was purified by silica gel column chromatography
(eluent: n-hexane/ethyl acetate=1/1) to give the title compound
(0.054 g).
20 1H-NMR (CDC13) 5: 1.30 (6H, d, J = 6.8 Hz), 1.44 (6H, s), 2.95-
3.05 (1H, m), 4.18 (3H, s), 4.53 (2H, d, J = 5.7 Hz), 6.34 (1H,
br s), 7.30-7.39 (3H, m), 7.50 (1H, d, J = 8.4 Hz), 7.91 (1H, d,
J = 2.2 Hz), 8.49-8.53 (2H, m).
[0504]
25 (6) N-14-chloro-3-[4-hydroxy-6-(4-isopropylpheny1)-1,3,5-
triazin-2-yl]benzyll-3,3,3-trifluoro-2,2-dimethylpropionamide
(Example No.1-98)
[0505]
* NCI 41 H CI
N.1?4,KF _________________________ * N INA(F
NN 0 FF NY'N 0 FF
,0 OH
141
CA 02936408 2016-06-29
[0506]
Under an argon atmosphere, to a solution of N-f4-chloro-
3-[4-(4-isopropylpheny1)-6-methoxy-1,3,5-triazin-2-yl]benzyll-
3,3,3-trifluoro-2,2-dimethylpropionamide (0.050 g, 0.099 mmol)
obtained in the above-mentioned (5) in methanol (0.50 ml) was
added 4M aqueous sodium hydroxide solution (0.20 ml) at room
temperature, and the mixture was stirred at 60 C for 2 hr. To
the reaction mixture were added 2N hydrochloric acid (0.40 ml)
and water at room temperature, and the mixture was stirred.
/0 The precipitated solid was collected by filtration, washed with
water, and dried under reduced pressure to give the title
compound (0.043 g, yield 89%).
[0507]
[Production Example 12]
/5 Synthesis of N-{4-chloro-3-[4-hydroxy-6-(4-isobutoxypheny1)-
1,3,5-triazin-2-yl]benzyll-3,3,3-trifluoro-2,2-
dimethylpropionamide (Example No.1-109)
[0508]
CI 4p
.N NyNcF
0 FF
NNA
OH
20 [0509]
(1) 2-chloro-4-(4-isobutoxypheny1)-6-methoxy-1,3,5-triazine
[0510]
o ci N C I
õ),0 161
-OH + NN#NNrCI
B
,o N`PN
OH
[0511]
25 Under an argon atmosphere, to a suspension of 4-
isobutoxyphenylboronic acid (0.50 g, 2.58 mmol), 2,4-dichloro-
6-methoxy-1,3,5-triazine (0.93 g, 5.15 mmol),
tetrakis(triphenylphosphine)palladium(0) (0.15 g, 0.129 mmol)
and sodium carbonate (0.819 g, 7.73 mmol) in toluene (5.0 ml)
30 was added distilled water (3.5 ml), and the mixture was stirred
142
CA 02936408 2016-06-29
at 86 C for 2 hr. At room temperature, to the reaction mixture
were added water and ethyl acetate, and the mixture was
partitioned. The organic layer was washed with saturated brine,
dried over sodium sulfate, filtered to remove sodium sulfate,
and concentrated under reduced pressure. The residue was
purified by silica gel column chromatography (eluent: n-
hexane/ethyl acetate=10/1) to give the title compound (0.606 g,
yield 80%).
1H-NMR (CDC13) 5: 1.05 (6H, d, J = 6.7 Hz), 2.07-2.17 (1H, m),
/0 3.81 (2H, d, J = 6.5 Hz), 4.14 (3H, s), 6.95-7.00 (2H, m),
8.42-8.46 (2H, m).
[0512]
(2) {4-chloro-3-[4-(4-isobutoxypheny1)-6-methoxy-1,3,5-triazin-
2-yl]phenylfmethanol
[0513]
CI Ail,-Lori& CI At
NCI + HO... IV OH ____________________________ qr OH ,N, I=W
NY'N
OH NY'N
,0 ,0
[0514]
Under an argon atmosphere, a suspension of 2-chloro-4-(4-
isobutoxypheny1)-6-methoxy-1,3,5-triazine (0.60 g, 2.0 mmol)
obtained in the above-mentioned (1), 2-chloro-5-
hydroxymethylphenylboronic acid (0.57 g, 3.1 mmol), [1,1'-
bis(diphenylphosphino)ferrocene]palladium(II)dich1oride
dichloromethane adduct (0.083 g, 0.10 mmol) and tripotassium
phosphate (1.3 g, 6.1 mmol) in N,N-dimethylformamide (6.0 ml)
was stirred at 60 C for 1.5 hr. At room temperature, to the
reaction mixture were added water and ethyl acetate, and the
mixture was partitioned. The organic layer was washed with
water and partitioned, washed with saturated brine, dried over
sodium sulfate, filtered to remove sodium sulfate, and
concentrated under reduced pressure. The residue was purified
by silica gel column chromatography (eluent: n-hexane/ethyl
acetate=3/2) to give the title compound (0.32 g, yield 39%).
143
CA 02936408 2016-06-29
1H-NMR (CDC13) 6: 1.05 (6H, d, J = 6.7 Hz), 1.77 (1H, t, J =
5.9 Hz), 2.08-2.18 (1H, m), 3.82 (2H, d, J = 6.5 Hz), 4.19 (3H,
s), 4.77 (2H, d, J = 5.9 Hz), 6.98-7.01 (2H, m), 7.46 (1H, dd,
J = 8.2, 2.2 Hz), 7.53 (1H, d, J = 8.2 Hz), 8.00 (1H, d, J =
2.2 Hz), 8.55 (2H, m).
[0515]
(3) tert-butyl N-{4-chloro-3-[4-(4-isobutoxypheny1)-6-methoxy-
1,3,5-triazin-2-yl]benzy1}-N-(tert-butoxycarbonyl)carbamate
[0516]
Lo.N OH C I ..ros,
N sits N
NyN 0
/0
[0517]
Under an argon atmosphere, to a solution of {4-chloro-3-
[4-(4-isobutoxypheny1)-6-methoxy-1,3,5-triazin-2-
yl]phenyllmethanol (0.24 g, 0.61 mmol) obtained in the above-
/5 mentioned (2) in tetrahydrofuran (2.0 ml) were added
triethylamine (0.11 ml, 0.79 mmol) and methanesulfonyl chloride
(0.052 ml, 0.67 mmol) under ice-cooling, and the mixture was
stirred for 0.5 hr. The reaction mixture was filtered, and the
filtrate was concentrated under reduced pressure. To a
20 solution of the residue in N,N-dimethylformamide (1.5 ml) were
added cesium carbonate (0.59 g, 1.8 mmol) and di-tert-butyl
iminodicarboxylate (0.16 g, 0.73 mmol) at room temperature, and
the mixture was stirred for 1.5 hr. To the reaction mixture
were added water and ethyl acetate, and the mixture was
25 partitioned. The organic layer was washed with saturated brine,
dried over magnesium sulfate, filtered to remove magnesium
sulfate, and concentrated under reduced pressure. The residue
was purified by silica gel column chromatography (eluent: n-
hexane/ethyl acetate-6/1) to give the title compound (0.34 g,
30 yield 92%).
1H-NMR (CDC13) 6: 1.05 (6H, d, J = 6.7 Hz), 1.47 (18H, s),
2.08-2.18 (1H, m), 3.82 (2H, d, J = 6.5 Hz), 4.18 (3H, s), 4.82
144
CA 02936408 2016-06-29
(2H, s), 6.96-7.00 (2H, m), 7.39 (1H, dd, J = 8.3, 2.3 Hz),
7.48 (1H, d, J = 8.3 Hz), 7.99 (1H, d, J = 2.3 Hz), 8.52-8.56
(2H, m).
[0518]
(4) 4-chloro-3-[4-(4-isobutoxypheny1)-6-methoxy-1,3,5-triazin-
2-yllbenzylamine hydrochloride
[0519]
,0.4p0
T )-õ0 C I 4N NH2 = NC I
N.io= N
,0 ,0
[0520]
lo Under an argon atmosphere, to a solution of tert-butyl N-
{4-chloro-3-[4-(4-isobutoxypheny1)-6-methoxy-1,3,5-triazin-2-
yl]benzylf-N-(tert-butoxycarbonyl)carbamate (0.34 g, 0.56 mmol)
obtained in the above-mentioned (3) in 1,4-dioxane (1.0 ml) was
added 4M hydrogen chloride/1,4-dioxane solution (3.0 ml) at
/5 room temperature, and the mixture was stirred for 2.5 hr. To
the reaction mixture was added n-hexane (20 ml), and the
mixture was stirred. The solid was collected by filtration
from the suspension, and dried under reduced pressure to give
the title compound (0.24 g, yield 95%).
20 1H-NMR (DMS0-06) 6: 1.01 (6H, d, J = 6.8 Hz), 2.01-2.11 (1H, m).
3.88 (2H, d, J = 6.4 Hz), 4.14 (3H, s), 4.12-4.17 (2H, m),
7.12-7.15 (2H, m), 7.72 (2H, br s), 8.13 (1H, br s), 8.40-8.51
(5H, m).
[0521]
25 (5) N-{4-chloro-3-[4-(4-isobutoxypheny1)-6-methoxy-1,3,5-
triazin-2-yl]benzy11-3,3,3-trifluoro-2,2-dimethylpropionamide
[0522]
16 aki
Nõ IV NH2 = HCI
CI
N. NIA<F
0 F F
14N
,0 ,0
[0523]
145
CA 02936408 2016-06-29
Under an argon atmosphere, to a solution of 4-chloro-3-
[4-(4-isobutoxypheny1)-6-methoxy-1,3,5-triazin-2-yl]benzylamine
hydrochloride (0.065 g, 0.14 mmol) obtained in the above-
mentioned (4), HOBt.H20 (0.033 g, 0.22 mmol) and 3,3,3-
trifluoro-2,2-dimethylpropionic acid (0.034 g, 0.22 mmol) in
N,N-dimethylformamide (0.70 ml) were added WSC.HC1 (0.042 g,
0.22 mmol) and triethylamine (0.030 ml, 0.22 mmol) at room
temperature, and the mixture was stirred for 5 hr. To the
reaction mixture were added 3,3,3-trifluoro-2,2-
/0 dimethylpropionic acid (0.034 g, 0.22 mmol), WS0-HC1 (0.042 g,
0.22 mmol), HOBt.H20 (0.033 g, 0.22 mmol) and triethylamine
(0.030 ml, 0.22 mmol), and the mixture was stirred for 1 hr.
To the reaction mixture were added water and ethyl acetate, and
the mixture was partitioned. The organic layer was washed with
/5 saturated brine, dried over magnesium sulfate, filtered to
remove magnesium sulfate, and concentrated under reduced
pressure. The residue was purified by silica gel column
chromatography (eluent: n-hexane/ethyl acetate=3/1) to give the
title compound (0.068 g, yield 86%).
20 1H-NMR (CDC13) 6: 1.06 (6H, d, J = 6.8 Hz), 1.44 (6H, br s),
2.08-2.18 (1H, m), 3.82 (2H, d, J = 6.6 Hz), 4.19 (3H, s), 4.55
(2H, d, J = 5.7 Hz), 6.21 (1H, br s), 6.97-7.01 (2H, m), 7.34
(1H, dd, J = 8.3, 2.3 Hz), 7.51 (1H, d, J = 8.3 Hz), 7.91 (11-I,
d, J = 2.3 Hz), 8.53-8.55 (2H, m).
25 [0524]
(6) N-14-chloro-3-[4-hydroxy-6-(4-isobutoxypheny1)-1,3,5-
triazin-2-yllbenzy11-3,3,3-trifluoro-2,2-dimethylpropionamide
(Example No.1-109)
[0525]
C)a,
N, 4,46 NC F
H
0 FF N.IX
N.,10N 0 FF
,0
30 OH
[0526]
Under an argon atmosphere, to a solution of N-{4-chloro-
146
CA 02936408 2016-06-29
3-[4-(4-isobutoxypheny1)-6-methoxy-1,3,5-triazin-2-yl]benzyll-
3,3,3-trifluoro-2,2-dimethylpropionamide (0.066 g, 0.12 mmol)
obtained in the above-mentioned (5) in methanol (1.1 ml) was
added 4M aqueous sodium hydroxide solution (0.18 ml) at room
temperature, and the mixture was stirred at 60 C for 2 hr. To
the reaction mixture were added 10% aqueous citric acid
solution (0.55 ml) and water at room temperature, and the
mixture was stirred. The precipitated solid was collected by
filtration, washed with water, and dried under reduced pressure
/o to give the title compound (0.057 g, yield 88%). A suspension
of the title compound (0.030 g) in acetonitrile (0.60 ml) was
stirred at room temperature, and the solid was collected by
filtration and dried to give the title compound as crystals
(0.011 g).
[0527]
[Production Example 131
Synthesis of N-{4-chloro-3-[4-hydroxy-6-(4-propoxypheny1)-
1,3,5-triazin-2-yl]benzy1}-3,3,3-trifluoro-2,2-
dimethylpropionamide (Example No.1-122)
[0528]
C.:!rx).......H
N
N.oN
0 F
OH
[0529]
(1) 2-chloro-4-methoxy-6-(4-propoxypheny1)-1,3,5-triazine
[0530]
CI N CI gui
410
B-OH N-r" N CI
1"/.
,0 NN
OH ,0
[0531]
Under an argon atmosphere, to a suspension of 4-
propoxyphenylboronic acid (1.0 g, 5.6 mmol), 2,4-dichloro-6-
methoxy-1,3,5-triazine (2.0 g, 11 mmol) and
147
CA 02936408 2016-06-29
tetrakis(triphenylphosphine)palladium(0) (0.65 g, 0.56 mmol) in
toluene (25 ml) was added 2M aqueous sodium carbonate solution
(8.4 ml), and the mixture was stirred at 100 C for 1 hr. At
room temperature, to the reaction mixture were added water and
ethyl acetate, and the mixture was partitioned. The organic
layer was washed with saturated brine, dried over magnesium
sulfate, filtered to remove magnesium sulfate, and concentrated
under reduced pressure. The residue was purified by silica gel
column chromatography (eluent: n-hexane/ethyl acetate=20/1) to
/o give the title compound (1.1 g, yield 70%).
1H-NMR (CDC13) 5: 1.06 (3H, t, J = 7.4 Hz), 1.83-1.87 (2H, m),
4.02 (2H, t, J = 6.6 Hz), 4.14 (3H, s), 6.96-6.99 (2H, m),
8.43-8.45 (2H, m).
[0532]
/5 (2) {4-chloro-3-[4-methoxy-6-(4-propoxypheny1)-1,3,5-triazin-2-
yl]phenyllmethanol
[0533]
CI righ.õ CI ahr
1PP, Ny C I + HO ,B gi OH ____________________ Lir N, 11.! OH
N 4,1
011 NN
,0 ,0
[0534]
20 Under an argon atmosphere, to a solution of 2-ch1oro-4-
methoxy-6-(4-propoxypheny1)-1,3,5-triazine (0.75 g, 2.7 mmol)
obtained in the above-mentioned (1), 2-chloro-5-
hydroxymethylphenylboronic acid (0.60 g, 3.2 mmol) and [1,1'-
bis(diphenylphosphino)ferrocene]palladium(II)dichloride
25 dichloromethane adduct (0.22 g, 0.27 mmol) in 1,4-dioxane (15
ml) was added 2M aqueous sodium carbonate solution (5.4 ml),
and the mixture was stirred at 100 C for 3 hr. At room
temperature, to the reaction mixture were added water and ethyl
acetate, and the mixture was partitioned. The organic layer
30 was washed with water and partitioned, washed with saturated
brine, dried over magnesium sulfate, filtered to remove
magnesium sulfate, and concentrated under reduced pressure.
1148
CA 02936408 2016-06-29
The residue was purified by silica gel column chromatography
(eluent: chloroform/ethyl acetate=10/1) to give the title
compound (0.95 g, yield 91%).
1H-NMR (CDC13) 5: 1.07 (3H, t, J = 7.4 Hz), 1.77 (11-I, t, J =
5.8 Hz), 1.84-1.87 (2H, m), 4.02 (2H, t, J = 6.6 Hz), 4.19 (3H,
s), 4.77 (2H, d, J = 5.8 Hz), 7.00 (2H, d, J = 8.7 Hz), 7.45
(111, dd, J = 8.3, 1.9 Hz), 7.53 (1H, d, J = 8.3 Hz), 8.00 (1H,
d, J = 1.9 Hz), 8.55 (2H, d, J = 8.7 Hz).
[0535]
/o (3) tert-butyl N-14-chloro-3-[4-methoxy-6-(4-propoxypheny1)-
1,3,5-triazin-2-yl]benzy1}-N-(tert-butoxycarbonyl)carbamate
[0536]
II& CI ahn
CI
.N, OH N,
. Y
Ny-N 0
NY'
,0 ,0
[0537]
Under an argon atmosphere, to a solution of {4-chloro-3-
[4-methoxy-6-(4-propoxypheny1)-1,3,5-triazin-2-
yl]phenyllmethanol (0.95 gr 2.5 mmol) obtained in the above-
mentioned (2) in tetrahydrofuran (13 ml) were added
triethylamine (0.45 ml, 3.2 mmol) and methanesulfonyl chloride
(0.23 ml, 3.0 mmol) under ice-cooling, and the mixture was
stirred for 0.5 hr. The reaction mixture was filtered, and the
filtrate was concentrated under reduced pressure. To a
solution of the residue in N,N-dimethylformamide (13 ml) were
added cesium carbonate (2.4 g, 7.4 mmol) and di-tert-butyl
iminodicarboxylate (0.64 gr 3.0 mmol) at room temperature, and
the mixture was stirred for 1 hr. To the reaction mixture were
added water and ethyl acetate, and the mixture was partitioned.
The organic layer was washed with saturated brine, dried over
magnesium sulfate, filtered to remove magnesium sulfate, and
concentrated under reduced pressure. The residue was purified
by silica gel column chromatography (eluent: n-hexane/ethyl
acetate=10/1) to give the title compound (1.3 g, yield 90%).
149
CA 02936408 2016-06-29
[0538]
(4) 4-chloro-3-[4-methoxy-6-(4-propoxypheny1)-1,3,5-triazin-2-
yl]benzylamine hydrochloride
[0539]
CI ,Ati 0,100
N MP Ny0A., _________________________ LIF .N NI-12.1-21
N,IoN 0 I N1014
,0 ,0
[0540]
Under an argon atmosphere, to tert-butyl N-{4-chloro-3-
[4-methoxy-6-(4-propoxypheny1)-1,3,5-triazin-2-yl]benzy1}-N-
(tert-butoxycarbonyl)carbamate(1.3 g, 2.2 mmol) obtained in the
above-mentioned (3) was added 4M hydrogen chloride/1,4-dioxane
solution (5.0 ml) at room temperature, and the mixture was
stirred for 30 min. To the reaction mixture were added 1,4-
dioxane (2.0 ml) and n-hexane (5.0 ml), and the mixture was
stirred for 45 min. The solid was collected by filtration from
/5 the suspension, and dried under reduced pressure to give the
title compound (0.68 g, yield 73%).
1H-NMR (DMSO-D6) 6: 1.00 (3H, t, J = 7.4 Hz), 1.73-1.83 (2H, m),
4.06 (2H, t, J = 6.5 Hz), 4.12-4.18 (2H, m), 4.14 (3H, s),
7.12-7.16 (2H, m), 7.69-7.74 (2H, m), 8.13 (1H, br s), 8.44 (3H,
br s), 8.45-8.50 (2H, m).
[0541]
(5) N-{4-chloro-3-[4-methoxy-6-(4-propoxypheny1)-1,3,5-triazin-
2-yl]benzy11-3,3,3-trifluoro-2,2-dimethylpropionamide
[0542]
CI .4k
...0^\"0 C I
. V NH2 = NC I N
N=iN Ny.N 0 FE
,0 ,0
[05431
Under an argon atmosphere, to a solution of 4-chloro-3-
[4-methoxy-6-(4-propoxypheny1)-1,3,5-triazin-2-yl]benzylamine
hydrochloride (0.10 g, 0.24 mmol) obtained in the above-
150
CA 02936408 2016-06-29
mentioned (4), HOBt.H20 (0.054 g, 0.36 mmol) and WSC.HC1 (0.068
g, 0.36 mmol) in N,N-dimethylformamide (1.5 ml) were added
3,3,3-trifluoro-2,2-dimethylpropionic acid (0.056 g, 0.36 mmol)
and triethylamine (0.099 ml, 0.71 mmol) at room temperature,
and the mixture was stirred for 4 hr. To the reaction mixture
were added water and ethyl acetate, and the mixture was
partitioned. The organic layer was washed with saturated brine,
dried over magnesium sulfate, filtered to remove magnesium
sulfate, and concentrated under reduced pressure. The residue
/0 was purified by silica gel column chromatography (eluent: n-
hexane/ethyl acetate=10/3) to give the title compound (0.096 g,
yield 78%).
1H-NMR (DMSO-D6) 5: 1.00 (3H, t, J = 7.3 Hz), 1.39 (6H, s),
1.73-1.83 (2H, m), 4.05 (2H, t, J = 6.5 Hz), 4.11 (3H, s), 4.39
/5 (2H, d, J = 5.9 Hz), 7.10-7.14 (2H, m), 7.44 (1H, dd, J = 8.1,
2.3 Hz), 7.61 (1H, d, J = 8.1 Hz), 7.86 (1H, d, J = 2.3 Hz),
8.42-8.47 (2H, m), 8.66 (1H, t, J = 5.9 Hz).
[0544]
(6) N-{4-chloro-3-[4-hydroxy-6-(4-propoxyphenyl)-1,3,5-triazin-
20 2-yl]benzyl}-3,3,3-trifluoro-2,2-dimethylpropionamide (Example
No.1-122)
[0545]
CI
N.XF 0 _________________________________ Occ 0 X
,11;a! FF N N,F
NsitoN 0 FF
-o NY'N
OH
[0546]
25 Under an argon atmosphere, to a solution of N-{4-chloro-
3-[4-methoxy-6-(4-propoxypheny1)-1,3,5-triazin-2-yl]benzyll-
3,3,3-trifluoro-2,2-dimethylpropionamide (0.094 g, 0.18 mmol)
obtained in the above-mentioned (5) in methanol (0.94 ml) was
added 4M aqueous sodium hydroxide solution (0.27 ml) at room
30 temperature, and the mixture was stirred at 65 C for 2 hr. To
the reaction mixture were added 2N hydrochloric acid (0.54 ml)
and water at room temperature, and the mixture was stirred.
The precipitated solid was collected by filtration, washed with
151
CA 02936408 2016-06-29
water, and dried under reduced pressure to give the title
compound (0.069 g, yield 75%). A suspension of the title
compound (0.050 g) in acetone (1.0 ml) was dissolved by heating
under reflux, and the solid was collected by filtration at room
temperature and dried to give the title compound as crystals
(0.012 g).
[0547]
[Production Example 141
Synthesis of N-(4-chloro-3-{4-hydroxy-6-[4-(1-
methylcyclopropylmethoxy)pheny1]-1,3,5-triazin-2-yllbenzy1)-
3,3,3-trifluoro-2,2-dimethylpropionamide (Example No.1-128)
[0548]
ioCI Ar
N Ny\cF
NN
0 F F
Y'
OH
[0549]
(1) 2-chloro-4-methoxy-6- (4-methoxyrnethoxyphenyl) -1, 3, 5-
triazine
[0550]
CI N CI Me0õ0 raw
Me0,0
us. B.OH NNOH
NC I
,,o NYN
,0
[0551]
Under an argon atmosphere, to a suspension of 4-
(methoxymethoxy)phenylboronic acid (1.0 g, 5.5 mmol), 2,4-
dichloro-6-methoxy-1,3,5-triazine (2.0 g, 11 mmol) and
tetrakis(triphenylphosphine)palladium(0) (0.64 g, 0.55 mmol) in
toluene (25 ml) was added 2M aqueous sodium carbonate solution
(8.3 ml), and the mixture was stirred at 100 C for 1 hr. At
room temperature, to the reaction mixture were added water and
ethyl acetate, and the mixture was partitioned. The organic
layer was washed with saturated brine, dried over magnesium
sulfate, filtered to remove magnesium sulfate, and concentrated
152
CA 02936408 2016-06-29
under reduced pressure. The residue was purified by silica gel
column chromatography (eluent: n-hexane/ethyl acetate=20/1 -
10/1) to give the title compound (1.3 g, yield 84%).
[0552]
(2) (4-chloro-3-[4-methoxy-6-(4-methoxymethoxypheny1)-1,3,5-
triazin-2-yl]phenyllmethanol
[0553]
Me0,0 io CI Ai Me0,0, CI
, MIllw OH =LiFfi N, µPJ OH
N,eN NN
OH
,0 ,0
[0554]
Under an argon atmosphere, to a solution of 2-chloro-4-
methoxy-6-(4-methoxymethoxyphenyl)-1,3,5-triazine (1.3 g, 4.4
mmol) obtained in the above-mentioned (1), 2-chloro-5-
hydroxymethylphenylboronic acid (0.99 g, 5.3 mmol) and [1,1'-
bis(diphenylphosphino)ferrocene]palladium(II)dichloride
/5 dichloromethane adduct (0.36 g, 0.44 mmol) in 1,4-dioxane (25
ml) was added 2M aqueous sodium carbonate solution (8.8 ml),
and the mixture was stirred at 100 C for 3 hr. At room
temperature, to the reaction mixture were added water and ethyl
acetate, and the mixture was partitioned. The organic layer
was washed with water, washed with saturated brine, dried over
magnesium sulfate, filtered to remove magnesium sulfate, and
concentrated under reduced pressure. The residue was purified
by silica gel column chromatography (eluent: chloroform/ethyl
acetate-10/1) to give the title compound (0.98 g, yield 56%).
[0555]
(3) tert-butyl N-{4-chloro-3-[4-methoxy-6-(4-
methoxymethoxypheny1)-1,3,5-triazin-2-yl]benzyll-N-(tert-
butoxycarbonyl)carbamate
[0556]
153
CA 02936408 2016-06-29
Me0,0 I& CI am Me0,0 461 CI 0.e0
OH Nõ= N OA
Y T
N-10 N.11#14 0
,0 ,0
[0557]
Under an argon atmosphere, to a solution of {4-chloro-3-
[4-methoxy-6-(4-methoxymethoxypheny1)-1,3,5-triazin-2-
yl]phenyllmethanol (0.78 g, 2.0 mmol) obtained in the above-
mentioned (2) in tetrahydrofuran (7.8 ml) were added
triethylamine (0.36 ml, 2.6 mmol) and methanesulfonyl chloride
(0.19 ml, 2.4 mmol) under ice-cooling, and the mixture was
stirred for 0.5 hr. The reaction mixture was filtered, and the
/0 filtrate was concentrated under reduced pressure. To a
solution of the residue in N,N-dimethylformamide (10 ml) were
added cesium carbonate (2.0 g, 6.0 mmol) and di-tert-butyl
iminodicarboxylate (0.53 g, 2.4 mmol), and the mixture was
stirred for 2 hr. To the reaction mixture were added water and
/5 ethyl acetate, and the mixture was partitioned. The organic
layer was washed with saturated brine, dried over magnesium
sulfate, filtered to remove magnesium sulfate, and concentrated
under reduced pressure. The residue was purified by silica gel
column chromatography (eluent: n-hexane/ethyl acetate=10/1) to
20 give the title compound (0.80 g, yield 68%).
1H-NMR (DMSO-D6) 5: 1.42 (18H, s), 3.41 (3H, s), 4.12 (3H, s),
4.77 (2H, s), 5.32 (2H, s), 7.18-7.23 (2H, m), 7.45 (1H, dd, J
= 8.2, 2.3 Hz), 7.65 (1H, d, J = 8.2 Hz), 7.91 (1H, d, J = 2.3
Hz), 8.43-8.47 (2H, m).
25 [0558]
(4) 4-[4-(5-aminomethy1-2-chloropheny1)-6-methoxy-1,3,5-
triazin-2-yl]phenol hydrochloride
[0559]
Wa.õ..0 gP 46, CI wit 0,100 HO* Ab,
,N, 111. Ny0.1./ N NH2-1-1CI
NY-N 0
,0 ,0
154
CA 02936408 2016-06-29
[0560]
Under an argon atmosphere, to tert-butyl N-{4-ch1oro-3-
[4-methoxy-6-(4-methoxymethoxypheny1)-1,3,5-triazin-2-
yl]benzyll-N-(tert-butoxycarbonyl)carbamate (0.40 g, 0.68 mmol)
obtained in the above-mentioned (3) was added 4M hydrogen
chloride/1,4-dioxane solution (2.0 ml) at room temperature, and
the mixture was stirred for 1 hr. To the reaction mixture was
added n-hexane (3.0 ml), and the mixture was stirred for 45 min.
The solid was collected by filtration, and dried under reduced
/0 pressure to give the title compound as a crude product (0.26 g).
[0561]
(5) 4-(4-{2-chloro-5-[(3,3,3-trifluoro-2,2-
dimethylpropionylamind)methyl]pheny11-6-methoxy-1,3,5-triazin-
2-yl)phenyl 3,3,3-trifluoro-2,2-dimethylpropionate
/5 [0562]
HO ri& M F>1)(1(0 M
MP NI(
N.
FF 0 Xle . RIP m=HM mr IN
NN 0 FF
.0 /0
[0563]
Under an argon atmosphere, to a solution of a crude
product (0.10 g) of 4-[4-(5-aminomethy1-2-chloropheny1)-6-
20 methoxy-1,3,5-triazin-2-yl]phenol hydrochloride obtained in the
above-mentioned (4), HOBt=H20 (0.061 g, 0.40 mmol) and WSC-HC1
(0.076 g, 0.40 mmol) in N,N-dimethylformamide (1.5 ml) were
added 3,3,3-trifluoro-2,2-dimethylpropionic acid (0.066 g, 0.40
mmol) and triethylamine (0.11 ml, 0.79 mmol) at room
25 temperature, and the mixture was stirred for 2 hr. To the
reaction mixture were added water and ethyl acetate, and the
mixture was partitioned. The organic layer was washed with
saturated brine, dried over magnesium sulfate, filtered to
remove magnesium sulfate, and concentrated under reduced
30 pressure. The residue was purified by silica gel column
chromatography (eluent: chloroform /ethyl acetate=10/1) to give
the title compound (0.090 g).
155
CA 02936408 2016-06-29
1H-NMR (DMSO-D6) 5: 1.39 (6H, s), 1.59 (6H, s), 4.15 (3H, s),
4.40 (2H, d, J = 6.0 Hz), 7.39-7.47 (3H, m), 7.62 (1H, d, J =
8.4 Hz), 7.88 (1H, d, J = 2.1 Hz), 8.55-8.60 (211, m), 8.66 (1H,
t, J = 6.0 Hz).
[0564]
(6) N-{4-chloro-3-[4-(4-hydroxypheny1)-6-methoxy-1,3,5-triazin-
2-yl]benzyll-3,3,3-trifluoro-2,2-dimethylpropionamide
[0565]
F)(e0 Ak, CI õ HO ri&h, M 4k
FF 0 IW RP '1,)(F.
9,P
0 FE 0 F
XF
NyN
NyN
[0566]
Under an argon atmosphere, to a solution of 4-(4-{2-
chloro-5-[(3,3,3-trifluoro-2,2-
dimethylpropionylamino)methyl]phenyll-6-methoxy-1,3,5-triazin-
2-yl)phenyl 3,3,3-trifluoro-2,2-dimethylpropionate (0.070 g,
/5 0.15 mmol) obtained in the above-mentioned (5) in methanol
(0.70 ml) was added 5M sodium methoxide/methanol solution
(0.032 ml) at room temperature, and the mixture was stirred for
1 hr. The reaction mixture was adjusted to pH=2 with 2N
hydrochloric acid under ice-cooling. To the reaction mixture
were added water and ethyl acetate, and the mixture was
partitioned. The organic layer was washed with saturated brine,
dried over magnesium sulfate, filtered to remove magnesium
sulfate, and concentrated under reduced pressure. The residue
was purified by silica gel column chromatography (eluent:
chloroform /ethyl acetate=4/1) to give the title compound
(0.036 g, yield 51%).
1H-NMR (DMSO-D6) 6: 1.38 (6H, s), 4.10 (3H, s), 4.39 (211, d, J
= 6.2 Hz), 6.91-6.95 (2H, m), 7.42 (1H, dd, J = 8.3, 2.3 Hz),
7.60 (1H, d, J = 8.3 Hz), 7.84 (1H, d, J = 2.3 Hz), 8.34-8.39
(2H, m), 8.65 (1H, t, J = 6.2 Hz), 10.38 (1H, br s).
[0567]
(7) N-(4-chloro-3-{4-methoxy-6-[4-(1-
156
CA 02936408 2016-06-29
methylcyclopropylmethoxy)pheny1]-1,3,5-triazin-2-yllbenzy1)-
3,3,3-trifluoro-2,2-dimethylpropionamide
[0568]
1-10,0eNCI = CI wA.
N 9.P
NyV,KF _________________ NA(F.
N
0 F F
0 F F 4 ,toN
,0 ,0
[0569]
. Under an argon atmosphere, to a solution of N-14-chloro-
3-[4-(4-hydroxypheny1)-6-methoxy-1,3,5-triazin-2-yl]benzyll-
3,3,3-trifluoro-2,2-dimethylpropionamide (0.036 g, 0.075 mmol)
obtained in the above-mentioned (6), 1-methyl-
/0 cyclopropanemethanol (0.0087 ml, 0.090 mmol) and
triphenylphosphine (0.024 g, 0.090 mmol) in tetrahydrofuran
(0.50 ml) was added 1.9M diethyl azodicarboxylate/toluene
solution (0.051 ml, 0.098 mmol) under ice-cooling, and the
mixture was stirred for 1 hr. The reaction mixture was stirred
/5 at room temperature for 1 hr, and 1.9M diethyl
azodicarboxylate/toluene solution (0.028 ml, 0.053 mmol) was
added. The reaction mixture was stirred at room temperature
for 1 hr, and purified by preparative thin layer chromatography
(eluent: chloroform /ethyl acetate=19/1) to give the title
20 compound (0.029 g, yield 70%).
1H-NMR (DMSO-DO 5: 0.42 (2H, dd, J = 5.6, 4.0 Hz), 0.56 (2H,
dd, J = 5.4, 4.2 Hz), 1.20 (3H, s), 1.39 (6H, s), 3.88 (2H, s),
4.11 (3H, s), 4.39 (2H, d, J = 5.9 Hz), 7.09-7.14 (2H, m), 7.43
(1H, dd, J = 8.2, 2.1 Hz), 7.60 (1H, d, J - 8.2 Hz), 7.85 (1H,
25 d, J = 2.1 Hz), 8.41-8.46 (2H, m), 8.66 (1H, t, J = 5.9 Hz).
[0570]
(8) N-(4-chloro-3-{4-hydroxy-6-[4-(1-
methylcyclopropylmethoxy)pheny1]-1,3,5-triazin-2-yllbenzyl)-
3,3,3-trifluoro-2,2-dimethylpropionamide (Example No.1-128)
30 [0571]
157
CA 02936408 2016-06-29
* N F ZA * c H
N Ny\cF
0 F F
F
NNoN N..10N 0 F
OH
[0572]
Under an argon atmosphere, to a solution of N-(4-chloro-
3-{4-methoxy-6-[4-(1-methylcyclopropylmethoxy)pheny1]-1,3,5-
triazin-2-yllbenzy1)-3,3,3-trifluoro-2,2-dimethylpropionamide
(0.028 g, 0.051 mmol) obtained in the above-mentioned (7) in
methanol (0.28 ml) was added 4M aqueous sodium hydroxide
solution (0.077 ml) at room temperature, and the mixture was
stirred at 60 C for 1 hr. To the reaction mixture were added
2N hydrochloric acid (0.16 ml) and water at room temperature,
and the mixture was stirred. The precipitated solid was
collected by filtration, washed with water, and dried under
reduced pressure to give the title compound (0.019 g, yield
69%).
[0573]
[Production Example 15]
Synthesis of N-{4-chloro-3-[4-(3-chloro-4-methylpheny1)-6-
hydroxy-1,3,5-triazin-2-yl]benzy11-3,3,3-trifluoro-2,2-
dimethylpropionamide (Example No.1-129)
[0574]
CI
CI = FNI1?(I(F
IN
0 F
OH
[0575]
(1) 2-chloro-4- (3-chloro-4-methylphenyl) -6-methoxy-1, 3, 5-
triazine
[0576]
Cl N Cl
10 cl
OH N, CI
CI
CI D- ,0 NYN
OH
158
CA 02936408 2016-06-29
[0577]
Under an argon atmosphere, to a suspension of 3-chloro-4-
methylphenylboronic acid (0.47 g, 2.8 mmol), 2,4-dichloro-6-
methoxy-1,3,5-triazine (1.0 g, 5.6 mmol) and
tetrakis(triphenylphosphine)palladium(0) (0.32 g, 0.28 mmol) in
toluene (5.0 m1) was added 2M aqueous sodium carbonate solution
(4.2 ml), and the mixture was stirred at 100 C for 2 hr. At
room temperature, to the reaction mixture were added water and
ethyl acetate, and the mixture was partitioned. The organic
/0 layer was washed with saturated brine, dried over sodium
sulfate, filtered to remove sodium sulfate, and concentrated
under reduced pressure. The residue was purified by silica gel
column chromatography (eluent: n-hexane/ethyl acetate=97/3 -
94/6) to give the title compound (0.61 g, yield 81%).
/5 1H-NMR (CDC13) 6: 2.47 (3H, s), 4.17 (3H, s), 7.37 (1H, d, J =
8.0 Hz), 8.28 (1H, dd, J = 8.0, 1.8 Hz), 8.47 (1H, d, J = 1.8
Hz).
[0578]
(2){4-chloro-3-[4-(3-chloro-4-methylpheny1)-6-methoxy-1,3,5-
20 triazin-2-yl]phenyllmethanol
[0579]
M CI
CI C I KyC I + HO.B OH OH
IsLiN
OH
,0 ,0
[0580]
Under an argon atmosphere, to a solution of 2-chloro-4-
25 (3-chloro-4-methy1pheny1)-6-methoxy-1,3,5-triazine (0.61 g, 2.3
mmol) obtained in the above-mentioned (1), 2-chloro-5-
hydroxymethylphenylboronic acid (0.51 g, 2.7 mmol) and [1,1'-
bis(diphenylphosphino)ferrocene]palladium(II)dichloride
dichloromethane adduct (0.19 g, 0.23 mmol) in 1,4-dioxane (6.0
30 ml) was added 2M aqueous sodium carbonate solution (4.5 ml),
and the mixture was stirred at 100 C for 1.5 hr. At room
temperature, to the reaction mixture were added water and ethyl
159
CA 02936408 2016-06-29
acetate, and the mixture was partitioned. The organic layer
was washed with saturated brine, dried over sodium sulfate,
filtered to remove sodium sulfate, and concentrated under
reduced pressure. The residue was purified by silica gel
column chromatography (eluent: n-hexane/ethyl acetate-8/2 -
6/4) to give the title compound (0.61 g, yield 71%).
1H-NMR (CD013) 5: 1.81 (1H, t, J = 5.9 Hz), 2.47 (3H, s), 4.21
(3H, s), 4.78 (2H, d, J = 5.9 Hz), 7.37 (1H, d, J = 7.9 Hz),
7.47 (1H, dd, J = 8.1, 2.2 Hz), 7.54 (1H, d, J = 8.1 Hz), 8.01
(1H, d, J = 2.2 Hz), 8.38 (1H, dd, J = 7.9, 1.8 Hz), 8.57 (1H,
d, J = 1.8 Hz).
[0581]
(3)4-chloro-3-[4-(3-chloro-4-methylpheny1)-6-methoxy-1,3,5-
triazin-2-yl]benzylamine hydrochloride
/5 10582]
NCI 4C)31.,e0
OH
CI 'WI N Ny0), SP N NH2
C
N.141 N..10N 0 tleN
[0583]
Under an argon atmosphere, to a solution of 14-chloro-3-
[4-(3-chloro-4-methylpheny1)-6-methoxy-1,3,5-triazin-2-
yl]phenyllmethanol (0.61 g, 1.6 mmol) obtained in the above-
mentioned (2) in tetrahydrofuran (6.0 ml) were added
triethylamine (0.29 ml, 2.1 mmol) and methanesulfonyl chloride
(0.15 ml, 1.9 mmol) under ice-cooling, and the mixture was
stirred for 1 hr. The reaction mixture was filtered, and the
filtrate was concentrated under reduced pressure. To a
solution of the residue in N,N-dimethylformamide (6.0 ml) were
added cesium carbonate (1.6 g, 4.8 mmol) and di-tert-butyl
iminodicarboxylate (0.42 g, 1.9 mmol) at room temperature, and
the mixture was stirred for 2 hr. To the reaction mixture were
added water and ethyl acetate, and the mixture was partitioned.
The organic layer was washed with saturated brine, dried over
sodium sulfate, filtered to remove sodium sulfate, and
160
CA 02936408 2016-06-29
concentrated under reduced pressure. The residue was purified
by silica gel column chromatography (eluent: n-hexane/ethyl
acetate=95/5 - 80/20). Under an argon atmosphere, to a
solution of the purified product in 1,4-dioxane (2.0 ml) was
added 4M hydrogen chloride /1,4-dioxane solution (8.0 ml) at
room temperature, and the mixture was stirred for 2.5 hr. To
the reaction mixture was added n-hexane, and the solid was
collected by filtration, and dried under reduced pressure to
give the title compound (0.67 g, yield 99%).
/o 1H-NMR (DMSO-D6) 5: 2.46 (3H, s), 4.12-4.21 (5H, m), 7.62 (1H,
d, J = 8.0 Hz), 7.73-7.75 (2H, m), 8.17 (1H, br s), 8.38 (1H,
dd, J - 8.0, 1.6 Hz), 8.47 (1H, d, J - 1.6 Hz), 8.48 (3H, br s).
[0584]
(4)N-{4-chloro-3-[4-(3-chloro-4-methylpheny1)-6-methoxy-1,3,5-
/5 triazin-2-yl]benzyll-3,3,3-trifluoro-2,2-dimethylpropionamide
[0585]
CI N NH2 = HC I C I CI
* N,
N,XF
F
N.eN NN 0 F
,0 ,0
[0586]
Under an argon atmosphere, to a solution of 4-chloro-3-
20 [4-(3-chloro-4-methylpheny1)-6-methoxy-1,3,5-triazin-2-
yl]benzylamine hydrochloride (0.070 g, 0.17 mmol) obtained in
the above-mentioned (3), HOBt.H20 (0.039 g, 0.26 mmol) and wsc.
HC1 (0.049 g, 0.26 mmol) in N,N-dimethylformamide (0.70 ml)
were added 3,3,3-trifluoro-2,2-dimethylpropionic acid (0.037 g,
25 0.24 mmol) and triethylamine (0.071 ml, 0.51 mmol) at room
temperature, and the mixture was stirred for 1 hr. To the
reaction mixture were added water and ethyl acetate, and the
mixture was partitioned. The organic layer was washed with
saturated brine, dried over sodium sulfate, filtered to remove
30 sodium sulfate, and concentrated under reduced pressure. The
residue was purified by silica gel column chromatography
(eluent: n-hexane/ethyl acetate=9/1 - 8/2) to give the title
161
CA 02936408 2016-06-29
compound (0.072 g, yield 82%).
111-NMR (CD013) 1.45 (6H, s), 2.47 (3H, s), 4.21 (3H, s),
4.56 (2H, d, J = 5.6 Hz), 6.24 (1H, br s), 7.34-7.39 (2H, m),
7.52 (1H, d, J = 8.2 Hz), 7.92 (1H, d, J = 2.3 Hz), 8.38 (1H,
dd, J = 8.2, 1.8 Hz), 8.56 (1H, d, J = 1.8 Hz).
[0587]
(5)N-{4-chloro-3-[4-(3-chloro-4-methylpheny1)-6-hydroxy-1,3,5-
triazin-2-yl]benzyll-3,3,3-trifluoro-2,2-dimethylpropionamide
(Example No.1-129)
[0588]
Cl 00 F * ,
Ny\cF CI kal H N,
NN 0 F 1N N,eN 0 F
,0 OH
[0589]
Under an argon atmosphere, to a solution of N-{4-chloro-
3-[4-(3-chloro-4-methylpheny1)-6-methoxy-1,3,5-triazin-2-
yl]benzyll-3,3,3-trifluoro-2,2-dimethylpropionamide (0.072 g,
0.14 mmol) obtained in the above-mentioned (4) in methanol
(0.70 ml) was added 4M aqueous sodium hydroxide solution (0.28
ml) at room temperature, and the mixture was stirred at 60 C
for 1 hr. To the reaction mixture were added 2N hydrochloric
acid (0.56 ml) and water at room temperature, and the mixture
was stirred. The precipitated solid was collected by
filtration, washed with water, and dried under reduced pressure
to give the title compound (0.057 g, yield 82%).
[0590]
[Production Example 16]
Synthesis of N-{4-chloro-3-[4-hydroxy-6-(3-isopropy1-4-
trifluoromethylpheny1)-1,3,5-triazin-2-yl]benzy1}-3,3,3-
trifluoro-2,2-dimethylpropionamide (Example No.1-130)
10591]
FE
CI
N FN,1?4,KF
rsLioN 0 F
OH
162
CA 02936408 2016-06-29
[0592]
(1)4-benzyloxy-2-bromo-l-trifluoromethylbenzene
[0593]
FE FE
F F *
Br
Br 0 is
[0594]
Under an argon atmosphere, to a solution of 2-bromo-4-
fluoro-l-trifluoromethylbenzene (1.5 g, 6.2 mmol) and sodium
hydride (0.74 g, 60 wt% oil dispersion) in N,N-
dimethylformamide (15 ml) was added benzyl alcohol (0.64 ml,
6.2 mmol) under ice-cooling, and the mixture was stirred for
0.5 hr. The reaction mixture was stirred at 60 C for 2 hr. At
room temperature, to the reaction mixture were added water and
ethyl acetate, and the mixture was partitioned. The organic
layer was washed with saturated brine, dried over sodium
sulfate, filtered to remove sodium sulfate, and concentrated
under reduced pressure. The residue was purified by silica gel
column chromatography (eluent: n-hexane/ethyl acetate-99/1 -
98/2) to give the title compound (1.3 g, yield 69%).
1H-NMR (CDC13) 6: 5.08 (2H, s), 6.93 (1H, dd, J = 8.8, 2.4 Hz),
7.30 (1H, d, J = 2.4 Hz), 7.33-7.41 (5H, m), 7.57 (1H, d, J =
8.8 Hz).
[0595]
(2)4-benzyloxy-2-isopropeny1-1-trifluoromethylbenzene
[0596]
FE FE
F F
Br 0 io ito
[0597]
Under an argon atmosphere, to a solution of 4-benzyloxy-
2-bromo-l-trifluoromethylbenzene (1.3 g, 3.9 mmol) obtained in
the above-mentioned (1) in 1,4-dioxane (13 ml) were added 2-
isopropeny1-4,4,5,5-tetramethyl-[1,3,21dioxaborolane (0.99 g,
5.9 mmol), [1,1f-
163
CA 02936408 2016-06-29
bis(diphenylphosphino)ferrocene]palladium(II)dichloride
dichloromethane adduct (0.32 g, 0.39 mmol) and 2M aqueous
sodium carbonate solution (5.9 ml) at room temperature, and the
mixture was stirred at 100 C for 2 hr. At room temperature, to
the reaction mixture were added water and ethyl acetate, and
the mixture was partitioned. The organic layer was washed with
saturated brine, dried over sodium sulfate, filtered to remove
sodium sulfate, and concentrated under reduced pressure. The
residue was purified by silica gel column chromatography
/o (eluent: n-hexane/ethyl acetate=99/1 - 97/3) to give the title
compound (1.1 g, yield 99%).
1H-NMR (CDC13) 5: 2.04 (3H, s), 4.88 (1H, br s), 5.08 (2H, s),
5.18 (1H, br s), 6.82 (1H, d, J = 2.6 Hz), 6.89 (1H, dd, J =
8.8, 2.6 Hz), 7.31-7.42 (5H, m), 7.54 (1H, d, J = 8.8 Hz).
/5 [0598]
(3) 3-isopropyl-4-trifluoromethylphenol
[0599]
FF FE
F
F
0 400 'Ne'v OH
[0600]
20 Under an argon atmosphere, to a solution of 4-benzy1oxy-
2-isopropeny1-1-trifluoromethylbenzene (1.2 g, 3.9 mmol)
obtained in the above-mentioned (2) in tetrahydrofuran (12 ml)
was added 10 wt% palladium carbon (0.23 g) at room temperature,
and the mixture was stirred under 1 atm hydrogen atmosphere for
25 5 hr. Under a nitrogen atmosphere, the reaction mixture was
filtered through celite and eluted with ethyl acetate. The
filtrate was concentrated under reduced pressure to give the
title compound (0.76 g, yield 96%).
1H-NMR (CDC13) 5: 1.23 (6H, d, J = 6.7 Hz), 3.24-3.35 (1H, m),
30 5.04 (1H, br s), 6.66 (1H, dd, J = 8.6, 2.6 Hz), 6.87 (1H, d, J
= 2.6 Hz), 7.46 (1H, d, J = 8.6 Hz).
[0601]
(4) 3-isopropyl-4-trifluoromethylphenyl
164
CA 02936408 2016-06-29
trifluoromethanesulfonate
[0602]
FF FF
F F rOO
OH
FF
[0603]
Under an argon atmosphere, to a solution of 3-isopropyl-
4-trifluoromethylphenol (0.77 g, 3.8 mmol) obtained in the
above-mentioned (3) in chloroform (8.0 ml) were added
triethylamine (0.58 ml, 4.1 mmol) and trifluoromethanesulfonic
anhydride (0.67 ml, 4.0 mmol) under ice-cooling, and the
/0 mixture was stirred for 1 hr. To the reaction mixture were
added water and chloroform, and the mixture was partitioned.
The organic layer was washed with saturated brine, dried over
sodium sulfate, filtered to remove sodium sulfate, and
concentrated under reduced pressure. The residue was purified
/5 by silica gel column chromatography (eluent: n-hexane/ethyl
acetate=98/2) to give the title compound (0.78 g, yield 62%).
1H-NMR (CDC13) 5: 1.28 (6H, d, J = 6.7 Hz), 3.34-3.46 (1H, m),
7.19 (1H, dd, J = 8.8, 2.4 Hz), 7.34 (1H, d, J = 2.4 Hz), 7.70
(1H, d, J = 8.8 Hz).
20 [0604]
(5) 2-(3-isopropy1-4-trifluoromethylphenyl)-4,4,5,5-
tetramethyl-[1,3,2]dioxaborolane
[06051
F
FE F
F Ons,O, F
-0
FF
25 [0 60 6]
Under an argon atmosphere, to a solution of 3-isopropyl-
4-trifluoromethylphenyl trifluoromethanesulfonate (0.78 g, 2.3
mmol) obtained in the above-mentioned (4) in DMSO (8.0 ml) were
added bis(pinacolato)diboron (0.71 g, 2.8 mmol), potassium
30 acetate (0.68 g, 7.0 mmol) and [1,1'-
165
CA 02936408 2016-06-29
bis(diphenylphosphino)ferrocene]palladium(II)dichloride
dichloromethane adduct (0.095 g, 0.12 mmol) at room temperature,
and the mixture was stirred at 80 C for 2 hr. At room
temperature, to the reaction mixture were added water and ethyl
acetate, and the mixture was partitioned. The organic layer
was washed with saturated brine, dried over sodium sulfate,
filtered to remove sodium sulfate, and concentrated under
reduced pressure. The residue was purified by silica gel
column chromatography (eluent: n-hexane/ethyl acetate=98/2) to
/0 give the title compound (0.48 g, yield 66%).
1H-NMR (CDC13) 6: 1.29 (6H, d, J = 7.0 Hz), 1.36 (12H, s),
3.29-3.40 (1H, m), 7.57 (1H, d, J = 7.9 Hz), 7.68 (1H, d, J =
7.9 Hz), 7.88 (1H, br s).
[0607]
/5 (6) 2-chloro-4-(3-isopropy1-4-trifluoromethylpheny1)-6-methoxy-
1,3,5-triazine
[0608]
FF F
CI N CI N CI
F rii
B-0 NN
NN
[0609]
Under an argon atmosphere, to a suspension of 2-(3-
isopropyl-4-trifluoromethylpheny1)-4,4,5,5-tetramethyl-
[1,3,2]dioxaborolane (0.48 g, 1.5 mmol) obtained in the above-
mentioned (5), 2,4-dichloro-6-methoxy-1,3,5-triazine (0.69 g,
3.8 mmol) and [1,1'-
bis(diphenylphosphino)ferrocene]palladium(II)dichloride
dichloromethane adduct (0.13 g, 0.15 mmol) in 1,4-dioxane (5.0
ml) was added 2M aqueous sodium carbonate solution (3.1 mL),
and the mixture was stirred at 100 C for 1 hr. At room
temperature, to the reaction mixture were added water and ethyl
acetate, and the mixture was partitioned. The organic layer
was washed with saturated brine, dried over sodium sulfate,
filtered to remove sodium sulfate, and concentrated under
166
CA 02936408 2016-06-29
reduced pressure. The residue was purified by silica gel
column chromatography (eluent: n-hexane/ethyl acetate=97/3 -
94/6) to give the title compound (0.36 g, yield 71%).
[0610]
(7) {4-chloro-3-[4-(3-isopropy1-4-trifluoromethylpheny1)-6-
methoxy-1,3,5-triazin-2-yl]phenyllmethanol
[0611]
FF FE
F th CI F CI
ati
+ H013 gliv OH -4-
'IP OH
N'Ta OH tisioN
,0 ,0
[0612]
Under an argon atmosphere, to a solution of 2-chloro-4-
(3-isopropyl-4-trifluoromethylpheny1)-6-methoxy-1,3,5-triazine
(0.36 g, 1.1 mmol) obtained in the above-mentioned (6), 2-
chloro-5-hydroxymethylphenylboronic acid (0.25 g, 1.3 mmol) and
[1,1'-bis(diphenylphosphino)ferrocene]palladium(II)dichloride
/5 dichloromethane adduct (0.089 g, 0.11 mmol) in 1,4-dioxane (3.6
ml) was added 2M aqueous sodium carbonate solution (2.2 ml),
and the mixture was stirred at 100 C for 1.5 hr. At room
temperature, to the reaction mixture were added water and ethyl
acetate, and the mixture was partitioned. The organic layer
was washed with saturated brine, dried over sodium sulfate,
filtered to remove sodium sulfate, and concentrated under
reduced pressure. The residue was purified by silica gel
column chromatography (eluent: n-hexane/ethyl acetate=8/2 -
1/1) to give the title compound (0.30 g, yield 62%).
1H-NMR (CDC13) 6: 1.36 (6H, d, J = 6.8 Hz), 1.79 (1H, t, J =
6.0 Hz), 3.37-3.48 (1H, m), 4.24 (3H, s), 4.79 (2H, d, J = 6.0
Hz), 7.49 (1H, dd, J = 8.4, 2.2 Hz), 7.57 (1H, d, J = 8.4 Hz),
7.75 (1H, d, J - 8.4 Hz), 8.07 (1H, d, J = 2.2 Hz), 8.47 (1H, d,
J = 8.4 Hz), 8.73 (1H, br s).
[0613]
(8)4-chloro-3-[4-(3-isopropy1-4-trifluoromethylpheny1)-6-
methoxy-1,3,5-triazin-2-yl]benzylamine hydrochloride
167
CA 02936408 2016-06-29
[0614]
FF
FF F
N OH 01 =0 0 FF
C I= s.CLe, N JA=w I
F== ,( N Iy04/- NH2 = HC I
Ny'N 0 I NioN
thrN
,0
[0615]
Under an argon atmosphere, to a solution of 14-chloro-3-
s [4-(3-isopropy1-4-trifluoromethylpheny1)-6-methoxy-1,3,5-
triazin-2-yl]phenyllmethanol (0.30 g, 0.68 mmol) obtained in
the above-mentioned (7) in tetrahydrofuran (3.0 ml) were added
triethylamine (0.12 ml, 0.89 mmol) and methanesulfonyl chloride
(0.063 ml, 0.82 mmol) under ice-cooling, and the mixture was
/0 stirred for 0.5 hr. The reaction mixture was filtered, and the
filtrate was concentrated under reduced pressure. To a
solution of the residue in N,N-dimethylformamide (3.0 ml) were
added cesium carbonate (0.67 g, 2.0 mmol) and di-tert-butyl
iminodicarboxylate (0.18 g, 0.82 mmol) at room temperature, and
15 the mixture was stirred for 1.5 hr. To the reaction mixture
were added water and ethyl acetate, and the mixture was
partitioned. The organic layer was washed with saturated brine,
dried over sodium sulfate, filtered to remove sodium sulfate,
and concentrated under reduced pressure. The residue was
20 purified by silica gel column chromatography (eluent: n-
hexane/ethyl acetate=95/5 - 80/20). Under an argon atmosphere,
to a solution (1.0 ml) of the purified product in 1,4-dioxane
was added 4M hydrogen chloride /1,4-dioxane solution (4.0 ml)
at room temperature, and the mixture was stirred for 1.5 hr.
25 To the reaction mixture was added n-hexane, and the solid was
collected by filtration and dried under reduced pressure to
give the title compound (0.24 g, yield 74%).
1H-NMR (DMSO-D6) 6: 1.33 (6H, d, J = 6.7 Hz), 3.28-3.40 (1H, m),
4.13-4.22 (5H, m), 7.73 (1H, dd, J = 8.2, 2.2 Hz), 7.77 (1H, d,
30 J = 8.3 Hz), 7.92 (1H, d, J = 8.3 Hz), 8.20 (1H, d, J = 2.2 Hz),
8.35 (3H, br s), 8.48 (1H, d, J = 8.8 Hz), 8.70 (1H, s).
[0616]
168
CA 02936408 2016-06-29
(9) N-{4-chloro-3-[4-(3-isopropy1-4-trifluoromethylpheny1)-6-
methoxy-1,3,5-triazin-2-yl]benzy11-3,3,3-trifluoro-2,2-
dimethylpropionamide
[0617]
FE M FF
41k 46, M H F
N, NE12=HM _______ F 461 MP N PIP
14.11A N.10N 0 FE
,0 ,0
[0618]
Under an argon atmosphere, to a solution of 4-chloro-3-
[4-(3-isopropy1-4-trifluoromethylpheny1)-6-methoxy-1,3,5-
triazin-2-yl]benzylamine hydrochloride (0.080 g, 0.17 mmol)
obtained in the above-mentioned (8), HOBt.H20 (0.039 g, 0.26
mmol) and WSC.HC1 (0.049 g, 0.26 mmol) in N,N-dimethylformamide
(0.80 ml) were added 3,3,3-trifluoro-2,2-dimethylpropionic acid
(0.037 g, 0.24 mmol) and triethylamine (0.071 ml, 0.51 mmol) at
room temperature, and the mixture was stirred for 1 hr. To the
/5 reaction mixture were added water and ethyl acetate, and the
mixture was partitioned. The organic layer was washed with
saturated brine, dried over sodium sulfate, filtered to remove
sodium sulfate, and concentrated under reduced pressure. The
residue was purified by silica gel column chromatography
(eluent: n-hexane/ethyl acetate=19/1 - 8/2) to give the title
compound (0.077 g, yield 79%).
1H-NMR (CD013) 5: 1.35 (6H, d, J = 6.0 Hz), 1.44 (6H, br s),
3.37-3.49 (1H, m), 4.23 (3H, s), 4.56 (2H, d, J = 5.8 Hz), 6.25
(1H, br s), 7.37 (1H, dd, J = 8.4, 2.3 Hz), 7.54 (1H, d, J =
8.4 Hz), 7.74 (1H, d, J = 8.4 Hz), 7.96 (1H, d, J = 2.3 Hz),
8.46 (1H, d, J = 8.4 Hz), 8.72 (1H, br s).
[0619]
(10) N-{4-chloro-3-[4-hydroxy-6-(3-isopropy1-4-
trifluoromethylpheny1)-1,3,5-triazin-2-yl]benzy11-3,3,3-
trifluoro-2,2-dimethylpropionamide (Example No.1-130)
[0620]
169
CA 02936408 2016-06-29
F F
N F NCI H
N, yY,,KF __ a N.XF
0 F F
NN NyN 0 FE
OH
[0621]
Under an argon atmosphere, to a solution of N-{4-chloro-
3-[4-(3-isopropy1-4-trifluoromethylpheny1)-6-methoxy-1,3,5-
triazin-2-yl]benzy11-3,3,3-trifluoro-2,2-dimethylpropionamide
(0.077 g, 0.13 mmol) obtained in the above-mentioned (9) in
methanol (0.80 ml) was added 4M aqueous sodium hydroxide
solution (0.27 ml) at room temperature, and the mixture was
stirred at 60 C for 1 hr. To the reaction mixture were added
/0 2N hydrochloric acid (0.54 ml) and water at room temperature,
and the mixture was stirred. The precipitated solid was
collected by filtration, washed with water, and dried under
reduced pressure to give the title compound (0.066 g, yield
88%).
/5 [0622]
[Production Example 17]
Synthesis of N-0-[4-(4-butoxypheny1)-6-hydroxy-1,3,5-triazin-
2-y1]-4-chlorobenzy11-3,3,3-trifluoro-2,2-dimethylpropionamide
(Example No.1-131)
20 [0623]
CI H
0 F F
NyN
OH
[0624]
(1) N-{3-[4-(4-butoxypheny1)-6-methoxy-1,3,5-triazin-2-y1]-4-
chlorobenzy11-3,3,3-trifluoro-2,2-dimethylpropionamide
25 [0625]
HOra. GI H u AL CI H µi
4F .N 1)1./C.KF 4, N, NyC.KF
F F
NyN 0 F NN 0 F
[0626]
170
CA 02936408 2016-06-29
Under an argon atmosphere, to a solution of N-{4-chloro-
3-[4-(4-hydroxypheny1)-6-methoxy-1,3,5-triazin-2-yl]benzyll-
3,3,3-trifluoro-2,2-dimethylpropionamide (0.10 g, 0.21 mmol)
obtained in the above-mentioned [Production Example 14] (6), n-
butanol (0.023 ml, 0.25 mmol) and triphenylphosphine (0.066 g,
0.25 mmol) in tetrahydrofuran (1.0 ml) was added bis(2-
methoxyethyl) azodicarboxylate (0.059 g, 0.25 mmol) under ice-
cooling, and the mixture was stirred for 1 hr. To the reaction
mixture were added n-butanol (0.019 ml, 0.21 mmol),
/0 triphenylphosphine (0.055 g, 0.21 mmol) and bis(2-methoxyethyl)
azodicarboxylate (0.049 g, 0.21 mmol), and the mixture was
stirred at room temperature for 2 hr. To the reaction mixture
were added water and ethyl acetate, and the mixture was
partitioned. The organic layer was washed with saturated brine,
dried over magnesium sulfate, filtered to remove magnesium
sulfate, and concentrated under reduced pressure. The residue
was purified by silica gel column chromatography (eluent: n-
hexane/ethyl acetate=1/1) to give the title compound (0.096 g,
yield 85%).
[0627]
(2) N-{3-[4-(4-butoxypheny1)-6-hydroxy-1,3,5-triazin-2-y1]-4-
chlorobenzy11-3,3,3-trifluoro-2,2-dimethylpropionamide (Example
No.1-131)
[0628]
CH
N 1. N,:Tja, 4P Ny\cF NF
0 FF ___ P- .
0 FF
N.e.N
O
H
[0629]
Under an argon atmosphere, to a solution of N-{3-[4-(4-
butoxypheny1)-6-methoxy-1,3,5-triazin-2-y1]-4-chlorobenzyll-
3,3,3-trifluoro-2,2-dimethy1propionamide (0.096 g, 0.18 mmol)
obtained in the above-mentioned (1) in methanol (0.96 ml) was
added 4M aqueous sodium hydroxide solution (0.27 ml) at room
temperature, and the mixture was stirred at 65 C for 2 hr. To
the reaction mixture wete added 2N hydrochloric acid (0.54 ml)
171
CA 02936408 2016-06-29
and water and the mixture was stirred at room temperature. The
precipitated solid was collected by filtration, washed with
water, and dried under reduced pressure to give the title
compound (0.086 g, yield 93%).
[0630]
[Production Example 18]
Synthesis of N-{4-chloro-3-[4-(3-cyclopropy1-4-fluoropheny1)-6-
hydroxy-1,3,5-triazin-2-yl]benzy1}-3,3,3-trifluoro-2,2-
dimethylpropionamide (Example No.1-135)
/o [0631]
FH
14.1?cF
V
0 FF
N.,eN
OH
[0632]
(1) 2-chloro-4-(3-cyclopropy1-4-fluoropheny1)-6-methoxy-1,3,5-
triazine
/5 [0633]
;)CL CI N CI
NyN _________________________________ 7X2)NirkIrCI
154' ,0
,0
[0634]
Under an argon atmosphere, to a suspension of 2-(3-
cyclopropy1-4-fluoropheny1)-4,4,5,5-tetramethyl-
20 [1,3,2]dioxaborolane (0.59 g, 2.2 mmol), 2,4-dichloro-6-
methoxy-1,3,5-triazine (0.81 g, 4.3 mmol) and [1,1'-
bis(diphenylphosphino)ferrocene]palladium(II)dichloride
dichloromethane adduct (0.18 g, 0.22 mmol) in 1,4-dioxane (3.0
ml) was added 2M aqueous sodium carbonate solution (3.4 ml),
25 and the mixture was stirred at 100 C for 1 hr. At room
temperature, to the reaction mixture were added water and ethyl
acetate, and the mixture was partitioned. The organic layer
was washed with saturated brine, dried over sodium sulfate,
filtered to remove sodium sulfate, and concentrated under
172
CA 02936408 2016-06-29
reduced pressure. The residue was purified by silica gel
column chromatography (eluent: n-hexane/ethyl acetate=25/1 -
20/1) to give the title compound as a crude product (0.44 g).
[0635]
(2) {4-chloro-3-[4-(3-cyclopropy1-4-fluoropheny1)-6-methoxy-
1,3,5-triazin-2-yl]phenyllmethanol
[0636]
F icw F 46, CI
N CI CI Ai
N, µP OH
= It,
+ HO.D OH =
NN
.0 OH ,0
[0637]
Under an argon atmosphere, to a solution of a crude
product (0.44 g) of 2-chloro-4-(3-cyclopropy1-4-fluoropheny1)-
6-methoxy-1,3,5-triazine obtained in the above-mentioned (1),
2-chloro-5-hydroxymethylphenylboronic acid (0.31 g, 1.6 mmol)
and [1,1'-
bis(diphenylphosphino)ferrocene]palladium(II)dichloride
dichloromethane adduct (0.11 g, 0.13 mmol) in 1,4-dioxane (5.4
ml) was added 2M aqueous sodium carbonate solution (2.7 ml),
and the mixture was stirred at 100 C for 1 hr. At room
temperature, to the reaction mixture were added water and ethyl
acetate, and the mixture was partitioned. The organic layer
was washed with saturated brine, dried over sodium sulfate,
filtered to remove sodium sulfate, and concentrated under
reduced pressure. The residue was purified by silica gel
column chromatography (eluent: n-hexane/ethyl acetate=5/3) to
give the title compound (0.32 g).
1H-NMR (CDC13) 5: 0.83-0.88 (2H, m), 1.01-1.07 (2H, m), 1.79
(1H, t, J = 6.0 Hz), 2.10-2.19 (1H, m), 4.20 (3H, s), 4.77 (2H,
d, J = 6.0 Hz), 7.13 (1H, t, J = 9.2 Hz), 7.47 (1H, d, J = 8.1
Hz), 7.54 (1H, d, J = 8.1 Hz), 8.01 (1H, br s), 8.20 (1H, d, J
= 7.6 Hz), 8.38-8.41 (1H, m).
[0638]
(3) tert-butyl N-{4-chloro-3-[4-(3-cyclopropy1-4-fluoropheny1)-
173
CA 02936408 2016-06-29
6-methoxy-1,3,5-triazin-2-yl]benzy1}-N-(tert-
butoxycarbonyl)carbamate
[0639]
4)
F CI.A0:00 NyN N N 0
,0
[0640]
Under an argon atmosphere, to a solution of {4-chloro-3-
[4-(3-cyclopropy1-4-fluoropheny1)-6-methoxy-1,3,5-triazin-2-
yl]phenyllmethanol (0.32 g, 0.82 mmol) obtained in the above-
mentioned (2) in tetrahydrofuran (3.3 ml) were added
/o triethylamine (0.15 ml, 1.1 mmol) and methanesulfonyl chloride
(0.076 ml, 0.98 mmol) under ice-cooling, and the mixture was
stirred for 0.5 hr. The reaction mixture was filtered, and the
filtrate was concentrated under reduced pressure. To a
solution of the residue in N,N-dimethylformamide (3.3 ml) were
/5 added cesium carbonate (0.80 g, 2.5 mmol) and di-tert-butyl
iminodicarboxylate (0.21 g, 0.98 mmol) at room temperature, and
the mixture was stirred for 1 hr. To the reaction mixture were
added water and ethyl acetate, and the mixture was partitioned.
The organic layer was washed with saturated brine, dried over
20 magnesium sulfate, filtered to remove magnesium sulfate, and
concentrated under reduced pressure. The residue was purified
by silica gel column chromatography (eluent: n-hexane/ethyl
acetate=7/1) to give the title compound (0.40 g, yield 83%).
1H-NMR (CDC13) 5: 0.84-0.88 (2H, m), 1.01-1.07 (2H, m), 1.47
25 (1814, s), 2.09-2.18 (1H, m), 1.18 (3H, s), 4.83 (2H, s), 7.11
(1H, dd, J = 9.7, 8.6 Hz), 7.40 (114, dd, J = 8.3, 2.2 Hz), 7.49
(11-1, d, J = 8.3 Hz), 8.00 (1H, d, J = 2.2 Hz), 8.19 (11-1, dd, J
= 7.5, 2.2 Hz), 8.36-8.41 (11-1, m).
[0641]
30 (4) 4-chloro-3-[4-(3-cyclopropy1-4-fluoropheny1)-6-methoxy-
1,3,5-triazin-2-yl]benzylamine hydrochloride
[0642]
174
CA 02936408 2016-06-29
VF C I 4CI ak, 0 0
v,C(etl, -e
N NH2- HG I
0 I N y4s1
,0 ,0
[0643]
Under an argon atmosphere, to tert-butyl N-14-chloro-3-
[4-(3-cyclopropy1-4-fluoropheny1)-6-methoxy-1,3,5-triazin-2-
yl]benzyll-N-(tert-butoxycarbonyl)carbamate(0.40 g, 0.68 mmol)
obtained in the above-mentioned (3) was added 4M hydrogen
chloride/1,4-dioxane solution (3.3 ml) at room temperature, and
the mixture was stirred for 1 hr. To the reaction mixture was
added ethyl acetate (35 ml), and the mixture was stirred. The
/o solid was collected by filtration and dried under reduced
pressure to give the title compound (0.26 g, yield 89%).
1H-NMR (DMSO-DO 6: 0.78-0.83 (2H, m), 1.05-1.10 (2H, m), 2.10-
2.19 (1H, m), 4.16 (3H, s), 4.16 (2H, s), 7.39 (1H, dd, J = 9.9,
8.7 Hz), 7.71 (1H, dd, J = 8.4, 2.1 Hz), 7.75 (1H, d, Jr = 8.4
/5 Hz), 8.13 (1H, dd, J = 7.7, 2.1 Hz), 8.16 (1H, d, J - 2.1 Hz),
8.35-8.37 (4H, m).
[0644]
(5) N-{4-chloro-3-[4-(3-cyclopropy1-4-fluoropheny1)-6-methoxy-
1,3,5-triazin-2-yl]benzy11-3,3,3-trifluoro-2,2-
20 dimethylpropionamide
[0645]
,A6
F 40 CI H
N,
4P N 4P NF12=NCI y
0 FF
N11.10 N
NN
,0 ,0
[0646]
Under an argon atmosphere, to a solution of 4-chloro-3-
25 [4-(3-cyclopropy1-4-fluoropheny1)-6-methoxy-1,3,5-triazin-2-
yl]benzylamine hydrochloride (0.070 g, 0.17 mmol) obtained in
the above-mentioned (4), HOBt.H20 (0.033 g, 0.22 mmol) and WSC.
HC1 (0.041 g, 0.22 mmol) in N,N-dimethylformamide (2.0 ml) were
added 3,3,3-trifluoro-2,2-dimethylpropionic acid (0.034 g, 0.22
175
CA 02936408 2016-06-29
mmol) and triethylamine (0.069 ml, 0.48 mmol) at room
temperature, and the mixture was stirred for 3 hr. To the
reaction mixture were added saturated aqueous sodium hydrogen
carbonate and ethyl acetate, and the mixture was partitioned.
The organic layer was washed with saturated brine, dried over
sodium sulfate, filtered to remove sodium sulfate, and
concentrated under reduced pressure. The residue was purified
by silica gel column chromatography (eluent: n-hexane/ethyl
acetate=5/3) to give the title compound (0.082 g, yield 94%).
/0 1H-NMR (CDC13) 5: 0.82-0.87 (2H, m), 1.01-1.05 (2H, m), 1.43
(6H, s), 2.10-2.16 (1H, m), 4.18 (3H, s), 4.54 (2H, d, J = 5.6
Hz), 6.21 (1H, br s), 7.11 (1H, t, J = 9.2 Hz), 7.34 (1H, d, J
= 8.3 Hz), 7.51 (1H, d, J = 8.3 Hz), 7.90 (111, s), 8.18 (1H, d,
J = 7.7 Hz), 8.36-8.40 (1H, m).
/5 [0647]
(6) N-{4-chloro-3-[4-(3-cyclopropy1-4-fluoropheny1)-6-hydroxy-
1,3,5-triazin-2-yl]benzy11-3,3,3-trifluoro-2,2-
dimethylpropionamide (Example No.1-135)
[0648]
F CI At, H
;)0LeCI F
WP ,N, N, RIP
V F
0 F 0 F
NY' NyN
OH
[0649]
Under an argon atmosphere, to a solution of N-(4-chloro-
3-[4-(3-cyclopropy1-4-fluoropheny1)-6-methoxy-1,3,5-triazin-2-
yl]benzyll-3,3,3-trifluoro-2,2-dimethylpropionamide (0.082 g,
0.16 mmol) obtained in the above-mentioned (5) in methanol (1.8
ml) was added 4M aqueous sodium hydroxide solution (0.24 ml) at
room temperature, and the mixture was stirred at 60 C for 3 hr.
To the reaction mixture were added 10% aqueous citric acid
solution (1.0 ml) and water, and the mixture was stirred at
room temperature. The precipitated solid was collected by
filtration, washed with water, and dried under reduced pressure
to give the title compound (0.065 g, yield 81%).
[0650]
176
CA 02936408 2016-06-29
[Production Example 19]
Synthesis of (R)-N-{4-chloro-3-[4-(4-chloro-3-methylpheny1)-6-
hydroxy-1,3,5-triazin-2-yl]benzy11-3,3,3-trifluoro-2-methoxy-2-
methylpropionamide (Example No.1-136)
[0651]
CI 46, CI Aki
H s OMe
,N, MiF N.NAKF
0 F
14).rA F
OH
[0652]
(1) benzyl (R)-3,3,3-trifluoro-2-hydroxy-2-methylpropionate
[0653]
;OH OH
HO-yAKF
0 FF 0 F F
[0654]
Under an argon atmosphere, to a suspension of (R)-3,3,3-
trifluoro-2-hydroxy-2-methylpropionic acid (2.2 g, 14 mmol) and
potassium carbonate (2.3 g, 16 mmol) in N,N-dimethylformamide
/5 (30 ml) was added benzyl bromide (1.8 ml, 15 mmol) at room
temperature, and the mixture was stirred for 4 hr. To the
reaction mixture were added water and ethyl acetate, and the
mixture was partitioned. The organic layer was washed with
saturated brine, dried over sodium sulfate, filtered to remove
sodium sulfate, and concentrated under reduced pressure. The
residue was purified by silica gel column chromatography
(eluent: n-hexane/ethyl acetate-6/1) to give the title compound
(3.0 g, yield 90%).
111-NMR (CDC13) 5: 1.60 (3H, s), 3.78 (1H, s), 5.31 (2H, s),
7.33-7.42 (5H, m).
[0655]
(2) benzyl (R)-3,3,3-trifluoro-2-methoxy-2-methylpropionate
[0656]
177
CA 02936408 2016-06-29
=. OH =OMe
0A(F 01A(F
0 FF 0 FF
[0657]
Under an argon atmosphere, to a solution of benzyl (R)-
3,3,3-trifluoro-2-hydroxy-2-methylpropionate (3.4 g, 14 mmol)
s obtained in the above-mentioned (1) in N,N-dimethylformamide
(40 ml) was added sodium hydride (0.60 g, 60 wt% oil
dispersion) under ice-cooling, and the mixture was stirred for
1 hr. To the reaction mixture was added methyl iodide (1.3 ml,
20 mmol), and the mixture was stirred at room temperature for 2
/o hr. To the reaction mixture were added saturated aqueous
ammonium chloride and ethyl acetate, and the mixture was
partitioned. The organic layer was washed with saturated brine,
dried over sodium sulfate, filtered to remove sodium sulfate,
and concentrated under reduced pressure. The residue was
/5 purified by silica gel column chromatography (eluent: n-
hexane/ethyl acetate-15/1) to give the title compound (2.8 g,
yield 78%).
1H-NMR (CDC13) 5: 1.59 (3H, s), 3.40 (3H, s), 5.26 (2H, s),
7.31-7.37 (5H, m).
20 [0658]
(3) (R)-3,3,3-trifluoro-2-methoxy-2-methylpropionic acid
[0659]
.OMe OMe
411 0...e)cF HO ye,....KF
0 FF 0 FF
[0660]
25 Under an argon atmosphere, to a solution of benzyl (R)-
3,3,3-trifluoro-2-methoxy-2-methylpropionate (2.8 g, 11 mmol)
obtained in the above-mentioned (2) in ethyl acetate (50 ml)
was added 10 wt% palladium carbon (0.23 g) at room temperature,
and the mixture was stirred under 1 atm hydrogen atmosphere for
30 5 hr. Under a nitrogen atmosphere, the reaction mixture was
filtered through celite and eluted with ethyl acetate. The
178
CA 02936408 2016-06-29
filtrate was concentrated under reduced pressure to give the
title compound (1.4 g, yield 78%).
1H-NMR (CDC13) 6: 1.68 (3H, s), 3.54 (3H, s).
[0661]
(4) 2-chloro-4-(4-chloro-3-methylpheny1)-6-methoxy-1,3,5-
triazine
[0662]
CI y. N CI CI rithi
CI 46 y
OH + NN NYCI
OH
1r 13' ,0 N.eN
,0
106631
Under an argon atmosphere, to a suspension of 4-chloro-3-
methylphenylboronic acid (0.47 g, 2.8 mmol), 2,4-dichloro-6-
methoxy-1,3,5-triazine (1.0 g, 5.6 mmol) and
tetrakis(triphenylphosphine)palladium(0) (0.32 g, 0.28 mmol) in
toluene (5.0 ml) was added 2M aqueous sodium carbonate solution
is (4.2 ml), and the mixture was stirred at 100 C for 2 hr. At
room temperature, to the reaction mixture were added water and
ethyl acetate, and the mixture was partitioned. The organic
layer was washed with saturated brine, dried over sodium
sulfate, filtered to remove sodium sulfate, and concentrated
under reduced pressure. The residue was purified by silica gel
column chromatography (eluent: n-hexane/ethyl acetate=98/2 -
95/5) to give the title compound (0.50 g, yield 48%).
1H-NMR (CDC13) 5: 2.47 (3H, s), 4.17 (3H, s), 7.47 (1H, d, J =
8.4 Hz), 8.26 (1H, dd, J = 8.4, 2.1 Hz), 8.36 (1H, d, J - 2.1
Hz) .
[0664]
(5) {4-chloro-3-[4-(4-chloro-3-methylphenyl)-6-methoxy-1,3,5-
triazin-2-yl]phenyllmethanol
[0665]
179
CA 02936408 2016-06-29
CI Ai ak 1W ir
CI
N% OH NCI
+ 1141P OH
N.IrN
,0 OH ,0
[0666]
Under an argon atmosphere, to a solution of 2-chloro-4-
(4-chloro-3-methylpheny1)-6-methoxy-1,3,5-triazine (0.50 g, 1.3
mmol) obtained in the above-mentioned (4), 2-chloro-5-
hydroxymethylphenylboronic acid (0.30 g, 1.6 mmol) and [1,1'-
bis(diphenylphosphino)ferrocene]palladium(II)dichloride
dichloromethane adduct (0.11 g, 0.13 mmol) in 1,4-dioxane (5.0
ml) was added 2M aqueous sodium carbonate solution (2.6 ml),
/o and the mixture was stirred at 100 C for 1.5 hr. At room
temperature, to the reaction mixture were added water and ethyl
acetate, and the mixture was partitioned. The organic layer
was washed with saturated brine, dried over sodium sulfate,
filtered to remove sodium sulfate, and concentrated under
reduced pressure. The residue was purified by silica gel
column chromatography (eluent: n-hexane/ethyl acetate=8/2 -
6/4) to give the title compound (0.40 g, yield 80%).
1H-NMR (CDC13) 6: 1.79 (1H, t, J = 5.3 Hz), 2.48 (3H, s), 4.21
(3H, s), 4.78 (2H, d, J = 5.3 Hz), 7.45-7.50 (2H, m), 7.54 (1H,
d, J = 8.1 Hz), 8.01 (1H, d, J = 2.1 Hz), 8.37 (1H, dd, J - 8.4,
2.1 Hz), 8.46 (1H, d, J = 2.1 Hz).
[0667]
(6) 4-chloro-3-[4-(4-chloro-3-methylpheny1)-6-methoxy-1,3,5-
triazin-2-yl]benzylamine hydrochloride
[0668]
CI *I CI N q, ak, M
OH )(
41 14C,IX)1..):1
NH2.HCI
4,10N N.rN o
,o ,o
,0
[0669]
Under an argon atmosphere, to a solution of {4-chloro-3-
[4-(4-chloro-3-methylpheny1)-6-methoxy-1,3,5-triazin-2-
180
CA 02936408 2016-06-29
yl]phenyllmethanol (0.40 g, 1.1 mmol) obtained in the above-
mentioned (5) in tetrahydrofuran (4.0 ml) were added
triethylamine (0.19 ml, 1.4 mmol) and methanesulfonyl chloride
(0.098 ml, 1.3 mmol) under ice-cooling, and the mixture was
stirred for 1 hr. The reaction mixture was filtered, and the
filtrate was concentrated under reduced pressure. To a
solution of the residue in N,N-dimethylformamide (2.0 ml) were
added cesium carbonate (1.0 g, 3.2 mmol) and di-tert-butyl
iminodicarboxylate (0.37 g, 1.7 mmol) at room temperature, and
/o the mixture was stirred for 3 hr. To the reaction mixture were
added water and ethyl acetate, and the mixture was partitioned.
The organic layer was washed with saturated brine, dried over
sodium sulfate, filtered to remove sodium sulfate, and
concentrated under reduced pressure. The residue was purified
by silica gel column chromatography (eluent: n-hexane/ethyl
acetate-95/5 - 80/20). Under an argon atmosphere, to a
solution (2.0 ml) of the purified product in 1,4-dioxane was
added 4M hydrogen chloride /1,4-dioxane solution (4.0 ml) at
room temperature, and the mixture was stirred for 2 hr. To the
reaction mixture was added n-hexane, and the solid was
collected by filtration and dried under reduced pressure to
give the title compound (0.43 g, yield 99%).
1H-NMR (DMSO-D6) 6: 2.47 (3H, s), 4.13-4.19 (5H, m), 7.67 (1H,
d, J = 8.3 Hz), 7.71-7.76 (2H, m), 8.16 (1H, d, J = 1.6 Hz),
8.35 (1H, dd, J - 8.3, 1.6 Hz), 8.41-8.50 (4H, m).
[0670]
(7) (R)-N-{4-chloro-3-[4-(4-chloro-3-methylpheny1)-6-methoxy-
1,3,5-triazin-2-yl]benzy11-3,3,3-trifluoro-2-methoxy-2-
methylpropionamide
[0671]
cj:),(Nci
., MPI
.N M-0
NN
N,14 0 F
'
,0 ,0
[0672]
181
CA 02936408 2016-06-29
Under an argon atmosphere, to a solution of 4-chloro-3-
[4-(4-chloro-3-methylpheny1)-6-methoxy-1,3,5-triazin-2-
yl]benzylamine hydrochloride (0.070 g, 0.17 mmol) obtained in
the above-mentioned (6), HOBt=H20 (0.039 g, 0.26 mmol) and WSC.
HC1 (0.049 g, 0.26 mmol) in N,N-dimethylformamide (0.70 ml)
were added (R)-3,3,3-trifluoro-2-methoxy-2-methylpropionic acid
(0.038 g, 0.22 mmol) obtained in the above-mentioned (3) and
triethylamine (0.071 ml, 0.51 mmol) at room temperature, and
the mixture was stirred for 18 hr. To the reaction mixture
/o were added saturated aqueous sodium hydrogen carbonate and
ethyl acetate, and the mixture was partitioned. The organic
layer was washed with saturated brine, dried over sodium
sulfate, filtered to remove sodium sulfate, and concentrated
under reduced pressure. The residue was purified by silica gel
is column chromatography (eluent: n-hexane/ethyl acetate=3/2) to
give the title compound (0.058 g, yield 65%).
1H-NMR (CDC12) 6: 1.66 (3H, s), 2.48 (3H, s), 3.45 (3H, s),
4.20 (3H, s), 4.48 (1H, dd, J = 15.1, 5.8 Hz), 4.63 (1H, dd, J
= 15.1, 6.5 Hz), 7.16 (1H, br s), 7.37 (1H, dd, J = 8.3, 2.3
20 Hz) , 7.48 (1H, d, J = 8.3 Hz), 7.53 (1H, d, J = 8.3 Hz), 7.92
(1H, d, J = 2.3 Hz), 8.36 (1H, dd, J - 8.3, 2.0 Hz), 8.46 (1H,
d, J = 2.0 Hz).
[0673]
(8) (R)-N-f4-chloro-3-[4-(4-chloro-3-methylpheny1)-6-hydroxy-
25 1,3,5-triazin-2-yl]benzy1}-3,3,3-trifluoro-2-methoxy-2-
methylpropionamide (Example No.1-136)
[0674]
CI Ci H OMe
CI Cl,
H OMe
N, NV(KF NydcF
0 F F NN 0 F
OH
[0675]
30 Under an argon atmosphere, to a solution of (R)-N-{4-
chloro-3-[4-(4-chloro-3-methylpheny1)-6-methoxy-1,3,5-triazin-
2-yl]benzyll-3,3,3-trifluoro-2-methoxy-2-methylpropionamide
(0.058 g, 0.11 mmol) obtained in the above-mentioned (7) in
182
CA 02936408 2016-06-29
methanol (1.3 ml) was added 4M aqueous sodium hydroxide
solution (0.17 ml) at room temperature, and the mixture was
stirred at 60 C for 3 hr. To the reaction mixture were added
10% aqueous citric acid solution (0.68 ml) and water, and the
mixture was stirred at room temperature. The precipitated
solid was collected by filtration, washed with water, and dried
under reduced pressure to give the title compound (0.051 g,
yield 88%).
[0676]
/0 [Production Example 20]
Synthesis of (R)-N-{4-chloro-3-[4-hydroxy-6-(4-propoxypheny1)-
1,3,5-triazin-2-yl]benzy11-3,3,3-trifluoro-2-methoxy-2-
methylpropionamide (Example No.1-137)
[0677]
NN N lytle
0 FF
H
O
[0678]
(1) (R)-N-{4-chloro-3-[4-methoxy-6-(4-propoxypheny1)-1,3,5-
triazin-2-yl]benzy11-3,3,3-trifluoro-2-methoxy-2-
methylpropionamide
[0679]
Aw Ari 40 ci ab, N or
mr .N, m-12=HCI N,
F
N,IoN NN 0 F
,0 ,0
[0680]
Under an argon atmosphere, to a solution of 4-chloro-3-
[4-methoxy-6-(4-propoxypheny1)-1,3,5-triazin-2-yl]benzylamine
hydrochloride (0.80 g, 0.19 mmol) obtained in [Production
Example 13] (4), HOBt.H20 (0.044 g, 0.28 mmol) and WSC.HC1
(0.055 g, 0.28 mmol) in N,N-dimethylformamide (1.0 ml) were
added (R)-3,3,3-trifluoro-2-methoxy-2-methylpropionic acid
(0.046 g, 0.27 mmol) obtained in [Production Example 19] (3)
and triethylamine (0.080 ml, 0.57 mmol) at room temperature,
183
CA 02936408 2016-06-29
and the mixture was stirred for 18 hr. To the reaction mixture
were added water and ethyl acetate, and the mixture was
partitioned. The organic layer was washed with saturated brine,
dried over sodium sulfate, filtered to remove sodium sulfate,
and concentrated under reduced pressure. The residue was
purified by silica gel column chromatography (eluent: n-
hexane/ethyl acetate=8/2 - 3/2) to give the title compound
(0.084 g, yield 82%).
1H-NMR (CDC13) 15: 1.07 (3H, t, J = 7.4 Hz), 1.66 (3H, br s),
/o 1.81-1.90 (2H, m), 3.45 (3H, br s), 4.02 (2H, t, J = 6.5 Hz),
4.19 (3H, s), 4.50 (1H, dd, J = 15.0, 5.8 Hz), 4.59 (1H, dd, J
= 15.0, 6.3 Hz), 6.97-7.02 (21-I, m), 7.14 (1H, br s), 7.35 (1H,
dd, J = 8.3, 2.3 Hz), 7.51 (1H, d, J - 8.3 Hz), 7.92 (1H, d, J
= 2.3 Hz), 8.52-8.56 (2H, m).
[0681]
(2) (R)-N-{4-chloro-3-[4-hydroxy-6-(4-propoxypheny1)-1,3,5-
triazin-2-yl]benzy11-3,3,3-trifluoro-2-methoxy-2-
methylpropionamide (Example No. 1-137)
[0682]
46,1 CI 10 H,ge ,N * H1114e
41" N F 4, , N F
0 FF
F
14.1A NYN 0 F
,0 OH
[0683]
Under an argon atmosphere, to a solution of (R)-N-{4-
chloro-3-[4-methoxy-6-(4-propoxypheny1)-1,3,5-triazin-2-
yl]benzy11-3,3,3-trifluoro-2-methoxy-2-methylpropionamide
(0.084 g, 0.16 mmol) obtained in the above-mentioned (1) in
methanol (0.80 ml) was added 4M aqueous sodium hydroxide
solution (0.30 ml) at room temperature, and the mixture was
stirred at 65 C for 1.5 hr. To the reaction mixture were added
2N hydrochloric acid (0.60 ml) and water, and the mixture was
stirred at room temperature. The precipitated solid was
collected by filtration, washed with water, and dried under
reduced pressure to give the title compound (0.072 g, yield
89%).
184
CA 02936408 2016-06-29
[0684]
[Production Example 21]
Synthesis of N-{4-chloro-3-[4-(3,4-dimethylpheny1)-6-hydroxy-
1,3,5-triazin-2-yl]benzy11-3,3,3-trifluoro-2,2-
dimethylpropionamide (Example No.1-150)
[0685]
C I Li F
-
N,rN 0 FF
OH
[0686]
(1) 2-chloro-4-(3,4-dimethylpheny1)-6-methoxy-1,3,5-triazine
[0687]
CI N CI
* .0H ISO N CI
+
N
OH ,0 NN
,0
[0688]
Under an argon atmosphere, to a suspension of 3,4-
dimethylbenzeneboronic acid (0.42 g, 2.8 mmol), 2,4-dichloro-6-
methoxy-1,3,5-triazine (1.0 g, 5.6 mmol) and
tetrakis(triphenylphosphine)palladium(0) (0.32 g, 0.28 mmol) in
toluene (8.4 ml) was added 2M aqueous sodium carbonate solution
(4.2 ml), and the mixture was stirred at 100 C for 2 hr. At
room temperature, to the reaction mixture were added water and
ethyl acetate, and the mixture was partitioned. The organic
layer was washed with saturated brine, dried over sodium
sulfate, filtered to remove sodium sulfate, and concentrated
under reduced pressure. The residue was purified by silica gel
column chromatography (eluent: n-hexane/ethyl acetate=20/1) to
give the title compound (0.64 g, 92%).
1H-NMR (CDC13) 6: 2.35 (6H, s), 4.16 (3H, s), 7.26 (3H, d, J =
7.8 Hz), 8.22 (1H, dd, J = 7.8, 2.1 Hz), 8.25 (1H, d, J = 2.1
Hz).
[0689]
185
CA 02936408 2016-06-29
(2) 14-chloro-3-[4-(3,4-dimethylpheny1)-6-methoxy-1,3,5-
triazin-2-yllphenylimethanol
[0690]
110 N CI
mr N RIP H
+ O HO. O
NO HNN
,0 OH ,0
[0691]
Under an argon atmosphere, to a solution of 2-chloro-4-
(3,4-dimethylpheny1)-6-methoxy-1,3,5-triazine (0.64 g, 2.6
mmol) obtained in the above-mentioned (1), 2-chloro-5-
hydroxymethylphenylboronic acid (0.57 g, 3.1 mmol) and [1,1'-
/0 bis(diphenylphosphino)ferrocene]palladium(II)dichloride
dichloromethane adduct (0.21 g, 0.26 mmol) in 1,4-dioxane (10
ml) was added 2M aqueous sodium carbonate solution (5.1 ml),
and the mixture was stirred at 100 C for 1 hr. At room
temperature, to the reaction mixture were added water and ethyl
/5 acetate, and the mixture was partitioned. The organic layer
was washed with saturated brine, dried over sodium sulfate,
filtered to remove sodium sulfate, and concentrated under
reduced pressure. The residue was purified by silica gel
column chromatography (eluent: n-hexane/ethyl acetate=5/3) to
20 give the title compound (0.54 g, yield 59%).
1H-NMR (CDC13) 6: 1.87 (1H, t, J = 5.0 Hz), 2.35 (3H, s), 2.36
(3H, s), 4.20 (3H, s), 4.76 (2H, d, J = 5.0 Hz), 7.27 (2H, d, J
= 8.2 Hz), 7.45'(1H, dd, J = 8.4, 1.6 Hz), 7.53 (1H, d, J = 8.4
Hz), 7.99 (1H, d, J = 1.6 Hz), 8.33 (1H, d, J = 8.2 Hz), 8.35
25 (1H, br s).
[0692]
(3) 4-chloro-3-[4-(3,4-dimethylpheny1)-6-methoxy-1,3,5-triazin-
2-yl]benzylamine hydrochloride
[06931
186
CA 02936408 2016-06-29
)ccNC,)a,OH CI al, OyO C I X ..1,9,a 4,:krN ,1 yOA
X;(6.N/NH2 = NC I
N NyN 0 I NyN
[0694]
Under an argon atmosphere, to a solution of {4-chloro-3-
[4-(3,4-dimethylpheny1)-6-methoxy-1,3,5-triazin-2-
yl]phenyllmethanol (0.54 g, 1.5 mmol) obtained in the above-
mentioned (2) in tetrahydrofuran (5.5 ml) were added
triethylamine (0.28 ml, 2.0 mmol) and methanesulfonyl chloride
(0.14 ml, 1.8 mmol) under ice-cooling, and the mixture was
stirred for 0.5 hr. The reaction mixture was filtered, and the
/o filtrate was concentrated under reduced pressure. To a
solution of the residue in N,N-dimethylformamide (5.5 ml) were
added cesium carbonate (1.5 g, 4.6 mmol) and di-tert-butyl
iminodicarboxylate (0.40 g, 1.8 mmol) under ice-cooling, and
the mixture was stirred at room temperature for 1 hr. To the
reaction mixture were added water and ethyl acetate, and the
mixture was partitioned. The organic layer was washed with
saturated brine, dried over sodium sulfate, filtered to remove
sodium sulfate, and concentrated under reduced pressure. The
residue was purified by silica gel column chromatography
(eluent: n-hexane/ethyl acetate=7/1). Under an argon
atmosphere, to the purified product was added 4M hydrogen
chloride/1,4-dioxane solution (6.5 ml) at room temperature, and
the mixture was stirred for 0.5 hr. To the reaction mixture
was added ethyl acetate, and the solid was collected by
filtration, and dried under reduced pressure to give the title
compound (0.56 g, yield 94%).
1H-NMR (DMSO-DO 5: 2.34 (3H, s), 2.35 (3H, s), 4.12-4.19 (5H,
m), 7.38 (1H, d, J = 7.9 Hz), 7.69-7.75 (2H, m), 8.12 (1H, d, J
= 1.9 Hz), 8.26 (1H, dd, J = 7.9, 1.6 Hz), 8.29 (1H, br s),
8.44 (3H, br s).
[0695]
(4) N-(4-chloro-3-[4-(3,4-dimethylpheny1)-6-methoxy-1,3,5-
187
CA 02936408 2016-06-29
triazin-2-yl]benzy11-3,3,3-trifluoro-2,2-dimethylpropionamide
[0696]
* N, NH 2 - HCI CI
N. FNII?cF
NyN NyN 0 FF
,0 ,0
[0697]
Under an argon atmosphere, to a solution of 4-chloro-3-
[4-(3,4-dimethylpheny1)-6-methoxy-1,3,5-triazin-2-
yl]benzylamine hydrochloride (0.070 g, 0.18 mmol) obtained in
the above-mentioned (3), HOBt=H20 (0.035 g, 0.23 mmol) and WSC.
HC1 (0.044 g, 0.23 mmol) in N,N-dimethylformamide (2.0 ml) were
/o added 3,3,3-trifluoro-2,2-dimethylpropionic acid (0.036 g, 0.23
mmol) and triethylamine (0.075 ml, 0.54 mmol) at room
temperature, and the mixture was stirred for 4 hr. To the
reaction mixture were added saturated aqueous sodium hydrogen
carbonate and ethyl acetate, and the mixture was partitioned.
The organic layer was washed with saturated brine, dried over
sodium sulfate, filtered to remove sodium sulfate, and
concentrated under reduced pressure. The residue was purified
by silica gel column chromatography (eluent: n-hexane/ethyl
acetate=2/1) to give the title compound (0.075 g, yield 85%).
1H-NMR (CDC13) 5: 1.44 (6H, s), 2.36 (3H, s), 2.37 (3H, s),
4.20 (3H, s), 4.55 (2H, d, J = 5.7 Hz), 6.22 (1H, br s), 7.27
(3H, d, J = 7.8 Hz), 7.35 (1H, dd, J = 8.2, 2.2 Hz), 7.52 (1H,
d, J = 8.2 Hz), 7.91 (1H, d, J = 2.2 Hz), 8.32 (1H, dd, J = 7.8,
1.7 Hz), 8.35 (1H, br s).
[0698]
(5) N-{4-chloro-3-[4-(3,4-dimethylpheny1)-6-hydroxy-1,3,5-
triazin-2-yl]benzy11-3,3,3-trifluoro-2,2-dimethylpropionamide
(Example No.1-150)
[0699]
* N, ri.i?(KF N C)a,F
,
NyN
0 F F
NyN 0 F
,0 O
H
188
CA 02936408 2016-06-29
[0700]
Under an argon atmosphere, to a solution of N-{4-chloro-
3-[4-(3,4-dimethylpheny1)-6-methoxy-1,3,5-triazin-2-yl]benzyll-
3,3,3-trifluoro-2,2-dimethylpropionamide (0.075 g, 0.15 mmol)
obtained in the above-mentioned (4) in methanol (1.8 ml) was
added 4M aqueous sodium hydroxide solution (0.23 ml) at room
temperature, and the mixture was stirred at 60 C for 4 hr. To
the reaction mixture were added 10% aqueous citric acid
solution (1.0 ml) and water at room temperature, and the
/o mixture was stirred. The precipitated solid was collected by
filtration, washed with water, and dried under reduced pressure
to give the title compound (0.063 g, yield 86%).
[0701]
[Production Example 22]
/5 Synthesis of N-{4-chloro-3-[4-(4-cyclopropylmethoxypheny1)-6-
hydroxy-1,3,5-triazin-2-yl]benzy11-3,3,3-trifluoro-2-methyl-2-
trifluoromethylpropionamide (Example No. 1-169)
[0702]
rg&I CI mAki HFT,F,F
IPP iN, N
.1r.1(F
0 F
N,11.4N
OH
20 [0703]
(1) 2-chloro-4-(4-cyclopropylmethoxypheny1)-6-methoxy-1,3,5-
triazine
[0704]
4k,=0 N CI
y N CI
qr BAH CI
NY-.14
OH ,0 N,irN
,0
25 [0705]
Under an argon atmosphere, to a suspension of 4-
(cyclopropylmethoxy)benzeneboronic acid (2.5 g, 13 mmol), 2,4-
dichloro-6-methoxy-1,3,5-triazine (4.7 g, 26 mmol) and
tetrakis(triphenylphosphine)palladium(0) (1.5 g, 1.3 mmol) in
189
CA 02936408 2016-06-29
toluene (25 ml) was added 2M aqueous sodium carbonate solution
(20 ml), and the mixture was stirred at 100 C for 2 hr. At
room temperature, to the reaction mixture were added water and
ethyl acetate, and the mixture was partitioned. The organic
layer was washed with saturated brine, dried over sodium
sulfate, filtered to remove sodium sulfate, and concentrated
under reduced pressure. The residue was purified by silica gel
column chromatography (eluent: n-hexane/ethyl acetate=90/10 -
80/20) to give the title compound (3.0 g, 79%).
/0 1H-NMR (C9C13) 5: 0.36-0.41 (2H, m), 0.65-0.71 (2H, m), 1.25-
1.36 (1H, m), 3.90 (2H, d, J = 7.0 Hz), 4.14 (3H, s), 6.96-7.00
(2H, m), 8.42-8.47 (2H, m).
[0706]
(2) {4-chloro-3-[4-(4-cyclopropylmethoxypheny1)-6-methoxy-
/5 1,3,5-triazin-2-yl]phenyllmethanol
[0707]
A,,0 = .6..õ0 40 ci op
.
N,CI + HO N. OH
.D 4P OH ____________________________
NN N.,e1
,0 OH ,0
[0708]
Under an argon atmosphere, to a solution of 2-chloro-4-
20 (4-cyclopropylmethoxypheny1)-6-methoxy-1,3,5-triazine (3.0 g,
mmol) obtained in the above-mentioned (1), 2-chloro-5-
hydroxymethylphenylboronic acid (2.3 g, 12 mmol) and [1,1'-
bis(diphenylphosphino)ferrocene]palladium(II)dichloride
dichloromethane adduct (0.84 g, 1.0 mmol) in 1,4-dioxane (30
25 ml) was added 2M aqueous sodium carbonate solution (21 ml), and
the mixture was stirred at 100 C for 3 hr. At room temperature,
to the reaction mixture were added water and ethyl acetate, and
the mixture was partitioned. The organic layer was washed with
saturated brine, dried over sodium sulfate, filtered to remove
30 sodium sulfate, and concentrated under reduced pressure. The
residue was purified by silica gel column chromatography
(eluent: n-hexane/ethyl acetate=8/2 - 1/1) to give the title
190
CA 02936408 2016-06-29
compound (2.9 g, yield 71%).
1H-NMR (CDC13) 5: 0.37-0.41 (2H, m), 0.65-0.71 (2H, m), 1.27-
1.36 (1H, m), 1.76 (1H, t, J = 6.0 Hz), 3.90 (2H, d, J = 6.7
Hz), 4.19 (3H, s), 4.77 (2H, d, J = 6.0 Hz), 6.98-7.02 (2H, m),
7.46 (1H, dd, J = 8.1, 1.9 Hz), 7.53 (1H, d, J = 8.1 Hz), 8.00
(1H, d, J = 1.9 Hz), 8.53-8.57 (2H, m).
[0709]
(3) 4-chloro-3-[4-(4-cyclopropylmethoxypheny1)-6-methoxy-1,3,5-
triazin-2-yl]benzylamine hydrochloride
[0710]
tcNC I OH GI .T.s.,0,e0
NH = HCI
14N
!CIA 0 I 2
[0711]
Under an argon atmosphere, to a solution of {4-chloro-3-
[4-(4-cyclopropylmethoxypheny1)-6-methoxy-1,3,5-triazin-2-
/5 yl]phenyllmethanol (2.9 g, 7.3 mmol) obtained in the above-
mentioned (2) in tetrahydrofuran (29 ml) were added
triethylamine (1.3 ml, 9.5 mmol) and methanesulfonyl chloride
(0.68 ml, 8.7 mmol) under ice-cooling, and the mixture was
stirred for 0.5 hr. The reaction mixture was filtered, and the
filtrate was concentrated under reduced pressure. To a
solution of the residue in N,N-dimethylformamide (29 ml) were
added cesium carbonate (7.1 g, 22 mmol) and di-tert-butyl
iminodicarboxylate (1.9 g, 8.7 mmol) under ice-cooling, and the
mixture was stirred at room temperature for 2 hr. To the
reaction mixture were added water and ethyl acetate, and the
mixture was partitioned. The organic layer was washed with
saturated brine, dried over sodium sulfate, filtered to remove
sodium sulfate, and concentrated under reduced pressure. The
residue was purified by silica gel column chromatography
(eluent: n-hexane/ethyl acetate=95/5 - 70/30). Under an argon
atmosphere, to a solution (9.3 ml) of the purified product in
1,4-dioxane was added 4M hydrogen chloride/1,4-dioxane solution
(37 ml) at room temperature, and the mixture was stirred for 3
191
CA 02936408 2016-06-29
hr. To the reaction mixture was added ethyl acetate, and the
solid was collected by filtration, and dried under reduced
pressure to give the title compound (3.1 g, yield 97%).
21-1-NMR (DMSO-D6) 5: 0.34-0.39 (2H, m), 0.57-0.63 (2H, m), 1.21-
1.32 (1H, m), 3.95 (2H, d, J - 7.0 Hz), 4.11-4.18 (5H, m),
7.11-7.15 (2H, m), 7.70-7.74 (2H, m), 8.13 (1H, br s), 8.42-
8.53 (5H, m).
[0712]
(4) N-{4-chloro-3-[4-(4-cyclopropylmethoxypheny1)-6-methoxy-
/0 1,3,5-triazin-2-yl]benzy11-3,3,3-trifluoro-2-methy1-2-
trifluoromethylpropionamide
[0713]
40 ci 'k...04k.CI CAF
N, IP 141-12=11C1 4P N.NN IP
NN 0 FF
,0 ,0
[0714]
Under an argon atmosphere, to a solution of 4-chloro-3-
[4-(4-cyclopropylmethoxypheny1)-6-methoxy-1,3,5-triazin-2-
yl]benzylamine hydrochloride (0.080 g, 0.18 mmol) obtained in
the above-mentioned (3), HOBt-H20 (0.037 g, 0.24 mmol) and WSC.
HC1 (0.046 g, 0.24 mmol) in N,N-dimethylformamide (2.0 ml) were
added 2,2-bis(trifluoromethyl)propionic acid (0.050 g, 0.24
mmol) and triethylamine (0.077 ml, 0.55 mmol) at room
temperature, and the mixture was stirred for 1.5 hr. To the
reaction mixture were added HOBt.1-120 (0.037 g, 0.24 mmol), WSC.
HC1 (0.046 g, 0.24 mmol), 2,2-bis(trifluoromethyl)propionic
acid (0.050 g, 0.24 mmol) and triethylamine (0.077 ml, 0.55
mmol), and the mixture was stirred for 2 hr. To the reaction
mixture were added HOBt.H20 (0.037 g, 0.24 mmol), WSC.HC1
(0.046 g, 0.24 mmol), 2,2-bis(trifluoromethyl)propionic acid
(0.050 g, 0.24 mmol) and triethylamine (0.077 ml, 0.55 mmol),
and the mixture was stirred for 1.5 hr. To the reaction
mixture were added saturated aqueous sodium hydrogen carbonate
and ethyl acetate, and the mixture was partitioned. The
192
CA 02936408 2016-06-29
organic layer was washed with saturated brine, dried over
sodium sulfate, filtered to remove sodium sulfate, and
concentrated under reduced pressure. The residue was purified
by silica gel column chromatography (eluent: n-hexane/ethyl
acetate=3/1) to give the title compound (0.045 g, yield 41%).
1H-NMR (CDC13) 5: 0.36-0.41 (2H, m), 0.65-0.71 (2H, m), 1.26-
1.35 (2H, m), 1.70 (3H, s), 3.90 (2H, d, J = 6.7 Hz), 4.19 (3H,
s), 4.61 (2H, d, J = 5.8 Hz), 6.49 (1H, br s), 6.98-7.02 (2H,
m), 7.32 (1H, dd, J = 8.5, 2.1 Hz), 7.53 (1H, d, J = 8.5 Hz),
/o 7.92 (111, d, J = 2.1 Hz), 8.52-8.56 (2H, m).
[0715]
(5) N-{4-chloro-3-[4-(4-cyclopropylmethoxypheny1)-6-hydroxy-
1,3,5-triaxin-2-yl]benzy11-3,3,3-trifluoro-2-methyl-2-
trifluoromethylpropionamide (Example No.1-169)
/5 [0716]
FF
4F 14,
C,11,10JFIXF 46 CI HF
. N, NyT(KF
NN 0 FF
N41 0 FF
,0 OH
[0717]
Under an argon atmosphere, to a solution of N-{4-chloro-
3-[4-(4-cyclopropylmethoxypheny1)-6-methoxy-1,3,5-triazin-2-
20 yl]benzy11-3,3,3-trifluoro-2-methy1-2-
trifluoromethylpropionamide (0.045 g, 0.076 mmol) obtained in
the above-mentioned (4) in methanol (0.70 ml) was added 4M
aqueous sodium hydroxide solution (0.11 ml) at room temperature,
and the mixture was stirred at 60 C for 4 hr. To the reaction
25 mixture were added 10% aqueous citric acid solution (0.50 ml)
and water, and the mixture was stirred at room temperature.
The precipitated solid was collected by filtration, washed with
water, and dried under reduced pressure to give the title
compound (0.039 g, yield 89%).
30 [0718]
[Production Example 23]
Synthesis of 1-trifluoromethylcyclopropanecarboxylic acid 4-
193
CA 02936408 2016-06-29
chloro-3-[4-hydroxy-6-(4-isobutoxypheny1)-1,3,5-triazin-2-
yl]benzylamide (Example No.1-178)
[0719]
ai CI
N NIrRie
,
NN
0 o FF
OH
[0720]
(1) 1-trifluoromethylcyclopropanecarboxylic acid 4-chloro-3-[4-
(4-isobutoxypheny1)-6-methoxy-1,3,5-triazin-2-yl]benzylamide
[0721]
*,
N NH2 = Hci 40 N,XDINA,,v,,F.
F
NN N-eN 0 F
,0 ,0
/0 .. [0722]
Under an argon atmosphere, to a solution of 4-chloro-3-
[4-(4-isobutoxypheny1)-6-methoxy-1,3,5-triazin-2-yl]benzylamine
hydrochloride (0.10 g, 0.23 mmol) obtained in [Production
Example 12] (4), HOBt.H20 (0.049 g, 0.32 mmol) and WSC-HC1
/5 (0.061 g, 0.32 mmol) in N,N-dimethylformamide (0.75 ml) were
added 1-trifluoromethylcyclopropane-1-carboxylic acid (0.050 g,
0.32 mmol) and triethylamine (0.064 ml, 0.46 mmol) at room
temperature, and the mixture was stirred for 1.5 hr. To the
reaction mixture were added water and ethyl acetate, and the
20 mixture was partitioned. The organic layer was washed with
saturated brine, dried over sodium sulfate, filtered to remove
sodium sulfate, and concentrated under reduced pressure. The
residue was purified by silica gel column chromatography
(eluent: n-hexane/ethy1 acetate=2/1, then chloroform/ethyl
25 acetate-9/1) to give the title compound (0.068 g, yield 55%).
1H-NMR (DMSO-DO 5: 1.01 (6H, d, J - 6.9 Hz), 1.23-1.27 (2H, m),
1.30-1.36 (2H, m), 2.00-2.11 (1H, m), 3.87 (2H, d, J - 6.4 Hz),
4.12 (31-I, s), 4.37 (2H, d, J = 5.9 Hz), 7.11-7.15 (2H, m), 7.43
(1H, dd, J = 8.2, 2.1 Hz), 7.60 (1H, d, J - 8.2 Hz), 7.85 (1H,
194
CA 02936408 2016-06-.29
d, J = 2.1 Hz), 8.43-8.47 (2H, m), 8.50 (1H, t, J = 5.9 Hz).
[0723]
(2) 1-trifluoromethyl-cyclopropanecarboxylic acid 4-chloro-3-
[4-hydroxy-6-(4-isobutoxypheny1)-1,3,5-triazin-2-yl]benzylamide
(Example No.1-178)
[0724]
CI N H L,C1 CI H
Nyy 4NIXF
NN 0 FF NN 0 FF
,0 01-1
[0725]
Under an argon atmosphere, to a solution of 1-
trifluoromethylcyclopropanecarboxylic acid 4-chloro-3-[4-(4-
isobutoxypheny1)-6-methoxy-1,3,5-triazin-2-yl]benzylamide
(0.065 g, 0.12 mmol) obtained in the above-mentioned (1) in
methanol (1.0 ml) was added 4M aqueous sodium hydroxide
solution (0.12 ml) at room temperature, and the mixture was
stirred at 60 C for 3 hr. To the reaction mixture were added
2N hydrochloric acid (0.24 ml) and water at room temperature,
and the mixture was stirred. The precipitated solid was
collected by filtration, washed with water, and dried under
reduced pressure to give the title compound (0.060 g, yield
94%).
[0726]
[Production Example 24]
Synthesis of N-(4-chloro-3-{4-[4-((S)-1-
cyclopropylethoxy)pheny1]-6-hydroxy-1,3,5-triazin-2-yllbenzy1)-
3,3,3-trifluoro-2,2-dimethylpropionamide (Example No.1-184)
[0727]
A.1,0 io CI H
0 FF
NyN
OH
[0728]
(1) N-(4-chloro-3-(4-[4-((S)-1-cyclopropylethoxy)pheny1]-6-
195
CA 02936408 2016-06-29
methoxy-1,3,5-triazin-2-yllbenzy1)-3,3,3-trifluoro-2,2-
dimethylpropionamide
[0729]
HO 46, H r&h, CI *
L.1 N 1,1 Ny\cF N NNY.KF
NyN
N 0 F F ______________________ 0 F F .10N
,0 ,0
[0730]
Under an argon atmosphere, to a solution of N-{4-chloro-
3-[4-(4-hydroxypheny1)-6-methoxy-1,3,5-triazin-2-yl]benzyll-
3,3,3-trifluoro-2,2-dimethylpropionamide (0.080 g, 0.17 mmol)
obtained in the above-mentioned [Production Example 14] (6),
/o (1R)-1-cyclopropylethan-1-ol (0.029 g, 0.33 mmol) and
triphenylphosphine (0.087 g, 0.33 mmol) in tetrahydrofuran (1.0
ml) was added bis(2-methoxyethyl)azodicarboxylate (0.078 g,
0.33 mmol) under ice-cooling, and the mixture was stirred at
room temperature for 17 hr. To the reaction mixture were added
water and ethyl acetate, and the mixture was partitioned. The
organic layer was washed with saturated brine, dried over
sodium sulfate, filtered to remove sodium sulfate, and
concentrated under reduced pressure. The residue was purified
by silica gel column chromatography (eluent: n-hexane/ethyl
acetate=2/1) to give the title compound (0.079 g, yield 86%).
1H-NMR (CDC13) 6: 0.28-0.36 (1H, m), 0.38-0.45 (1H, m), 0.53-
0.63 (2H, m), 1.12-1.21 (11-1, m), 1.41 (3H, d, J - 6.0 Hz), 1.44
(6H, s), 3.95-4.05 (1H, m), 4.18 (3H, s), 4.54 (2H, d, J = 5.6
Hz), 6.20 (1H, br s), 6.95-7.00 (2H, m), 7.34 (1H, dd, J = 8.3,
1.9 Hz), 7.51 (1H, d, J = 8.3 Hz), 7.91 (1H, d, J = 1.9 Hz),
8.50-8.55 (2H, m).
[0731]
(2) N-(4-chloro-3-{4-[4-((S)-1-cyclopropylethoxy)pheny1]-6-
. hydroxy-1,3,5-triazin-2-yllbenzy1)-3,3,3-trifluoro-2,2-
dimethylpropionamide (Example No.1-184)
[0732]
196
CA 02936408 2016-06-29
Aio
* N, H
N.XF 410 Lyi NC:
[Nly\cF
0 FF
0 FF 14A
,0 OH
[0733]
Under an argon atmosphere, to a solution of N-(4-chloro-
3-14-[4-((S)-1-cyclopropylethoxy)pheny1]-6-methoxy-1,3,5-
triazin-2-yllbenzy1)-3,3,3-trifluoro-2,2-dimethylpropionamide
(0.079 g, 0.14 mmol) obtained in the above-mentioned (1) in
methanol (1.3 ml) was added 4M aqueous sodium hydroxide
solution (0.22 ml) at room temperature, and the mixture was
stirred at 65 C for 4 hr. To the reaction mixture were added
/o 10% aqueous citric acid solution (0.90 ml) and water at room
temperature, and the mixture was stirred. The precipitated
solid was collected by filtration, washed with water, and dried
under reduced pressure to give the title compound (0.072 g,
yield 93%).
/5 [0734]
[Production Example 25]
Synthesis of N-(4-chloro-3-{4-[4-((R)-1-
cyclopropylethoxy)pheny1]-6-hydroxy-1,3,5-triazin-2-yl}benzyl)-
3,3,3-trifluoro-2,2-dimethylpropionamide (Example No.1-185)
20 [0735]
CI
N ?(KF
411 0 FF
OH
10736]
(1) N-(4-chloro-3-{4-[4-((R)-1-cyclopropylethoxy)pheny1]-6-
methoxy-1,3,5-triazin-2-yllbenzy1)-3,3,3-trifluoro-2,2-
25 dimethylpropionamide
[0737]
197
CA 02936408 2016-06-29
HO C I Air = C I = H
Lir N
F
F
N 0 F NyN 0 F
.0
[0738]
Under an argon atmosphere, to a solution of N-14-chloro-
3-[4-(4-hydroxypheny1)-6-methoxy-1,3,5-triazin-2-yl]benzyll-
3,3,3-trifluoro-2,2-dimethylpropionamide (0.080 g, 0.17 mmol)
obtained in the above-mentioned [Production Example 14] (6),
(1S)-1-cyclopropylethan-l-ol (0.029 g, 0.33 mmol) and
triphenylphosphine (0.087 g, 0.33 mmol) in tetrahydrofuran (1.0
ml) was added bis(2-methoxyethyl) azodicarboxylate (0.078 g,
/0 0.33 mmol) under ice-cooling, and the mixture was stirred at
room temperature for 17 hr. To the reaction mixture were added
water and ethyl acetate, and the mixture was partitioned. The
organic layer was washed with saturated brine, dried over
sodium sulfate, filtered to remove sodium sulfate, and
/5 concentrated under reduced pressure. The residue was purified
by silica gel column chromatography (eluent: n-hexane/ethyl
acetate=2/1) to give the title compound (0.038 g, yield 41%).
1H-NMR (CDC13) 5: 0.28-0.36 (1H, m), 0.38-0.45 (1H, m), 0.53-
0.63 (2H, m), 1.12-1.21 (1H, m), 1.41 (3H, d, J = 6.0 Hz), 1.44
20 (6H, s), 3.95-4.05 (1H, m), 4.18 (3H, s), 4.54 (2H, d, J = 5.6
Hz), 6.20 (1H, br s), 6.95-7.00 (2H, m), 7.34 (1H, dd, J = 8.3,
1.9 Hz), 7.51 (1H, d, J = 8.3 Hz), 7.91 (1H, d, J - 1.9 Hz),
8.50-8.55 (2H, m).
[0739]
25 (2) N-(4-chloro-3-{4-[4-((R)-1-cyclopropylethoxy)pheny1]-6-
hydroxy-1,3,5-triazin-2-yl}benzy1)-3,3,3-trifluoro-2,2-
dimethylpropionamide (Example No.1-185)
[0740]
4T 46 N CI I*
N F N.XF
F ______
0 F
N 0 F NyN F
OH
198
CA 02936408 2016-06-29
[0741]
Under an argon atmosphere, to a solution of N-(4-chloro-
3-{4-[4-((R)-1-cyclopropylethoxy)pheny1]-6-methoxy-1,3,5-
triazin-2-yllbenzy1)-3,3,3-trifluoro-2,2-dimethylpropionamide
(0.038 g, 0.069 mmol) obtained in the above-mentioned (1) in
methanol (0.62 ml) was added 4M aqueous sodium hydroxide
solution (0.10 ml) at room temperature, and the mixture was
stirred at 65 C for 4 hr. To the reaction mixture were added
10% aqueous citric acid solution (0.42 ml) and water at room
/0 temperature, and the mixture was stirred. The precipitated
solid was collected by filtration, washed with water, and dried
under reduced pressure to give the title compound (0.034 g,
yield 91%).
[0742]
The compounds of Example 1-1 to Example 1-267, Example 2-
1 to Example 2-130, and Example 3-1 to Example 3-23 were
obtained according to the above-mentioned Production Methods.
The structural formulas and property data of the Example
compounds are shown in Table 1-1 to Table 1-34, Table 2-1 to
Table 2-15, and Table 3-1 to Table 3-3. In the Tables, the
notes show the following.
[0743]
199
CA 02936408 2016-06-29
F CI F CI
0 N 4111 o NaBH 4 101 N 401 OH
d ,N Ni N
..,r
B
racemate
\,.....,*
F Ci 0 õ0.0
___________ _ 40 N 0 A 0
Production NI N T ,õ.h Production
1 . ,
Example 1 (3) Example 1(4)
C
racemate
F a O F Cl,
HO ' F
110 N 010 NH, f)<F
E =N lisi!)1,$F
6) N F
T =
D =HCI Production
Example 1(5) NLI
F
racemate diastereomeric mixture
F CI F CI
ao N 010 ii iCf,<i< F _ =N 40 1+$ F
i N
,
d N F
T
Fl Production
Example 1(6) TH
less polar diastereomer 1-188
silica gel
chromatography F Cl F CI
40 N Ilf$F
Production
F2 Example 1 (6) 41H
more polar diastereomer 1-189
[0744]
Note 1 (Example No. 1-188, 1-189)
Using 2,4-dichloro-6-methoxy-1,3,5-triazine, 4-fluoro-3-
methylphenylboronic acid instead of 4-(2,2-
dimethylpropoxy)phenylboronic acid, and 5-acety1-2-
chlorophenylboronic acid instead of 2-chloro-5-
hydroxymethylphenylboronic acid, and by a method similar to
/0 that in Production Example 1 (1) and (2), compound A was
obtained. .
Racemic compound B was obtained by reducing the carbonyl
group of compound A with sodium borohydride.
Racemic compound D was obtained by treating compound B in
/5 the same manner as in Production Example 1 (3) and (4).
200
CA 02936408 2016-06-29
Compound F as a diastereomer mixture was obtained by
reacting racemic compound D with pure enantiomer compound E.
Compound Fl which is a less polar diastereomer (Merck TLC
Silica gel 60G F254 25 Glassplates, eluent: n-hexane/ethyl
acetate=2/1) and compound F2 which is a more polar diastereomer
were obtained by purifying compound F by silica gel column
chromatography. While compound Fl and compound F2 are single
stereoisomers, the absolute configuration of the asymmetric
carbon at the benzyl position is undetermined.
The compound of Example No. 1-188 was obtained by
hydrolyzing compound Fl in the same manner as in Production
Example 1 (6). Similarly, the compound of Example No. 1-189
was obtained from compound F2. While the compound of Example
No. 1-188 and the compound of Example No. 1-189 are single
is stereoisomers, the absolute configuration of the asymmetric
carbon at the benzyl position is undetermined.
[0745]
201
CA 02936408 2016-06-29
>I) Cl )L1 CI
1110 NIJZLr NaBH 4
0 -3... 0 N 0 OH ___________ ...
, ,.
is) fs) N Production
TJ , õT. K Example 1(3)
racemate
0,0 >I) CI ,
HO TS$F
T
F
0
i ,..
N 0 ________ 010 011 1,2 ________
N E
-..-
14 --g- '1 Production ,I N ....N
Production
1 , Example 1(4)
.6 m 40 Example 1(5)
racemate racemate
>I) CI 10 N 0
ll k=sµF
d N g rF
io N 40 +$F ______________________________________ j Ni
N) N F silica gel
)j) less polar diastereomer
Tchromatographya
N
_______________________________________________________________ I. N 0 1+$F
_
diastereomeric mixture
d N F
>1) CI I N2
more polar diastereomer
Ni =N le il<F.
less polar Production
l,) N F
diastereomer Example 1 (6)
TH
>INI 4&õ Cl 1-200
______________________ r
N2 I .1 N
Production
more polar rs) , N TSY F
Example 1 (6)
diastereomer
IH
1-201
[0746]
Note 2 (Example No. 1-200, 1-201)
Using 2,4-dichloro-6-methoxy-1,3,5-triazine, 4-(2,2-
dimethylpropoxy)phenylboronic acid, and 5-acety1-2-
chlorophenylboronic acid instead of 2-chloro-5-
hydroxymethylphenylboronic acid, and by a method similar to
that in Production Example 1 (1) and (2), compound J was
obtained.
202
CA 02936408 2016-06-29
Racemic compound K was obtained by reducing the carbonyl
group of compound J with sodium borohydride.
Racemic compound M was obtained by treating compound K in
the same manner as in Production Example 1 (3) and (4).
Compound N as a diastereomer mixture was obtained by
reacting racemic compound M with pure enantiomer compound E.
Compound N was purified by silica gel column
chromatography in the same manner as in note 1, by a method
similar to that in Production Example 1 (6), the compound of
/0 Example No. 1-200 was obtained from compound Ni which is a less
polar diastereomer (Merck TLC Silica gel 60G F254 25
Glassplates, eluent: n-hexane/ethyl acetate=2/1), and the
compound of Example No. 1-201 was obtained from compound N2
which is a more polar diastereomer. While the compounds of
Example Nos. 1-200 and 1-201 are single stereoisomers, the
absolute configuration of the asymmetric carbon at the benzyl
position is undetermined.
[0747]
Note 3 (Example Nos. 1-256, 1-257)
While they are single stereoisomers, the relative
configuration thereof is undetermined.
[0748]
Note 4 (Example No. 1-266)
While it is a single stereoisomer, the relative
configuration of the tert-butyl group is undetermined.
[0749]
Note 5 (Example No. 1-267)
While it is a single stereoisomer, the relative
configuration of the methoxy group is undetermined.
203
CA 02936408 2016-06-29
[ 0 7 5 0 ]
[Table 1-1]
Example Structure NMR MS(M+H) MS(M-H)
Note
F F
F
1H-NMR (DMSO-D6) 6:2.50 (3H, s), 7,38
= (1H, td, J = 8.3, 2.5 Hz), 7.46 (1H, dd, J = 8.4,
1-1 HC 5.3 Hz), 7.56-7.65 (1H, br m), 7.95 (2H, d, J = 350
348
N' NI, = 8.4 Hz), 8.55 (2H, d, J = 8.4 Hz), 13.33 (1H,
)=N br S).
HO F
F F
F
1H-NMR (DM50-D6) 6: 2.35 (3H, s), 2.50
(3H, s), 7.30 (1H, d, J = 7.7 Hz), 7.34 (1H, d,
1-2 FisC J = 7.7 Hz), 7.51 (1H, br s), 7.94 (2H, d, .1 = 346
344
NI NI\ . 8.1 Hz), 8.55 (2H, d, J = 8.1 Hz), 13.17 (1H,
)=-IN br s).
HO CH,
. .
F F
F
* 1H-NMR (DMSO-D6) 6: 2.50 (3H, s), 7.45
(1H, d, J = 8.4 Hz), 7.59 (1H, dd, J = 8.4, 2.3
1-3 HsC 366 364
NI NI\ 11 Hz), 7.81 (1H, br s), 7.94 (2H, d, J = 8.1 Hz),
8.54 (2H, d, J = 8.1 Hz), 13.33 (1H, s).
)=N
HO CI
F F
F
* 1H-NMR (DM50-D6) 6: 2.38 (3H, s), 7.46
1-4 a (1H, d, J = 8.1 Hz), 7.55 (1H, d, J = 8.1 Hz),
366 364
N 7.64 (1H, br s), 7.94 (2H, d, .1= 8.4 Hz), 8.54
NI \ 41
)=-N (2H, d, J = 8.4 Hz), 13.49 (1H, br s).
HO CH,
F F
F_
1H-NMR (DMSO-D6) 6:7.69 (1H, dd, J =
a 8.8,2.2 Hz), 7.83 (1H, d, J = 8.8 Hz), 7.91
1 -5 r N, (1H, d, J = 2.2 Hz), 7.95 (2H, d, J = 8.2 Hz), 436
434
N )-0
)=N
0¨(-F 8.53 (2H, d, J = 8.2 Hz), 13.67 (1H, br s).
HO
F
F F
F
1H-NMR (DMSO-D6) 0: 3.83 (3H, s), 7.21
* (1H, dd, J = 8.8, 3.1 Hz), 7.41 (1H, d, J = 3.1
1-6 Hz), 7.57 (1H, d, J = 8.8 Hz), 7.94 (2H, d, J = 382
380
N' N"--ICI 8.4 Hz), 8.54 (2H, d, J = 8.4 Hz), 13.52 (1H,
)=N br s).
HO 0-CH,
F F
F
= 1H-NMR (DMS0-D6) 6: 7.01 (1H, dd, J =
8.6, 2.9 Hz), 7.17 (1H, s), 7.44 (1H, d, J = 8.6
CI 368 366 1-7
\ II Hz), 7.94 (2H, d, J = 8.4 Hz), 8.53 (2H, d, J =
N' N
8.4 Hz), 13.17 (1H, s), 13.46 (1H, br s).
)=T4
HO OH
Fr
1H-NMR (DMS0-D6) 6: 7.81 (1H, d, J = 8.4
Hz), 7.94 (2H, d, J = 8.4 Hz), 8.12 (1H, dd, J
1-8 396 394
= 8.5, 2.0 Hz), 8.36 (1H, d, J = 1.9 Hz), 8.54
N 1S-4._ .
)=N (2H, d, J = 8.4 Hz), 13.53 (2H, br s).
HO OH
0
204
CA 02936408 2016-06-29
,
[0751]
[Table 1-2]
F F
Fa
1H-NMR (DMSO-D6) 6: 2.63 (3H, s), 7.66
1-9 s4_N H,C (1H, d, J = 8.2 Hz),
7.88 (1H, dd, J = 8.3, 1.7 400
398
Nj \ * Hz), 7.95 (2H, d, J = 8.4 Hz), 8.11 (1H, br s),
)=N 8.54 (2H, d, J = 8.4 Hz), 13.41 (1H, br s).
HO F
F F
4 F_ 1H-NMR (DMSO-D6) 6: 2.61 (3H, s), 7.54
H,C (1H, d, J = 7.9 Hz), 7.94 (2H, d, J = 8.4 Hz),
1-10 376 374
14/ \ 8.04(1H, dd, J= 7.9, 1.8 Hz), 8.30 (1H, br s),
)=N 8.55 (2H, d, J = 8.4 Hz), 13.23 (2H, br s).
HO OH
0
F-F-...
1H-NMR (DMSO-D6) 8:2.59 (3H, s), 7.46
(1H, br s), 7.50 (1H, d, J = 8.2 Hz), 7.94(2H,
1-11 HaC d, J = 8.4 Hz), 8.00 (1H, dd, J = 7.9, 1.8 Hz),
375 373
N ' * 8.01 (1H, br s), 8.24 (1H, br s), 8.56 (2H, d,
J
)=N
HO NH, = 8.4 Hz), 13.28 (11-1 s).
0
F F
F
1H-NMR (DIVISO-D6) 6:4.58 (2H, d, J = 5.5
ID. Hz), 5.45 (1H, t, J = 5.6 Hz), 7.56 (1H, dd, J=
1-12 a 8.2, 2.0 Hz), 7.62 (1H, d, J = 8.2 Hz), 7.74
382 380
r4, N\ . (1H, br s), 7.94 (2H, d, J= 8.4 Hz), 8.54(2K,
)=N d, J = 8.4 Hz), 13.53 (1H, br s).
HO OH
F F
F---._
1H-NMR (DMSO-D6) 6:2.65 (3H, s), 7.84
(1H, d, J = 8.4 Hz), 7.95 (2H, d, J = 8.4 Hz),
1-13 N CI 8.16 (1H, dd, J= 8.4, 2.2 Hz), 8.38 (1H, d, J =
394 392
2.2 Hz), 8.54 (2H, d, J = 8.4 Hz), 13.65 (1H,
N)_N
HO H, s).
0
F F
F
1H-NMR (DM50-D8) 6. 1.22 (3H, t, J = 7.7
If Hz), 2.50 (3H, s), 2.66 (2H, q, J -= 7.6 Hz),
1-14 H,C 7.32 (1H, d, J = 7.9 Hz), 7.37 (1H, dd, J =
7.8, 360 358
N
N', \ to, 1.7 Hz), 7.55 (1H, br s), 7.94 (2H, d, J = 8.4
)=-N Hz), 8.55 (2H, d, J = 8.4 Hz), 13.19 (1H, br
s).
HO CH,
F-4F F
C---c- 1H-NMR (DMSO-D6) 6: 1.39 (9H, s), 4.20
CI
(2H, d, J = 6.0 Hz), 7.47-7.53 (2H, m), 7.62
1-15 N/ a (1H, d, J = 8.4 Hz), 7.66 (1H, br s), 7.93 (2H,
481 479
I d, J = 8.4 Hz), 8.53 (2H, d, J = 8.4 Hz), 13.54
:I HO 1
_ (1H, s).
<:, )\--.H,
1-1,0 CH,
F F
F-40,,,_ 1H-NMR (DMSO-D6) 6:1.89 (3H, s), 4.32
(2H, d, J = 6.0 Hz), 7.49 (1H, dd, J = 8.3,2.3
0 Hz), 7.62(1K, d, J = 8.2 Hz), 7.67 (1H, d, J =
1-16423 421
\
2.2 Hz), 7.94 (2H, d, J = 8.4 Hz), 8.46 (1H, t, J
Fr = 6.0 Hz), 8.53 (2H, d, J = 8.4 Hz), 13.55 (1H,
HO N)-CH, br s).
o
205
CA 02936408 2016-06-29
[0752]
[Table 1-3]
F F
F
40 1H-NMR (DIVISO-D6) 6:4.13 (2H, br s), 7.72-
1-17 CI 7.77 (2H, m), 7.93-7.97(3H, m), 8.39 (3H, br 381
379
N' ", 4* , 8.54 2H, d, J = 8.4 Hz), 13.67
1H, s .
s) ( ( )
)--N
Ho HCI NH2.
F F
F--b)_
1H-NMR (DMSO-D6) 0:1,36 (3H, d, J = 6.4
Hz), 4.78-4.84 (1H, m), 5.42 (1H, d, J = 4.2
al
1-18 Hz), 7.57-7.62 (2H, m), 7.77 (1H, br s), 7.94 396
394
NI N * ) (2H, d, J = 8.2 Hz), 8.54 (2H, d, J = 8.2 Hz),
-N
HO OH 13.52 (1H, br S).
H,C
F F
F---1
1H-NMR (DMSO-D6) 5: 3.34 (3H, s), 4.50
(2H, s), 7.57 (1H, dd, J = 8.3,2.1 Hz), 7.65
ci
1-19 (1H, d, J = 8.2 Hz), 7.76 (1H, d, J = 2.0 Hz), 396
394
N I* 7.94 (2H, d, J = 8.4 Hz), 8.54 (2H, d, J = 8.4
HO q Hz), 13.54 (1H, br s).
CH,
F F
FI:_ 1H-NMR (DMSO-D6) 5: 2.93 (3H, s), 4.25
(2H, d, J = 6.4 Hz), 7.60 (1H, dd, J = 8.4,2.0
1-20
CI Hz), 7.66 (1H, d, J = 8.4 Hz), 7.70 (1H, t, J =
N
Ni \ 6.4 Hz), 7.78 (1H, d, J = 2.0 Hz), 7.94)2K, d, 459
457
J = 8.4 Hz), 8.54(2K, d, J = 8.4 Hz), 13.58
HO N
t)S,' (1H, br s).
CH,
__.,F. F
F 1H-NMR (DMSO-D6) 5: 2.07 (1.0H, s), 2.08
1-21 -1"- c (2.0H, s), 2.82 (1.0H, s), 2.96 (2.0H, s), 4.56
(1.3H, s), 4.64 (0.7H, s), 7.47 (1.0H, d, J = 8.2
437 435
Hz), 7.61-7.68 (2.0H, m), 7.94 (2.0H, d, J =
8.4 Hz), 8.53 (2.0H, d, J = 8.4 Hz), 13.56
N.-CH, (1.01-1, s).
F-F-4. 1H-NMR (DMSO-D6) 5: 3.56 (3H, s), 4.26
(2H, d, J = 6.2 Hz), 7.50 (1H, dd, J = 8.5, 2.1
el Hz), 7.63 (1H, d, J= 8.4 Hz), 7.68 (1H, d, J = 439
1-22 437
2.0 Hz), 7.80 (1H, t, J = 6.2 Hz), 7.94(2K, d, J
= 8.4 Hz), 8.53 (2H, d, J = 8.4 Hz), 13.54 (1H,
12/-0
'OH, s).
F- Fl
1H-NMR (DMSO-D6) 0:3.71 (2H, s), 7.53
(1H, dd, J = 8.3, 1.9 Hz), 7.62 (1H, d, J = 8.2
1-23 Hz), 7.71 (1H, d, J = 1.8 Hz), 7.94(2K, d, J = 410
408
8.4 Hz), 8.54(2K, d, J = 8.4 Hz), 12.53 (1H,
br s), 13.54 (1H, br s).
HO
OH
FF
F-i_ 1H-NMR (DMSO-D6) 0:1.13 (9H, s), 4.32
1-24
(2H, d, J = 6.0 Hz), 7.45 (1H, dd, J = 8.3, 2.1
a Hz), 7.61 (1H, d, J= 8.2 Hz), 7.65 (1H, d, J =-
465 2.0 Hz), 7.94 (2H, d, J = 8.4 Hz), 8.18 (1H, t, J
463
H = 6.1 Hz), 8.53 (2H, d, J = 8.4 Hz), 13.55 (1H,
HO C (CM, br s).
0 CH,
206
CA 02936408 2016-06-29
[07531
[Table 1-4]
.._.F F
F
1H-NMR (DMSO-D6) 6: 2.09 (3H, s), 5.16
(2H, s), 7.63 (1H, dd, J = 8.3, 2.1 Hz), 7.68
1-25 (1H, d, J = 82 Hz), 7.81 (1H, d, J = 2.0 Hz), 424
422
.)=N 7.94 (2H, d, J = 8.4 Hz), 8.54 (2H, d, J = 8.4
HO Hz), 13.57 (1H, br s).
0,---a-1,
F F
F--N_ 1H-NMR (DMSO-06) 6:2,59 (3H, d, J = 4.6
Hz), 3.50 (2H, s), 7.50 (1H, dd, J = 8.3, 2.1
C Hz), 7.60 (1H, d, J = 8.4 Hz), 7.67 (1H, d, J =
1-26 N/ N\ A04 2.0 Hz), 7.94 (2H, d, J = 8.4 Hz), 8.01-8.06 423
421
)=N W a (1H, br m), 8.54(2K, d, J = 8.4 Hz), 13.54
HO
N-CH, (1H, s).
FE
FI 1H-NMR (DMSO-D6) 6: 1.02 (3H, t, J = 7.6
Hz), 2.16 (2H, q, J = 7.6 Hz), 4.32 (2H, d, J =
a 6.0 Hz), 7.49 (1H, dd, J = 84, 2.2 Hz), 7.62
1-27 r., 437 435
N (1H, d, J = 8.4 Hz), 7.67 (1H, d, J = 2.2 Hz),
)=/ N\)-)\Z
HO rl 7.94 (2H, d, J = 8.4 Hz), 8.39 (1H, t, J = 6.0
Hz), 8.53 (2H, d, J = 8.4 Hz), 13.55(1K, br s).
0 CH,
Ff-14 1H-NMR (DMSO-D6) 6: 1.04 (6H, d, J = 7.1
Hz), 2.38-2.48 (1H, m), 4.32 (2H, d, J = 6.2
a Hz), 7.47 (11-1, dd, J = 8.4,2.2 Hz), 7.62 (1K,
1-28
N/ N, ) _ _ q _ 451 449
d, J =8.4 Hz), 7.66 (1H, d, J = 2.2 Hz), 7.94
)=. H CH, (2H, d, J = 8.4 Hz), 8.37 (1H, t, J = 6.2 Hz),
NH
0 CH, 8.53 (2H, d, J = 8.4 Hz), 13.55 (1H, br s).
, F 1H-NMR (DMSO-D6) 6: 1.11-1.40(5H, m),
F-
1.57-1.76 (5H, m), 2.13-2.20 (1H, m), 4.31
(2H, d, J = 6.2 Hz), 7.46 (1H, dd, J = 8.3,2.1
a
1-29 Hz), 7.61 (1H, d, J = 8.2 Hz), 7.65 (1H, d, J = 491
489
H 2.0 Hz), 7.93 (2H, d, J = 8.4 Hz), 8.34 (1H, t, J
HO NI-- \ = 6.1 Hz), 8.53 (2H, d, J = 8.4 Hz), 13.55 (1H,
br s).
..F..._
F 1H-NMR (DM50436) 6:1.44-1.82 (8H, m),
2.58-2.66 (1H, m), 4.32 (2H, d, J = 6.2 Hz),
a 7.47 (1H, dd, J = 8.3, 2.1 Hz), 7.62 (1H, d, J = 477
1-30 475
8.2 Hz), 7.66 (1H, d, J = 2.0 Hz), 7.93 (2H, d,
HO J = 8.4 Hz), 8.39 (1H, t, J = 6.2 Hz), 8.53 (2H,
¨<D d, J = 8.4 Hz), 13.55 (1H, br s).
0
,_ F_.\_ 1H-NMR (DMSO-D6) 6: 1.20 (3H, t, J = 7.3
Hz), 3.02 (2H, q, J = 7.4 Hz), 4.23 (2H, d, J =
c 6.5 Hz), 7.60 (1H, dd, J = 8.4, 2.1 Hz), 7.66
1-31 473 471
(1H, d, J = 8.4 Hz), 7.72 (1H, t, J = 6.4 Hz),
HO I , 1 7.77 (1H, d, J = 2.1 Hz), 7.94 (2H, d, J = 8.4
o'sLoH, Hz), 8.54 (2H, d, J = 8.4 Hz), 13.57 (1H, br s).
F
1-32 , )-Ncl 1H-NMR (DMSO-D6) 6:1.31 (9H, s), 4.32
(2H, d, J = 6.4 Hz), 7.60-7.66 (3H, m), 7.76
501 499
'----N7¨._ii (1H, br s), 7.94 (2H, d, J = 8.4 Hz), 8.53 (2H,
rt 0 d, J = 8.4 Hz), 13.58(1K, bra).
0)H
8,0 CM, .
207
CA 02936408 2016-06-29
[0754]
[Table 1-5]
F-5.4 1H-NMR (DMSO-06) 6:1.24 (6H, d, J = 6.8
Hz), 3.14-3.20 (1H, m), 4.25 (2H, d, .1= 6.4
CI
N Hz), 7.60 (1H, dd, J = 8.5, 1.9 Hz), 7.66 (1H,
1-33 487 485
'=1,\I . õ d, J = 8.4 Hz), 7.70 (1H, 1, J = 6.5 Hz), 7.77
HO N. (1H, d, J = 1.8 Hz), 7.94 (2H, d, J = 8.2 Hz),
- i-CH, 8.53 (2H, d, J = 8.2 Hz), 13.58 (1H, br s).
H,C
F-F-, a_r 1H-NMR (DMSO-D6) 6:2.81 (6H, s), 4.28
(2H, d, J = 5.8 Hz), 6.98 (1H, t, J = 5.9 Hz),
a 7.50 (1H, dd, J = 8.3, 2.0 Hz), 7.59 (1H, d, J =
1-34
Ni , = 8.4 Hz), 7.68 (1H, d, J = 1.9 Hz), 7.94 (2H, d, 452
450
H
HO CH J = 8.4 Hz), 8.53 (2H, d, J = 8.4 Hz), 13.54
?.,õ
0 'CH, (1H, br s).
F IF
F---,_ 1H-NMR (DMSO-D6) 6: 2.56 (3H, d, J = 4.6
1-35
Hz), 4.26 (2H, d, J = 6.2 Hz), 5.90 (1H, q, J =
ci 4.6 Hz), 6.52 (1H, t, J = 6.2 Hz), 7.49 (1H, dd,
N
J= 8.3, 2.1 Hz), 7.60 (1H, d, J = 8.4 Hz), 7.66 438 436
>=N \W H
HO N 4, (1H, d, J= 2.0 Hz), 7.94 (2H, d, J = 8.4 Hz),
),
8.53 (2H, d, J - 8.4 Hz), 13.55 (1H, br s).
0 CH,
. .
CF
F 1H-NMR (DMSO-D6) 5:0.85 (3H, t, J = 7.4
Hz), 1.54 (2H, sextet, J = 7.4 Hz), 2.13 (2H, t,
c J = 7.4 Hz), 4.33 (2H, d, J = 6.2 Hz), 7.48
1-36 N'\ (1H, dd, J = 8.2, 2.0 Hz), 7.62 (1H, d, J = 8.2 451
449 '
)=N H Hz), 7.66 (1H, d, J = 2.0 Hz), 7.94 (2H, d, J =
HO N 8.2 Hz), 8.41 (1H, t, J = 6.1 Hz), 8.53 (2H, d,
---\_
0 CH, J - 8.2 Hz), 13.55 (1H, br s).
, F
F--,6)õ,
1H-NMR (DMSO-D6) 6: 0.87 (6H, d, J = 6.4
Hz), 1.96-2.06 (3H, m), 4.33 (2H, d, J = 6.0
a
Hz), 7.48 (1H, dd, J = 8.2, 2.0 Hz), 7.61 (1H,
N., \ -m- 465 463 1-37
)=N \WI d, J =8.2 Hz), 7.66 (1H, d, J= 2.0 Hz), 7.93
HO r4 (2H, d, J = 8.4 Hz), 8.42 (1H, t, J = 6.1 Hz),
,,,-
Fcc CC, 8.53 (2H, d, J = 8.4 Hz), 13.55 (1H, br s).
F
F 1H-NMR (DO-D8) 5:1.16 (3H, t, J = 7.1
Hz), 4.01 (2H, q, J = 7.1 Hz), 4.25 (2H, d, J =
CI 6.2 Hz), 7.50 (1H, dd, J = 8.4, 2.0 Hz), 7.63 453
1-38 451
vi-11 (1H, d, J = 8.4 Hz), 7.68 (1H, d, J = 2.0 Hz),
HO }N' 7.76 (1H, t, J = 6.3 Hz), 7.94 (2H, d, J 08.4
--,:, 0 -CH,
Hz), 8.53 (2H, d, J = 8.4 Hz), 13.55 (1H, br s).
\
F
1H-NMR (DMSO-D6) 5:1.17 (6H, d, J = 6.2
Hz), 4.24 (2H, d, J = 6.2 Hz), 4.73-4.80 (1H,
m), 7.49 (1H, dd, J = 8.4, 2.0 Hz), 7.63 (1H, d,
1-39
H J = 8.4 Hz), 7.66-7.71 (2H, m), 7.93 (2H, d, J 467
465
µ = 8.4 Hz), 8.53 (2H, d, J = 8.4 Hz), 13.55 (1H,
/
0 -011, br s).
H,C
.-
----
F F
).,_
1H-NMR (DMSO-D6) 5:2.85 (3H, s), 3.05
a (3H, s), 3.80 (2H, s), 7.47 (1H, dd, J = 8.4,2.2
140 , \
)=N 0 Hz), 7.59 (1H, d, J= 8.4 Hz), 7.65 (1H, d, J = 437
435
2.2 Hz), 7.94 (2H, d, J = 8.4 Hz), 8.54 (2H, d,
HO J= 8.4 Hz), 13.54 (1H, br s).
HN-CH,
3e
208
CA 02936408 2016-06-29
[0755]
[Table 1-6]
Ff,(P 1H-NMR (DMSO-D6) 6:1.25 (9H, s), 3.47
ci l (2H, s), 7.49 (1H, dd, J = 8.5, 2.1 Hz), 7.59
1-41. (1H, d, J = 8.4 Hz), 7.66 (1H, d, J = 2.0 Hz), 465
463
--c \ * .
7.77 (1H, s), 7.94 (2H, d, J = 8.4 Hz), 8.54
HO CH, (2H, d, J = 8.4 Hz), 13.54 (1H, s).
,.f..,L 11-1-NMR (DMSO-D6) 8:1.51-1.71 (4H, m),
1.83-1.92 (4H, m), 3.47-3.54 (1H, m), 4.26
ci
(2H, d, J = 6.4 Hz), 7.59 (1H, d, J = 8.3 Hz),
1-42 ¨:' \ lk 513 511
7.66 (1H, d, J = 8.3 Hz), 7.72 (1H, t, J = 6.3
.,?=" N.. Hz), 7.77 (1H, s), 7.94 (2H, d, J = 8.3 Hz),
,s*
0 b 8.53(2H, d, J= 8.3 Hz), 13,58(1H, br s).
. R ci 1H-NMR (DMSO-D6) 6:1.13 (9H, s), 4.31
(2H, d, J = 6.0 Hz), 7.44 (1H, dd, J = 8.2, 2.0
Ni \
1-43 X=N H Hz), 7.56-7.58 (3H, m), 7.64-7.69 (2H, m), 397
395
HO N CH, 8.18 (1H, t, J = 6.0 Hz), 8.34 (2H, d, ,J = 7.1
(C13 Hz), 13.34 (1H, br s).
0 CH3
IV
1H-NMR (DMSO-D6) 6: 0.91 (3H, t, J = 7.4
ID Hz), 1.13 (9H, s), 1.62-1.66 (2H, m), 2.65
cr (2H, t, J = 7.5 Hz), 4.31 (2H, d, J = 6.0 Hz),
1-44 7.38 (2H, d, J = 8.2 Hz), 7.43 (1H, dd, J = 8.4, 439
437
1.=r..1 la 6 2.0 Hz), 7.59 (1H, d, J = 8.4 Hz), 7.64 (1H, br
HO 6 (%Ik s), 8.17 (1H, t, J = 6.1 Hz), 8.26 (2H, d, J=
0 OH, 8.2 Hz), 13.25 (1H, br s).
F F
F
1H-NMR (DMSO-D6) 6: 2.51 (3H, s), 4.55
lik (2H, d, J = 5.5 Hz), 5.29 (1H, t, J = 5.6 Hz),
1-45 11,0 7.36 (1H, d, J = 7.9 Hz), 7.46 (1H, dd, J = 7.8, 362
360
Ni N\ * 1.7 Hz), 7.65 (1H, br s), 7.94 (2H, d, J = 8.4
)=N Hz), 8.55 (2H, d, J = 8.4 Hz), 13.22 (1H, br s).
HO OH
CH,
H,C
----- CI 1H-NMR (DM50-D6) 6: 1.13 (9H, s), 1.24
(6H, d, J = 6.8 Hz), 2.96-3.03 (1H, m), 4.31
(2H, d, J = 6.0 Hz), 7.41-7.46 (3H, m), 7.58
1-46 439 437
/ H (1H, d, J= 8.4 Hz), 7.64 (1H, br s), 8.17 (1H,
HO N CH I, J = 6.0 Hz), 8.27 (2H, d, J = 8.2 Hz), 13.26
CH,
( ' (1H, br s).
0 CH,
1H-NMR (DM30-D6) 6: 1.88 (3H, s), 2.50
(3H, s), 4.29 (2H, d, J = 6.0 Hz), 7.35 (1H, d,
1s0 J = 7.9 Hz), 7.39 (1H, dd, J = 7.9, 1.8 Hz),
1-47 )-1',,
7.59 (1H, br s), 7.94 (2H, d, J = 8.2 Hz), 8.37 403 401
H HO (1H, t, J = 6.0 Hz), 8.54 (2H, d, J = 8.2 Hz),
0'1.--CH, 13.26 (1H, br s).
r.,4).__
F
1H-NMR (DMSO-D6) 6:1.13 (9H, s), 2.50
HO (3H, s), 4.30 (2H, d, J = 6.0 Hz), 7.34-7.35
1-48 , (2H, br m), 7.57 (1H, br s), 7.93 (2H, d, J -- 445
443
N/ \ *
)=N H 8.4 Hz), 8.09 (1H, t, J = 6.1 Hz), 8.54 (2H, d, J
HO NI (OH, = 8.4 Hz), 13.24 (1H, br s).
0 OH,
209
CA 02936408 2016-06-29
[ 0 7 5 6 ]
[Table 1-7]
H,C to
1H-NMR (DMSO-D6) 0:1.13 (9H, s), 1.25
H,C CI (6H, d, J = 7.0 Hz), 2.96-3.03 (1H, m), 4.32
1-49 N' \ *
(2H, d, J = 5.8 Hz), 7.44 (1H, dd, J = 8.1, 1.2
)-=N H Hz), 7.48 (1H, t, J = 7.7 Hz), 7.56 (1H, d, J = 439
437
HO 14) KCH, 7.7 Hz), 7.59 (1H, d, J = 8.1 Hz), 7.65 (1H, br
O CH, s), 8.16-8.20 (3H, m), 13.30 (1H, br s).
H,C *
1H-NMR (DMSO-D6) 0:0.91 (3H, t, J = 7.3
oi Hz), 1.13 (9H, s), 1.61-1.65 (2H, m), 2.65
N \ .
HO )=N (2H, t, J = 7.5 Hz), 4.31 (2H, d, J = 6.2 Hz),
1-50 H 7.43-7.50 (3H, m), 7.59 (1H, d, J = 8.2 Hz), 439
437
N CH3
( CH, 7.64 (1H, br s), 8.16-8.18 (3H, m), 13.30 (1H,
O CH, S).
H,C
1H-NMR (DMSO-D6) 6: 0.88 (6H, d, J = 6.6
H,C . Hz), 1.13 (9H, s), 1.88-1.92 (1H, m), 2.55
ci (2H, d, J = 7.1 Hz), 4.31 (2H, d, J -= 6.2 Hz),
1-51 7.35 (2H, d, J = 8.2 Hz), 7.43 (1H, dd, J = 8.4, 439
437
\/=N H 2.0 Hz), 7.58 (1H, d, J = 8.2 Hz), 7.64 (1H, br
HO N C'',,. S), 8.17 (1H, t, J = 6.1 Hz), 8.26 (2H, d, J=
O CH, 8.4 Hz), 13.25 (1H, br s).
1H-NMR (DM50-D6) 0:1.06 (3H, s), 1.14-
CI
1-52 I
1.49 (8H, m), 1.91-1.98 (2H, m), 4.32 (2H, d,
rt H N J = 5.8 Hz), 7.43 (1H, d, J = 8.1 Hz), 7.52-
' 437 435
0 cm, 7.59 (3H, m), 7.62-7.67 (2H, m), 8.16 (1H, t, J
I = 5.9 Hz), 8.32 (2H, d, J = 8.1 Hz), 13.31 (1H,
OH br s).
C_ a 1H-NMR (DMSO-D6) 0:1.26 (6H, s), 3.15
Ni N It
)=N\ H (3H, s), 432 (2H, d, J ¨6.3 Hz), 7.45 (1H, d,
1-53 J = 7.2 Hz), 7.53-7.59 (3H, m), 7.63-7.68 (2H, 413
411
HO CH, m), 8.32 (2H, d, J = 7.9 Hz), 8.46 (1H, t, J =
{CHa 6.3 Hz), 13.31 (1H, br s).
0 0-CH,
FF II 1H-NMR (DMSO-D6) 0:1.12 (9H, s), 4.31
F CI (2H, d, J = 6.0 Hz), 7.45 (1H, d, J = 8.4 Hz),
1-54 N
IN' ' if 7.60 (1H, d, J = 8.4 Hz), 7.63 (1H, s), 7.81
465 463
H
HO
)-N
CH, (1H, t, J = 7.9 Hz), 8.03 (1H, d, J = 7.4 Hz),
), ( cHa 8.16 (1H, t, J = 5.9 Hz), 8.57-8.63 (2H, m),
O CH, 13.51 (1H, br s).
H,C iia 1H-NMR (DMSO-D6) 5: 1.13 (9H, s), 1.22
(3H, t, J = 7.6 Hz), 2.70 (2H, q, J = 7.6 Hz),
1-55 N/ , tk,
>=N H 4.31 (2H, d, J = 6.0 Hz), 7.42-7.53 (3H, m), 425
423
HO N oft 7.59 (1H, d, J = 8.2 Hz), 7.64 (1H, s), 8.15-
{ CH, 8.19 (3H, m), 1331 (1H, br s).
O CH,
FF
F
%--¨ c 1H-NMR (DMSO-D6) 5: 1.28 (6H, s), 3.17
(3H, s), 4.33 (2H, d, J = 6.2 Hz), 7.48(1H, dd,
1-56
J = 8.4, 2.1 Hz), 7.61 (1H, d, J = 8.3 Hz), 7.67
N/ % a-
)=. - (1H, s), 7.94 (2H, d, J = 8.3 Hz), 8.48 (1H, t, J
481 479
,-,
HO = 6.3 Hz), 8.52 (2H, d, J = 8.3 Hz), 13.55 (1H,
0 0-CH, br s).
210
CA 02936408 2016-06-29
[0757]
[Table 1-8]
HC ig
H,C 11-I-NMR (DMSO-D6) 8:1.13 (9H, s), 1.34
H c 3C (9H, s), 4.31 (2H, d, J = 6.0 Hz), 7.43 (1H, dd,
1-57
rscr,\J . J = 8.2, 2.0 Hz), 7.49 (1H, t, J = 7.8 Hz), 7.59
(1H, d, J = 8.2 Hz), 7.66 (1H, s), 7.72 (1H, d, 453 451
H
HO N (CFcl,H3 J = 8.2 Hz), 8.15-8.18 (2H, m), 3.38(1H, s),
0 CH, 13.33 (1H, br s).
F
F 11 1H-NMR (DMSO-D6) 6: 0.72 (3H, t, J = 7.4
Hz), 1.08 (6H, s), 1.49 (2H, q, J = 7.4 Hz),
F , N CI
1-58 N
) \ *
=N 4.32 (2H, d, J = 6.0 Hz), 7,47 (1H, dd, J = 8.2,
2.0 Hz), 7.61 (1H, d, J = 8.2 Hz), 7.65 (1H, s), 479 477
HO '4 01{, 7.82 (1H, t, J = 7.8 Hz), 8.04 (1H, d, J = 7.9
fl3 Hz)' 8.15 (1H, t, J = 6.1 Hz), 8.59-8.63 (2H,
0 CH,
m), 13.54 (1H, s).
F
F *
F a 1H-NMR (DMSO-D6) 8:1.37 (6H, s), 4.36
1-59 N)ir'N).--4,_
H (2H, d, J = 5.6 Hz), 7.45 (1H, d, J = 8.4 Hz),
7.62 (1H, d, J = 8.4 Hz), 7.64 (1H, s), 7.81 519 517
HO N Chi (1H, t, J= 7.7 Hz), 8.03 (1H, d, J = 7.9 Hz),
o ),C_HF, 8.58-8.66 (3H, m), 13.53 (1H, br s).
Fr
CI . 1H-NMR (DMSO-D6) 6: 1.13 (9H, s), 4.31
N 2H ( H, d, J = 6.0 Hz), 7.45 (1H, d, J = 8.4 Hz),
1-60 F-F-(or 41 ¨ ()_
ON 7.55 (2H, d, J = 8.7 Hz), 7.61 (1H, d, J = 8.4 481
479
\N-1(N H,C CH, Hz), 7.64 (1H, s), 8.18 (1H, t, J = 6.0 Hz),
OH 8.46 (2H, d, J= 8.7 Hz), 13.45 (1H, br s).
1H-NMR (DMSO-D6) 6:1.13 (9H, s), 4.31
CI
F
F¨)-0 NH (2H, d, J = 6.0 Hz), 7.45 (1H, dd, J = 8.4,2.2
1-61 F ¨ 0 Hz), 7.60 (1H, d, J = 8.4 Hz), 7.63-7.73 (3H, 481
0 \ I
N-C:13 m), 8.18 (1H, t, J = 6.0 Hz), 8.21 (1H, s), 8.37
I-130 CH 479
(N
(1H, dt, J = 7.4, 1.5 Hz), 13.50 (1H, br s).
OH
H3C¨ \c}Au 1H-NMR (DMSO-D6) 6: 1.12 (9H, s), 1.34
\_ a (3H, t, J = 7.0 Hz), 4.09 (2H, q, J = 7.0 Hz),
) r, ii , H 4.30 (2H, d, J= 6.0 Hz), 7.20(1H, dd, J = 8.1,
1-62 2.3 Hz), 7.41-7.46 (2H, m), 7.57 (1H, d, J = 441
439
Fio Nµ ,01-13 8.4 Hz), 7.63 (1H, s), 7.84 (1H, s), 7.91 (1H,
r-i d, J = 7.7 Hz), 8.16 (1H, 1, J= 6.0 Hz), 13.30
01t0 CH,
(1H, br s).
1H-NMR (DMSO-D6) 6: 1.13 (9H, s), 2.41
Ci
NH (3H, s), 4.31 (2H, d, J = 6.0 Hz), 7.37 (2H, d,
1-63 ii N¨ 0 J = 8.1 Hz), 7.43 (1H, d, J = 8.1 Hz), 7.59
411 409
Fw \ n1 1\¨CI-1 (1H, d, J = 8.1 Hz), 7.64 (1H, s), 8.17 (1H, t, J
N--( H,C CH, = 6.0 Hz), 8.24 (2H, d, J = 8.1 Hz), 13.24 (1H,
OH
br s).
CI FI,C NH 1H-NMR (DMSO-D6) 6:1.14 (9H, s), 2.40
4. \
N¨ 0 . (3H, s), 4.32 (2H, d, J = 6.0 Hz), 7.41-7.51
cit (3H, m), 7.60 (1H, d, J = 8.4 Hz), 7.64 (1H, s),
N-4N I-I .._C CH, 8.11-8.20 (3H, m), 13.30 (1H, br
s). 411 409
1-64
OH
211
CA 02936408 2016-06-29
[0758]
[Table 1-9)
1H-NMR (DMSO-06) 0:1.60-1.71 (6H, m),
1.79-1.83 (6H, m), 1.94-1.98 (3H, m), 4.30
1-65 til N` 41 (2H, d, J = 6.0 Hz), 7.42 (1H, d, J = 8.6 Hz),
475 473
)=N H 7.53-7.59 (3H, m), 7.63-7.68 (2H, m), 8.10
HO N> jr0 (1H, t, J = 6.1 Hz), 8.34 (2H, d, J = 7.5 Hz),
o 13.34(1H, br s).
1H-NMR (DMSO-D6) 6:1.72-1.94 (2H, m),
CI 1.99-2.08(2H, m), 2.10-2.20(2H, m), 3.03-
1-66 / N,,
N 1, 3.11 (1H, m), 4.31 (2H, d, J = 6.0 Hz), 7.45
(1H, dd, J = 8.4,2.0 Hz), 7.54-7.69 (5H, m), 395 393
HO Fr 8.28 (1H, t, J = 6.0 Hz), 8.34 (2H, d, J = 7.3
Hz), 13.34 (1H, br s).
1H-NMR (DMSO-D6) 6: 1.46-1.81 (8H, m),
RN CI 2.59-2.66 (1H, m), 4.32 (2H, d, J = 6.0 Hz),
1-67 Ni ' * 7.45 (1H, dd, J = 8.4, 2.2 Hz), 7.56 (2H, t, J =
409 407
)=N H 7.6 Hz), 7.60 (1H, d, J = 8.2 Hz), 7.64-7.69
HO 'kip (2H, m), 8.34 (2H, d, J = 7.5 Hz), 8.40 (1H, t,
o J = 6.1 Hz), 13.34 (1H, br s).
C._
1H-NMR (DMSO-D6) 0:1.50-1.68 (4H, m), CI
N 1.82-1.91 (2H, m), 2.29-2.36 (2H, m), 4.37
N \ ID (2H, d, J = 5.8 Hz), 7.41 (1H, d, J = 8.8 Hz),
1-68 ),..--N 477 = 475
HO N) 7.54 (2H, t, J = 7.7 Hz), 7.59 (1H, d, .1= 8.4
Hz), 7.62-7.67 (2H, m), 8.32 (2H, d, J = 7.7
0 r
Fr Hz), 8.69 (1H, t, J = 5.9 Hz), 13.33 (1H, br s).
C_N
1H-NMR (DMSO-D6) 6:1.38 (6H, s), 4.37 ci
(2H, d, J = 6.0 Hz), 7.44 (1H, dd, J = 8.3,2.1
1-69 is-N * Hz), 7.56 (2H, t, J = 7.6 Hz), 7.61 (1H, d, J =
451 449
H 8.4 Hz), 7.64-7.69 (2H, m), 8.34 (2H, d, J =
HO
7.5 Hz), 8.64 (1H, t, J = 6.0 Hz), 13.35 (1H, br
) OH,
H F, s).
F F
(-- 1H-NMR (DM50-D6) 6:1.77-1.94 (2H, m),
__. ci
2.30-2.39 (2H, m), 2.45-2.57 (2H, m), 4.39
1-70 (2H, d, J = 5.8 Hz), 7.44 (1H, d, J = 7.4 Hz), 463
461
HO isi, c3H 7.54 (2H, t, J = 7.7 Hz), 7.60 (1H, d, J = 8.4
Hz), 7.63-7.68 (2H, m), 8.33 (2H, d, J = 7.7
Or-----F r Hz), 8.78 (1H, t, J = 5.9 Hz), 13.32 (1H, br s).
F
CI 1H-NMR (DMSO-D6) 6:1.08-1.42 (5H, m),
C-N 1.57-1.77 (5H, m), 2.13-2.21 (1H, m), 4.31
1-71 N \ *
)---N (2H, d, J = 6.0 Hz), 7.44 (1H, dd, J = 8.2,2.2 423
421
11
Ho Hz), 7.54-7.60 (3H, m), 7.65-7.69 (2H, m),
r"-----0 8.33-8.35 (3H, m), 13.34 (1H, br s).
o
1H-NMR (DMS0-D6) 6:1.35 (3H, s), 1.63-
1.76 (3H, m), 1.84-1.93 (1H, m), 2.30-2.37 '
(2H, m), 4.32 (2H, d, J = 6.2 Hz), 7.45 (1H,
1-72 N \ =
)=N dd, J = 8.4, 2.0 Hz), 7.56 (2H, t, J = 7.6 Hz), 409 407
HO MAD 7.60 (1H, d, J = 8.4 Hz), 7.64-7.68 (2H, m),
8.18 (1H, t, J = 6.1 Hz), 8.34 (2H, d, J = 7.5
CH' Hz), 13.35 (1H, br s).
212
CA 02936408 2016-06-29
[0759]
[Table 1-10]
1H-NMR (DMSO-D6) 6: 1.19 (3H, s), 1.35-
1.43 (2H, m), 1.51-1.62 (4H, m), 1.98-2.05
is="31 (2H, m), 4.32 (2H, d, J = 6.0 Hz), 7.44 (1H,
1-73
dd, J = 8.3, 2.1 Hz), 7.54-7.60 (3H, m), 7.64- 423 421
HO 7.69 (2H, m), 8.20 (1H, t, J = 6.1 Hz), 8.34
0 CH, (2H, d, J = 7.3 Hz), 13.34 (1H, br O.
F
1H-NMR (DMSO-D6) 6:1.12 (9H, s), 4.30
'L.._ a (2H, d, J = 6.0 Hz), 7.37 (1H, d, J = 8.8 Hz),
1-74 tql , .
)=N 7.39 (11-i, d, J= 8.8 Hz), 7.42 (1H, dd, J = 8.5,
2.0 Hz), 7.58 (1H, d, J = 8.4 Hz), 7.62 (1H, s), 415 413
U
HO N CI-1 8.16 (1H, t, J = 5.9 Hz), 8.38 (1H, d, J = 8.8
H,
OH,c CH, Hz), 8.40 (1H, d, J = 8.8 Hz), 13.33 (1H, br S).
EL,C-0 *
1H-NMR (DMSO-D6) 6:1.13 (9H, s), 3.32
a (3H, s), 4.31 (2H, d, J = 6.0 Hz), 4.50 (2H, s),
1,1' \ *
H0= 7.43 (1H, d, J = 8.6 Hz), 7.53 (1H, t, J = 7.7
H Hz), 7.59 (2H, d, J = 8.1 Hz), 7.63 (1H, s), 441 439
1-75 )N
N-4CH3 8.18 (1H, t, J = 6.0 Hz), 8.26 (1H, d, ,J = 7.7
oitd a% Hz), 8.30 (1H, s), 13,34 (1H, br s).
F ID 1H-NMR (DMSO-D6) 6: 1.14 (9H, s), 4.32
a (2H, d, J = 6.0 Hz), 7.45 (1H, dd, J = 8.4,2.1
NI' N
\ *
)= Hz), 7.52 (1H, td, J = 8.4, 2.7 Hz), 7.59-7.63
(2H, m), 7.65 (1H, d, .1= 2.1 Hz), 8.05 (1H, dt, 415 413
1-76 -N
H
HO
NHCH, J = 9.8, 2.0 Hz), 8.16-8.20 (2H, m), 13.43
OH,C CH, (1H, br s).
Fr4¨C_ CI
F 1H-NMR (DMSO-D6) 6:1.38 (6H, s), 4.37
(2H, d, J = 5.8 Hz), 7.41 (1H, d, J = 8.4 Hz),
Ni \ *
)=N 7.58 (1H, d, J = 8.4 Hz), 7.61-7.65 (2H, m),
1-77
H F 7.69 (1H, t, J = 7.8 Hz), 8.21 (1H, s), 8.36 535
533
Ho NF
F (1H, d, J = 7.7 Hz), 8.63 (1H, t, J = 5.8 Hz),
OH,o CH, 13.52 (1H, br s).
F
-0
FF \
a 1H-NMR (DMSO-D6) 6:1.48-1.71 (4H, m),
O__.81-1.941 (2H, m), 2.30-2.39 (2H, m),439
1-78 41¨ ` .
(2H, d, J= 5.9 Hz), 7.45 (1H, dd, J = 8.3,1.4
Hz), 7.59-7.75 (4H, m), 8.22 (1H, br s), 8.35- 561 559
)=N
Ho
8.39 (1H, m), 8.72 (1H, t, J = 5.9 Hz), 13.51
(41\_0
\-F (11-I, br s).
F F
FF * 1H-NMR (DMSO-D6) 6:1.50-1.69 (4H, m),
F CI
1.83-1.93 (2H, m), 2.29-2.39 (21-I, m), 4.39
1-79 N' Nµ * (2H, d, J = 6.0 Hz), 7.44 (1H, dd, J = 8.3,1.9
545
)=N 543
F*
Hz), 7.60-7.66 (2H, m), 7.82 (1H, t, J = 7.7
HO
n
Hz), 8.03 (1H, d, J = 7.7 Hz), 8.59-8.65 (2H,
F F m), 8.71 (1H, 1, .1= 6.0 Hz), 13.54 (1H, br S).
HC * 1H-NMR (DMSO-D6) 6: 1.34(9H, s), 1.49-
,13C
a
V 1.69 (4H, m), 1.83-1.92 (2H, m), 2.29-2.38
/ Nµ (2H, m), 4.38 (2H, d, J = 6.0 Hz), 7.42 (1H, d,
1-80 =.1,1 1, ti J = 8.3 Hz), 7.49 (1H, t, J =
7.8 Hz), 7.61 (1H, 533 531
HO '' __ d, J = 8.3 Hz), 7.65 (1H, s),7.71 (1H, d, J =
0 F 7.8 Hz), 8.15 (1H, d, J = 7.8 Hz), 8.38 (1H, 8),
F F 8.71 (1H, t, J = 6.0 Hz), 13.35 (1H, br s).
213
CA 02936408 2016-06-29
[0760]
[Table 1-11]
F
1H-NMR (DMSO-D6) 6:1.37 (6H, s), 2.32
CI (3H, d, J = 1.2 Hz), 4.36 (2H, d, J = 5.9 Hz),
NH
_ 1-81 NC o\ (F 7.50-7.43 (2H, m), 7.60(14-I, d, J = 8.4 Hz),
483 481
F 7.64(1H, br s), 7.99 (1H, d, J = 10.9 Hz), 8.08
\N-1(isi NC CH) (1H, dd, J = 7.8, 1.5 Hz), 8.63 (1H, t, J = 5.9
OH Hz), 13.36 (1H, s).
1H-NMR (DMSO-D6) 6:113 (9H, s), 1.31
H,C g_
(6H, d, J = 6.0 Hz), 4.31 (2H, d, J = 6.0 Hz),
N, I)___µC 4.72-4.82 (1H, m), 7.06 (2H, d, J = 8.9 Hz),
1-82 455 453
11 7.42(14-I, d, J = 8.4 Hz), 7.58 (1H, d, J = 8.4
C HO I,k H, Hz), 7.63 (1H, s), 8.17 (1H, t, J = 6.0 Hz),
i> (c"' 8.29 (2H, d, J = 8.9 Hz), 13.12 (1H, br s).
0 CH,
ti3HG,C
1H-NMR (DMSO-06) 6:1.17 (6H, d, J = 6.3
H,C CI
Hz), 1.34 (9H, s), 4.23 (2H, d, J = 6.0 Hz),
1-83 =
rscNNµ * H 4.72-4.80 (1H, m), 7.43-7.52 (2H, m), 7.60
455 453
HO N (1H, d, J = 8.4 Hz), 7.65-7,73 (3H, in), 8.15
)--.0 (1H, d, J = 7.7 Hz), 8.38 (1H, s), 13.33 (1H, br
0
I-IC s).
H,C CH. 1H-NMR (DMSO-D6) 6:1.27 (6H, s), 1.34
NC CI (9H, s), 3.16 (3H, s), 4.33 (2H, d, J = 6.3 Hz),
N' N, .
7.42-7.46(1H, m), 7.49 (1H, d, J = 7.9 Hz),
7.57 (1H, d, J = 8.1 Hz), 7.66-7.71 (2H, m), 469 467
1-84 )=N H
HO
NO CH3 8.14 (1H, d, J= 7.9 Hz), 8.38 (1H, s), 8.47
6Nkcri, (1H, t, J = 6.3 Hz), 13.32 (1H, br s).
o 4.
NC-1 CI 1H-NMR (DM50-D6) 6:1.36 (3H, t, J = 7.0
Hz), 1.51-1.69 (4H, m), 1.84-1.91 (2H, m),
N' N' 1, 2.30-2.38 (2H, m), 4.10(2k, q, J = 7.0 Hz),
1-85 )---N
4.38 (2H, d, J = 6.0 Hz), 7.20 (1H, dd, J = 8.3,
521 519
HO N
H ' FF 2.4 Hz), 7.39-7.43 (1H, m), 7.46 (1H, d, J =
) - 7.9 Hz), 7.59 (1H, d, J = 8.3 Hz), 7.03(1k, s),
o
7.85(1H, d, J = 2.4 Hz), 7.89-7.96 (1H, m),
8.71 (1H, t, J = 6.0 Hz), 13.33 (1H, br s).
1H-NMR (DMSO-D6) 6: 1.02(9H, s), 1.37
NC CH, CI 411 (6H, s), 3.73 (2H, s), 4.35 (2H, d, J = 5.8 Hz),
L-Chi' NH
1-86
7.08 (2H, d, J = 9.1 Hz), 7.40 (1H, dd, J = 8.3,
537 535
o ifr rivi \ N O1\ <FF 2.2 Hz), 7.58(1k, d, J = 8.3 Hz), 7.62 (1H, d,
N=( NC CNF J = 1.9 Hz), 8.29 (2H, d, J = 9.1 Hz), 8.62
OH
(11-1, t, J = 5.81-1z), 13.13(1k, s).
1H-NMR (DMS0-D6) 6: 1.54 (3H, s), 3.36
Qr ci
(3H, s), 4.32-4.44(2k, m), 7.46 (1H, d, J =
1-87 is=NNµ 41)
H PH3 8.2 Hz), 7.53-7.71 (5H, m), 8.34 (2H, d, J = 467
465
HO N.,a 7.5 Hz), 9.04 (1H, t, J = 6.3 Hz), 13.35 (1H, br
O F
s).
F F
ItC)__\
1H-NMR (DM50-D6) 5:1.00 (6H, d, J = 6.8
H,C 0¨C_ Hz), 1.38 (6H, s), 1.99-2.10 (1H, m), 3.83
CI
(2H, d, J = 6.4 Hz), 4.37 (2H, d, J = 6.0 Hz),
N' \ *
1-88 )-=N 7.23 (1H, dd, J = 8.2, 2.6 Hz), 7.41-7.49 (2H, 523
521
HO l'', CE-1 m), 7.61 (1H, d, J = 8.2 Hz), 7.66 (1H, s),
0 1 7.84-7.88(1H, m), 7.93(1k, d, J = 7.9 Hz),
F F 8.64 (1H, t, J = 6.0 Hz), 13.33 (1H, br s).
214
CA 02936408 2016-06-29
[0761]
[Table 1-12]
1H-NMR (DMSO-D6) 6: 1.54 (3H, s), 3.36 C 01
1-89 N' )=. \ 4,
, pH, (3H, s), 4.32-4.44 (2H, m), 7.46 (1H, d, J =
8.2 Hz), 7.53-7.71 (5H, m), 8.34 (2H, d, J = 467 465
HO ; 7.5 Hz), 9.04 (1H, t, J = 6.3 Hz), 13.35 (1H, br
No:..HFa
6).
F F .
F
H C¨L 1H-NMR (DMSO-D6) 6: 1.38 (6H, s), 2,31
CI (3H, s), 4.37 (2H, d, J = 5.8 Hz), 7.31 (1H, t, J
1-90 N' rµ * = 9.1 Hz), 7.43 (1H, dd, J = 8.4, 2.0 Hz), 7.60
483 481
(1H, d, J = 8.4 Hz), 7.63 (1H, s), 8.21 (1H, s),
HO _-F
hi F
NIF 8.28 (1H, d, J = 7.4 Hz), 8.64 (1H, t, J = 5.8
OH,c OH, Hz), 13.32 (1H, br s).
1H-NMR (DMSO-D6) 8:1.30 (6H, d, J = 6.0
C,'R¨N a Hz), 1.38 (6H, s), 4.37 (2H, d, J = 5.8 Hz),
Ali \
)=N H F 4.66-4.72 (1H, m), 7.20 (1H, dd, J = 8.4,2.1
1-91 . Hz), 7.42-7.47 (2H, m), 7.60 (1H, d, J = 8.4 509
507
HO NvF Hz), 7.66 (1H, s), 7.84-7.86 (1H, m), 7.90
F
OitCH, (1H, d, J = 7.7 Hz), 8.64 (1H, t, J = 5.8 Hz),
p
13.32(1H, br s).
Hp CH. 1H-NMR (DMSO-D6) 6: 1.34(9H, s), 1.38
H,C CI (6H, s), 4.37 (2H, d, J = 6.0 Hz), 7.42 (1H, d,
1-92 Ni Nµ *
>=N H F J = 8.4 Hz), 7.48 (1H, t, J = 7.9 Hz), 7.59 (1H,
d, J = 8.4 Hz), 7.66 (1H, s), 7.70 (1H, d, J = 507 505
HO N.v,F 7.7 Hz), 8.15 (1H, d, J = 7.7 Hz), 8.37-8.39
(11-I, m), 8.63 (1H, t, J = 6.0 Hz), 13.33 (1H, br
OH,c CH,
6).
CH,
H,C
--qN CI 1H-NMR (D4SO-D6) 0:1.38 (6H, s), 2.35
(6H, s), 4.37 (2H, d, J = 5.8 Hz), 7.30 (1H, s),
1-93 NI ' 0
F 7.44(1H, d, J= 8.4 Hz), 7.60 (1H, d, J = 8.4 479
477
Hz), 7.63 (1H, s), 7.96 (2H, s), 8.64 (1H, t, J =
HO W\vF
F 5.8 Hz), 13.27 (1H, br s).
OH,c CH,
H,C CH.
1H-NMR (DMSO-D6) 6: 1.33 (9H, s), 4.55
Hp a (2H, d, J = 5.8 Hz), 7.45-7.50 (3H, m), 7.52-
,
N N
\ *
= 7.56 (2H, m), 7.61 (1H, d, J = 8.4 Hz), 7.71
(1H, d, J = 8.4 Hz), 7.78 (1H, s), 7.89-7.91 473 471
1-94 >N H
HO
NC) (2H, m), 8.14 (1H, d, J . 7.7 Hz), 8.37 (1H, s),
0 9.15 (1H, t, J = 5.8 Hz), 13.33 (1H, br s).
OH,
H,C * 1H-NMR (DMSO-D6) 6: 0.88 (6H, d, J = 6.6
a Hz), 1.38 (6H, s), 1.82-1.94 (1H, m), 2.55
1-95 . ti' ir
>=N (2H, d, J = 7.1 Hz), 4.37 (2H, d, J = 6.0 Hz), 507
505
7.42-7.50 (3H, m), 7.59-7.67 (2H, m), 8.12-
Ho
Ir- rtu'i 8.20 (2H, m), 8.64 (1H, t, J = 6.0 Hz), 13.31
,:
, F F' (1H, br s).
1H-NMR (DMSO-D6) 6:1.19 (3H, t, J = 7.1
R N\ ci
Hz), 1.54(3H, s), 3.46-3.54 (1H, m), 3.57-
= FE
)=N ,C 3.66 (11-1, m), 4.40 (2H, d, J = 6.2 Hz), 7.46
(1H, d, J = 8.4 Hz), 7.54-7.70 (5H, m), 8.34 481 479
1 -96 1,1' H )
HO N;-\\ .CH, (2H, d, J = 7.5 Hz), 8.86(1K, t, J = 6.2 Hz),
0 iN-F
F F 13.35 (1H, br s).
215
CA 02936408 2016-06-29
[0762]
[Table 1-13]
C_
1H-NMR (DMSO-D6) 6:1.19 (3H, t, J = 7.1 ci
Hz), 1.54 (3H, s), 3.46-3.54 (1H, m), 3.57-
&a
õ, H C 3.66 (1H, m), 4.40 (2H, d, J = 6.2 Hz), 7.46
1-97 481 479
.>=N ,w, H '0)
(1H, d, J = 8.4 Hz), 7.54-7.70 (5H, m), 8.34
HO
\--CH3 (2H, d, J = 7.5 Hz), 8.86 (1H, t, J = 6.2 Hz),
0 i\---F 13.35 (1H, br s).
F F
CH,
N,C_
1H-NMR (DMSO-D6) 6:1.24 (6H, d, J = 7.0
a Hz), 1.38 (6H, s), 4.36 (2H, d, J = 5.8 Hz),
1-98 Ni N, if 7.35-7.40(3H, m), 7.54 (1H, d, J = 8.4 Hz), 493
491
>=" 7.61 (1H, d, J = 2.1 Hz), 8.25 (2H, d, J = 8.4
HO Q,FF
Hz), 8.62 (1H, t, J = 5.8 Hz), 13.26 (1H, br s).
00,0 CH,
1H-NMR (DMSO-D6) 6:1.38 (6H, s), 4.37
Fx_13-C_ ci (2H, d, J = 5.8 Hz), 4.86 (2H, q, J = 8.8 Hz),
F F N 7.36 (1H, dd, J = 8.0, 2.4 Hz), 7.43 (1H, dd, J
1-99
N/ \ *
)=N H F = 8.0, 2.4 Hz), 7.53 (1H, t, J = 8.0 Hz), 7.60 549 547
HO Ns )F (1H, d, J = 8.0 Hz), 7.65 (1H, s), 7.93-7.95
(1H, m), 8.03 (1H, d, J = 7.7 Hz), 8.64 (1H, t,
OH,C CH,
J = 5.8 Hz), 13.35 (1H, br s).
. .
1H-NMR (DMSO-D6) 6:1.36 (6H, s), 1.79-
1.87 (1H, m), 1.93-2.05 (1H, m), 2.07-2.18
1-100 N>=N / N, . (2H, m), 2.29-2.36 (2H, m), 3.55-3.64 (1H,
m), 4.35 (2H, d, J= 6.0 Hz), 7.37-7.48(3H, 505 503
F
HO H Nµ )F M), 7.56 (1H, d, J= 8.1 Hz), 7.61 (1H, s),
OH3o CH, 8.13 (1H, d, J = 7.0 Hz), 8.18 (1H, s), 8.61
(1H, t, J = 6.0 Hz), 13.31 (1H, br s).
11,0
0,0 1H-NMR (DMSO-D6) 5:0.88 (6H, d, J = 6.5
)--:?),_
Hz), 1.25 (9H, s), 1.84-1.95 (1H, m), 2.55
ci
1-101 J = 8.1 Hz), 7.46 (1H, d, J = 8.4 Hz), 7.57
N (2H, d, J = 7.2 Hz), 3.45 (2H, s), 7.35 (2H, d,
453 451
N \ 41,
)=" 0
Flo CH, (1H, d, J = 8.4 Hz), 7.65 (1H, s), 7.76 (1H, s),
N¨ECH, 8.26 (2H, d, J = 8.1 Hz), 13.24 (1H, br s).
. CH,
. 1H-NMR (DM50-D6) 6: 0.91 (3H, t, J = 7.6
HEc ci Hz), 1.38 (6H, s), 1.58-1.69 (2H, m), 2.64
N'
N
N \ * (2H, t, J = 7.6 Hz), 4.37 (2H, d, J = 6.0 Hz),
1-102
>-=-N H F 7.40-7.46 (3H, m), 7.58 (1H, d, J = 8.1 Hz),
493 491
HO
NVFF 7.63 (1H, d, J = 1.9 Hz), 8.14-8.18 (2H, m),
H,0 CH, 8.63 (1H, t, J = 6.0 Hz), 13.32 (1H, br s).
1H-NMR (DMS0-D6) 6:1.54 (3H, s), 3.36
a (3H, s), 4.32-4.46 (2H, m), 7.48 (1H, d, J =
1-103 `,'¨s Nµ * 7.7 Hz), 7.60-7.75 (4H, m), 8.22 (1H, s), 8.37 551
549
EN, pH, .
HO (1H, d, J = 7.3 Hz), 9.04 (1H, t, J = 6.3 Hz),
.
..,>-',,cF 21, 13.52 (1H, br s).
Fr
H,C ip
1H-NMR (DMSO-D6) b: 0.91 (3H, t, J = 7.4
CI Hz), 1.54 (3H, s), 1.58-1.69 (2H, m), 2.65
N
N \ . (2H, t, J = 7.6 Hz), 3.36 (3H, s), 4.32-4.45
509 507
1-104 >---N Eil ,ch,õ
(2H, m), 7.43-7.52 (3H, m), 7.61 (1H, d, J =
HO
¨'Co,\__ 8.4 Hz), 7.67 (1H, s), 8.13-8.19 (2H, m), 9.04
O F
0_ F (1H, t, J = 6.2 Hz), 13.31 (1H, br s).
216
CA 02936408 2016-06-29
[0763]
[Table 1-14]
NC
1H-NMR (DMSO-06) 6:1.54 (3H, s), 2.34
CI (3H, d, J = 1.1 Hz), 3.36 (3H, s), 4.33-4.45
1-105 N/ , M
sm` ,4 CH, (2H, m), 7.44-7.52 (2H, m), 7.61 (1H, d, J =
8.2 Hz), 7.67 (1H, s), 8.00(1K, d, J = 11.0 499 497
)=-N
HO
Hz), 8.09 (1H, dd, J = 7.9, 1.5 Hz), 9.04 (1H,
0 F 1, J = 6.2 Hz), 13.38 (1H, br s).
F F
F 1H-NMR (DMSO-D6) 8:1.54 (3H, s), 2.32
H,C¨q (3H, d, J = 1.3 Hz), 3.36 (3H, s), 4.32-4.44
CI
(2H, m), 7.32 (1H, t, J = 9.0 Hz), 7.46 (1H, d,
1-106
'cl,µ, * H H3 p J = 8.3 Hz), 7.61 (1H, d, J = 8.3 Hz), 7.65 499
497
HO (1H, s), 8.19-8.25 (1H, m), 8.28 (1H, d, J ,-
cH, 7.3 Hz), 9.03 (1H, t, J = 6.3 Hz), 13.33 (1H, br
F F s).
H,C 0
I-1,C CI 1H-NMR (DMSO-06) 6:1.25 (6H, d, J = 6.9
¨N Hz), 1.38 (6H, s), 2.94-3.06 (1H, m), 4.37
N, 7 , *
1-107 ¨11 (2H, d, J = 5.9 Hz), 7.41-7.68 (5H, m), 8.13- 493
491
HO
Er:tjCAH, 8.19(1H, m), 8.22 (1H, br s), 8.64 (1H, t, J =
6 ,A.., 5.9 Hz), 13.33 (1H, br s).
. ,
NC 0
H,C CI 1H-NMR (DMSO-D6) 6:1.25 (6H, d, J = 7.3
¨N =
Hz), 1.54 (3H, s), 2.94-3.07 (1H, m), 3.36
1-108 N).--K1 . H .c,, (3H, s), 4.31-4.46 (2H, m), 7.42-
7.71 (5H, m), 509 507
HO NA 8.16 (1H, d, J = 7.7 Hz), 8.22 (1H, br s), 9.04
0 F (1H, t, .1= 6.0 Hz), 13.32 (1H, br s).
F F
1H-NMR (DMSO-D6) b: 0.98 (6H, d, J = 6.5
V 11 Hz), 1.37 (6H, s), 2.07-2.00 (1H, m), 3.85
CI
(2H, d, J = 6.5 Hz), 4.35 (2H, d, J = 6.0 Hz),
1-109 F 7.07 (2H, d, J = 9.1 Hz), 7.41 (1H, dd, J = 8.1,
523 521
0¨OHe ¨ N JsX4H 2.1 Hz), 7.58 (1H, d, J = 8.1 Hz), 7.62 (11-I, s),
\r.14 (F V CH
CH 8.29 (2H, d, J = 9.1 Hz), 8.63 (1H, t, J = 5.9
Hz), 13.13 (1H, br S).
HC it
1H-NMR (DM80-D6) 6: 1.22 (3H, t, J -= 7.6
CI Hz), 1.38 (6H, s), 2.70 (2H, q, J = 7.6 Hz),
4.37 (2H, d, J = 6.0 Hz), 7.42-7.54(3H, m),
1-110 )=14 H 7.61 (1H, d, J = 8.4 Hz), 7.65 (1H, s), 8.16 479
477
HO N CH,
CH, (1H, d, J= 7.7 Hz), 8.19 (1H, s), 8.65 (1H, t, J
O (r = 6.0 Hz), 13.32 (1H, br s).
FIC¨,c:
el 1H-NMR (DMS0-06) 6:1.38 (6H, s), 2.40
N (3H, s), 4.37 (2H, d, J = 6.0 Hz), 7.41-7.50
1-111 N Y-1\ *4 H (3H, m), 7.61 (1H, d, J = 8.4
Hz), 7.65 (1H, s), 465 463
HO Is. _!1 õ 8.11-8.18 (2H, m), 8.65 (1H, t, J= 6.0 Hz),
0 -H,F 13.32 (1H, br s).
F F
CI
1H-NMR (DM80-D6) 6:1.38 (6H, s), 2.42
FI,C¨.t?>_
ci (3H, s), 4.37 (2H, d, J = 6.0 Hz), 7.44 (1H, dd,
1-112 Hi N, 4, J = 8.4, 2.1 Hz), 7.61 (2H, dd, J = 8.4, 2.1
499 497
)=N H F Hz), 7.64 (1H, d, J = 2.1 Hz), 8.17 (1H, dd, J
HO N VF = 8.4,2.1 Hz), 8.30 (1H, d, J = 2.1 Hz), 8.65
OH,C CH, (1H,1, J = 6.0 Hz), 13.39 (1H, br s).
217
CA 02936408 2016-06-29
[0764]
[Table 1-15]
FF,1:b 1H-NMR (DMSO-06) 8:1.38 (6H, s), 4.36
a (2H, d, J = 6.0 Hz), 4.89 (2H, q, J = 8.8 Hz),
1-113 7.20 (2H, d, J = 9.1 Hz), 7.39 (1H, dd, J = 8.3,
549 547
)=N ,, F 2.0 Hz), 7.56 (1H, d, J = 8.3 Hz), 7.62 (1H, d,
HO N4\a'FF J = 2.0 Hz), 8.33 (2H, d, J = 9.1 Hz), 8.64
0,1c al, (1H, t, J - 6.0 Hz), 13.24 (1H, br s).
HA
--CH,
1H-NMR (DMS0-06) 6: 0.94 (6H, d, J = 6.6
4 Hz), 1.37 (6H, s), 1.63 (2H, q, J = 6.6 Hz),
1.79(1H, m), 4,04 (2H, t, J = 6.6 Hz), 4.33
1-114 (2H, d, J = 6.0 Hz), 6.95 (2H, d, J = 8.9 Hz), 537
535
7.23 (1H, d, J = 8.3 Hz), 7.42 (1H, d, J = 8.3
Hz), 7.50 (1H, d, J = 2.0 Hz), 8.22 (2H, d, J =
0 F 8.9 Hz), 8.59 (1H, t, J = 6.0 Hz).
F F
sOH,
1H-NMR (DMSO-D6) 6: 1.38 (6H, s), 2.55
(3H, s), 4.36 (2H, d, J = 6.0 Hz), 7.39 (2H, d,
a
J = 8.7 Hz), 7.40 (1H, d, J = 8.3 Hz), 7.58
1-115 '\¨/¨,
''=-NI H (1H, d, J = 8.3 Hz), 7.63 (1H, s), 8.26 (2H, d, 497
495
HO CH. J = 8.7 Hz), 8.64 (1H, t, ,J = 6.0 Hz), 13.26
on,
0 F (1H, s).
, F
1H-NMR (DMSO-D6) 8:1.37 (6H, s), 1.94-
1-11 6 P0 cN ,,
i_ 0\(.F 170 (4H, m), 2.11-2.04 (2H, m), 2.77-2.69
NH (1H, m), 4.05 (2H, d, J = 6.7 Hz), 4.35 (2H, d,
J ¨ 5.8 Hz), 7.07 (2H, d, J = 9.1 Hz), 7.40 535 533
o \ /14
N¨K I-6C CHf (1H, dd, J = 8.4,2.1 Hz), 7.57(1H, d, J = 8.4
OH Hz), 7.62 (1H, s), 8.28 (2H, d, J = 9.1 Hz),
8.62 (1H, t, J = 5.8 Hz), 13.13 (1H, s).
F
HC * 1H-NMR (DMSO-D6) 6:1.27 (6H, d, J = 7.1
HC CI Hz), 1.38(6K, s), 3.19-3.28 (1H, m), 4.37
1-117 ,, ,I, (2H, d, J = 6.0 Hz), 7.33 (1H, t, J = 9.5 Hz),
511 509
)=N 7.44 (1H, d, J = 8.4 Hz), 7.59-7.68 (21-1, m),
HO H
' 8.21-8.26 (1H, m), 8.33 (1H, dd, J = 7.5, 2.2
cr)--c-c-" HF' Hz), 8.64 (1H, t, J= 6.0 Hz), 13.36 (1H, br s).
F F
F
H,C-- 1H-NMR (DMSO-06) 6: 0.92 (3H, t, J = 7.3
a Hz), 1.38 (6H, s), 1.56-1.67(2K, m), 2.67
N)..A
N/ ' (2H, t, J = 7.7 Hz), 4.37 (2H, d, J = 6.0 Hz),
1-11 8 )=N H 7.33 (1H, t, J = 9.3 Hz), 7.44 (1H, d, J = 8.4 511
509
HO N CH,
(CH, Hz), 7.59-7.66 (2H, m), 8.21-8.30 (2H, m),
k--., 8.65 (1H, t, J = 6.0 Hz), 13.34(1K, br S).
F,
F
FI.O¨J_ 1H-NMR (DMSO-D6) 6: 1.38 (6H, s), 2.01
(3H, t, J = 19.0 Hz), 4.37 (2H, d, J = 5.8 Hz),
c" 7.44 (1H, dd, J = 8.4, 2.1 Hz), 7.61 (2H, d, J = 515
1-119 N' Nµ lik 513
8.1 Hz), 7.65 (2H, d, J = 2.1 Hz), 7.74 (2H, d,
)=N n ' HO F J = 8.4 Hz), 8.43 (2H, d, J = 8.1 Hz), 8.64
""--F
(1H, t, J = 5.8 Hz), 13.46 (111, br s).
oH.c 01-1.
CH,
1H-NMR (DMSO-D6) 6: 1.01 (6H, d, J = 6.7
F F
Hz), 1.37 (6H, s), 2.04-2.10 (1H, m), 3.95
*
(2H, d, J = 6.7 Hz), 4.33 (2H, d, J = 6.0 Hz),
a
1-120 7.25 (1H, dd, J = 8.3, 2.2 Hz), 7.29 (1H, d, J = 591
589
V , ik
)=-N H F 8.3 Hz), 7.44 (1H, d, J = 8.3 Hz), 7.51 (1H, d,
HO rsI4siF J = 2.2 Hz), 8.49-8.53(2K, m), 8.56-8.62 (1H,
011,0 CH, in).
218
CA 02936408 2016-06-29
[ 0 7 6 5 ]
[Table 1-16]
HC *
1H-NMR (DMSO-06) 8:1.23 (3H, t, J = 7.7
CI
Hz), 1.54 (3H, s), 2.70 (2H, q, J = 7.7 Hz),
,c_NN., 4 ri
3.36 (3H, s), 4.32-4.45 (2H, m), 7.44-7.54
1-1 21 495 493
\Wf ki pi-1
(3H, m), 7.61 (1H, d, J = 8.4 Hz), 7.67 (1H, s),
HO
\;73 8.13-8.19 (2H, m), 9.03 (1H, t, J = 6.3 Hz),
0
, FF 13.31 (1H, br s).
CH.
0 1H-NMR (DMSO-D6) 6: 0.99 (3H, t, J = 7.4
' Hz), 1.38 (6H, s), 1.76 (2H, m), 4.04 (2H, t, J
1-122
= 6.6 Hz), 4.36 (2H, d, J = 5.8 Hz), 7.07 (2H,
,_,,,,, c,
509 507
d, J = 8.8 Hz), 7.40 (1H, d, J = 6.0 Hz), 7.57
H (1H, d, J= 6.0 Hz), 7.62 (1H, s), 8.29 (2H, d,
HO r..__IGH,
J= 8.8 Hz), 8.63 (1H, s), 13.14 (1H, s).
O'H,G7F
1H-NMR (DMSO-D6) 8:1.00 (6H, d, J = 6.9
H,.....,-H4
Hz), 1.54(3H, s), 1.98-2.12 (1H, m), 3,36
GI
-N (3H, s), 3.86 (2H, d, J = 6.2 Hz), 4.30-4.45
1-123 N , * (2H, m), 7.09 (2H, d, ,J = 8.5 Ft), 7.44 (1H, d, 539
537
X-' N
HO 11 "CH J = 8.5 Hz), 7.59 (1H, d, J = 8.5 Hz), 7.66
(1H, br s), 8.30 (2H, d, J = 8.9 Hz), 9.03 (1H,
O F F ,F t, J = 6.2 Hz), 13.14 (1H, br s).
F 1H-NMR (DMSO-D6) 5: 1.21 (3H, t, J = 7.6
11,0 *
Hz), 1.38(6H, s), 2.71 (2H, q, J = 7.6 Hz),
c
4.37 (2H, d, J = 6.0 Hz), 7.33 (1H, t, J = 9.3
1-124 N)=N IP Hz), 7.44 (1H, dd, J = 8.5,2.1 Hz), 7.59-7.66 497
495
H
HO i_14: (2H, m), 8.21-8.26 (1H, m), 8.30 (1H, dd, J =
7.7, 2.2 Hz), 8.65 (1H, t, J = 6.0 Hz), 13.35
0 F
F F (1H, br 3).
F
1H-NMR (DMSO-D6) 5: 1.75-2.00 (2H, m),
c, 2.28-2.43 (5H, m), 2.45-2.61 (2H, m), 4.40
-=N 1-1 2 5 ,,,, (2H, d, J = 5.7 Hz), 7.33 (1H, t, J = 9.1 Hz),
.
7.46 (1H, dd, J = 8.4, 1.8 Hz), 7.63 (1H, d, J = 495 493
HO
8.4 Hz), 7.66 (1H, br s), 8.19-8.32(2H, m),
F 8.81 (1H, t, J = 5.7 Hz), 13.33 (1H, br s).
F F
'
F F
F
1H-NMR (DM50-D6) 8:1.54 (3H, s), 3.36
(3H, s), 4.32-4.46 (2H, m), 7.48 (1H, dd, J =
c,
8.4, 1.6 Hz), 7.63 (1H, d, J = 8.4 Hz), 7.68
1-1 2 6 535 533 N)_,,,, *
H GH, (1H, br s), 7.94 (2H, d, J = 8.4 Hz), 8.53 (2H,
HO NO\.) d, J = 8.4 Hz), 9.04 (1H, t, J = 6.0 Hz), 13.56
0 F (1H, br S).
F F
F
H,C
1H-NMR (DMSO-D6) 6: 1.20-1.39 (4H, m),
ci 2.32 (3H, s), 4.35 (2H, d, J = 5.9 Hz), 7.33
---'tN (1H, t, J = 9.1 Hz), 7.45 (1H, dd, J = 8.4, 1.8
1-127 "/, *
Hz), 7.61 (1H, d, J = 8.4 Hz), 7.64(1H, s), 481 479
HO lk._>,
8.18-8.31 (2H, m),13.48 (1H, t, J = 5.9 Hz),
OnvF 13.32 (1H, br S).
F F
H,C-c0
g_ 1H-NMR (DMSO-D6) 5: 0.41 (2H, dd, J =
5.8, 4.0 Hz), 0.55 (2H, dd, J = 5.2, 4.0 Hz),
CI
N 1.19 (3H, s), 1.38 (6H, s), 3.87 (2H, s), 4.36
1-1 2 8 N (2H, d, J = 5.8 Hz), 7.07 (2H, d, J = 8.9 Hz), 535
533
HO 1 CH 7.41 (11-1, d, J = 7.3 Hz), 7.58 (1H, d, J = 7.3
V", Hz), 7.63 (1H, s), 8.29 (2H, d, J = 8.9 Hz),
0 F
F F 8.64 (1H, t, J = 5.8 Hz), 13.14 (1H, s).
219
CA 02936408 2016-06-29
[0766]
[Table 1-17]
H3C
1H-NMR (DMSO-D6) 5:1.39 (6H, s), 2.43
ci-
0 (3H, s), 4.37 (2H, d, J = 6.0 Hz), 7.44 (1H, d,
1-129 NI N, 0 J = 8.4 Hz), 7.55 (1H, d, J = 8.4 Hz), 7.61
499 497
F (1H, d, J = 8.4 Hz), 7.64 (1H, s), 8.20 (1H, dd,
HO N\---FJ = 8.4, 1.5 Hz), 8.31 (1H, d, J = 1.5 Hz), 8.64
OH,c CH3 (1H, t, J = 6.0 Hz), 13.39 (1H, br s).
,
F 1H-NMR (DMSO-D6) 6: 1.30 (6H, d, J = 6.7
F),ak
5.8 Hz), Hz), 1.38 (6H, s), 4.37 (2H, d, J H,c =
H,0 CI 7.43(1k, dd, J = 8.4, 2.0 Hz), 7.60 (1H, d, J =
1-130 N
N \ . 8.4 Hz), 7.65 (1H, d, J = 2.0 Hz), 7.83 (1H, d, 561
559
)=N H F J = 8.4 Hz), 8.29 (1H, d, J = 8.4 Hz), 8.52
110
NF
(1H, s), 8.63 (1H, t, J = 5.8 Hz), 13.55 (1H, br
OH,c CH, s).
. .
H,C' g_ 1H-NMR (DMSO-D6) 6: 0.94 (3H, t, J = 7.3
a Hz), 1.38 (6H, s), 1.45 (2H, m), 1.69-1.76
,,c,)__tz
(2H, m), 3.17 (2H, d, J = 5.1 Hz), 4.08(2H,
1-131 N 523 521
H m), 4.37 (2H, d, J = 5.8 Hz), 7.10 (2H, d, J =
N CH,
HO (cu, 9.1 Hz), 7.44 (1H, s), 7.60 (m, s), 8.31 (2H, d,
0 )\---F J = 9.1 Hz), 8.64(1k, s), 13.14 (1H, s).
FE
H'C\ -0
1H-NMR (DMSO-D6) 5:1.35 (3H, t, J = 7.1
Hz), 1.37 (6H, s), 4.13 (2H, q, J = 7.1 Hz),
4.35 (2H, d, J = 6.0 Hz), 7.07 (2H, d, J = 8.8
1-132 N N')--4 495 493
)=N H Hz), 7.42 (aH, brs), 7.60 (2H, brs), 8.29 (2H,
HO ik C),;_,,,, d, J = 8.8 Hz), 8.62 (1H,t, J = 6.0 Hz), 13.13
1 F (1H, s).
FE
<:L Z 1H-NMR (DMSO-D6) 5:0.34 (2H, m), 0.57
(2H, m), 1.23(1k, m), 1.37 (6H, s), 3.92 (2H, --._ CI d, J = 6.7 Hz), 4.35
(2H, d, J = 6.0 Hz), 7.07
1-133 521 519
N' * (2H, s), 7.42(1k, s), 7.59 (2H, s), 8.28 (2H, d,
>F=FN
HO PN CH, J = 9.1 Hz), 8.62 (1H, t, J = 6.0 Hz), 13.13
11,-F (1H, s).
F F
HO
1H-NMR (DMSO-D6) 5:1.38 (6H, s), 4.36
q... ci (2H, d, J = 5.8 Hz), 6.90 (2H, d, J = 8.8 Hz),
N
1-134 74 \ 4,
)--N H 7.42 (1H, d, J = 8.6 Hz), 7.59 (1H, d, J = 8.6 467
465
HO 'j CH3 Hz), 7.64 (1H, s), 8.23(2k, d, J = 8.8 Hz),
O te-HF' 8.64(1H, t, J = 5.8 Hz), 10.46 (1H, s).
, F
F
1H-NMR (DMSO-D6) 5. 0.74-0.87 (2H, m),
1.01-1.09 (2H, m), 1.38 (6H, 5), 2.07-2.15
1)-4_ a
N (1H, m), 4.37 (2H, d, J = 6.0 Hz), 7.33 (1H, t,
1-135 N' \ It
)=N J = 9.3 Hz), 7.44 (1H, d, J = 8.2 Hz), 7.61 509 507
HO Ill CH, (1H, d, J = 8.2 Hz), 7.65 (1H, s), 7.96 (1H, dd,
.C__H J = 7.4, 1.9 Hz), 8.15-8.21 (1H, m), 8.64 (1H,
O
F F F I, J = 6.0 Hz), 13.33 (1H, br s).
CI
1H-NMR (DMSO-D6) 6: 1.54 (3H, s), 2.42
ci (3H, s), 3.36(3k, s), 4.32-4.45 (2H, m), 7.46
1-136
c" to. (1H, dd, J = 8.4,2.0 Hz), 7.58-7.68 (3H, m),
515 513
H PH, 8.16 (1H, dd, J = 8.4, 2.0 Hz), 8.30 (1H, d, J =
2.0 Hz), 9.04 (1H, t, J = 6.2 Hz), 13.39 (1H, br
0 F F F s).
220
CA 02936408 2016-06-29
[0 7 67 ]
[Table 1-1E]
1H-NMR (DMSO-D6) 5: 0.99 (3H, t, J = 7.4
H,C--r- Hz), 1.54(3K, s), 1.71-1.81 (2H, m),
C , 3.36 (3H, s), 4.04 (2H, 1, J = 6.6 Hz), 4.32-
1-137 N ' N\ *
>=N H 4.43 (2H, m), 7.07 (2H, d, J = 9.0 Hz), 7.42
(1H, dd, J = 8.3, 1.9 Hz), 7.58 (1H, d, J = 8.3 525 523
HO N-CH,
...CH Hz), 7.65 (1H, d, J = 1.9 Hz), 8.29 (2H, d, J =
o F F
9.0 Hz), 9.03 (1H, t, J= 6.6 Hz), 13.15 (1H, br
F
s).
OF
HC- 1H-NMR (DM50-D6) 8:1.54 (3H, s), 2.01
(3H, t, J = 19.0 Hz), 3.36 (3H, s, J . 8.8 Hz),
a 4.38 (2H, dd, J = 6.3, 2.8 Hz), 7.44 (1H, dd, J
1-138 N ' * = 8.4,2.1 Hz), 7.60 (1H, d, J = 8.4 Hz), 7.66 531
529
-CH CI H, d, J = 2.1 Hz), 7.73 (2H, d, J = 8.4 Hz),
8.42 (2H, d, J = 8.4 Hz), 9.03 (1H, t, J = 6.3
0
F FF Hz), 13.47 (1H, s).
CH,
d
1H-NIVR (DMSO-D6) 5:1.38 (6H, s), 3.86
(3H, s), 4.37 (2H, d, J = 6.0 Hz), 7.10 (2H, d,
'----( c,
1-139 IV '1, .1, J = 8.8 Hz), 7.42 (1H, d, J = 8.6 Hz), 7.59
481 479
)=N
H (1H, d, J = 8.6 Hz), 7.64 (1H, s), 8.32 (2H, d,
HO t,, ICHen, J = 8.8 Hz), 8.63 (1H,1, J = 6.0 Hz), 13.15
0)O-F (1H, s).
F F
.a0
)¨cry
1H-NMR (DM50-06) 6:1.31 (6H, d, J = 6.0
Hz), 1.38 (6H, s), 4.37(2K, d, J = 5.8 Hz),
.--_ a
4.77 (1H, m), 7.06 (2H, d, J = 8.8 Hz), 7.41
1-140 509 507
N (1H, d, J = 8.4 Hz), 7.59 (1H, d, J = 8.4 Hz),
)=N
N').¨}1 CH
F+3 c.:2. 7.64 (1H, s), 8.29 (2H, d, J = 8.8 Hz), 8.63
(1H, t, J = 5.8 Hz), 13.13 (1H, s).
0 F
FF
. . .
oP
1H-NM R (DMSO-D6) 5:1.38 (6H, s), 1.66
(2H, m), 1.85 (2H, m), 2,07 (2H, m), 4.36 (2H,
ik_ c d, J = 5.8 Hz), 4.81 (1H,m), 6.98 (2H, d, J =
1-141 k1 521 519
N 8.8 Hz), 7.40 (1H, d, J . 7.9 Hz), 7.57 (11-I, d,
)='4?-
HO CH J . 7.9 Hz), 7.62 (1H, s), 8.28 (2H, d, J . 8.8
c'H, Hz), 8.63 (1H, t, J = 5.8 Hz), 13.14 (1H, s).
0 --F
, F
F
F.,,.,,c,
11-I-NIVR (DMSO-D6) 5: 1.38 (6H, s), 2.83
1-142 q¨ (2H, td, J = 11.3, 5.5 Hz), 4.33 (2H, t, J = 5.8
Hz), 4.37 (2H, d, J = 6.0 Hz), 7.12 (2H, d, J =
µF
563 561
8.8 Hz), 7.43 (1H, s), 7.58(1K, s), 7.64(1K,
I.K.1, S) , 8.32 (2H, d, J . 8.8 Hz), 8.64 (1H, d, J =
o cHF3 6.0 Hz), 13.18 (1H, s).
F F
1H-NMR (DMSO-D6) 6: 1.38 (3H, s), 1.39
0 (6H, s), 4.18 (2H, s), 4.32 (2H, d, J = 5.8 Hz),
k a 4.37 (2H, d, J = 5.8 Hz), 4.51 (2H, d, J = 5.8
1-143 Hz), 7.15(2K, d, J = 8.8 Hz), 7.43 (1H, d, J = 551
549
_
HO csH' 7.7 Hz), 7.60 (11-1, d, J = 7.7 Hz), 7.64(1K, s),
8.33 (2H, d, J = 8.8 Hz), 8.64(1K, t, J = 5.8
o -F
F0 Hz), 13.17 (1H, s).
H,c- ,---"0 1H-NMR (DM50-D6) 5: 1.38 (6H, s), 3.32
(3H, s), 3.69 (2H, t, J = 4.4 Hz), 4.21 (2H, 1, J
C_Ft, = 4.4 Hz), 4.37 (2H, d, J = 5.8 Hz), 7.11 (2H,
1-144 d, J = 8.8 Hz), 7.42 (1H, d, J = 8.1 Hz), 7.60 525
523
H0.>"7¨¨r.,, c, (1H, d, J = 8.1 Hz), 7.64 (1H, s), 8.31 (2H, d,
_c..."= J = 8.8 Hz), 8.63 (1H, d, J = 5.8 Hz), 13.15
0 F
F. F (1 H, s).
221
CA 02936408 2016-06-29
[0768]
[Table 1-19]
1H-NIVIR (DMSO-D6) 5: 0.91 (3H, t, J = 7.6
H,0Wo
Hz), 1.38 (6H, s), 130 (2H, q, J = 7.6 Hz),
o C_
4.21 (2H, s), 4.35 (2H, d, J = 6.0 Hz), 4.37
1-145 IV' ')---, (2H, d, J = 5.8 Hz), 446 (2H, d, J = 6.0 Hz),
565 563
)=N 7.15 (2H, d, J . 8.8 Hz), 7.42 (1H, d, J = 8.4
HO H CH
Hz), 7.59 (1H, d, J = 8.4 Hz), 7.64 (1H, s),
0 ).--F 8.32 (2H, d, J = 8.8 Hz), 8.64 (1H, t, J =5.8
, F
Hz), 13.17 (1H, s).
V ( 1H-NMR (DMSO-D6) 8:1.38 (6H, s), 1.84
CI (3H, t, J = 2.2 Hz), 4.37 (2H, d, J = 5.8 Hz),
1-146
4.87 (2H, d, J = 2.2 Hz), 7.12 (2H, d, J = 8.8
'c N\ * 519 517
H Hz), 7.43 (1H, d, J= 8.4 Hz), 7.60 (1H, d, J=
HO N 8.4 Hz), 7.65 (1H, s), 8.32 (2H, d, J = 8.8 Hz),
0 ).---F 8.64. (1H, 1, J = 5.8 Hz), 13.17 (1H, s).
F ,
F F
F
1H-NMR (DM00-D6) 5: 1.38 (6H, s), 2.53
H,C4 (3H, s), 4.37 (2H, d, J =6.0 Hz), 7.42 (1H, dd,
0;
J = 8.1,2.1 Hz), 7.59 (1H, d, J = 8.1 Hz), 7.63
1-147 N e
533 531
(1H, d, J= 2.1 Hz), 7.84(1H, d, J= 8.1 Hz),
HO 01 CH, 8.30 (1H, d, J = 8.1 Hz), 8.34 (1H, s), 8.64
0, 1.CH ,
(1H, t, J = 6.0 Hz), 13.53 (1H, br s).
F F F
Fr
F
1H-NMR (DMSO-D6) 8:1.54 (3H, s), 2.54
ri,o. (3H, s), 3.36 (3H, s), 4.33-4.44 (2H, m), 7.47
k (1H, dd, J = 8.3, 2.0 Hz), 7.62 (1H, d, J = 8.3
1-148 549 547
N ut...' . _
Hz), 7.66 (1H, d, J = 2.0 Hz), 7.86 (1H, d, J --
--(coc,''' 8.3 Hz), 8.31 (1H, d, J = 8.3 Hz), 8.35 (1H, s),
0 9.04 (1H, t, J = 6.4 Hz), 13.53 (1H, br s).
FTH
F F
F
1H-NMR (DMSO-D6) 5: 1.22-1.36(4H, m),
1-149 H
H,C.__ 2.53 (3H, s), 4.34 (2H, d, J = 6.0 Hz), 7.40
a
(1H, dd, J = 8.4,2.1 Hz), 7.57 (1H, d, J= 8.4
531 529
Hz), 7.61 (1H, d, J . 2.1 Hz), 7.82 (1H, d, J =
HO 8.4 Hz), 8.30(1K, d, J = 8.4Hz), 8.34 (1H, s),
,
8.47 (1H, t, J = 6.0 Hz), 13.53 (111, br s).
rµor-'FF
HC
1H-NMR (DM00-D6) 8:1.38 (6H, s), 2.31
_c_.,, (3H, s), 2.32 (3H, s), 4,37 (2H, d, J = 6.0 Hz),
1-150
N` N 7.33 (1H, d, J = 8.2 Hz), 7.43 (1H, d, J = 8.2 479
)=
H Hz), 7.58-7.67 (2H, m), 8.07 (1H, d, J = 8.2 477
<xt
HO ' ¨N CH, H, Hz), 8.12 (1H, s), 8.65 (1H, t, J= 6.0 Hz),
o 13.23 (1H, br s).
F F
F
1H-NMR (DMSO-D6) 5:1.21 (3H, t, J = 7.5
F1,0 *
Hz), 1.54 (3H, s), 2.71 (2H, q, J = 7.5 Hz),
ci
3.36 (3H, s), 4.32-4.45 (2H, m), 7.33 (1H, t, J
N\
1-151 CH= 9.3 Hz), 7.46 (1H, dd, J = 6.4, 2.0 Hz), 7.61 513
511
HO N _6 (1H, d, .1= 8.4 Hz), 7.66 (1H, s), 8.20-8.26
\ ". (1H, m), 8.29 (1H, dd, J . 7.6, 2.3 Hz), 9.04
0 F
F F (1H, t, J = 6.3 Hz), 13.35 (1H, br s).
F
H,C . 1H-NMR (DMS0-D6) 5: 1.19-1.27(5H, m),
1.32-1.37 (2H, m), 2.71 (2H, q, J = 7.5 Hz),
c
4.35 (2H, d, J = 6.0 Hz), 7.33 (1H, t, J = 9.2
is, ,
1-152 )---N H Hz), 7.45 (1H, dd, J = 8.4, 2.0 Hz), 7.61 (1H, 495
493
HO d, J = 8.4 Hz), 7.65 (1H, s), 8.21-8.26 (1H,
m), 8.30 (1H, dd, J = 7.5, 2.0 Hz), 8.48 (1H, t,
IKF
F F J= 6.0 Hz), 13.34 (1H, br s).
222
CA 02936408 2016-06-29
[0769]
[Table 1-20]
F
1H-NMR (DMSO-D6) 8:1.39 (6H, s), 4.37
(2H, d, J = 6.0 Hz), 7.45 (1H, dd, J = 8.3,2.1
. 1-1 5 3 N>---i?q_cl Hz), 7.59-7.66 (3H,
m), 8.32-8.38 (1H, m), 503 501
HO 4., 8.45 (1H, dd, J = 7.4, 2.1 Hz), 8.65 (1H, t, J =
o p 6.0 Hz), 13.48 (OH, br s).
F r
H,C--\_. 1H-NMR (DMSO-D6) 6: 0.99 (3H, t, J = 7.4
Hz), 1.22-1.27 (2H, m), 1.31-1.37 (2H, m),
1.71-1.81 (2H, m), 4.04 (2H, t, J = 6.5 Hz),
1-1 54 4.34 (2H, d, J = 6.0 Hz), 7.09 (2H, d, J =
9.0
507 505
=N H
)
Hz), 7.43 (1H, dd, J = 8.4, 2.0 Hz), 7.59 (1H, "1"/
HO Fi)_____ d, J = 8.4 Hz), 7.64 (1H, s), 8.31 (2H, d, J =
O , 9.0 Hz), 8.47 (1H, t, J = 6.0 Hz),
13.14 (1H, br
F0 s).
CH, 1H-NMR (DMSO-D6) 6: 0.90 (3H, t, J = 7.3
H,0--'0 Hz), 1.27 (3H, d, J = 6.0 Hz), 1.37 (6H,$),
1.43 (2H, m), 1.52-1.60 (1H, m), 1.67 (1H,
m), 4.37 (2H, d, J = 5.8 Hz), 4.62 (1H, m),
1-1 5 5 537 535
7.07 (2H, d, J = 9.1 Hz), 742 (1H, d, J = 8.1
>=N
HO on Hz), 7.59 (1H, d, J = 8.1 Hz), 7.64 (1H, s),
CH
8.29 (2H, d, J = 9.1 Hz), 8.63 (1H, t, J = 5.8
F= F Hz), 13.13 (1H, s).
OH, 1H-NMR (DMSO-D6) 6:0.90 (3H, t, J = 7.3
Hz), 1.27 (31-1, d, J = 6.0 Hz), 1.36 (6H, s),
1.43(211, m), 1.51-1.60 (1H, m), 1.65 (1H,
m), 4.37 (2H, d, J= 5.8 Hz), 4.62 (1H, m),
1-1 5 6 537 535
7.06 (2H, d, J = 8.8 Hz), 741 (1H, d, J = 8.1
m c,11: Hz), 7.59 (1H, d, J = 8.1 Hz), 7.64 (1H, s),
O -1' 8.29 (211, d, J = 8.8 Hz), 8.63 (1H,
t, J = 5.8
F F Hz), 13.13 (1H, s).
F 1H-NMR (DMSO-06) 6:0.77-0.83 (2H, m),
= . 1.02-1.08(2H, m), 1.22-1.27(2H, m),
a 1.31-1.36 (2H, m), 2.07-2.15 (1H, m), 4.34
iscN, if (2H, d, J = 5.8 Hz), 7.33 (1H, t, J = 9.3 Hz),
507 505
1-1 5 7
¨N 7.44(1H, d, J= 8.4 Hz), 7.60(1H, d, J = 8.4
H
HO Hz), 7.65 (1H, s), 7.96 (1H, d, J = 7.9 Hz),
K, 8.15-8.20 (1H, m), 8.47 (1H, t, J = 5.8 Hz),
F F 13.31 (1H, br s).
H,c,-...0
1H-NMR (DMSO-D6) 6: 0.99(311, t, J = 7.5
Hz), 1.21 (6H, s), 1.76 (2H,m), 3.03(2H, s),
(),I._ a
4.04 (2H, t, J = 6.5 Hz), 4.40 (2H, s), 7.09
1-158 453 451
11 .--1.)-k
CH
(2H, d, J = 8.9 Hz), 7.47 (1H, d, J = 8.3 Hz),
HO N?' 7.65 (1H, d, J = 8.3 Hz), 7.67 (1H, s), 8.31
. OH. (2H, d, J = 8.9 Hz), 13.14 (1H, s).
= 111 1H-NMR (DMSO-D6) 6: 0.72-0.77 (211,
m),
ci
1-1 5 9
0.97-1.04 (2H, m), 1.38 (6H, s), 1.99-2.07
-= (1H, m), 4.37 (2H, d, J = 6.0 Hz), 7.34-7.45
491 489
HO N CH, (3H, m), 7.59 (1H, d, J = 8.4 Hz), 7.65 (1H, s),
K;2-13 8.03 (1H, s), 8.10 (1H, d, J = 7.7 Hz), 8.64
0 F
F F (1H, t, J = 6.0 Hz), 13.32 (1H, br s).
= . 1H-NMR (DMSO-D6) 6: 0.72-0.78 (2H, m),
ci 0.98-1.04 (2H, m), 1.21-1.27 (2H, m), 1.31-
N, N., . 1.36 (2H, m), 2.00-2.07 (1H, m), 4.34 (2H,
d,
1-160 =)--N H J = 5.8 Hz), 7.35-
7.46 (3H, m), 7.60 (1H, d, J 489 487
HO = 8.1 Hz), 7.66 (1H, s), 8.03 (1H, s), 8.10 (1H,
0 F d, J = 7.4 Hz), 8.47 (1H, t, J = 5.8 Hz), 13.30
F F (1H, br s).
,
223
CA 02936408 2016-06-29
[0770]
[Table 1-211
1H-NMR (DM,SO-D6) 6: 1.32-1.38(9K, m),
2.55 (3H, s), 4.10 (2H, q, J = 7.2 Hz), 4.35
'(,_ a
1-1 61 HC et, (2H, d, J = 5.8 Hz), 6.86-6.92 (2H, m), 7.39
509 507
,, (1H, d, J = 8.6 Hz), 7.56 (1H, d, J= 8.6 Hz),
HO N CH, 7.62 (1H, s), 7.81 (1H, br s), 8.61 (1H, t, J --
,: -F
O--", 5.8 Ft), 13.08 (1H, br s).
F F
1H-NMR (DMSO-D6) 5:0.35 (2H, q, J = 5.1
/-0
<I ,(:_ Hz), 0.57-0.60 (2H, m), 1.22-1.30 (1H, m),
ci 1.54 (3H, s), 3.36 (3H, s), 3.93 (2H, d, J = 7.0
,,,õ Jr', * Hz), 4.37 (2H, dd, J = 5.9, 2.9 Hz), 7.07 (2H,
537 535
1-162
H CH
d, J = 8.8 Hz), 7.42(1H, d, J = 8.4 Hz), 7.58
..,
HO U:CH, (1H, d, J = 8.4 Hz), 7.65 (1H, s), 8.29(2K, d,
o' ,)(F J = 8.8 Hz), 9.02 (1H, t, J = 5.9 Hz), 13,14
F (1H, br s).
0
c 1H-NMR (DMSO-D6) 6: 0.33-0.37 (2H, m),
0.57-0.61 (2H, m), 1.22-1.35 (5H, m), 3.92
(2H, d, J = 7.0 Hz), 4.33 (2H, d, J= 5.8 Hz),
1-163 /....P,1,>____Iz
7.05 (2H, d, J = 8.8 Hz), 7.39 (1H, dd, J = 8.3, 519 517
H 1.9 Hz), 7.55 (1H, d, J= 8.3 Hz), 7.61 (1H, d,
HO
'53 J = 1.9 Hz), 8.28 (2H, d, ..I= 8.8 Hz), 8.46
o F F (1H, t, J = 5.8 Hz), 13.15(1H, br s).
,Hz...
111-NMR (DM30-06) 6: 1.05 (2H, m), 1.10
(2H, m), 1.38(6H, s), 4.20 (2H, s), 4.34 (2H,
. d, J = 5.6 Hz), 7.02 (2H, d, .1 = 7.9 Hz), 7.32
1-164 589 587
(1H, d, J = 7.5 Hz), 7.49 (1H, d, J = 7.5 Hz),
HO P.,.. 7.56 (1H, s), 8.26 (2H, d, J = 7.9 Hz), 8.61
r-V-73 (1H, t, J = 5.6 Hz), 13.18(1H, s).
F
11-1-NMR (DM50-D6) 6: 0.77-0.82 (2H, m),
1.01-1.07 (2H, m), 1.54 (3H, s), 2.07-2.15
.
(1H, m), 3.35(3K, s), 4.31-4.44 (2H, m), 7.32
1-165 II' \ 1,
)=N H pi% (1H, t, J = 9.3 Hz), 7.44 (1H, d,
J = 8.4 Hz), 525 523
HO 7.60 (1H, d, J = 8.4 Hz), 7.67 (1H, s), 7.95
(1H, d, J = 7.2 Hz), 8.14-8.19 (1H, m), 9.02
0 F
F F (1H, t, J = 6.3 Hz), 13.31 (1H, br s).
.(._o 1H-NMR (DM50-D6) 6: 0.33-0.38 (2H, m),
0.56-0.62(2K, m), 1.19-1.31 (7H, m), 2.59
(2H, q, J = 12.1 Hz), 3.93 (2H, d, J = 7.1 Hz),
1-166 C: 4.33 (2H, d, J = 6.0 Hz), 7.07 (2H, d, J = 9.0 535
533
q.. F F Hz), 7.42 (1H, d, J = 8.4 Hz), 7.58 (1H, d, J =
Fio U, (j:J., 8.4 Hz), 7.63 (1H, s), 8.29 (2H, d, J = 9.0
Hz),
CI CHõ 8.35 (11-I, t, J = 6.0 Hz), 13.14 (11-1, br s).
. . . .
I>--¨o 1H-NMR (DMSO-D6) 5:0.11-0.16 (2H, m),
0.41-0,48(2K, m), 0.79-0.90 (11-1, m), 1.38
1-1 6 7
(6H, s), 1.65 (2H, q, J = 6.5 Hz), 4.14 (2H, t, J
c
g-N
Flµ * = 6.5 Hz), 4.37 (2H, d, J = 6.0 Hz), 7.09 (2H,
d, J = 9.0 Hz), 7.41 (1H, dd, J = 8.4, 2.0 Hz), 535 533
HO " cH, 7.59 (1H, d, J = 8.4 Hz), 7.64(1K, d, J = 2.0
(c_H3 Hz), 8.30 (2H, d, J = 9.0 Hz), 8.64 (1H, t, J =
0 F
F F 6.0 Hz), 13.15(1K, br s).
<-.13 1H-NMR (DMSO-D6) 6: 0.32-0.38 (2H, m),
0.56-0.62 (2H, m), 1.01 (3H, s), 1.12 (3H, s),
1.19-1.30 (1H, m), 1.78-1.85 (2H, m), t 493 1.90-
--_ ci 1.97 (2H, m), 2.95-3.05 (11-I, m), 3.93 (2H, d,
1-1 68 491
J = 7.0 Hz), 4.30 (2H, d, J = 6.0 Hz), 7.08
',), H (2H, d, J = 8.6 Hz), 7.43 (1H, d, J = 8.4 Hz),
HO CH 7.58 (1H, d, J = 8.4 Hz), 7.62 (1H, s), 8.25-
o CH, 8.32 (3H, m), 13.13 (1H, br s).
224
CA 02936408 2016-06-29
[ 0 7 7 1 ]
[Table 1-22]
1H-NMR (DMSO-D6) 6: 0.32-0.38 (2H, m),
0.55-0.62 (2H, m), 1.20-1.29 (1H, m), 1.74
g
(3H, s), 3.93 (2H, d, J = 6.7 Hz), 4.43 (2H, d, _ GI
1 -1 69 J = 6.0 Hz), 7.07 (2H, d, J = 8.4 Hz), 7.41 575
573
F;_c,F3 (1H, d, J = 8.4 Hz), 7.60 (1H, d, J = 8.4 Hz),
HO
rsk 7.65 (1H, s), 8.29 (2H, d, J = 8.4 Hz), 9.10
0 ,..-F (1H, t, J = 6.0 Hz), 13.14 (1H, br s).
F F
.(--0 1H-NMR (DMSO-06) 6: 0.33-0.38 (2H, m),
0.56-0.62 (2H, m), 1.20-1.31 (1H, m), 1.57-
1.90 (6H, m), 1.97-2.09 (2H, m), 2.29-2.39
'--_ c (1H, m), 3.93 (2H, d, J = 7.1 Hz), 4.31-4.33
1-170 529 527
NJ/ \ le (2H, br m), 7.08 (2H, d, J = 8.8 Hz), 7.44 (1H,
)=N H d, J = 8.4 Hz), 7.58 (1H, d, J = 8.4 Hz), 7.64
HO l'0(F (11-1, s), 8.29 (2H, d, J -8.8 Hz), 8.50 (1H, t, J
F = 6.0 Hz), 13.14 (1H, br s).
<L0 1H-NMR (DMSO-D6) 6: 0.33-0.38 (2H, m),
0.56-0.62 (2H, m), 0.79 (6H, t, J = 7.5 Hz),
1.20-1.54 (5H, m), 1.98-2.07 (1H, m), 3.94
()µIt.. - (2H, d, J = 7.1 Hz), 4.34 (2H, d, J = 6.0 Hz),
1-171 481 479
7.08 (2H, d, J = 9.0 Hz), 7.46 (1H, d, J = 8.2
Hz), 7.60 (1H, d, J = 8.2 Hz), 7.66 (1H, s),
8.29 (2H, d, J = 9.0 Hz), 8.46 (1H, t, J = 5.7
0 CH, Hz), 13.14 (1H, br s).
go 1H-NMR (DMSO-D6) 8:0.99-1.33 (5H, m),
1.38 (6H, s), 1.62-1.86 (6H, m), 3.89 (2H, d, J
= 6.2 Hz), 4.36(2H, d, J = 6.0 Hz), 7.06 (2H,
1-172
0)._ Cr
,,,' l' * d, J = 9.0 Hz), 7.40 (1H, dd, J = 8.4, 2.0 Hz), 563
561
)=" 7.57 (1H, d, J = 8.4 Hz), 7.62 (1H, d, J = 2.0
HO N CH, Hz), 8.29 (2H, d, J = 9.0 Hz), 8.64 (1H, t, J =
6.0 Hz), 13.15 (1H, br s).
F F
<LO 1H-NMR (DSO-D6) 0:0.33-0.37 (2H, m),
0.56-0.62 (2H, m), 1.11 (6H, s), 1.17 (6H, s),
1.20-1.29 (2H, m), 3.93 (2H, d, J = 7.1 Hz),
1-173 4.29 (2H, d, J = 6.0 Hz), 7.07 (2H, d, J = 8.8 507
505
Hz), 7.43(1K, dd, J = 8.4, 2.0 Hz), 7.57(1K,
,v)_N
'4416 d, J = 8.4 Hz), 7.62 (1H, d, J = 2.0 Hz), 8.29
(2H, d, J = 8.8 Hz), 8.37 (1H, t, J = 6.0 Hz),
0
CH, 13.14 (1H, brs).
N 4
CH 1H-NMR (DMSO-D6) 0: 2.51 (3H, s), 7.49-
7.46 (3H, m), 7.63-7.60 (2H, m), 7.66 (1H, d,
1-174 J = 7.9 Hz), 7.77 (2H, d, J = 8.6 Hz), 7.96 389
387
(1H, d, J = 7.9 Hz), 8.22 (1H, s), 8.53 (2H, d,
OH J = 8.6 Hz), 13.46 (1H, s).
c(i)4H,
1H-NMR (DM5O-D6) 6: 0.36 (2H, td, J = 5.2,
3.9 Hz), 0.56-0.60 (2H, m), 1.23-1.30 (1H, m),
a
1.38 (6H, s), 2.21 (3H, s), 3.91 (2H, d, J = 6.7
1-175 .1)=-'1, 41), Hz), 4.34 (2H, d, J = 5.8 Hz), 6.97 (1H, d, J =
535 533
N
HO EF1 CH, 8.6 Hz), 7.29 (1H, dd, J = 8.3, 1.9 Hz), 7.47
(1H, d, J = 8.4 Hz), 7.53 (1H, d, J = 1.9 Hz),
F F F 8.08-8.14 (2H, m), 8.61 (1H, t, J = 5.8 Hz).
225
CA 02936408 2016-06-29
[0772]
[Table 1-23]
.ks_ 11-I-NMR (DMSO-D6) 8:0.30 (2H, td, J = 5.3,
4.0 Hz), 0.56 (2H, ddd, J = 9.2, 5.3, 3.1 Hz),
H C 1.22-1.27 (1H, m), 1.38 (6H, s), 2.29 (6H, s),
' -1q1 c 3.69 (2H, d, J = 7.0 Hz), 4.36 (2H, d, J = 5.8
1-176 N ' ¨,q_ Hz), 7.41 (1H, dd, J = 8.4, 1.9 Hz), 7.58 (1H, 549
547
)=N
HO RH H., d, J = 8.4 Hz), 7.61 (1H, d, J = 1.9 Hz), 8.02
!'., (2H, s), 8.64 (1H, t, J = 5.8 Hz), 13.18 (1H, br
O ,
F F S).
H,C
1H-NMR (DMSO-D6) 8:0.88 (6H, d, J = 6.4
H,C .
Hz), 1.54 (3H, s), 1.83-1.98 (1H, m), 2.55
CI (2H, d, J = 7.3 Hz), 3.36 (3H, s), 4.31-4.45
1-177 _
14,-N 4* H .CH. (2H, m), 7.35 (2H, d, J = 8.3 Hz), 7.45 (1H,
dd, J = 8.1, 2.0 Hz), 7.60 (1H, d, J = 8.1 Hz), 523 521
HO
NO,,Ils 7.67 (1H, br s), 8.26 (2H, d, J = 8.3 Hz), 9.03
O F
F H (1H, t, J = 6.2 Hz), 13.26 (1H, br s).
_CI, 1H-NM2 (DMSO-D6) 8:0.99 (6H, d, J = 6.4
'- Hz), 1,20-1.39 (4H, m), 1.96-2.13 (1H, m),
3.84 (2H, d, J = 6.4 Hz), 4.33 (2H, d, J = 6.0
1-178 Hz), 7.05 (2H, d, J = 9.1 Hz), 7.37 (1H, dd, J 521
519
8.3, 2.0 Hz), 7.54 (1H, d, J = 8.3 Hz), 7.60
(1H, d, J = 2.0 Hz), 8.28 (2H, d, J = 9.1 Hz),
OF 8.46 (1H, t, J = 5.8 Hz), 13.15 (1H, br S).
F F
H,C)0_o 1H-NA/R (DMSO-D6) 6: 0.94 (3H, s), 0.95
ri,c (3H, s), 1.27-1.36 (2H, m), 1.38 (6H, s), 1.41-
1.49 (2H, m), 1.56-1.66 (2H, m), 1.80-1.89
- )¨k N a (2H, m), 4.36 (2H, d, J = 5.7 Hz), 4.45-4.53
1-1 7 9 N µ 577 575
(1H, m), 7.07 (2H, d, J = 9.0 Hz), 7.40 (1H,
HO N c7H3. dd, J = 8.2, 2.0 Hz), 7.58 (1H, d, J = 8.2 Hz),
O'F'' 7.63 (1H, d, J = 2.0 Hz), 8.28 (2H, d, J = 9.0
O
F F Hz), 8.63 (1H, t, J = 6.1 Hz), 13.13 (1H, br s).
Isc
1I4NMR (DMSO-D6) 6: 0.91 (3H, t, J = 7.3
* c Hz), 1.27-1.37 (2H, m), 1.38 (6H, s), 1.55-
1.54 (2H, m), 2.67 (2H, t, J = 7.7 Hz), 4.37
1-180 N' \ * (2H, d, J = 6.0 Hz), 7.38 (2H, d, J = 8.2 Hz), 507
505
)==,, N HO CH, 7.42 (1H, d, J = 8.4 Hz), 7.59 (1H, dõ) = 8.4
OH, Hz), 7.64 (1H, s), 8.25 (2H, d, J = 8.2 Hz),
O
FIF 8.64 (1H, t, J = 6.0 Hz), 13.27 (1H, br s).
H,C
1H-NMR (DMSO-D6) 6: 0.90 (3H, t, J = 7.7
* Hz), 1.26-1.37 (21-I, m), 1.54 (3H, s), 1.55-
,,, ,,C1 1.64 (2H, m), 2.67 (2H, t, J = 7.7 Hz), 3.36
1-181 (3H, s), 4.32-4.44 (2H, m), 7.38 (2H, d, J = 523
521
7.5 Hz), 7.44 (1H, d, J = 8.4 Hz), 7.59 (1H, d,
.),--7o., J = 8.4 Hz), 7.66 (1H, s), 8.25 (2H, d, J = 7.5
F F Hz), 9.03 (1H, t, J = 6.2 Hz), 13.27 (1H, br s).
1H-N1- (DMSO-D6) 8:0.99 (6H, t, J = 6.0
,-.3.-1 Hz), 1.37 (6H, s), 2.00-2.10 (1H, m), 4.11
(2H, d, J = 6.5 Hz), 4.34 (2H, d, J = 6.0 Hz),
6.88 (1H, d, J = 8.7 Hz), 7.30 (1H, dd, J = 8.1,
1-182 524 522
2.1 Hz), 7.48 (1H, d, J = 8.1 Hz), 7.57 (1H, d,
No
= 2.1 Hz), 8.47 (1H, dd, J = 8.7, 2.4 Hz),
8.60 (1H, t, J = 6.0 Hz), 9.02 (1H, d, J = 2.4
F F
Hz).
,
1H-NMR (DMSO-D6) 8:1.24 (6H, s), 2.32
H,C-t))_ õ, CH, (3H, d, J = 1.3 Hz), 2.59 (2H, q, J = 12.1 Hz),
1-183
4.34 (2H, d, J = 6.2 Hz), 7.32 (1H, t, J = 9.2
Hz), 7.44 (1H, dd, J = 8.4, 2.0 Hz), 7.59 (1H, 497 495
1.=r,1\ * .
H CH, d, J = 8.4 Hz), 7.63 (1H, d, J = 2.0 Hz), 8.198.19-
0 8.25 (1H, m), 8.28 (1H, d, J = 7.7 Hz), 8.35
F F F (1H, t, J = 5.8 Hz), 13.33 (1H, br s).
226
CA 02936408 2016-06-29
[0773]
[Table 1-24]
1H-NMR (DMSO-D6) 6: 0.29-0.39 (2H, m),
0.47-0.55 (2H, m), 1.08-1.17 (1H, m), 1.32
H,C
(3H, d, J = 6.3 Hz), 1.38 (6H, s), 4.10-4.18
(1H, m), 4.36 (2H, d, J = 6.0 Hz), 7.05 (2H, d,
1-1 84 535 533
c,, J = 8.8 Hz), 7.41 (1H, d, J = 8.0 Hz), 7.58
HO (1H, d, J = 8.0 Hz), 7.63 (1H, s), 8.27 (2H, d,
c,''' Vir' J = 8.8 Hz), 8.63 (1H, t, J = 6.0 Hz), 13.13
F F (1 H, br s).
1H-NMR (DO-D6) 6: 0.29-0.39 (2H, m),
0.47-0.55(2H, m), 1.08-1.17(1H, m), 1.32
(3H, d, J = 6.3 Hz), 1.38 (6H, s), 4.10-4.18
CI (1H, m), 4.36 (2H, d, J = 6.0 Hz), 7.05 (2H, d,
1-1 85 . J = 8.8 Hz), 7.41 (1H, d, J = 8.0 Hz), 7.58 535
533
HO)=N c,1' (1H, d, J = 8.0 Hz), 7.63 (1H, s), 8.27 (2H, d,
O F
c", J = 8.8 Hz), 8.63(1K, t, J = 6.0 Hz), 13.13
F F (1H, br s).
F
1H-NMR (DO-D6) 6:1.37 (6H, s), 2.28
(3H, d, J = 1.2 Hz), 4.33 (2H, d, J = 6.0 Hz),
1186 N *
\ =N 7.15 (1H, t, J = 9.1 Hz), 7.22 (1H, dd, J
F
2.3 Hz), 7A1 (1H, d, J = 8.4 Hz), 7A9 (11-I, d, 505 503
N.* ci .LF J = 2.3 Hz), 8.10-8.16 (1H, m), 8.19 (1H, dd, J
0 ,,,Ch = 8.1, 1.6 Hz), 8.59 (1H, t, J = 6.0 Hz).
,
1-i I6V cb 1H-NMR (DO-D6) 6:1.02 (9H, s), 3.75
CH (2H, s), 4.57 (2H, d, J = 5.7 Hz), 5.42 (1H, t, J
Cl = 5.7 Hz), 7.10 (21-I, d, J = 8.8 Hz), 7.53 (1H,
1-1 8 7 400 398
,11¨NN . d, J = 8.4 Hz), 7.59(1H, d, J = 8.4 Hz), 7.71
)=INI (1H, s), 8.31 (2H, d, J = 8.8 Hz), 13.13 (1H, br
HO OH s).
F
1-188 HC-
1H-NMR (DNASO-D6) 0:1.45 (3H, d, J = 6.8
,
a Hz), 1.49 (3H, s), 2.32 (3H, s), 3.33 (3H, s),
N
N *
)=N ,4 p H, 5.02-5.10(1K, m), 7.32 (1H, t, J
= 9.3 Hz), 513 511
7.60 (2H, s), 7.76(1K, s), 8.18-8.24 (1H, m), 1
HO
CH 8.27 (1H, d, J = 6.8 Hz), 8.81 (11-I, d, J = 8.4
,,, ,.. ,
Hz), 13.32 (1H, s).
F F
F 1H-NMR (DMSO-D6) 0:1.46 (3H, d, J = 6.8
H,C- . Hz), 1.54 (3H, s), 2.31 (3H, s), 3.37 (3H, s),
5.02-5.11(1K, m),7.32 (11-1, t, J = 9.2 Hz),
1-189 7.54 (1H, d, J = 8.4 Hz), 7.61 (1H, d, J = 8.4 513
511 1
HO Hz), 7.72 (1H, s), 8.19-8.25 (1H, m), 8.28
:,/-\\52i,, (1H, d, J = 7.3 Hz), 8.83 (1H, d, J = 8.2 Hz),
F F 13.33 (1H, br s).
1H-NMR (DMSO-06) 6:0.33-0.37 (2H, m),
1901-
. N- O 0.56-0.62 (2H, m) , 1.21-1.30(1K, m), 2.85
(3H, br s), 2.90 (3H, br s), 3.94 (2H, d, J = 7.1 455
Hz), 5.13 (2H, s), 7.09 (2H, d, J = 8.6 Hz),
e µ1,44' h,Cl'-- ''' 7.56-7.67 (2H, br m), 7.78 (1H, br s), 8.30
OH
(2H, d, J = 8.6 Hz), 13.15 (1H, br s).
1H-NMR (DM50-D6) 6:1.30-1.40 (9H, m),
1.44-1.55 (3H, m), 1.64-1.74 (2H, m), 1.80-
1.88 (2H, m), 2.63-2.70 (1H, m), 4.33 (2H, d,
1-1 91 \ ci J = 6.0 Hz), 7.25 (1H, dd, J = 8.6, 2.1 Hz), 557
555
7.40-7.46 (3H, m), 7.52 (1H, d, J = 2.1 Hz),
"
HO N CH, 8.25 (2H, d, J = 8.1 Hz), 8.59 (11-1, t, J = 6.0
1 ,_C___HF, Hz).
F F
227
CA 02936408 2016-06-29
[07741
[Table 1-25]
0,_ 1H-NMR (DO-D6) 6: 0.35 (2H, dt, J = 7.9,
2.8 Hz), 0.57-0.61 (2H, m),
a 1.21-1.30 (1H, m), 3.94 (2H, d, J = 7.0 Hz),
1-192 )/-14,
11)
r'=N 7.09 (2H, d, J = 8.8 Hz), 398 396
7.77 (1H, d, J = 8.4 Hz), 8.09 (1H, dd, J = 8.4,
HO OH 1.6 Hz), 8.30 (2H, d, J = 9.0 Hz),
O 8.33 (1H, s), 13.31 (1H, s).
<r k 1H-NMR (DO-D6) 6:0.35 (2H, td, J = 5.2,
4.1 Hz), 0.56-0.62 (2H, m), 1.21-1.29 (1H, m),
a 3.94 (2H, d, J = 7.0 Hz), 7.08 (2H, d, J = 8.8
1-193 N Hz), 7.58 (1H, s), 7.74 (1H, d, J = 8.4 Hz), 397
395
Ni \
)=-N 8.06 (1H, d, J = 8.4 Hz), 8.17 (1H, s), 8.27
HO NH, (1H, d, J = 2.1 Hz), 8.31 (2H, d, J = 8.8 Hz),
O 13.14 (11-I, s).
<(-- _ 1H-NMR (DMSO-D6) 6: 0.35 (2H, q, J = 4.8
Hz), 0.57-0.61 (2H, m), 1.22-1.29 (1H, m),
a 2.81 (3H, d, J = 4.4 Hz), 3.94 (2H, d, J = 7.0
1-194 / N, Hz), 7.09 (2H, d, J = 8.8 Hz), 7.75 (1H, d, J = 411
409
Fµ=N H 8.4 Hz), 8.02 (1H, d, J = 8.1 Hz), 8.24 (1H, s),
HO N, 8.31 (2H, d, J = 8.8 Hz), 8.63-8.67 (1H, m),
O CH, 13.19 (1H, s).
o 1H-NMR (DMSO-06) 6:0.33-0,37 (2H, m),
0.57-0.61 (2H, m), 1.20-1.30 (1H, m), 2.95
a (3H, s), 3.00 (3H, s), 3.94 (2H, d, J = 7.0 Hz),
1-195 ¨1/ rs 4* 7.09 (2H, d, J = 8.8 Hz), 7.63 (1H, d, J = 9.1 425
423
)=N ,CH, Hz), 7.70 (1H, d, J = 8.1 Hz), 7.83 (1H, d, J =
HO N, 1.9 Hz), 8.30 (2H, d, J = 9.1 Hz), 13.16 (1H,
O CH, s).
11,0 OH
1H-NMR (DMSO-06) 6:1.02 (9H, s), 1.51
ci (6H, s), 3.05 (3H, s), 3.75 (2H, s), 4.65 (2H,
1-196 s), 7.10 (2H, d, J = 8.8 Hz), 7.41 (1H, d, J = 551
549
N '
8.6 Hz), 7.61-7.66 (2H, m), 8.31 (2H, d, J =
HO 14' ' CH
8.8 Hz), 13.15 (1H, br s).
F ,
H,0 CH,
H,C .
1H-NMR (DMSO-D6) 0:1.02 (9H, s), 3.34
(3H, s), 3.75 (2H, s), 4.49 (2H, s), 7.10 (2H, d,
1-197 Cl J = 8.8 Hz), 7.53 (1H, dd, J = 8.2, 2.0 Hz), 414
412
N' Nµ * >=N 7.62 (1H, d, J = 8.2 Hz), 7.72 (1H, d, J = 2.0
HO Hz), 8.31 (2H, d, J = 8.8 Hz), 13.14 (1H, br s).
ROH,
H CT-0,
H,e\ 1H-NMR (DMSO-D6) 0:1.02 (9H, s), 2.79
CH, (2H, t, J = 6.6 Hz), 3.65 (21-I, td, J = 6.6, 5.1
ci Hz), 3.75 (2H, s), 4.69 (1H, t, .1 = 5.1 Hz),
1 -1 98 -i--", 414 412
7.10 (2H, d, J = 8.8 Hz), 7.47 (1H, s), 7.54
=N OH (1H, d, J = 8.1 Hz), 7.63 (1H, s), 8.31 (2H, d,
HO J= 8.8 Hz), 13.10 (1H, IN S).
HC c0
H,:. 1H-NMR (DMSO-D6) 6:1.02 (9H, s), 2.89
ci
CH,, (2H, t, J = 6.5 Hz), 3.25 (3H, s), 3.58 (2H, t, J
= 6.5 Hz), 3.75 (2H, s), 7.10 (2H, d, J = 8.8
1-199 , N 428 426
14' \ Hz), 7.47 (1H, d, J = 8.1 Hz), 7.55 (1H, d, J =
)=-N 0-CH, 8.1 Hz), 7.65 (1H, d, J = 1.9 Hz), 8.31 (2H, d,
HO J = 8.8 Hz), 13.10 (1H, s).
228
CA 02936408 2016-06-29
[0775]
[Table 1-26]
1H-NMR (DM50-D6) 8:1.02 (9H, s), 1.45
* a (3H, d, J = 7.1 Hz), 1.49 (3H, s), 3.33 (3H, s),
1-200 3.75 (2H, s), 5.02-5.11 (1H, m), 7.09 (2H, d, J
= = 8.8 Hz), 7.58 (2H, s), 7.76
(1H, s), 8.29 (2H, 567 565 2
HO d, J = 8.8 Hz), 8.82 (1H, d, J = 8.2 Hz), 13.14
110 . 3
= ',_.9 (1H, br s).
0 -F
F F
He_NCI,D
1H-NMR (DMSO-D6) 8:1.02 (9H, s), 1.47
(3H, d, J = 7.1 Hz), 1.54 (3H, s), 3.37(3K, s),
(-_,_ a 3.75 (2H, s), 5.02-5.11 (1H, m), 7.09 (2H, d, J
1-201 = 8.2 Hz), 7.51 (1H, d, J = 8.4 Hz), 7.59 (1H, 567
565 2
.'
pH, d, J = 8.4 Hz), 7.72 (1H, s), 8.31 (2H, d, J =
HO 8.2 Hz), 8.83 (1H, d, J = 8.2 Hz), 13.15 (1H,
0 F br s).
, F
a
1H-NMR (DMSO-D6) 6: 1.48 (6H, s), 4.29
(2H, d, J = 6.0 Hz), 7.08 (1H, t, J = 7.6 Hz),
C?_
1-202 is === N
H 7.21 (2H, t, J = 7.6 Hz), 7.30 (2H, d, J = 8.4
459 457
HO ¨I,1 Hz), 7.33-7.41 (21-1, m), 7.52-7.60 (3H, m),
______________ CH 7.68 (1H, t, J = 7.2 Hz), 8.03 (1H, t, J= 6.0
0
Hz), 8.34 (2H, d, J = 8.1 Hz), 13.33 (1H, br s).
HH,6V:\-b 1H-NMR (DMSO-D6) 6: 1.00 (9H, t, J = 16.5
CH Hz), 1.29 (6H, s), 2.80 (2H, t, J = 7.0 Hz),
cl 3.30 (4H, s), 3.34 (3H, q, J = 6.7 Hz), 3.73
1-203
N , F
H.C4 T1 (2H, s), 7.07 (2H, d, J = 8.8 Hz), 7.37 (1H, dd, 551
549
N 'IF J = 8.4, 2.0 Hz), 7.51 (1H, d, J = 8.4 Hz), 7.57
HO (1H, d, J = 2.1 Hz), 8.00 (1H, t, J = 5.6 Hz),
8.29 (2H, d, J = 8.8 Hz), 13.10 (1H, br s).
HH,69- (- ,-_-__ 1H-NMR (DMSO-D6) 6: 0.89 (6H, d, J = 6.7
CH. Hz), 1.02 (9H, s), 1.81-1.91 (1H, m), 3.25
a (2H, d, J = 6.5 Hz), 3.75 (2H, s), 4.53 (2H, s),
1-204 456 454
N/ N\ 41,1 t 7.10 (2H, d, J = 8.8 Hz), 7.54(1K, d, J = 8.4
'=N /HO Hz), 7.62 (1H, d, J = 8.1 Hz), 7.73 (1H, s),
HO 0 CH, 8.31 (2H, d, J = 8.8 Hz), 13.12 (1H, s).
1H-NMR (DMSO-D6) 6: 0.91 (3H, t, J = 7.3
HH,6 -=i Hz), 1.02 (9H, s), 1.28-1.37 (2H, m), 1.55-
043 1.62 (2H, m), 2.65 (2H, t, J = 7.7 Hz), 3.75
a
1-205 (2H, s), 7.10 (2H, d, J = 9.1 Hz), 7.43 (1H, d, 426
424
NI Ts J = 8.1 Hz), 7.53 (1H, d, J = 8.1 Hz), 7.61
>=N OH,(1H, d, J = 2.1 Hz), 8.31 (2H, d, J = 9.1 Hz),
HO
13.09(1H, s). ,
H,C
1H-NMR (DMSO-D6) 6: 0.88 (OH, d, J = 6.6
Hz), 1.51 (6H, s), 1.84-1.95 (1H, m), 2.55
a
(2H, d, J = 7.3 Hz), 3.05 (3H, s), 4.65 (2H, s),
1-206 521 519
,,,,_k
PH3 7.35 (2H, d, J = 8.4 Hz), 7.41 (1H, d, J = 8.2
'4 '. /-i Hz), 7.62-7.66 (2H, m), 8.26 (2H, d, J = 8.4
ciii,
0 F Hz), 13.26 (1H, br s).
p F
9,0_\ CI,
FtC 1H-NMR (DMSO-D6) 6: 1.01 (OH, s), 3.75
(2H, s), 4.67 (2H, d, J = 5.5 Hz), 5.55 (1H, t, J
F F = 5.5 Hz), 7.10 (2H, d, J = 8.8 Hz), 7.73 (1H,
1-207 t P 434 432
d, J = 7.9 Hz), 7.78 (1H, s), 7.90 (1H, d, J =
i--",
IC
7.9 Hz), 8.29 (2H, d, J = 8.8 Hz), 13.21 (1H,
N)_N
OH br s).
229
CA 02936408 2016-06-29
[0776]
[Table 1-27]
H,He...C.
1H-NMR (DO-D6) 8:1.01 (9H, s), 1.39
F F (6H, s), 3.74 (2H, s), 4.44 (2H, d, J = 6.0 Hz),
1-208
g_,,,k 7.08 (2H, d, J = 8.6 Hz), 7.57 (1H, d, J = 8.1
571 569
'')=N Hz), 7.68 (1H, s), 7.88 (1H, d, J = 8.1 Hz),
'4 OH, 8.28 (2H, d, J = 8.6 Hz), 8.69 (1H, t, J = 6.0
1,f_FI, Hz), 13.23 (1H, br s).
0 F F E
ii.0µ/-0_
H,C'. \cm. 1H-NMR (CDCI3) 8:1.07 (9H, s), 1.12 (3H, t,
CI H,C CH, J = 5.8 Hz), 1.48 (9H, br s), 3.27 (2H, br s),
1-209 ,.7¨cH 3.70 (2H, s), 4.48 (2H, s), 7.02
(2H, d, J = 8.6 527 525
-13 Hz), 7.41 (1H, br s), 7.50 (1H, d, J = 8.1 Hz),
HO N 7.89 (1H, s), 8.50 (2H, d, .1 = 8.4 Hz).
"¨CH,
. . .
H H. 6Vc, 4 30? =
1H-NMR (DMSO-D6) 8:1.02 (9H, s), 1.23
ci (3H, t, J = 7.2 Hz), 2.99 (2H, dt, Si = 19.7, 7.2
1-210 )f¨N
N ' 41 Hz), 3.76 (2H, s), 4.23 (2H, t, J = 6.0 Hz),
427 425
)=N 7.13 (2H, d, J = 9.1 Hz), 7.74 (2H, s), 7.97
HO Eici k_OF, (1H, s), 8.33 (2H, d, J = 9.1 Hz), 9.05 (2H, s).
go 1H-N (DMSO-D6) 6: 1.00-1.32(5H, m),
1-211
1.51 (6H, s), 1.61-1.85 (6H, m), 3.05 (3H, s), .
3.89 (2H, d, J = 6.2 Hz), 4.65 (2H, s), 7.08 _,,, 577 575
N)=N
NP"' cH, (2H, d, J = 9.0 Hz), 7.40 (1H, d, Si = 8.2 Hz),
7.61-7.65 (2H, m), 8.30 (2H, d, J = 9.0 Hz),
( cH, 13.14 (1H, br sj.
F F
HH3 CC- C h c
CH, 1H-NMR (DMSO-D6) 6: 1.02 (9H, s), 3.24
(2H, q, J = 9.5 Hz), 3.75 (2H, s), 3.86 (2H, s),
1-212 cni 1, 7.10 (2H, d, J = 8.6 Hz), 7.54-7.63 (2H, m), 481
479
H 7.74 (1H, s), 8.32 (2H, d, Si = 8.6 Hz), 13.11
HO N \ _7(F (1H, s).
F F
1H-NMR (DO-D6) 8:1,30-1,41 (3H, m),
1.44-1.56 (9H, m), 1.65-1.73 (2H, m), 1.81-
1-213 0, 1.88 (2H, m), 2.66-2.73 (1H, m), 3.05 (3H, s), 571
569
4.65 (2H, s), 7.42 (1H, d, Si = 8.6 Hz), 7.54
N \
(2H, d, J = 8.4 Hz), 7.62-7.66 (2H, m), 8.30
HO N CH,
( e. (2H, d, J = 8.4 Hz), 13.36 (1H, br s).
0 c---F
F ,
1H-NMR (DMSO-06) 0:1.02 (9H, s), 1.09
CH,
a (6H, s), 2.72 (2H, s), 3.75 (2H, s), 4.40 (1H,
1-214 1,1)_ / N, s), 7.10 (2H, d, J = 8.8 Hz),
7.44 (1H, d, J = 442 440
N
H 8.8 Hz), 7.53 (1H, d, J = 8.1 Hz), 7.61 (1H, s),
HO 8.31 (2H, d, J = 8.8 Hz), 13.10 (1H, br s).
CHC3 H3
HC C:
H
1H-NMR (DMSO-D6) 8:1.02 (9H, s), 1.10
CH/) a (6H, s), 2.81 (2H, s), 3.17 (3H, s), 3.75 (2H,
s), 7.10 (2H, d, J = 8.8 Hz), 7.41 (1H, dd, J =
1-215 /-1" 456 454
8.5, 1.7 Hz), 7.53 (1H, d, Si = 8.5 Hz), 7.58
NxN
0-CH3 HO (1H, d, J = 1.7 Hz), 8.31 (2H, d, J = 8.8 Hz),
OH, ''' 13.10 (1H, s).
230
CA 02936408 2016-06-29
[0777]
[Table 1-28]
,, 1H-NMR (DMSO-06) 6: 1.00 (9H, s), 1.06
ecH,:h (3H, d, J = 6.3 Hz), 2.68 (2H, d, J = 6.0 Hz),
a 3.73 (2H, s), 3.82-3.88 (1H, m), 4.60 (1H, d, J
1-216 ',11-N\ ik. = 4.9 Hz), 7.09 (2H, d, J = 9.1 Hz),
7.42 (1H, 428 426
>=-N OH d, J = 9.3 Hz), 7.51 (1H, d, J = 8.1 Hz), 7.59
HO (1H, s), 8.30 (2H, d, J = 9.1 Hz), 13.08 (1H,
CH, s).
,
HC CH,
H,C 0
1H-NMR (DMSO-D6) 6: 1.02 (9H, s), 1,20
(9H, s), 2.36 (2H, t, J = 7.6 Hz), 2.86 (2H, t, J
'.._ GI
= 7.6 Hz), 3.75 (2H, s), 7.10 (2H, d, J = 8.8
1-217 497 495
'c=N 41 Hz), 7.40-7.46 (2H, m), 7.53 (1H, d, J = 8.2
HO H Hz), 7.61 (1H, s), 8.31 (2H, d, J = 8.8 Hz),
13.11 (1H, br S).
H,C CH,
H,Ki,
HC o
1H-NMR (DMSO-D6) 6: 1.02 (9H, s), 2.66
(2H, t, J = 7.6 Hz), 2.81 (3H, s), 2.87 (2H, 1, J
= 7.6 Hz), 2.95 (3H, s), 3.75 (2H, s), 7.10 (2H,
li
1-218 469 467
d, J = 8.8 Hz), 7.46-7.56 (2H, m), 7.66 (1H, d,
hN
J = 2.0 Hz), 8.31 (2H, d, J = 9.0 Hz), 13.11
HO PH,
(1H, br s).
0 CH,
1H-NMR (D4SO-D6) 8:0.89 (6H, d, J = 6.5
Hz), 1.30-1.40 (3H, m), 1.46-1.55 (3H, m),
1.65-1.73(2H, m), 1.80-1.90(3H, m), 2.67-
2, m), 3, d, J = 6, 453
1-219 476 474
\.72 (1H .25 (2H .5 Hz). ci (2H, s), 7.54 (2H, d, J = 8.4 Hz), 7.57
(1H, d,
J = 1.6 Hz), 7.64 (1H, d, J = 8.1 Hz), 7.73
N N' * CH,
)=N 0/¨K (1H, s), 8.31 (2H, d, J = 8.4 Hz), 13.33 (1H, br
HO
Qh C
1H-NMR (DMSO-D6) 5:1.51 (6H, s), 3.06
N' \ 40 (3H, s), 4.65(2H, s), 7.42 (1H, d, J = 8.4 Hz),
1-220 )=N
7.56 (2H, 1, J = 7.7 Hz), 7.62-7.69 (3H, m), 465 463
HO N CHõ
? _CII 8.34 (2H, d, J = 7.7 Hz), 1334 (1H, br s).
(
F F
RN CI 1H-NMR (DO-D6) 5:1.24 (9H, s), 3.02
1-221 Ni , lip (3H, s), 4.62 (2H, s), 7.40 (1H, dd, J = 8.4, 1.8
465 463
)=N P-1 Hz), 7.56 (2H, t, J = 7.6 Hz), 7.61-7.69 (3H,
HO h H 111), 8.34(2H, d, J = 7.6 Hz), 13.34 (1H, br s).
, (ceii,
O CH,
1H-NMR (DMSO-D6) 6: 1.01 (1.8H, d, J =
9_ a 6.7 Hz), 1.04 (4.2H, d, J = 6.7 Hz), 2.84
N 1-222 (0.9H, s), 2.84-2.88 (0.3H, m), 2.90-2.97
)=N Pt (0.7H, m), 3.01 (2.1H, s), 4.57 (1.4H, s), 4.71 397
395
HO N CH, (0.6H, s), 7.42 (1H, dd, J = 83, 1.9 Hz), 7.57
H (2H, t, J = 7.6 Hz), 7.60-7.69 (3H, m), 8.34
O CH, (2H, d, J = 7.6 Hz), 13.34 (1H, br s).
1H-NMR (DMSO-D6) 5:1.02 (9H, s), 1.37
HH:CC)cH,k (9H, s), 2.79 (3H, s), 3.75 (2H, s), 4.50 (2H,
ci
s), 7.11 (2H, d, J = 8.9 Hz), 7.55 (1H, dd, J =
N
/ \
(,) pi-i 8.1, 1.6 Hz), 7.68 (1H, d, J = 8.1 Hz), 7.72 533
531
1-223
' (1H, s), 8.31 (2H, d, J = 8.9 Hz), 13.17(1K, br
HO N, CH,
CH, s).
231
CA 02936408 2016-06-29
[ 0 7 7 8 ]
[Table 1-29]
Rci 1H-NMR (DMSO-D6) 6:0.97-1.05 (3H, m),
1-224 1,4/ ii, s2).344-.827.43(1(42HH:
sm)),428.835(0(089HH,s1),7244.96(1(2H.1, Hd: 383
381
)-=N CH,
HO 1,1 J = 8.4 Hz), 7.54-7.69 (5H, m), 8.34 (2H, d, J
= 8.4 Hz), 13.35 (1H, br s).
O CH,
R
1H-NMR (DMS0-06) 5: 0.84-0.93 (3H, m),
a
N 1.50-1.60 (2H, m), 2.31-2.38 (2H, m), 2.84
1-225 Ni \ *
)=N pH, (0.9H, s), 2.96 (2.1H, s), 4.57 (1.4H, s), 4.66 397
395
HO N (0.6H, s), 7.41-7.46 (1H, m), 7.54-7.69 (5H,
¨\_ m), 8.34 (2H, d, J = 7.6 Hz), 13.34 (1H, br s).
0 CH,
1H-NMR (DMSO-D6) 5: 0.87-0.93 (6H, m),
1.99-2.10 (1H, m), 2.22-2.28 (2H, m), 2.84
1-226 i'-'1 *
-N 4CH, (0.9H, s), 2.97 (2.1H, s), 4.58 (1.4H, s), 4.66
411 409
(0.6H, s), 7.40-7.46 (1H, m), 7.56 (2H, t, J =
HO
7.6 Hz), 7.60-7.70 (3H, m), 8.34 (2H, d, J =
0-CH,
H,C 7.6 Hz), 13.34 (1H, br s).
1H-NMR (DMSO-D6) 6:1.02 (9H, s), 1.43
HH6c,_,,i k
(6H, s), 2.88 (2H, t, J = 7.5 Hz), 3.03 (3H, s),
,
a F 3.55 (2H, 1, J = 7.5 Hz), 3.74 (2H, s), 7.09
CH
1-227 N F F (2H, d, J = 9.0 Hz), 7.45 (1H,
dd, J = 8.0, 2.0 565 563
N>=N * 3C, g. 'i. Hz) 7.55 (1H, d, J= 8.0 Hz), 7.64 (1H, d, J =
HO 0 2.0 Hz), 8.30 (2H, d, J = 9.0 Hz), 1311 (1H,
br s).
C1H-NMR (DMSO-D6) 6:1.46-1.56 (8H, m),
CI 2.83 (09H, s), 2.96-3.10 (1H, m), 3.01 (2.1H,
'-N
\ s), 4.57 (1.4H, s), 4.72 (0.6H, s), 7.42 (1H, d,
1-228
N)=N IIP pH, J = 8.3 Hz), 7.56 (2H, t, J = 7.6 Hz), 7.60-7.69 423
421
HO
VCII (3H, m), 8.34 (2H, d, J = 7.6 Hz), 13.33 (1H,
O br s).
1H-NMR (DO-D6) 6: 1.10-1.43 (5H, m),
CI 1.58-1.77 (5H, m), 2.56-2.68 (1H, m), 2.81
1-229 (0.9H, s), 3.01 (2.1H, s), 4.56 (1.4H, s), 4.70
437 435
CH, (0.6H, s), 7.38-7.43 (1H, m), 7.56 (2H, t, J =
HO N 7.6 Hz), 7.59-7.69 (3H, m), 8.34 (2H, d, J =
o 7.6 Hz), 13.34 (1H, br s). ,
R
1H-NMR (DM90-D6) 6:2.87-2.97 (3H, m),
a
1-230 NI' l' * 4.54 (0.8H, s), 4.75 (1.2H, s), 7.39-7.51
)=N pH (5.4H, m), 7.54-7.61 (2.6H, m), 7.62-7.70 431 429
,
(2.4H, m), 7.74-7.83 (0.6H, m), 8.35 (2H, d, J .
HO
= = 7.6 Hz), 13.35 (1H, br s).
o
Cci 1H-NMR (DMSO-06) 6: 0.79 (31-1, t, J = 7.4
N/ N, * Hz), 1.19 (6H, s), 1.64 (2H, q, J = 7.4 Hz),
1-231 3.02 (3H, s), 4.61 (2H, s), 7.43 (1H, d, J = 8.3 425
423
'=-N CH,
HO Hz), 7.56 (2H, t, J = 7.6 Hz), 7.61-7.69 (3H,
Cial't m), 8.34 (2H, d, J = 7.6 Hz), 13.33 (1H, br s).
O CH,
232
CA 02936408 2016-06-29
[0779]
[Table 1-30]
H,C
H,C 1H-NMR (DMSO-D6) 6: 0.88 (6H, d, J = 6.7
Hz), 1.35 (9H, s), 1.84-1.95 (1H, m), 2.55
¨N
1-232 CI
N/ (2H, d, J = 7.4 Hz), 2.90 (3H, s), 3.77 (2H, s),
7.35 (2H, d, J = 8.1 Hz), 7.41 (1H, d, J = 8.3 467 465
)¨N 0
HO CH, Hz), 7.57 (1H, d, J = 8.3 Hz), 7.62 (1H, s),
,H¨EPH, 8.26 (2H, d, J = 8.1 Hz), 13.24 (1H, br s).
9,0 CH,
1H-NMR (DO-D6) 6:0.75-0.8-4 (6H, m),
a 1.33-1.46 (2H, m), 1.47-1.60 (2H, m), 2.62-
N/ \ 2.71 (1H, m), 2.88 (0.9H, s), 3.03 (2.1H, s),
1-233 =-N pH, 4.61 (1.4H, s), 4.72 (0.6H, s), 7.41-7.47 (1H,
425 423
HO N¨CH, m), 7.56 (2H, t, J = 7.6 Hz), 7.61-7.69 (3H,
0"¨CH, m), 8.33 (2H, d, J = 7.6 Hz), 13.35 (1H, br s).
R1H-NMR (DO-D6) 6:137 (6H, s), 2.78
a (0.6H, br s), 3.14 (3H, s), 3.23 (2.4H, br s),
/ N\ 4.59 (1.6H, s), 5.09 (0.4H, br s), 7.45 (1H, d, J
rs1}---N li pH, = 7.9 Hz), 7.56 (2H, t, J = 7.9 Hz), 7.61-7.69 427
425 1-234
HO N OH,
(3H, m), 8.33 (2H, d, J = 7.9 Hz), 13.33 (1H,
0 0-OH, br s).
H3cv-4 1H-NMR (DMSO-D6) 6: 1.02 (9H, s), 1.12
H,C-- \ch.
a (3H, t, J = 6.8 Hz), 1.50 (6H, s), 3.42 (2H, br
, f=t ,a, F4_, s), 3.75 (2H, s), 4.66 (2H, s), 7.09 (2H, d, J =
565
1-235 563
N)=N
WI ( CH, 8.8 Hz), 7.40 (1H, d, J = 8.3 Hz), 7.61 (1H, d,
HO N CH, J = 8.3 Hz), 7.62(1k, s), 8.30 (2H, d, J = 8.8
)
H,C Hz), 13.14 (1H, s).
CCI 1H-NMR (DO-D6) 0:1.21 (6H, s), 3.04
1-236 N1¨N ' * (2H, s), 4.41 (2H, s), 7.48 (1H, d, J = 8.6 Hz),
395 393
)=N N"CH, 7.57 (2H, t, J = 7.6 Hz), 7.64-7.71 (3H, m),
HO 8.35 (2H, d, J = 7.6 Hz), 13.34 (1H, br s).
N,
,, 'CH,
0
0
CI 1H-NMR (DMSO-D6) 6:1.48 (6H, s), 2.45
H .
,CH, (3H, br s), 4.55 (2H, br s), 7.18 (1H, t, J = 7.2
1-237 x_hi
Hz), 7.22-7.26 (2H, m), 7.28-7.34 (2H, m), 473 471
HO %1;.6
7.41 (1H, br s), 7.53-7.68 (5H, m), 8.35 (211,
0 d, J = 8.1 Hz), 13.34 (1H, br s).
c 1H-NMR (DMS0-136) 8:1.56-1.67 (4H, m),
2.08-2.17 (2H, m), 2.37-2.46 (2H, m), 3.02
1-238 >=N CH, (31-1, s), 4.65 (2H, s), 7.39(1k, d, J = 8.3 Hz),
491 489
HO NyI 7.55 (2H, t, J = 8.0 Hz), 7.60-7.68 (3H, m),
0 F 8.34 (2H, d, J = 8.0 Hz), 13.34 (1H, br 8).
F F
C_ CI
1H-NMR (DMS0-86) 6: 1.23 (6H, s), 3.02
1-239 N> (3H, PH, (3H, s), 3.20 (3H, s), 3.43 (2H, s), 4.63
(2H,
441 439
110 N CH, s), 7.42 (1H, d, J = 8.3 Hz), 7.54-7.70 (5H,
c,, cf0H, m), 8.34 (2H, d, J = 7.6 Hz), 13.36 (1H, br s).
'CH,
233
CA 02936408 2016-06-29
[0780]
[Table 1-31]
(---_ ci 1H-NMR (DMSO-06) 0:1.07 (6H, s), 1.83
1-240 NI (2H, t, J = 6.9 Hz), 3.21 (2H, t, J = 6.9 Hz),
)N 4.44 (2H, s), 7.42 (1H, d, J = 8.3 Hz), 7.57 409
407
=
(2H, t, J = 7.6 Hz), 7.62-7.69 (3H, m), 8.34
c.
HO N 0H,
., CH (2H, d, J = 7.6 Hz), 13.34 (1H, br s).
0 3
9_ CI 1H-NMR (DMSO-D6) O= 1.15 (6H, s), 1.64-
1-241
r'=NN\ * 1.69 (2H, m), 1.74-1.81 (2H, m), 3.26 (2H, t, J
= 6.0 Hz), 4.53 (2H, s), 7.42 (1H, d, J = 8.1 423 421
HO Hz), 7.56 (2H, t, J = 7.4 Hz), 7.60-7.69 (3H,
1Pat m), 8.35 (2H, d, J = 7.4 Hz), 13.33 (1H, br s).
0 ci-13
0 1H-NMR (DMSO-D6) 0:1.61 (3H, s), 2.82
c
(0.6H, br s), 3.23 (2.4H, s), 3.37 (3H, s), 4.64
1-242 N ' *
-=-N ?H, OH, (1.6H, s), 4.87-5.12 (0.4H, m), 7.46 (1H, d, J
481 479
= 8.3 Hz), 7.56 (2H, t, J = 7.6 Hz), 7.63-7.71
HO FV_\,..
--CH, (3H, m), 8.34 (2H, d, J = 7.6 Hz), 13.34 (1H,
0 F br s).
FE
1H-NMR (DMSO-06) 0: 1.61 (3H, s), 2.82
C_ a
(0.6H, br s), 3.23 (2.4H, s), 3.37 (3H, s), 4.64
1-243 N)=% 1, H (1.6H, s), 4.87-5.12 (0.4H, m), 7.46 (11-1, d, J
481 479
HO ?,, 3dCH,
= 8.3 Hz), 7.56 (2H, t, J = 7.6 Hz), 7.63-7.71
.7CH, (3H, m), 8.34 (2H, d, J = 7.6 Hz), 13.34 (1H,
0 -F F F br s).
1H-NMR (DMSO-D6) 6:1.18-1.31 (3H, m),
(--¨N 1.46-1.59(3H, m), 1.63-1.72(2H, m), 2.51-
N \ * 1-244 -=1,1 2.58 (21-1, m), 3.15 (3H, s),4.71 (2H, s), 7.43
V 505 503
Hz),
7d d.6,3J-7=689.1(,31H.6mH)z, )8, .734.56(2( H2 Hd, t, , JJ :775.5
HO
C jF FE Hz), 13.36 (1H, br s).
C.._. CI 1H-NMR (DO-D6) 0: 0.81 (3H, t, J = 7.4
N \ * Hz), 1.15-1.25 (8H, m), 1.64-160 (2H, m),
1-245 )=-N pH, 3.02 (3H, s), 4.61 (2H, s), 7.42
(1H, d, J = 8.6 439 437
HO ni c- Hz), 7.56 (2H, t, J = 7.4 Hz), 7.60-7.69 (3H,
c,
m), 8.34(2H, d, J = 7.4 Hz), 13.34 (1H, br s).
Olt
1H-NMR (DMSO-D6) 0: 2.88 (0.9H, s), 3.04-
'(11¨rsi cim 3.22 (6.1H, m), 3.63-3.77 (1H, m),4.62 (1.4H,
1-246 N \
)=N p,$), 4.80 (0.6H, s), 7.42-7.48 (1H, m), 7.52- 471 469
HO 7.58 (2H, m), 7.60-7.69 (3H, m), 8.34 (2H, d,
J = 7.9 Hz), 13.35 (1H, br s).
o
1H-NMR (DMSO-D6) 0:1.14-1.36 (5H, m),
C' 1.38-1.50 (3H, m), 1.89-1.97 (2H, m), 3.37
N' µ .
(2H, s), 4.36 (2H, d, J = 6.0 Hz), 4.75 (1H, br
Qs), 7.49 (1H, d, J = 8.3 Hz), 7.53-7.59 (3H, 453 451
1-247
HO FFII\ Q m), 7.64-7.70 (2H, m), 8.09(1K, t, J = 6.0
d oH Hz), 8.34 (2H, d, J = 7.4 Hz), 13.32 (1H, br s).
234
CA 02936408 2016-06-29
[0781]
[Table 1-32]
1H-NMR (DMSO-D6) 5:1.26-1.37 (3H, m),
(4__ CI
N 1.42-1.50 (1H, m), 1.59-1.71 (6H, m), 3.02
1-248 NI \ * (2H, s), 4.40 (2H, s), 7.47 (1H, dd, J = 8.1, 2.1
435 433
)=N
N?0 Hz), 7.56 (2H, t, J = 7.9 Hz), 7.63-7.69 (3H,
HO
m), 8.34 (2H, d, J = 7.9 Hz), 13.33 (1H, br s).
o
1H-NMR (DMSO-D6) 8:1.21 (6H, s), 2.94
'RrN, si
l'=ti (2H, s), 3.11 (3H, s), 4.63 (2H, s), 7.06-7.10
(2H, m), 7.11-7.16 (1H, m), 7.16-7.22 (2H,
1-249 HO CH, m), 7.39 (1H, dd, J = 7.9, 1.8 Hz), 7.55 (2H, t,
453 451
NoH.
J = 7.4 Hz), 7.59-7.67 (3H, m), 8.34 (2H, d, J
= 7.4 Hz), 13.35 (1 H, br s).
'
1H-NMR (DMSO-06) 6: 0.71 (61-I, t, J = 7.4
'(I.__ CI Hz), 1.51 (4H, q, J = 7.4 Hz), 3.47 (2H, d, J =
N
1-250 N \ . 4.0 Hz), 4.34 (2H, d, J = 5.7 Hz), 4.62 (1H, br 441
439
)=N H CF1 s), 7.48 (1H, d, J = 7.7 Hz), 7.53-7.61 (3H,
HO .\_:_CEI.3 .. m), 7.64-7.71 (2H, m), 8.11 (1H, t, J = 5.7
0 OH
Hz), 8.34 (2H, d, J = 7.3 Hz), 13.34 (1H, br s).
1H-NMR (DMSO-06) 8:0.87 (6H, t, J = 74
N Hz), 1.52-1.63 (4H, m), 3.01 (2H, s), 4.40
1-251 Ni \ . (2H, s), 7.49 (1H, d, J = 8.3 Hz), 7.57 (2H, t, J
423 421
)=N CH = 7.9 Hz), 7.64-7.72 (3H, m), 8.34 (2H, d, J =
HO NCH 7.9 Hz), 13.35 (1H, br s).
0
1H-NMR (DM50-D6) 8:1.02 (0.6H, br s),
R ci 1.17 (2.4H, t, J = 6.9 Hz), 1.62 (3H, s), 2.81
is=NNµ *(0.6H, s), 3.25 (2.4H, s), 3.54-3.67 (2H, m),
1-252 H,1¨CH, 4.63 (1.6H, s), 4.90-5.17 (0.4H, m), 7.45 (1H,
495 493
HO N 0 dd, J = 8.2, 1.8 Hz), 7.56 (2H, t, J = 7.6 Hz),
C1---= =CH,
\"-F 7.63-7.69 (3H, m), 8.34 (2H, d, J = 7.6 Hz),
F F 13.34 (1H, br s).
1H-NMR (DA/SO-D6) 5:1.02 (0.6H, br s),
C c 1.17 (2.4H, t, J = 6.9 Hz), 1.62 (3H, s), 2.81
(0.6H, s), 3.25 (2.4H, s), 3.54-3.67 (2H, m),
1-253 P--", * y H3 ,¨CH3 4.63 (1.6H, s), 4.90-5.17 (0.4H,
m), 7.45 (1H, 495 493
HO N 0 dd, J = 8.2, 1.8 Hz), 7.56 (2H, t, J = 7.6 Hz),
. CH,
(,)--7--F 7.63-7.69 (3H, m), 8.34 (2H, d, J = 7.6 Hz),
F F 13.34 (1H, br s).
1H-NMR (DMS0-06) 5:1.51-1.55 (6H, m),
q¨N G 1.86-1.95 (2H, m), 3.46 (2H, s), 4.35 (2H, d, J
N1 % litt = 6.0 Hz), 4.99 (1H, br s), 7.47 (1H, dd, J =
1-254
)=N 8.4, 2.0 Hz), 7.54-7.60 (3H, m), 7.64-7.69 439
437
HO Ft1 n (2H, m), 8.12 (1H, t, J = 6.0 Hz), 8.34 (2H, d,
O \¨oit J = 7.7 Hz), 13.34 (1H, br s).
(R 1H-NMR (DM60-D6) 5:1.53-1.68 (4H, m),
_ GI
N\ le 1.77-1.89 (4H, m), 3.17 (2H, s), 4.42 (2H, s),
1-255 NiX=
7.47 (1H, dd, J = 8.3, 2.1 Hz), 7.56 (2H, t, J = 421 .. 419
1,1 =
7.6 Hz), 7.64-7.69 (3H, m), 8.35 (2H, d, J =
HO NA .0
7.6 Hz).
-
235
CA 02936408 2016-06-29
[0782]
[Table 1-33]
1H-NMR (DMSO-D6) 0: 0.69 (3H, d, J = 6.2
a Hz), 0.85-0.98 (2H, m), 1.06-1.28 (3H, m),
1-256 Ni N\ 1, 1.42-1.50 (2H, m), 2.05-2.12 (2H, m), 3.23
CH. (2H, s), 4.36 (2H, d, J = 6.0 Hz), 4.73(1K, br 467
465 3
)=-N H
HO N 3), 7.49 (1H, d, J = 8.1 Hz), 7.53-7.59 (3H,
m), 7.63-7.69 (2H, m), 8.10 (1H, t, J = 6.0
0 OH Hz), 8.34 (2H, d, J = 7.9 Hz), 13.34 (1H, br s).
1H-NMR (DO-D6) 6: 0.89 (3H, d, J = 5.5
(1-1- CI Hz), 1.33-1.46 (3H, m), 1.51-1.62 (4H, m),
, N
1-257 N' \ 11 1.87-1.94 (2H, m), 2.94 (2H, s), 4.39 (2H, s),
449 447 3
)=1,1 7.47 (1H, dd, J = 8.3, 2.3 Hz), 7.56 (2H, t, J =
HO N?&CH3 7.9 Hz), 7.63-7.69 (3H, m), 8.34 (2H, d, J =
o 7.9 Hz), 13.33 (1H, br s).
1H-NMR (DO-D6) 8:1.34 (6H, s), 4.99
'(1 a (2H, s), 6.97 (1H, d, J = 7.6 Hz), 7.05 (1H, t, J
= 7.6 Hz), 7.20 (1H, t, J = 7.6 Hz), 7.39 (1H,
).Ni N \ ID d, J = 7.6 Hz), 7.48(1H, dd, J = 8.3, 1.8 Hz), 457
455
1-258
--
HO N 7.55 (2H, t, J = 7.6 Hz), 7.59-7.68 (2H, m),
, CH,
g 7.75 (1H, d, J = 1.8 Hz), 8.29 (2H, d, J = 7.6
O CH,
Hz), 13.32 (1H, br s).
. .
1H-NMR (DO-D6) b: 0.77 (6H, t, J = 7.3
R Hz), 1.03-1.19 (4H, m), 1.36-1.50)4K, m),
a
i N 3.46 (2H, s), 4.33 (2H, d, J = 6.0 Hz), 4.62
1-259 N \ * H.,c
)-='N H (1H, br s), 7.47 (1H, d, J = 8.4 Hz), 7.53-7.60 469
467
HO N, (/¨OH, (3H, m), 7.61-7,69(2K, m), 8.12 (1H, 1, J =
6.0 Hz), 8.34 (2H, d, J = 7.6 Hz), 13.35 (1H,
0 OH
br s).
C1H-NMR (DMSO-D6) 8:0.84 (6H, t, J = 7.2
a Hz), 1.14-1.29 (2H, m), 1.30-1.58(6H, rr1),
NI/ \ * 3.02 2H s 4.39 2H s 7.48 1H dd J =
( , ), ( , ), ( õ
1-260 )=N 8.3, 2.1 Hz), 7.57 (2H, t, J = 7.9 Hz), 7.64- 451
449
HO NKCH'
7.70 (3H, m), 8.34 (2H, d, J = 7.9 Hz), 13.36
O CH, (1H, br s).
(-1H-NMR (DO-D6) 8:0.96-1.06 (3.9H, m), --__ a 1.10 (2.1H, t, J = 7.2 Hz),
2.31 (0.6H, q, J =
1-261 NI N\ * 7.2 Hz), 2.42 (1.4H, q, J = 7.2 Hz), 3.29-3.35
397 395
(2H, m), 4.56 (1.4H, s), 4.63 (0.6H, s), 7.45
HO N (1H, d, J = 8.3 Hz), 7.54-7.69(5K, m), 8.34
0 CH, (2H, d, J = 7.9 Hz), 13.33 (1H, br s).
1H-NMR (DM5O-D6) 0:1.28 (3H, s), 2.75
C._ ci (2H, d, J = 15.7 Hz), 3.36 (2H, d, J = 15.7
/ N\
ts=N II Hz), 4.37 (2H, d, J = 6.0 Hz), 7.06-7.11(2K,
1-262 m), 7.14-7.18 (2H, m), 7.44 (1H, dd, J = 8.3, 471
469
H HO 2.1 Hz), 7.52-7.62 (4H, m), 7.66 (1H, t, J =
N
7.4 Hz), 8.34 (2H, d, J = 7.4 Hz), 8.41 (1H, t, J
O CI-6 = 6.0 Hz), 13.32 (1H, br s).
1H-NMR (DMSO-D6) 8:1.13 (3H, t, J = 6.9
'R/_,,, a
Hz), 1.50 (6H, s), 3.42 (2H, br s), 4.66 (2H,
1-263 1.1_,, 1,
/-011, s), 7.41 (1H, dd, J = 8.3, 1.8 Hz), 7.56 (2H, t, 479
477
HO N CH, J = 7.9 Hz), 7.61-7.69 (3H, m), 8.34 (2H, d, J
I._C_I-1
0 F = 7.9 Hz), 13.33 (1H, br S).
F F
236
CA 02936408 2016-06-29
[ 0 7 8 3 ]
[Table 1-34]
1H-NMR (DMSO-06) 6: 1.31 (3H, s), 2.91
d H
(
(2, , J = 16.0 Hz), 3.04 (3H, br s), 3.51 (2H, .
N d, J = 16.0 Hz), 4.66 (2H, br s), 7.11-7.15
NJ'
=N \ * 4i (2H, m), 7.17-7.21 (2H, m), 7.45 (1H, dd, J = 485
483
1-264 ) pH,
HO N a, 8.3, 2.1 Hz), 7.54 (2H, t, J - 7.9 Hz), 7.61-
7.67 (3H, m), 8.33 (2H, d, J = 7.9 Hz), 13.33
0 CH,
(1H, br s).
1H-NMR (DMSO-D6) 5:1.34-1.42 (2H, m),
R a
1.40(9H, s), 1.53-1.63 (2H, m), 1.96 (2H, t, J
N = 6.8 Hz), 2.86-3.00 (2H, m), 3.25 (2H, t, J =-
1-265 HO )I------) 6.8 Hz), 3.78-3.87 (2H, m),
4.46 (2H, s), 7.42 550 548
c, ..õ.õ..Ny0 (1H, dd, J = 8.3, 2.1 Hz), 7.54-7,59 (2H, m),
7.60-7.69 (3H, m), 8.34 (2H, d, J = 7.7 Hz),
IF: 13.34 (1H, br s).
1H-NMR (DMSO-06) 6: 0.83 (9H, s), 0.90-
q_ a 0.99 (1H, m), 1.41-1.67 (6H, m), 1.96-2.03
N-=fsl * (2H, m), 2.92 (2H, s), 4.38 (2H, s), 7.47 (1H,
?,0_( dd, J = 8.3, 1.8 Hz), 7.56 (2H, t, J = 7.6 Hz),
1-266 491 489 4
HO N CH' 7.63-7.69 (3H, m), 8.34 (2H, d, J = 7.6 Hz),
CH,
0 - 13.34 (1H, br s).
,
1H-NMR (DO-D6) 5:1.48-1.65 (4H, m),
C)_ a 1.67-1.77 (2H, m), 1.82-1.91 (2H, m), 3.03
1-267 (2H, s), 3.21 (3H, s), 3.23-3.29 (1H, m), 4.40
465 463 5
l'=N W ?0,_ (2H, s), 7.48 (1H, dd, J = 8.1, 1.8 Hz), 7.56
HO N (3` (2H, t, J = 7.6 Hz), 7.63-7.70 (3H, m), 8.34
o (2H, d, J = 7.6 Hz), 13.34 (1H, br s).
237
CA 02936408 2016-06-29
[0784]
[Table 2-1]
Example Structure NMR MS(M+H) MS(M-1-1)
Note
FF-\
1H-NMR (DMSO-D6) 0:2.24 (6H, s), 7.21
2-1 H G (2H, d, J = 7.6 Hz), 7.37 (1H, t, J = 7.6 Hz),
346 344
,--N 3 7.91 (2H, d, J = 8.4 Hz), 8.53 (2H, d, J = 8.4
N
)=N Hz), 13.35 (1H, br s).
HO 1-1,,C
2-2 HaC 1H-NMR (C 0C13) 6: 2.34 (6H, s), 7.17(2H,
d, J = 7.7 Hz), 7.33 (1H, t, J - 7.7 Hz), 749
N NI, * (2H, t, J = 7.7 Hz), 7.60 (1H, t, J= 7.7 Hz), 278
276
,--N 8.52 (2H, dd, J = 7.7, 1.2 Hz), 11.87 (1H, s).
HO HaC
F 1H-NMR (C DC13) 0:2.32 (6H, s), 2.72 (3H,
2-3 H3G s), 7.17 (2H, d, J = 7.7 Hz), 7.34 (1H, t, J =
360 358
1-13C -N N 7.7 Hz), 7.53-7.56 (2H, m), 8.12-8.16 (1H, m),
,--N 11.29 (1H, s).
HO 1-1G
F_\
F_
1H-NMR (DMSO-D6) 6: 3.84 (3H, s), 7.25
a (2H, d, J = 8.3 Hz), 7.59 (1H, t, J = 8.3 Hz),
2-4 Nc 382 380
7.92 (2H, d, J --- 8.3 Hz), 8.51 (2H, d, J = 8.3
-NI Hz), 13.59 (1H, br S).
HO 0,
CH,
i=e--0
1H-NMR (DO-D6) 0:2.22 (6H, s), 5.22
N
(2H, s), 7.13-7.21 (2H, m), 7.32-7.37 (2H, m),
2-5 -N)::), 384 382
7.38-7.43 (2H, m), 7.46-7.48 (2H, m), 8.28-
Ni 8.32 (2H, m), 12.98 (1H, br s).
HO HG
HO
1H-NMR (DMS0-06) 0:2.20 (6H, s), 6.86
(2H, dl, J = 9.4, 2.4 Hz), 7.17 (2H, d, J = 7.7
N
2-6 qFI3C Hz), 7.32 (1H, t, J = 7.6 Hz), 8.19 (2H, dl, J =
294 292
N, --0 9.5, 2.3 Hz), 10.32 (1H, br s), 12.87 (1H, br
}-N s).
HO HC
H3C CH3
2-7 H'C.--\4- H3C 1H-NMR (DIVISO-D6) 6: 1.32 (9H, s), 2.22
(6H, s), 7.20 (2H, d, J = 7.7 Hz), 7.35 (1H, t' J 334 332
= 7.7 Hz), 7.56 (2H, d, J = 8.5 Hz), 8.28 (2H,
N -Ni) d, J = 8.5 Hz), 13.08 (1H, br S).
)-N
HO HC
CH,
1H-NMR (DMS0-06) 0:1.23 (6H, d, J = 7.3
Hz), 2.22 (6H, s), 2.90-3.05 (1H, m), 7.20
2-8 I-13C;D (2H, d, J = 7.7 Hz), 7.35 (1H, t, J = 7.7 Hz), 320
318
N, / 7.41 (2H, d, J = 8.3 Hz), 8.27 (2H, d, J = 8.3
)-N Hz), 13.09 (1H, br S).
HO FIG
F F1:_
1H-NMR (DMSO-D6) 6: 2.24 (6H, s), 7.19
(2H, d, J = 7.7 Hz), 7.34 (1H, t, J = 7.7 Hz),
2-9 H,C 364 362
F , NN"._Ø 7.73 (1H, d, J = 8.1 Hz), 7.85 (1H, d, J = 10.7
Hz), 8.24 (1H, t, J = 7.9 Hz), 13.42 (1H, br s).
HO H,C
238
CA 02936408 2016-06-29
[ 0 7 8 5 ]
[Table 2-2]
F!.._.. 1H-NMR (DMSO-06) 5: 7.50 (1H, t, J = 8.8
Hz), 7.57 (1H, d, J = 8.4 Hz), 7.67-7.73 (1H,
2-10 a 370 368
, N m), 7.94(2H, d, J = 8.1 Hz), 8.51 (2H, d, J =
8.1 Hz), 13.90 (1H, br s).
-=1,1
HO F
0 1H-NMR (DMSO-D6) 6:2.24 (6H, s), 7.20
(2H, d, J = 7.7 Hz), 7.35 (1H, t, J = 7.7 Hz),
2-11 7.45-7.47 (3H, m), 7.59-7.63 (2H, m), 7.71 378 376
I (2H, dd, J = 6.9, 2.0 Hz), 8.37 (2H, dd, J =
CR,
6.9, 2.0 Hz), 13.20 (1H, br s).
OH
'
H3C 0 1H-NMR (DMSO-D6) 6: 2.22 (6H, s), 2,89-
2-12 N(. 3.00 (4H, m), 7.16-7.29 (7H, m), 7.33 (1H, d,
382 380
I J = 7.7 Hz), 7.38 (2H, d, J = 8.4 Hz), 8.24
N ..- N CH3
y (2H, d, J = 8.4 Hz), 13.09 (1H, br s).
OH
H3C . 1H-NMR (DMSO-06) 6: 2.23 (6H, s), 2.39
H3C
(3H, s), 7.20 (2H, d, J = 7.6 Hz), 7.35 (1H, t, J
2-13 292 290
Ns / . = 7.6 Hz), 7.40-7.48 (2H, m), 8.11-8.18 (2H,
)=N m), 13.14 (1H, br s).
HO H3C
H3C
0 1H-NMR (DMSO-D6) 6: 2.23 (6H, s), 3.83
H3C
2-14 ¨N (3H, s), 7.18-7.24(3H, m), 7.36 (1H, t, J = 7.8
308 306
N
41 Hz), 7.45 (1H, t, J = 7.8 Hz), 7.83-7.86(1 H,
m), 7.94 (1H, d, J = 7.8 Hz), 13.17 (1H, br s).
HO H3C
F . 1H-NMR (DMSO-D6) 6: 2.23 (6H, s), 7.21
H3C (2H, d, J = 7.6 Hz), 7.36 (1H, t, J = 7.6 Hz),
/ N
N \ I/ 7.47-7.53 (1H, m), 7.57-7.63 (1H, m), 8.00- 296
294 2-15
)=N 8.05 (1H, m), 8.19 (1H, dt, J = 7.9, 1.3 Hz),
HO H3C 13.27 (11-I, br s).
F F
F¨ 1H-NMR (DMSO-D6) 6: 6.97 (1H, dd, J =
8.1, 0.7 Hz), 7.05 (1H, dd, J= 8.1, 0.7 Hz),
2-16 7.39 (1H, t, J = 8.1 Hz), 7.90 (2H, d, ,J = 8.4 368
366
Hz), 8.50 (2H, d, J = 8.4 Hz), 10.74 (1H, br s),
)=14 13.38 (1H, br s).
HO HO
FF¨._ 1H-NMR (DM50-D6) 6: 1.20 (3H, t, J = 7.0
Hz), 4.12 (2H, q, J = 7.0 Hz), 7.21 (2H, d, J =
N GI 2-17 8.3 Hz), 7.55 (1H, t, J = 8.3 Hz), 7.91 (2H, d, J 396
394
= 8.3 Hz), 8.50 (2H, d, J = 8.3 Hz), 13.53 (1H,
HO 0 br s).
3
1H-NMR (DMSO-D6) 6:1.31-1.40 (31-I, m),
1.45-1.54 (3H, m), 1.65-1.72 (2H, m), 1.81-
Hac ak 1.88 (2H, m), 2.22 (6H, s), 2.67-2.71 (1H, m),
2-18 384 382
IN. WI 7.20 (2H, d, J = 7.7 Hz), 7.35 (1H, t, J = 7.7
NN CH, Hz), 7.51 (2H, dd, J = 6.7, 1.9 Hz), 8.29 (2H,
I
OH dd, J = 6.7, 1.9 Hz), 13.16 (1H, br s).
239
CA 02936408 2016-06-29
[0786]
[Table 2-3]
F- F,_
1H-NUR (DMSO-D6) 6:2.29 (3H, s), 7.38-
7.41 (1H, m), 7.47-7.52 (2H, m), 7.92 (2H, d,
2-19 366 364
, rs J = 8.1 Hz), 8.52 (2H, d, J = 8.1 Hz), 13.61
N)'
(1H, br s).
HO H,C
F F
FI_____
1H-NMR (DMS0-06) 5: 0.80 (3H, t, J = 7.3
a 2-20 Hz), 7.22 (2H, t, J = 8.3 Hz Hz), 1.55-1.63 (2H, in), 4.02
(2H, t, J = 6.3
), 7.55 (1H, t, J = 410 408
N)__:1)1).
8.3 Hz), 7.90 (21-1, d, J = 8.3 Hz), 8.50 (21-1, d,
HO O\_, J = 8.3 Hz), 13.54 (1H, br S).
CH
Ft F 1H-NMR (DMS0-06) 6: 1.18 (6H, d, J = 6.0
Hz), 4.65-4.71 (1H, m), 7.20 (1H, d, J = 8.4
2-21 N Hz), 7.25 (1H, d, 1= 8.4 Hz), 7.54 (1H, t, J = 410 408
8.4 Hz), 7.91 (2H, d, J = 8.4 Hz), 8.50 (21-I, d,
HO 0 J = 8.4 Hz), 13.49 (1H, br S).
}-CH,
14,0
FF_\4._ 11-1-NMR (DMSO-D6) 5: 3.59-3.62 (2H, br
m), 4.09 (2H, t, J = 5.0 Hz), 4.81 (1H, br s),
2-22 7.24 (2H, t, J = 8.3 Hz), 7.56 (1H, t, J = 8.3 412 410
)=N Hz), 7.92 (2H, d, J = 8.4 Hz), 8.52 (2H, d, J =
HO 0 8.4 Hz), 13.49 (1H, s).
OH
_... ... õ .. ,
F F
F¨___.4., N, c 1 1H-NMR (DMSO-D6) 5: 1.71-1.77 (2H, m),
= 3.39 (2H, t, J = 6.2 Hz), 4.14 (2H, t, J = 6.2
Hz), 4.45(1H, br s), 7.23(1H, d, J = 8.3 Hz),
2-23426 424
7.24 (1H, d, J = 8.3 Hz), 7.56 (1H, t, J = 8.3
)=',1)--'P
HO 0 Hz), 7.92 (2H, d, J = 8.4 Hz), 8.52 (2H, d, J =
\--OH 8.4 Hz), 13.56 (1H, br 3).
F
1H-NMR (DMSO-06) 6:2.23 (6H, s), 7.20
2-24 qN,F)._,,,0 (2H, d, J = 7.7 Hz), 7.35 (1H, t, J = 7.7 Hz),
296 294
7.60 (2H, d, J = 8.6 Hz), 8.34 (2H, d, J = 8.6
N>=N Hz), 13.21 (1H, br S).
HO I-1,C
Cl
2-25
1H-NMR (DMS0-06) 5: 2.23 (6H, s), 7.20
'__1,1,1,>:_oH C (2H, d, J = 7.6 Hz), 7.35 (1H, t, J = 7.6 Hz),
312 310
7.60 (2H, d, J = 8.6 Hz), 8.34 (2H, d, J = 8.6
)=N Hz), 13.21 (1H, br s).
HO FI,C
'
I-1,C .
1H-NMR (DMSO-D6) 5: 2.22 (6H, s), 2.40
2-26 31¨, NHID. (3H, s), 7.20 (21-I, d, J - 7.5 Hz), 7.32-7.37
292 290
(3H, m), 8.23 (2H, d, J = 8.2 Hz), 13.08 (1H,
)¨N br s).
HO H,C
'
IV-0
2-27
1H-NMR (DMSO-D6) 5: 2.22 (6H, s), 3.85
1 , , ., ., ., ,
,,, _N\7), (3H s) 707 (21-I, d J = 90 Hz) 719 (2H d 308 306
J = 7.6 Hz), 7.34 (1H, t, J = 7.6 Hz), 8.31 (2H,
)=-N d, J = 9.0 Hz), 12.98 (1H, S).
HO FI,C
240
CA 02936408 2016-06-29
[0787]
[Table 2-4]
F
F 2-28 1H-NMR (DO-D6) 8:2.24 (6H, s), 7.21
F H3C (2H, d, J = 7.7 Hz), 7.37 (1H, t, J = 7.7 Hz),
Ni N;Is . 7.80 (1H, t, J = 7.9 Hz), 8.03 (1H, d, J = 7.9 346
344
}=N Hz), 8.57 (1H, s), 8.62 (1H, d, J = 7.9 Hz),
HO H3C 13.33 (1H, br s).
2-29
KO 1H-NMR (DMSO-D6) 8:2.22 (6H, s), 5.19
NaC (2H, s), 7.20 (2H, d, J = 7.5 Hz), 7.27-7.42
lisil)-0 (5H, m), 7.43-7.49 (3H, m), 7.92-7.96 (2H, 384 382
m), 13.17 (1H, br S).
HO NG
HO li1H-NMR (DMSO-06) 6: 2.22 (6H, s), 6.99-
H3C
2-30 , N = 7.03 (1H, m), 7.20 (2H, d, J = 7.7 Hz), 7.30-
N \ 7.37 (2H, in), 7.76-7.80 (2H, m), 9.69 (1H, s), 294
292
)=N 13.12 (1H, br s).
HO H3C
FF-,L 1H-NMR (DMSO-D6) 8:0.76 (3H, t, J = 7.4
Hz), 1.22-1.31 (2H, in), 1.53-1.60 (2H, m),
4.07 (2H, t, J = 6.2 Hz), 7.23 (2H, dd, J = 8.4,
2-31 424 422
2.2 Hz), 7.56 (1H, t, J = 8.4 Hz), 7.92 (2H, d, J
\''''cri01
HO 0 = 8.4 Hz), 8.51 (2H, d, J = 8.4 Hz), 13.56 (1H,
br s).
F F
F
1H-NMR (DSO-D6) 8:5,24 (2H, s), 7.35-
. c ___,I 7.24 (7H, m), 7.57 (1H, t, J = 8.3 Hz), 7.93 458
456
2-32 ---¨N
(2H, d, J = 8.2 Hz), 8.52 (2H, d, J = 8.2 Hz),
13.66 (1H, br s).
HO 0,_0
F F
F-
1H-NAAR (DMSO-D6) 8:0.80 (6H, d, J = 6.7
Hz), 1.82-1.92 (1H, m), 3.83 (2H, d, J = 6.0
2-33 --::(7-1S-C-1 I) Hz), 7.20 (2H, dd, J = 8.3, 3.5 Hz),
7.54 (1H, 424 422
ni>õ
t, J = 8.3 Hz), 7.90 (2H, d, J = 8.4 Hz), 8.50
HO
0\_<1 (2H, d, J = 8.4 Hz), 13.56 (1H, br S).
CH,
F F
F
2-34 ---''' \¨. 1H-NR (DMS0-06) 8:3.12 (3H, s), 3.53
a
(2H, t, J = 4.5 Hz), 4.18 (2H, t, J = 4.5 Hz),
7.24 (2H, dd, J = 8.3,3.8 Hz), 7.55 (1H, t, J = 426 424
N)=-N¨P .. 8.3 Hz), 7.90 (2H, d, J = 8.4 14z), 8.50 (2H, d,
HO O_\ J = 8.4 Hz), 13.54 (1H, 518).
0-CH
0
c, 1H-N8 R (DSO-D6) 6:3.83 (3H, s), 5.22
(2H, s), 7.16 (2H, d, J = 8.8 Hz), 7.22 (2H, d,
2-35 IV' \ 4, J = 8.8 Hz), 7.37-7.32 (1H, m), 7.43-7.38 (2H, 420
418
)=N m), 7.50-7.45 (2H, m), 7.61-7.53 (1H, rn),
HO 0, 8.28 (2H, d, J = 8.8 Hz), 13.17 (1H, s).
CH,
. .
F
Ft.
2-36
1H-NM8 (DMSO-D6) 8:4.90 (2H, q, J = 8.7
CI Hz), 7.38 (2H, dd, J = 8.4, 2.4 Hz), 7.64 (1H,
--,%__:---
rµ=n1 ).¨', t, J = 8.4 Hz), 7.93 (2H, d, J = 8.2 Hz), 8.51
450 448
HO 0 F (2H, d, J = 8.2 Hz), 13.68 (1H, Sr s).
, ( F
F
241
CA 02936408 2016-06-29
1 0 7 8 8 ]
[Table 2-5]
_
1.13-1.30 (3H, m), 1.61-1.83 (6H, m), 2.20
H C (6H, s), 386 (2H, d, J = 6.3 Hz), 7.04 (2H, d,
2-37 1H-NMR (DMSO-D6) 6: 0.99-1.10 (2H, m),
390 388
N;=_NN`)10 J = 9.1 Hz), 7.17 (2H, d, J = 7.7 Hz), 7.32
(1H, t, J = 7.7 Hz), 8.26 (2H, d, J = 9.1 Hz),
HO H,C 12.95 (1H, br s).
HC
>-0 1H-NMR (DMSO-D6) 8:128 (6H, d, J = 6.0
H,C .L_
Hz), 2.20 (6H, s), 4.70-4.76 (1H, m), 7.02
2-38 HC (2H, d, J = 8.8 Hz), 7.18 (2H, d, J = 7.6 Hz), 336
334
Ni ' * 7.32 (1H, t, J = 7.6 Hz), 8.26 (2H, d, J =8.8
)=N Hz), 12.94 (1H, br s).
HO H,C
H3C
1H-NMR (DMSO-D6) 6: 0.88 (6H, d, J = 6.4
H3C *
Hz), 1.84-1.94 (1H, m), 2.23 (6H, s), 2.54
2-39 Hac (2H, d, J = 6.9 Hz), 7.20 (2H, d, J = 7.7 Hz), 334
332
-NHO
N , 7.30-7.38 (3H, m), 8.26 (2H, d, J = 8.5 Hz),
)-N 13.09(1H, br s).
HO H,C
/-0
H3C 1H-NMR (DMS0-136) 8:1.35 (31-I, t, J = 6.9
2-40 H'C
Hz), 2.22 (6H, s), 4.13 (2H, q, J = 6.9 Hz),
-N g 7.05 (2H, d, J = 8.8 Hz), 7.20 (2H, d, J = 7.5 322
320
l\--N
\ lit Hz), 7.34 (1H, t, J = 7.5 Hz), 8.29 (2H, d, J -
HO H3C 8.8 Hz), 12.97 (1H, br s).
/-0
ti_ 1H-NMR (DMSO-D6) 5: 0.99 (3H, t, J = 7.4
Hz), 1.71-1.80 (2H, m), 2.22 (6H, s), 4.03
H,C
2-41 (2H, t, J = 6.6 Hz), 7.06 (2H, d, J = 9.0 Hz), 336
334
N/ N \)-0 7.20 (2H, d, J = 7.5 Hz), 7.34 (1H, t, J = 7.5
)-N
HO H3C Hz), 8.29 (2H, d, J = 9.0 Hz), 12.98 (1H, br S).
H3C-5 C = 1H-NMR (DMSO-D6) 6: 0.99 (6H, d, J = 6.8
CH3
H3C Hz), 2.01-2.08 (1H, m), 2.22 (61-1, s), 3.85
2-42 ).i-N (2H, d, J = 6.6 Hz), 7.06 (2H, d, J = 8.8 Hz), 350
348
N \ It 7.20 (2H, d, J = 7.5 Hz), 7.35 (1H, t, J = 7.5
)---N
HO H3C Hz), 8.29 (2H, d, J = 8.8 Hz), 12.97 (1H, br S).
. .
1H-NMR (DMSO-06) 8:1.58 (3H, d, J = 6.4
HaC Hz), 2.19 (6H, s), 5.66 (1H, q, J = 6.4 Hz),
2-43 a_<CH3
N- CH3 7.04 (2H, d, J = 9.0 Hz), 7.17 (2H, d, J = 7.7
398 396
o 41 N Hz), 7.23-7.28 (1H, m), 7.30-7.37 (3H, m),
ni4 7.41-7.43 (21-1, m), 8.20 (2H, d, J = 9.0 Hz),
OH
12.96(1H, br s).
1H-NMR (DMSO-D6) 6: 1.58 (3H, d, J = 6.4
0
H3C Hz), 2.19 (6H, s), 5.66 (1H, q, J = 6.4 Hz),
CH, 7.04 (2H, d, J = 9.0 Hz), 7.18 (2H, d, J = 7.7
2-44 10, 4 N- CH3 398 396
, N Hz), 7.24-7.28 (1H, m), 7.30-7.37 (3H, m),
N2( OH 7.41-7.43 (2H, m), 8.20 (2H, d, J = 9.0 Hz),
12.96 (1H, br s).
ci 1H-NMR (DMSO-D6) 6: 5.32 (2H, s), 7.34-
F N- 0-
2-45 b 7.27 (414, m), 7.57 (1H, t, J = 8.2 Hz), 7.71
459 457
F 4111 \ (1H, td, J = 7.7, 1.7 Hz), 7.93 (2H, d, J = 8.2
OH
F N=( N _s Hz), 8.55-8.51 (3H, m), 13.74 (1H, s).
242
=
CA 02936408 2016-06-29
[0789]
[Table 2-6]
1H-NMR (DMSO-D6) 5:1.23-1.32 (1H, m),
2-46 4 t-t3C
N- CH3 1.35-1.57 (5H, m), 1.68-1.75 (2H, m), 1.92-
1.98 (2H, m), 2.22 (6H, s), 4.47-4.51 (1H, m),
376 374
0 * , 7.06 (2H, d, J = 8.8 Hz), 7.19 (2H, d, J = 7.6
NI Hz), 7.34 (1H, t, J = 7.6 Hz), 8.27 (2H, d, J =
OH 8.8 Hz), 12.96(1H, br s).
1H-NMR (DMSO-D6) 6: 0.94 (6H, d, J = 4.2
HõCn Hz), 1.26-1.35 (2H, m), 1.41-1.48 (2H, to),,
1.56-1.65 (2H, m), 1.81-1.87 (2H, m), 2.22
2-47 0 0 HC N- N CH, (6H, s), 4.46-4.50 (1H, m), 7.06
(2H, d, J = 404 402
N4 8.8 Hz), 7.19 (2H, d, J = 7.5 Hz), 7.34 (1H, t, J
OH -= 7.5 Hz), 8.27 (2H, d, J = 8.8 Hz), 1296 (1H,
br s).
cp_\ !)=\
o 1H-NMR (DMSO-D6) 5: 2.23 (6H, 5), 5.31
(2H, s), 7.19-7.23 (21-I, m), 7.32-7.43 (4H, m),
1130
2-48 \=N)_.4) 7.48-7.53 (2H, m), 7.63 (1H, d, J = 8.4 Hz), 418
416
N / 7.97 (1H, dd, J = 8.4, 1.7 Hz), 8.10 (1H, d, J =
,-N
HO H.õO 1.7 Hz), 13.22 (1H, br s).
,
1H-NMR (DMSO-D6) 5: 0.99(3K, t, J = 7.5
CI Hz), 2.55 (2H, q, J = 7.5 Hz), 5.22 (2H, s),
F N
H3C 7.07 (1H, t, J = 6.8 Hz), 7.16 (1H, d, J = 6.8
-'0
2_49 F = \ ,N Hz), 7.22 (1H, t, J = 6.8 Hz), 7.27 (1H, d, J =
486 484
F N=K 8.2 Hz), 7.31 (1H, d, J = 6.8 Hz), 7.42 (1H, d,
OH J = 8.2 Hz), 7.60 (1H, t, J = 8.2 Hz), 7.91 (2H,
d, J = 8.6 Hz), 8.48 (2H, d, J = 8.6 Hz), 13.63
(1H, s).
1H-NMR (DMSO-D6) 8:1.30-1.36 (2H, m),
R3C
1.50-1.65 (41-I, m), 1.74-1.82 (2H, m), 2.22
2-50 ID-Tho N- CH, (6H, s), 2.29-2.36 (1H, m), 3.95 (2H, d, J =
W \r2(N 7.1 Hz), 7.06 (2H, d, J = 8.8 Hz), 7.20 (2H, d,
376 374
µ1
OH J = 7.7 Hz), 7.34 (1H, t, J = 7.7 Hz), 8.28 (2H,
d, J = 8.8 Hz), 12.97 (1H, br s).
I-13C 1H-NMR (DMSO-DS) 5: 1.81-1.94 (4H, m),
2.05-2.12 (2H, m), 2.22 (6H, s), 2.70-2.78
K¨' N- CH3 (1H, m), 4.05)2K, d, J = 6.6 Hz), 7.06 (2H, d,
2-51 õN J = 8.8 Hz), 7.20 (2H, d, J = 7.5 Hz), 7.34 362
360
N (1H, t, J = 7.5 Hz), 8.29 (211, d, J = 8.8 Hz),
OH
12.97 (1H, br s).
1H-NMR (DMSO-D6) 5'. 1.38(3K, t, J = 6.9
H,c
Hz), 2.22 (6H, s), 4.19 (2H, q, J = 6.9 Hz),
NA, 7.10(2K, d, J = 7.6 Hz), 7.34 (1H, t, J = 7.6
2-52 ci 0 , N 356 354
N-'< Hz), 7.58 (1H, d, J = 8.3 Hz), 7.92 (1 I-1, dd, J
/--0 OH = 8.3, 1.7 Hz), 7.96 (1H, d, J = 1.7 Hz), 13.19
11,C (1H, br s).
CI 1H-NMR (DMS0-06) 5: 2.18 (3H, s), 5.18
(2H, s), 7.04 (1H, t, J = 7.4 Hz), 7.16-7.09
F N- 0 CH3 (2H, m), 7.21 (1H, d, J = 7.9 Hz), 7.28 (1H, d,
2-53 F 41 \ ,N J = 7.4 Hz), 7.34(1K, d, J = 8.4 Hz), 7.57- 472
470
F N-A
OH 7.49(1K, m), 7.88(2K, d, J = 8.4 Hz), 8.47
(2H, d, J = 8.4 Hz), 13.63 (1H, s).
1H-N (DMSO-D6) 8:1.20 (3H, t, J = 7.5
I-I,C
Hz), 2.23 (6H, s), 2.80 (2H, q, J = 7.5 Hz),
NPCH, 7.21 (21-1, d, J = 7.6 Hz), 7.36 (1H, t, J = 7.6
2-54 ci 110 , N Hz), 7.58(1K, d, J = 8.4 Hz),
8.17 (1H, dd, J 340 338
N2( = 8.4, 2.0 Hz), 8.29 (1H, d, J = 2.0 Hz), 13.20
I-1,C OH
(1H, bus).
243
CA 02936408 2016-06-29
[0790]
[Table 2-7]
1H-NMR (DMSO-D6) 6: 2.11 (3H, s), 5.17
ci (2H, s), 7.04 (1H, d, J = 7.7 Hz), 7.17-7.06
(3H, m), 7.25 (1H, d, J = 8.3 Hz), 7.29 (1H, d,
2-55 472 470
F 'N 41 -b_ J = 8.3 Hz), 7.57 (1H, 1, J = 8.3
Hz), 7.91 (2H,
F CH3 d, J = 8.1 Hz), 8.52 (2H, d, J = 8.1 Hz),
13.64
OH
(1H, br s).
'
CI 1H-NMR (DMSO-D6) 0:2.22 (3H, s), 5.16
(2H, 8), 7.06 (21-I, d, J = 7.9 Hz), 7.20 (2H, d,
F 2-56 F * N¨ 0 J = 7.9 Hz), 7.23 (1H, d, J = 7.9 Hz), 7.28
472 470
= F N=( (1H, d, J = 7.9 Hz), 7.55 (1H, t, J =
8.4 Hz),
OH 7.92 (2H, d, J = 8.4 Hz), 8.49 (2H, d, J = 8.4
CH, Hz), 13.62 (1H, br s).
1H-NMR (DMSO-D6) 0:1,34-1.23 (2H, m),
H3C 1.62-1.38(6H, m), 1.72-1.63(2H, m), 1.86-
2-57 0-0 =
N-..H., 1.77 (2H, m), 2.00-1.88 (1H, m), 2.22 (6H,
s),
*\ iN 3.86 (2H, d, J = 6.8 Hz), 7.06 (2H, d, J =
8.8 404 402
N--{ Hz), 7.20 (2H, d, J = 7.6 Hz), 7.34 (1H, t, J
=
OH 7.6 Hz), 8.28 (2H, d, J = 8.8 Hz), 12.97 (1H,
br s).
H,C 1H-NMR (DMSO-D6) 6: 1.01 (9H, s), 2.22
(OH, s), 3.74 (2H, s), 7.07 (2H, d, J = 8.8 Hz), 364
2-58 H,C ) \ N¨ CH, 362
1-1,c 0 = \ ,,N 7.20 (2H, d, J = 7.7 Hz), 7.35 (1H,
t, J = 7.7
N( Hz), 8.29 (2H, d, J = 8.8 Hz), 12.97 (1H, br
s).
OH
I-IC 1H-NMR (DMSO-D6) 6: 2.24 (6H, s), 5.46
\ (2H, s), 7.02 (1H, d, J = 8.8 Hz), 7.20 (2H, d,
2-59 = ¨ , CH' J = 7.7 Hz), 7.31-7.41 (4H, m), 7.46-7.49
(2H, 385 383
µ N¨ N4 in), 8.53 (1H, dd, J = 8.8, 2.0 Hz), 9.10
(1H, d,
OH J = 2.0 Hz), 13.13 (1H, br s).
Hz), 7.93 (2H, d, J = 8.4 Hz), 8.48 (1H, dd, J
1H-NMR (DMSO-D6) 6: 5.30 (2H, s), 7.28
CI (1H, d, J = 7.9 Hz), 7.30-7.35 (2H, m), 7.59
F
2-60 F =N-20 (1H, t, J = 8.4 Hz), 7.73 (1H, dt, J =
7.9,1.5
459 457
\ M
/ \
F N OH N¨
= 4.9, 1.5 Hz), 8.51 (2H, d, J = 8.4 Hz), 8.56
(1H, d, J = 1.5 Hz), 13.67 (1H, br s).
CI 1H-NMR (DMSO-06) 0: 5.33 (2H, s), 7.23-
2-61 N2C) 7.32 (4H, m), 7.57 (11-I, t, J = 8.4 Hz),
7.94
459 457
FF 41 \ N , , (2H, d, J = 8.4 Hz), 8.48 (2H, d, J = 5.3
Hz),
OH N
8.54 (2H, d, J = 8.4 Hz), 13.72 (1H, br s).
¨
1H-NMR (DMSO-D6) 6: 1.00 (9H, s), 3.73
H3C CH, CI (2H, s), 5.30 (2H, s), 7.08 (2H, t, J = 4.5
Hz),
)i¨CH,
2-62 N.20 7.30-7.20(3H, m), 7.33 (1H, d, J= 7.7 Hz),
477 475
0 4110 N , \ 7.52 (1H, t, J = 8.1 Hz), 7.69 (1H, td,
J = 7.7,
N4 ¨ 1.7 Hz), 8.28 (2H, d, J = 8.8 Hz), 8.53-
8.49
OH
(1H, m), 13.27 (1H, br s).
1H-NMR (DM50-D6) 0:1.01 (9H, s), 1.46
H3C CH, CI (3H, d, J = 6.2 Hz), 3.74 (2H, s), 5.60 (1H, q,
l¨CH, pit J = 6.2 Hz), 7.04-7.11 (3H, m), 7.17 (1H, d, J
N
2-63 . N¨ 0 ' _ 7.7 Hz), 7.27(1K, dd, J = 7.0, 5.1 Hz),
7.37- 491 489
7.44 (2H, m), 7.72 (1H, t, J = 7.0 Hz), 8.30
OH ¨ (2H, d, J = 8.8 Hz), 8.51 (1H, d, J = 4.2 Hz),
13.32 (1H, br s).
244
CA 02936408 2016-06-29
[0791]
[Table 2-81
1H-NMR (DM50-D6) 6: 1.01 (9H, s), 1.47
H,C CH, CI (3H, d, J = 6.3 Hz), 3.74 (2H, s), 5.60 (1H, q,
1¨CH,
N 0 CH3 .. J = 6.3 Hz), 7.13-7.02 (3H, m), 7.18 (1H, d, J
2-64 0 e \ N \ = 7.7 Hz), 7.27 (1H, dd, J = 7.1,
5.2 Hz), 7.48- 491 489
_
OH
Nc N, 7.36 (2H, m), 7.72 (1H, t, J = 7.1 Hz), 8.31
(2H, d, J = 8.8 Hz), 8.51 (1H, d, J = 4.2 Hz),
13.32 (1H, br s).
HaC CH, CI
CH, 1H-NMR (DMSO-06) 6: 1.01 (9H, s), 1.40
2-65 N¨ 0 (3H, d, J = 6.2 Hz), 3.74 (2H, s), 5.62 (1H, q,
0 Illfr \ õN J = 6.2 Hz), 7.05-7.15 (4H, m), 7.21-7.41 (6H,
490 488
N( m), 8.31 (2H, d, J = 8.8 Hz), 13.21 (1H, br s).
OH
1H-NMR (DMSO-D6) 6:0.99 (6H, d, J = 6.6
HC CI i Hz), 2.04 (1H, td, J = 13.3, 6.6 Hz), 3.86 (2H,
tCH,
d, J = 6.6 Hz), 5.31 (2H, s), 7.08 (2H, d, J =
N?0
2-66 0 * \ NI õ 8.8 Hz), 7.31-7.21 (3H, m),
7.34 (1H, d, J = 463 461
= OH
_s 7.7 Hz), 7.57-7.48 (1H, m), 7.70 (1H, td, J =
7.7, 1.6 Hz), 8.30 (2H, d, J = 8.8 Hz), 8.53
(1H, d, J = 4.9 Hz), 13.29 (1H, br s).
1H-NMR (DM50-D6) 6: 1.00 (6H, d, J = 6.6
HC CI Hz), 1.48 (3H, d, J = 6.6 Hz), 2.09-2.02 (1H,
,
.¨CH, 0H3 m), 3.87 (2H, d, J = 6.6 Hz), 5.61 (1H, q, J .
4.0 ¨ 0 6.2 Hz), 7.14-7.04 (3H, m), 7.19 (1H, d, J =
2-67 477 475
0 \N4N Ni \ 7.9 Hz), 7.31-7.25 (1H, m), 7.48-7.37 (2H, m),
OH ¨ 7.73(1H, td, J= 7.9, 1.6 Hz), 8.32 (2H, d, J=
9.0 Hz), 8.53 (1H, d, J = 4.9 Hz), 13.33 (1H,
br s).
HC CH, CI 1H-NMR (DMSO-D6) 6:1.02 (9H, s), 3.74
N=, (2H, s), 5.40 (2H, s), 7.08 (2H, d, J = 8.8 Hz),
0--\
2-68 0 * \ ,N ),¨N 7.24 (2H, d, J = 7.7 Hz),
7.44 (1H, t, J = 4.9 478 476
N4 N')Hz), 7.51 (1H, br s), 8.27 (2H, d, J = 8.8 Hz),
_
OH 8.78 (2H, d, J = 4.9 Hz), 13.19 (1H, br s).
1H-NMR (DMSO-D6) 6: 0.88 (3H, t, J = 7.2
H3C Hz), 1.31-1.42 (4H, m), 1.69-1.76 (2H, m),
2-69
N_ cH, 2.21 (6H, s), 4.05 (2H, t, J = 6.5 Hz), 7.04
0 * \ (2H, d, J = 8.8 Hz), 7.18 (2H, d, J = 7.4 Hz), 364
362
N¨ 7.33
7.33 (1H, t, J = 7.4 Hz), 8.27 (2H, d, J = 8.8
OH
Hz), 12.96 (1H, br s).
1H-NMR (DMS0-06) 6:0.92 (3H, t, J = 7.3
HC) HC¨> Hz), 1.38-1.48 (2H, m), 1.67-1.74 (2H, M),
2-70
N_ CI-1 2.21 (61A, s), 4.06 (2H, t, J =
6.5 Hz), 7.05 0 410 \ ,N (2H, d, J = 8.8 Hz), 7.18 (2H, d, J = 7.7 Hz),
350 348
N=( 7.33 (1H, t, J = 7.7 Hz), 8.27 (2H, d, J = 8.8
OH Hz), 12.96 (1H, br s).
CH, 11-I-NMR (DMSO-D6) 6: 0.92 (6H, d, J = 6.6 .
H,C¨ H,C Hz), 1.63 (2H, q, J = 6.6 Hz), 1.72-1.82 (1H,
2-71 N¨ CH, m), 2.21 (6H, s), 4.08 (2H, t, J = 6.6 Hz), 7.05
364 41 362
µNj( (2H, d, J = 8.8 Hz), 7.18 (2H, d, J = 7.4 Hz),
Nj
7.33 (1H, t, J = 7.4 Hz), 8.27 (2H, d, J = 8.8
OH Hz), 12.96 (1H, br s).
1H-NMR (DMSO-D6) 6:0.98 (6H, d, J = 6.5
HC CI Hz), 2.00-2.07 (1H, m), 2.19 (3H, s), 3.84
,
CH, (2H, d, J = 6.5 Hz), 5.31 (2H, s), 7.05 (2H, d,
2-72 ims- ni¨ 0 CH, J = 8.8 Hz), 7.20-7.26
(2H, m), 7.40 (1H, d, J 477 475
Wi 'N4N N/ \ = 8.1 Hz), 7.50-7.57 (2H, m), 8.23 (2H, d, J =
OH ¨ 8.8 Hz), 8.33 (1H, d, J = 3.7 Hz), 13.25 (1H,
br s).
245
CA 02936408 2016-06-29
[0792]
[Table 2-9]
NC I-I3C 1H-NMR (DMSO-D6) 6: 0.90 (6H, t, J = 7.4
H30, N_4 CH Hz), 1.60-1.69 (4H, m), 2.22 (6H, s), 4.36-
0 N '' ' '" - "' '
2-73 3 4 42 (1H m) 7 06 (2H d J - 8 8 Hz) 7
20 364 362
4. ,
N2( (2H, d, J = 7.5 Hz), 7.35(111, t, J = 7.5 Hz),
OH 8.28 (2H, d, J = 8.8 Hz), 12.97(111, br s).
1H-NMR (DMSO-D6) 8:0.31-0.35 (2H, m),
2-74 NC
NPCN 0.55-0.59 (2H, m), 1.20-1.27 (1H, m), 2.21
(6H, s), 3.91 (2H, d, J = 7.0 Hz), 7.04 (2H, d,
0 * \ N
N-i{ J = 8.8 Hz), 7.18 (2H, d, J = 7.4 Hz), 7.33 348
346
(1H, t, J = 7.4 Hz), 8.27 (2H, d, J = 8.8 Hz),
OH 12.95 (1H, br s).
1H-NMR (DMSO-D6) 0:1.94-1.80 (411, m),
P CI
NO 2.11-2.03(211, m), 2.76-2.69 (1H, m), 4.05
2-75
(2H, d, J = 6.7 Hz), 5.29 (2H, s), 7.07 (21-1, d,
J = 8.8 Hz), 7.29-7.23 (3H, m), 7.32 (1H, d, J 475 473
0 = \N 14N Ni \ = 7.9 Hz), 7.56-7.48(111, m), 7.71-7.66 (1H,
OH - m), 8.28 (2H, d, J = 8.8 Hz), 8.52-8.50 (1H,
m), 13.28 (1H, br s).
1H-NMR (DMSO-D6) 0:1.40-1.31 (3H, m),
a 1.54-1.45 (3H, m), 1.73-1.65 (2H, m), 1.88-
Nio 1.80 (2H, m), 2.73-2.66 (1H, m), 5.31 (2H, s),
2-76 - s ,N -b 7.31-7.25 (3H, m), 7.33 (1H, d, J = 7.7 Hz), . 497 495
OH - 7.57-7.51 (3H, m), 7.70 (1H, td, J = 7.7, 1.7 :
Hz), 8.30 (2H, d, J = 8.4 Hz), 8.52 (1H, d, J =
4.6 Hz), 13.53 (1H, br s).
1H-NMR (DO-D6) 6:1.30-0.99 (5H, m),
p CI 1.83-1.60 (6H, m), 3.87 (2H, d, J = 6.3 Hz),
5.29 (2H, s), 7.06 (2H, d, J = 8.8 Hz), 7.29-
N20
N 7.23 (3H, m), 7.32 (1H, d, J = 7.7 Hz), 7.55- 503 501 2-
77 o = \ ,
N=( Ni \ 7.49 (1H, m), 7.68 (1H, t, J. 7.7 Hz), 8.27
OH - (2H, d, J = 8.8 Hz), 8.51 (1H, d, J = 4.9 Hz),
13.27 (1H, br s).
1H-NMR (DMSO-D6) 6: 0.90 (3H, t, J = 7.3
Hz), 1.27 (3H, d, J = 6.0 Hz), 1.47-1.31 (2H,
NC-\ CI
m), 1.60-1.51 (1H, m), 1.72-1.63 (1H, m),
H3C- im\ N- Ob 4.65-4.59 (1H, m), 5.31 (21-
I, s), 7.06 (2H, d, J , 477 2-78 475
0 lir \NIN' N, \ = 9.0 Hz), 7.31-7.24 (3H, m), 7.34 (1H, d, J =
OH - 7.7 Hz), 7.53 (1H, 1, J = 7.7 Hz), 7.70 (1H, Id, '
J = 7.7, 1.5 Hz), 828 (2H, d, J = 9.0 Hz), 8.53
(1H, d, J= 4.2 Hz), 13.28 (1H, br s).
1H-NMR (DMS0-06) 6: 0.90 (311, t, J = 7.3
Hz), 1.27 (3H, d, J = 6.0 Hz), 1.47-1.33 (2H,
No m), 1.61-1.51 (1H, m), 1.72-1.62(111, m),
2_79 Nc.-c) 0 4.65-4.59 (1H, m), 5.31
(2H, s), 7.06 (2H, d, J =
477 475
\N4N ) \ = 9.0 Hz), 7.31-7.24 (3H, m), 7.34 (1H, d, J =
01-1 - 7.9 Hz), 7.53 (1H, t, J = 7.9 Hz), 7.72-7.68
(1H, m), 8.28 (2H, d, J = 9.0 Hz), 8.53 (1H, d,
J = 4.0 Hz), 13.28(111, br s).
_ .
1H-NMR (DMSO-06) 0: 5.31 (2H, s), 7.30-
CI 7.25 (3H, m), 7.33 (1H, d, J = 7.7 Hz), 7.47-
N- Ob 7.43 (3H, m), 7.54 (1H, t, J =
8.5 Hz), 7.62-
2-80 -
4N N, \ 7.57 (2H, m), 7.73-7.67 (311,
m), 8.36 (2H, d, 491 489
OH - J = 8.4 Hz), 8.52 (1H, d, J = 4.0 Hz), 13.56 ,
(1H, br s). ,
246
CA 02936408 2016-06-29
[0793]
[Table 2-10]
1K-NR (DMSO-D6) 6: 1.76-1.54 (6H, m),
2.04-1.95 (2H, m), 2.95-2.88 (1H, Fr), 5.31
N0
2-81 N -s)..3 (2H, s), 7.34-7.25 (4H, m), 7.58-7.51 (3H, m), 483
481
N4 NI\ 7.70 (1H, td, J = 7.7, 1.8 Hz), 8.29 (2H, d, J =
OH 8.4 Hz), 8.54-8.52 (1H, m), 13.53 (1H, br s).
1H-NNR (DMSO-D6) 6:0.81-0.76 (2H, m),
ci 0.96-0.90 (2H, m), 1.64-1.55 (1H, m), 5.31
N- 0 (2H, s), 7.33-7.25 (4H, m), 7.58-7.50 (31-I, m),
2-82 455 453
,N4N \ 7.70 (1H, td, J = 7.7, 1.7 Hz), 8.28 (2H, d, J =
OH ¨ 8.4 Hz), 8.53 (1H, d, J = 4.0 Hz), 13.52 (1H,
br s).
1H-NMR (DMSO-D6) 5:1.31-1.40 (3H, m),
1.45-1.54 (3H, m), 1.65-1.72 (2H, m), 1.81-
, m) , m), , s),
1+20
1.87 (2H, 2.67-2.72 (1H 5.44 (2H
2-83 ;44N 565 563
7.25-7.30 (2H, m), 7.51-7.56 (4H, m), 8.14
OH
k -
F (1H, d, J = 8.2 Hz), 8.29 (2H, d, J = 8.6 Hz),
F F 8.94 (1H, s), 13.52 (1H, Sr s).
1H-N (DMSO-D6) 5:0.94 (6H, d, J = 4.2
HC P0
Hz), 1.35-1.25 (2H, m), 1.49-1.40 (2H, m),
1.66-1.55 (2H, m), 1.89-1.79 (2H, m), 4.53-
2-84 0 40N 4.44 (1H, m), 5.30 (2H, s), 7.07 (2H, d, J =
517 515
N-2( Is1/ \ 8.8 Hz), 7.31-7.21 (3H, m), 7.34 (1H, d, J =
OH - 7.7 Hz), 7.56-7.48 (1H, m), 7.70 (1H, t, J =
7.1 Hz), 8.27 (2H, d, J = 8.8 Hz), 8.53 (1H, d,
J = 4.6 Hz), 13.28 (1H, s).
1H-NMR (DMSO-D6) 6: 5.38 (2H, s), 7.28
(1H, d, J = 8.1 Hz), 7.31 (1H, d, J = 8.1 Hz),
2-85 N20__b 7.47-7.40 (5H, m), 7.55 (1H, d, J = 8.4 Hz),
491 489
7.61-7.57 (2H, m), 7.72 (2H, d, J = 8.8 Hz),
OH 7.88-7.84(1K, m), 8.36 (2H, d, J = 8.8 Hz),
HCI
8.58 (1H, d, J = 4.4 Hz).
ci 11-I-NMR (DMSO-D6) 6: 1.51 (3H, d, J = 6.4
CFI, Hz), 5.65 (11-I, q, J = 6.4 Hz), 7.11 (1H, d, J =
2-86 - 8.6 Hz), 7.22 (1H, d, J = 7.7 Hz), 7.32 (1H,
505 503
N2( Ni dd, J = 6.9, 5.4 Hz), 7.50-7.41 (5H, m), 7.63-
HCI - 7.59 (2H, m), 7.81-7.73(3K, m), 8.40 (2H, d,
J = 8.6 Hz), 8.55 (1H, d, J = 4.2 Hz).
1H-NM (DMSO-D6) 6: 2.53 (3H, s), 5.40
ci
2-87
(2H, s), 7.30 (1H, d, J = 8.2 Hz), 7.33 (1H, d,
N20 J = 8.2 Hz), 7.42-7.35 (2H, m), 7.49-7.44 (3H,
505 503
µ1.1(N m), 7.64-7.56 (3H, m), 7.73 (2H, d, J = 8.8
OH ¨ Hz), 7.91-7.88 (1H, m), 8.37 (2H, d, J = 8.8
HC
HCI Hz).
1H-NMR (CDCI3) 8: 5.50(0.90K, s), 5.60
(1.10H, s), 7.43-7.30 (5.45H, m), 7.69-7.54
2-88 N- 0-\); (50.0405
) ( -11-1 d J 7 , m ), 7.99711 )18 (82.7W1 60 (2 H8'
'7* 8.0555H 482 480
OH 8.88(0.55K, d, J = 4.2 Hz), 11.44 (0.45H, s),
14.69 (0.55H, br s).
11-I-NMR (DMSO-D6) 8:0.38-0.32 (2H, m),
/m.\ CI
0.62-0.56)2K, m), 1.30-1.20 (1H, m), 3.93
N-IPO (2H, d, J = 6.8 Hz), 5.32 (2H, s), 7.08 (2H, d,
2-89 461 459
0 W. firs1 ,-b J = 7.5 Hz), 7.36-7.24 (4H, m), 7.54 (1H, t, J
N
OH ¨ = 8.4 Hz), 7.71 (1H, t, J = 7.6 Hz), 8.29 (2H,
HCI d, J = 7.5 Hz), 8.53 (1H, d, J = 4.6 Hz).
247
CA 02936408 2016-06-29
[0 7 94 ]
[Table 2-11]
1H-NMR (DMSO-D6) 6:0.32-0.35 (2H, m),
Cl2 0.55-0.59 (2H, m), 1.20-1.25 (1H, m), 2.79
(3H, s), 2.91 (3H, s), 3.91 (2H, d, J = 7.0 Hz),
2-90 -,N (3./_,,,,iclt 4.98 (2H, s), 7.05 (2H, d, J = 8.8 Hz), 7.16
455 453
N-( 0 DI-I., (1H, d, J = 8.4 Hz), 7.23 (1H, d, J = 8.4
Hz),
OH 7.51 (1H, t, J = 8.4 Hz), 8.26 (2H, d, J = 8.8
Hz), 13.15 (1H, br s).
11-I-NMR (DMSO-D6) 6:1.76-1.53 (6H, m),
cio 2.05-1.93 (2H, m), 2.95-2.88 (1H, m), 5.36
rsi4 (2H, s), 7.28 (1H, dd, J = 7.9, 0.7 Hz), 7.30
2-91 = µN (1H, d, J = 7.9 Hz), 7.43-7.36 (2H, m), 7.59- 483
481
OH \=í 7.50 (3H, m), 7.81 (1H, td, J = 7.7, 1.8 Hz),
HCI 8.29 (2H, d, J = 8.6 Hz), 8.57 (1H, dq, J = 5.0,
0.8 Hz).
1H-NF R (DM50-D6) 6:1.41-1.30 (3H, in),
ci 1.56-1.45 (3H, m), 1.74-1.64 (2H, m), 1.89-
1 .80 (2H, m), 2.74-2.65 (1H, m), 5.37 (2H, s),
_
2-92 14-44 N' \ 7.28 (1H, dd, J = 8.0, 0.6
Hz), 7.31 (1H, d, J = 497 495
OH - 8.0 Hz), 7.46-7.40 (2H, m), 7.59-7.52 (3H, M),
HCI 7.85 (1H, td, J = 7.8, 1.6 Hz), 8.29 (2H, d, J =
8.6 Hz), 8.59-8.58 (1H, m).
1H-NMR (DMSO-D6) 6: 0.33-0.37 (2H, in),
0.54-0.59 (2H, m), 1.23-1.30 (1H, in), 4.21
(2H, d, J = 7.3 Hz), 5.23 (2H, s), 6.97 (1H, d,
2-93 n¨N-- r=PO 461 459
\ i J = 8.8 Hz), 7.23-7.35 (7H, m), 7.55 (1H, t, J
b
= 8.0 Hz), 8.48 (1H, dd, J = 8.8, 2.2 Hz), 9.05
OH
(1H, d, J = 2.2 Hz), 13.41 (1H, br s). '
1H-NMR (DMSO-D6) 6: 1.31 (9H, s), 5.38
ci
(2H, s), 7.28 (1H, d, J = 8.2 Hz), 7.31 (1H, d,
11,C NO J = 8.2 Hz), 7.47-7.41 (2H, m), 7.52 (2H, d, J
2-94 1-1,c = 41 s N - b 471 469
Hsc N-'( 8.8 Hz), 7.56 (1H, t, J = 8.4 Hz), 7.86 (1H,
OH td, J = 7.7, 1.5 Hz), 8.29 (2H, d, J = 8.8 Hz),
HCI 8.59 (1H, dd, J = 5.0, 0.8 Hz).
F+_n 1H-NMR (DMS0-136) 6: 5.38 (2H, s), 7.39-
F 7.34 (2H, m), 7.46-7.43 (3H, rn), 7.54 (1H, d,
F
7.9 Hz), 7.61-7.57 (2H, m), 7.66 (1H, d, J
2-95 N=r- ob 525 523
`N4N N j- 8.6 Hz), 7.72 (2H, d, J = 8.4 Hz), 7.82-7.76
OH - (2H, m), 8.34 (2H, d, J = 8.4 Hz), 8.56 (1H, d,
HCI J = 4.9 Hz).
1H-NMR (DMS0-D6) 6: 5.25 (2H, s), 7.36-
7
.24 (8H, m), 7.46 (1H, ddd, J = 7.8, 4.9, 1.0
N- 0 Hz), 7.57 (1H, t, J = 8.3 Hz), 7.72 (1H, dl, J =
/ \ = 491 489
2-96
-N µN_ZKN b 7.8, 1.0 Hz), 7.79 (2H, d, J . 8.6 Hz), 7.90
OH (1H, td, J= 7.8, 1.8 Hz), 8.40 (2H, d, J= 8.6
HCI
Hz), 8.65 (1H, dq, J = 4.9,0.9 Hz).
. .
1H-NMR (DMS0-D6) 6: 5.40 (2H, s), 7.30
ci
(1H, dd, J = 8.2, 0.7 Hz), 7.33 (1H, d, J = 8.2
\ = 1,1,...0_, Hz), 7.51-7.43 (3FI, m), 7.58 (1H, t, J = 8.2
2-97 -N IN4 N' \ Hz), 7.75 (1H, dt, J = 7.8,
1.0 Hz), 7.80 (2H, 492 490
3
OH - dd, J = 6.7, 1.9 Hz), 7.95-7.87 (2H, in), 8.40
HCI HCI
(2H, dd, J = 6.7, 1.9 Hz), 8.61 (1H, d, J= 5.0
Hz), 8.66 (1H, dq, J = 5.0, 0.9 Hz).
F+_n, 1H-NMR (DMS0-D6) 6: 2.48 (3H, s), 5.37
F
F (2H, s), 7.23 (1H, d, J= 7.3 Hz), 7.28 (1H, d,
2-98
N=r0 J = 7.3 Hz), 7.48-7.45 (3H, m), 7.56 (1H, d, J
539 537
= 7.9 Hz), 7.64-7.59 (2H, m), 7.67 (1H, d, J =
OH - 8.6 Hz), 7.82-7.72 (4H, m), 8.35 (2H, dd, J =
NCI HC
6.8, 2.0 Hz).
_.....
248
CA 02936408 2016-06-29
1 0 7 9 5 I
[Table 2-12]
1HH, s), 7.0
-NMR(D9 (1MSHOr d, j . 77 H
D6)6:2.41z)(1-1 714 H
,8),(51.30
(2 d.
= / \ \ ¨C.:\ J = 7.7 Hz), 7,51-7.45 (3H, m), 7.54 (1H,
d, J
2-99 = 7.7 Hz), 7.60 (1H, t, J = 7.7 Hz), 7.66-
7.64 540 538
'-' ¨ (3H, m), 7.78(111, d, J = 8.2 Hz), 7.81
(11-I,
11,
dd, J = 8.2, 0.8 Hz), 8.61 (1H, dd, J = 8.2, 0.8
Hz), 9.40-9.39 (1H, m), 13.78 (1H, br s).
1H-NMR (DMSO-D6) 8:2.50 (3H, s), 5.41
F
Clt F (2H, s), 7.29-7.24 (1H, m), 7.35 (2H, dd, J
=
N- 0 4.9, 1.1 Hz), 7.43-7.39 (2H, m), 7.56 (2H,
dd,
2-100 \ ,N 537
N---( b J = 7.7, 4.2 Hz), 7.67 (1H, d, J = 8.6 Hz),
7.73 539
Ha OH ¨ (2H, d, J = 8.6 Hz), 7.86-7.78 (2H, m),
8.36
(2H, d, J = 8.6 Hz), 8.59-8.57 (1H, m).
1H-NMR (DMSO-D6) 8:2.34 (3H, s), 5.41
F _p =
(2H, s), 7.27 (1H, d, J = 7.7 Hz), 7.34 (1H, t, J
FIC F F = 7.7 Hz), 7.43-7.39 (4H, m), 7.56 (1H, d, J
=
N- 0
2-101 \ 7.7 Hz), 7.68 (1H, d,
J = 8.4 Hz), 7.72 (2H, 539 537
µrs14N HCI b dd, J = 6.7, 1.9 Hz), 7.87-7.78 (2H, m), 8.35
OH
(2H, dd, J = 6.7, 1.9 Hz), 8.59 (1H, d, J = 4.4
Hz).
1H-NMR (DMSO-D6) 8:2.35 (3H, s), 5.40
F_n,
F (2H, s), 7.27 (2H, d, J = 7.9 Hz), 7.42-7.37
F (2H, m), 7.49 (2H, d, J = 7.9 Hz), 7.56 (1H,
d,
N=r90-,
2-102 H,C ¨ , N )-. J = 7.9 Hz), 7,67
(1H, d, J = 8.6 Hz), 7.71 539 537
OH N \..) (2H, d, J = 8.6 Hz), 7.85-7.77 (2H, m), 8.34
HCI (2H, d, J = 8.6 Hz), 8.58 (1H, dq, J = 4.9,
0.9
Hz).
1H-NMR (DMS0-06) 6:5.39 (2H, s), 7.39-
F F F 7.35 (2H, m), 7.56 (1H, d, J = 7.9 Hz), 7.69-
F FN_ o 7.64 (2H, m), 7.72 (2H, dd, J = 6.7, 1.9
Hz),
2-103 593 591
,õ, 783-7 = ' N , 7 H m 7 9-
7 85 2H m 8.39
, o 5 (3 ' ), '8= ( ' ),
HCI OH ¨ (2H, dd, J = 6.7, 1.9 Hz), 8.57 (1H, d, J
= 4.9
Hz).
1H-NMR (DMSO-D6) 8:5.40 (2H, s), 7.40-
F F FF) 2 7.36 (2H, m), 7.56 (1H, d, J = 7.9 Hz), 7.67
F
/ \ _ / \ 0-b (1H, d, J = 8.6 Hz), 7.72 (11-1, d, J = 7.9
Hz),
2-104 593 591
_ \ N , \ 7.84-7.76 (5H, m), 7.92 (1H, d, J =
7.7 Hz),
HCI OH ¨ 7.99 (1H, br s), 8.37 (2H, dd, J = 6.8,
2.0 Hz),
8.57 (1H, dq, J = 4.9, 0.9 Hz).
F _p
F 1H-NMR (DMSO-D6) 5:5.40 (21-1, s), 7.41-
F 7.36(211, m), 7.56(111, d, J = 7.9 Hz), 7.68
N- 0
2-105 FF
= .... ,,N )3 (1H, d, J = 8.6 Hz), 7.84-7.77 (8H, m),
8.37 593 591
\OH - (2H, dd, J = 6.7, 1.9 Hz), 8.57 (1H, d, J
= 4.9
HCI Hz).
F+i 1H-NMR (DMSO-D6) 6: 5.40 (211, s), 7.41-
F 7.36 (2H, m), 7.51-7.45 (3H, m), 7.57 (1H,
d,
N- 0 J = 7.7 Hz), 7.64-7.60 (2H, m), 7.68 (1H, d,
J
2-106 =
\N4N N' \ = 8.4 Hz), 7.84-7.79 (3H, m), 8.10 (1H,
dd, J 543 541
. F HCI OH ¨ = 10.5, 1.4 Hz), 8.19 (1H, dd, J =
8.2, 1.5 Hz),
8.57 (1H, dq, J = 4.9, 0.9 Hz).
F FF)
1H-NMR (DMS0-06) 8:2.54 (3H, s), 5.45
Q
(2H, s), 7.30(111, td, J = 7.6,1.1 Hz), 7.44-
FN=( b
2-107 ¨ / \ 7.35 (3H, m), 7.56-7.50 (1H, m), 7.58 (1H,
d,
557 555
¨ , N NJ( ' \ J = 7.9 Hz), 7.71-7.67 (2H, m),
7.75 (2H, dd, J
HO' OH ric = 6.7, 1.9 Hz), 7.81 (1H, t, J = 7.9 Hz),
7.92
(1H, br s), 8.36 (2H, dd, .1= 6.7, 1.9 Hz).
249
CA 02936408 2016-06-29
[ 0 7 9 6 ]
[Table 2-13]
1H-NMR (DMSO-D6) 6: 2.52 (3H, s), 5.43
2-108
FF+2 (2H, s), 7.33 (1H, d, J = 7.7 Hz), 7.38 (1H, d,
CI F
N- 0 J = 7.7 Hz), 7.43 (1H, td, J = 7.7, 1.4 Hz),
= ,N4r4 , , 7.48 (1H, td, J = 7.7, 1.9 Hz), 7.57
(1H, d, J = 573 571
- 8.0 Hz), 7.63 (1H, dd, J = 8.0, 1.2 Hz), 7.68
HCI CH 1-1,C (1H, d, J = 8.3 Hz), 7.76-7.72 (3H, m), 7.81
(1H, t, J = 8.3 Hz), 7.90-7.84 (1H, m), 8.37
(2H, dd, J = 6.7,1.9 Hz).
F_)__) 1H-NMR (DMSO-D6) 6: 2.51 (3H, s), 3.88
H,C0 F (3H, s), 5.41 (2H, s), 7.00 (1H, td, J = 7.5,0.9
F
- 0 Hz), 7.12 (1H, d, J = 7.9 Hz), 7.29 (1H, d, J =
= ,N4N N, \ 7.9 Hz), 7.34 (1H, d, J = 7.5 Hz), 7.43 (1H,
2-109 569 567
HCI OH - ddd, J = 8.8, 7.1, 1.3 Hz), 7.52 (1H, dd, J .
NCI NC 7.5, 1.7 Hz), 7.57 (1H, d, J = 7.9 Hz), 7.69-
7.66 (3H, m), 7.85-7.78 (2H, m), 8.34 (2H, dd,
J = 6.8, 2.0 Hz).
FF) 2 1H-NMR (DMSO-D6) 6: 2.24 (3H, s), 2.49
F
_ 0 (3H, s), 5.41 (2H, s), 7.22 (1H, br s), 7.31
2-110 = L4N -_c,õ (1H, br s), 7.46-7.43 (3H, m), 7.60-7.57 (3H, 553
551
- m), 7.72-7.68 (31-1, m), 7.82 (1H, t, J = 8.3
OH H C
Hz), 8.33 (2H, dd, J = 6.7, 1.8 Hz).
F 1H-NMR (DMS0-06) 6: 5.42 (2H, d, J = 1.6
Fr*NPO Hz), 7.42-7.48 (4H, rn), 7.54(1K, 1, J = 4.2
2-111 = N -6 Hz), 7.59-7.63 (2H, m), 7.64-7.73 (3H, m), 543 541
7.81 (2H, d, J = 4.2 Hz), 8.29 (2H, d, J = 8.6
HCI OH -
Hz), 8.35-8.37 (1H, m).
4 n
1H-NMR (DMSO-D6) 6:5.37 (2H, s), 7.37
,_.
(1H, d, J = 8.3 Hz), 7.44-7.48 (3H, m), 7.55
-1-ko (1H, d, J = 7.6 Hz), 7.58-7.66 (3H, m), 7.73
2-112 = 559 557
(2H, d, J = 8.6 Hz), 7.79 (1H, t, J = 8.1 Hz),
OH - 7.88 (1H, dd, J = 8.6, 2.3 Hz), 8.34 (2H, d, J =
HO
CI 8.6 Hz), 8.59 (1H, d, J = 2.3 Hz).
1H-NMR (DMSO-D6) 6: 2.27 (3H, s), 5.43
F,
(2H, s), 7.35 (1H, s), 7.39 (11-1, d, J = 5.8 Hz),
N 0
2-113 =. ,Nrif;\ --b_ 7.44-7.48 (3H, m), 7.57-7.63 (3H,
m), 7.69- 539 537
CH, 7.75 (3H, m), 7.83 (1H, t, J = 8.1 Hz), 8.35
HCI OH -
(2H, d, J = 8.3 Hz), 8.51 (1H, d, J = 5.3 Hz).
FF* 1H-NMR (DMSO-D6) 6: 7.36 (1H, d, J = 7.9
O Hz), 7.44-7.48(3K, m), 7.56 (1H, d, J = 7.9
2-114 = ' _,sr, - Hz), 7.59-7.63 (2H, m), 7.66-7.75
(4H, m), 539 537
N---k
H. OH - 7.79 (1H, t, J = 8.1 Hz), 8.34 (2H, d, J = 8.6
CH, Hz), 8.44 (11-I, s).
r> 1H-NMR (DMSO-D6) 6: 5.36(2K, s), 7.41
_i
F - (11-I, dd, J = 8.8, 4.4 Hz), 7.44-7.48 (3H, m),
0 7.55 (1H, d, J = 7.9 Hz), 7.58-7.63 (2H, m),
2-115 = p ' N
7.55.7.75)4K, m), 7.79 (1H, t, J = 8.1 Hz), 543 541
HCI OH - 8.34(2K, d, J = 8.6 Hz), 8.53 (1H, d, J = 3.0
F Hz).
F ...
F 1H-NMR (DMSO-D6) 6: 2.53(3K, s), 5.44
F F 2(2H, s), 7.54-7.30 (6H, m), 7.58 (1H, d, J =
N- 0
2-116 7.7 Hz), 7.69(1K, d, J = 8.0 Hz), 7.74 (2H, 557 555
N--OH N -' dd, J = 6.8, 1.8 Hz), 7.81 (1H, t, J = 8.0 Hz),
HCI HC 7.90 (11-1, br s), 8.35 (2H, dd, J = 6.8, 1.8 Hz).
250
'
CA 02936408 2016-06-29
[0 7 9 7 ]
[Table 2-14]
FF-}-- 1H-NMR (DMSO-D6) 6: 2.51 (3H, s), 5.42
F
_ 0 (2H, s), 7.33-7.29 (3H, m), 7.37 (1H, d, J =
2-117 F , N ,,N 7. 9 Hz)' . 7 57 (1H, d, J = 7.9
Hz), 7.69-7.65 557 555
--( N '
OH - (3H, m), 7.72 (2H, dd, J = 6.8, 1.8 Hz), 7.89-
NCI HC 7.78 (2H, in), 8.34 (2H, dd, J = 6.8, 1.8 Hz).
FFF*0 1H-NMR (CDC13) 6: 3.87 (3H, s), 5.27 (2H,
5)6.61 (1H, d, J= 8.2 Hz), 6.86(1k, d, J=
¨ 7.3 Hz), 7.31 (1H, d, J = 8.6 Hz), 7.35-7.39
2-118
N44 ' \ (3H, m), 7.43-7.51 (2H, m), 7.63-
7.60 (3H, 555 553
OH -
a, m), 7.64 (2H, d, J = 8.4 Hz), 8.50 (2H, d, J =
CH3 8.4 Hz).
FFIO. 1H-NMR (DMSO-D6) 6: 5.10 (2H, s), 6.16-
6.32 (2H, m), 7.32-7.38 (1H, m), 7.44-7.48
N4 b
2-119 = ' N õ (3H, m), 7.54-7.63 (4H, m), 7.70-
7.75 (2H, 541 539
N={ N OH >
_s m), 7.77-7.84 (1H, m), 8.34 (2H, d, J = 8.6
HO Hz).
F42
FF 1H-NMR (DMSO-D6) 6: 3.89 (3H, s), 5.48
(2H, s), 7.20-7.26 (2H, m), 7.44-7.49 (3H, m),
2-120 = 'N44 ,_,õ 7.58-7.64 (3H, m), 7.69-7.75 (3H,
m), 7.84 555 553
OH ¨ CH (1H, t, J = 8.2 Hz), 8.33 (2H, d,
J = 8.6 Hz),
HCI
8.56 (1H, d, J = 6.0 Hz).
F _,
FF 1H-NMR (DMSO-D6) 6: 5.47(2k, s), 7.44-
7.48(3k, m), 7.55-7.63 (4H, m), 7.68 (1H, d,
2-121 ¨ ' µ,N o , \ J = 8.6 Hz), 7.73 (2H, d, J = 8.6
Hz), 7.78- 593 591
N=coH - 7.84 (2H, m), 8.03 (1H, t, J = 8.1 Hz), 8.35
F (2H, d, J = 8.6 Hz), 13.58 (1H, br s).
F F
;4- 1H-NMR (DMSO-D6) 6: 5.47(2k, s), 7.44-
F
, o 7.51 (4H, in), 7.56-7.63 (3H, m), 7.67-734
2-122 ' 593 591
NN=.<N -64\ FF (4H, m), 7.82 (1H, t, J = 8.1 Hz), 8.34 (2H, d,
Ho OH - F J = 8.6 Hz), 8.83 (1H, d, J = 5.1 Hz).
F p 1H-NMR (DMS0-06) 6: 2.50 (3H, s), 5.40
F
CI (2H, s), 7.29 (1H, d, J - 7.7 Hz), 7.33 (1H, d,
FN_ 0
J = 7.7 Hz), 7.59-7.46 (4H, m), 7.68 (1H, d, J õ.,
2-123 = 571
µNj(N N' \ = 8.4 Hz), 7.71-7.69 (1H, m),
7.75 (2H, dd, J '' '
OH >- = 6.7, 1.9 Hz), 7.84-7.78 (2H, m), 8.36(2k.
FICI H,C
dd, J = 6.7, 1.9 Hz).
F
p+_$, 1H-NMR (DIVIS0-06) 5: 2.49(3k, s), 5.39
(2H, s), 7.26 (1H, d, J .-- 7.5 Hz), 7.31 (1H, d,
F
N- 0 J = 7.5 Hz), 7.53(2k, dt, J = 8.7, 2.2 Hz),
2-124 ci µN4N -0 7.56 (1H, d, J - 7.9 Hz), 7.63 (2H, dt, J = 8.7, 573
571
OH - 2.2 Hz), 7.67 (1H, d, J = 8.4 Hz), 7.74 (2H,
HC, H,C
dd, J = 6.7, 1.9 Hz), 7.83-7.76 (2H, m), 8.35
(2H, dd, J = 6.7, 1.9 Hz).
1H-NMR (DMSO-D6) 6: 2.50 (3H, s), 3.80
oCH
F' (3H, s), 5.40 (2H, s), 7.03 (1H, dq, J = 8.6, 1.2
II(F
N- 0 Hz), 7.19-7.14(2k, m), 7.29(1k, d, J = 7.3
....=
2-125 µ1,4_4'N ' \ Hz), 7.39-7.32(2k, m), 7.57(1k,
d, J - 7.9 569 567
OH - Hz), 7.67 (1H, d, J = 8.6 Hz), 7.73 (2H, dd, J
HG I HC
= 6.7, 1.9 Hz), 7.85-7.77 (2H, m), 8.34 (2H,
dd, J = 6.7, 1.9 Hz).
251
CA 02936408 2016-06-29
[0798]
[Table 2-15]
1H-NMR (DMSO-D6) 6: 2.49 (3H, s), 3.81
FF+p
F (3H, s), 540 (2H, s), 7.01 (2H, dt, J = 9.5, 2.4
H,qo _ o Hz), 7.28 (1H, d, J = 6.8 Hz), 7.32 (1H, d, J =
2-126567
)14N Nz \ 7.5 Hz), 7.57-7.53 (3H, m), 7.70-7.66 (3H, m), 569
OH ¨
nct i.IG 7.80 (2H, t, ,J = 7.9 Hz), 8.33 (2H, dd, .1 = 6.8,
2.0 Hz).
1H-NMR (DMSO-D6) 6:2.35 (3H, s), 2.51
F
F (3H, s), 5.42 (2H, s), 7.27 (2H, d, J = 7.7 Hz),
N_ 0 7.32 (1H, d, J = 7.7 Hz), 7.36 (1H, d, J = 7.7
2-127 1-13C 551
µ1,14N ..b Hz), 749 (2H, d, J = 8.2 Hz), 7.57 (1H, d, J = 553
OH
HCI H, C 7.7 Hz), 7.72-7.66 (3H, m), 7.88-7.77 (2H, m),
8.33 (2H, dd, J = 6.7, 1.9 Hz).
1H-NMR (DMSO-D6) 6:1.19 (3H, t, J = 7.5
F ...._n Hz), 2.52 (3H, s), 2.65 (2H, q, J = 7.6 Hz),
F
5.43 (21-I, s), 7.30 (2H, d, J = 8.4 Hz), 7.34
i-IC ill _ yM N=C\C) (1H, d, J = 7.7 Hz), 7.39 (1H, d, J = 7.7 Hz),
2-128 567 565
N¨( N 7.52 (2H, d, J = 8.4 Hz), 7.57 (1H, d, J = 7.7
OH ¨
HCI H,c HZ), 7.72-7.67 (3H, m), 7.81 (1H, t, J = 8.3
Hz), 7.87(1H, br s), 8.33 (2H, dd, J = 6.7, 1.9
Hz).
F F
F-X FF 4
1H-NMR (DMSO-D6) 6: 2.51 (3H, s), 5.42
0 F - (2H, s), 7.32 (1H, d, J = 7.1 Hz), 7.37 (1H, d,
N 0
2-129 , ,N õ J = 7.7 Hz), 7.63-7.42(4K, m),
7.72-7.67 (3H, 623 621
N N : m), 7.89-7.77 (3H, m), 8.37 (2H, dd, J = 6.8,
OH ..
HCI Ftc 2.0 Hz).
1H-NMR (DMSO-D6) 6:2.55 (3H, s), 5.47
F
FFAF F = 0 2-130 (2H, s), 7.40 (1H, d, J = 7.1 Hz), 7.48-7.43
o = (3H, m), 7.58 (1H, d, J = 7.7 Hz), 7.69 (1H, d,
µN-2(N N' \ J = 8.5 Hz), 7.77-7.72 (4H, m), 7.82 (1H, t, J 623
621
H OH ¨
CI HC = 8.5 Hz), 7.95 (1H, br s), 8.35 (2H, dd, J =
6.7, 1.9 Hz).
252
CA 02936408 2016-06-29
[07991
[Table 3-1]
Example Structure NMR MS(M+H) MS(M-K)
Note
FF F
* 1 H-NMR (DMSO-D6) 8:2.19 (6H, s), 2.30
3-1 H,C (3H, s), 7.01 (2H, s), 7.90 (2H, d, J = 8.4 Hz),
360 358
N1 rs * /¨I 8.51 (2H, d, J = 8.4 Hz), 13.26 (1H, br s).
>=N
HO H,C
F _F_
1H¨NMR (DMSO-D6) 6: 3.72 (3H, s), 4.59
(2H, d, J = 5.5 Hz), 5.41 (1H, t, J = 5.5 Hz),
ci
3-2
N\ 7.45 (1H, d, J = 8.4 Hz), 7.67 (1H, d, Si = 8.4 412
410
Hz), 7.92 (2H, d, J = 8.4 Hz), 8.53 (2H, d, J =
HO 0, =H 8.4 Hz), 13.70 (1H, br S).
CH,
F F
F--\_
1H-NMR (DMSO-D6) 6: 2.31 (3H, s), 3.71
3-3
(3H, s), 7.36 (1H, d, J = 8.4 Hz), 7.49 (1H, d, 396 N' N-C-, J = 8.4
Hz), 7.93 (2H, d, Si = 8.3 Hz), 8.53 394
)=N (2H, d, Si = 8.3 Hz), 13.67 (1H, br s).
HO 0 CH.
CH,
F F
F--__.
1H-NMR (DMSO-D6) 6: 1.39(3H, t, J = 7.0
Hz), 2.30 (3H, s), 3.94 (2H, q, J = 7.0 Hz),
3-4 7.34 (1H, d, J = 8.2 Hz), 7.48 (1H, d, Si = 8.2 410
408
N i N¨C::\, Hz), 7.93 (2H, d, J = 8.2 Hz), 8.53 (2H, d, J =
)=¨N
HO 0 CH, 8.2 Hz), 13.66 (1H, br s).
"¨CU,
,!_\ 1H-NMR (DMSO-D6) 6:1.91 (3H, s), 3.74
(3H, s), 4.32(2K, d, J = 5.8 Hz), 7.43 (1H, d,
0
3-5
,,r_Nµ * J = 8.4 Hz), 7.49 (1H, d, Si = 8.4 Hz), 7.92 453 451
H (2H, d, J = 8.4 Hz), 8.42 (1H, t, J = 5.8 Hz),
H gCH, r)i.--CH, 8.53(2H, d, J = 8.4 Hz), 13.73 (1H, br s).
0
F F
F
1H-NMR (DMSO-D6) 6: 2.17 (3H, s), 4.55
(2H, d, Si = 5.1 Hz), 5.35 (1H, t, J = 5.2 Hz),
3-6 a 7.48 (1H, d, J = 8.4 Hz), 7.60 (1H, d, Si = 8.4 396
394
N" 14\ * Hz), 7.91 (2H, d, J = 8.6 Hz), 8.51 (2H, d, J =
8.6 Hz), 13.61 (1H, br S).
HO H,C OR
,
_., \
FF F
3-7 --j-- a 1 H-NMR (DMSO-D6) 6: 1.90(3H, s), 2.21
(3H, s), 4.28(2K, d, J = 5.7 Hz), 7.41 (1H, d,
J = 8.4 Hz), 7.47 (1H, d, J = 8.4 Hz), 7.91 437 435
', If H (2H, d, Si = 8.2 Hz), 8.37(1K, t, J = 5.8 Hz),
HO H,C I.1 8.51 (2H, d, J = 8.2 Hz), 13.62 (1H, br s).
._, __,,F F
F
11-I-NMR (DMSO-D6) 6: 1.16 (9H, s), 2.21
c (3H, s), 4.27 (2H, d, J = 5.7 Hz), 7.34 (1H, d,
3-8 ,4 / , a J -= 8.4 Hz), 7.46 (1H, d, Si = 8.4 Hz), 7.91 479
477 '
H (2H, d, Si = 8.2 Hz), 8.09 (1H, 1, J = 5.6 Hz),
HO H,C Ni CH
( CH 8.51 (2H, d, J = 8.2 Hz), 13.64 (1H, br s).
253
- CA 02936408 2016-06-29
108001
[Table 3-2]
F F
F
1H-NMR (DNISO-D6) 6: 232(3H, s), 3.47
(2H, t, J = 4.9 Hz), 3.88 (2H, t, J = 4.8 Hz),
3-9 -_0::? 4.70 (1H, br s), 7.34 (1H, d, J = 8.1 Hz), 7.47 426
424
N)_,,,.
(1H, d, J = 8.1 Hz), 7.92 (2H, d, J = 8.4 Hz),
HO 0 CH, 8.51 (2H, d, J = 8.4 Hz), 13.56 (1H, br s).
\--\OH
. . .
F F
F--r
1H-NMR (DMSO-D6) 8:1,33 (9H, s), 2.22
a (3H, s), 4.30 (2H, d, J = 6.0 Hz), 7.52-7.54
3-10 ,
l'="N * L.! (2H, m), 7.60 (1H, d, J = 8.4 Hz), 7.91 (2H, d, 515
513
J = 8.4 Hz), 8.51 (2H, d, J = 8.4 Hz), 13.65
Ho H3C .,, ,
(1H, br s).
O'Sx_cm,
H,C CH,
.ir.F F , j,>_;,;
F
1H-NMR (DMS0-06) 6: 3.79-3.87 (3H, m),
7.28 (1H, dd, J = 9.3, 3.7 Hz), 7.67 (1H, t, J '-
3-11 400 398
9.2 Hz), 7.93 (2FI, d, J = 8.6 Hz), 8.51 (2H, d,
>=KI J = 8.6 Hz), 13.68 (1H, br s).
HO 0,
CH,
( j-02_\.,
1H-NNIR (DMSO-D6) 6: 3.82 (3H, s), 5.22
(2H, s), 7.17 (2H, d, J = 9.0 Hz), 7.24-7.27
CI F
(1H, br m), 7.35 (1H, t, J = 7.2 Hz), 7.41 (2H, 438
3-12 ¨1/ I'S 436
1, J = 7.3 Hz), 7.47 (2H, d, J = 7.1 Hz), 7.63-
)=N
7.66 (1H, br m), 8.28 (2H, d, J = 9.0 Hz),
HO 0,
CH, 13.26 (1H, br s).
11-1-NMR (DMSO-D6) 6:2.36 (3H, s), 5.01
ci cH3 (2H, s), 7.11-7.15 (1H, m), 7.22 (1H, d, J =
7.7 Hz), 7.39 (1H, d, J = 8.4 Hz), 7.52 (1H, d,
3-13 F N¨ 0 473 471
J = 8.4 Hz), 7.60 (1H, td, J = 7.7, 1.7 Hz),
F N4 NI \ 7.86 (2H, d, J = 8.4 Hz), 8.31 (1H, d, J = 4.0
OH ¨ Hz), 8.41 (2H, d, J = 8.4 Hz), 13.61 (1H, br s).
6,0
H,C)---b_ 1H-NMR (DMSO-D6) b: 0.88 (6H, d, J = 6.6
Hz), 1.41 (6H, s), 1.83-1.95 (1H, m), 2.19
Ci
N (3H, s), 2.54 (2H, d, J = 7.3 Hz), 4.33 (2H, d,
3-14 N , * 521 519
)=N H J = 5.5 Hz), 7.28-7.38 (3H, m), 7.46 (1H, d, J
N,
HO 4,0 CH, = 8.4 Hz), 8.24 (2H, d, J = 8.2 Hz), 8.52-8.60
,_ØHF,
,, (1H, m), 13.35 (1H, br s).
F F
1H-NMR (DMSO-D6) 6:0.88 (6H, d, J = 6.6
H,2-t)_ Hz), 1.18(3H, t, J = 7.1 Hz), 1.83-1.94 (1H,
m), 2.19 (3H, s), 2.54 (2H, d, J = 7.1 Hz),
0
4.02 (2H, q, J = 7.1 Hz), 4.21 (2H, d, J = 5.7
3-15 \ 1r Hz), 7.33 (2H, d, J = 8.4 Hz), 7.39 (1H, d, J = 455
453
H HO HaO 8.2 Hz), 7.46 (1H, d, J = 8.2 Hz), 7.69-7.75
N
¨c-J (1H, m), 8.24 (2H, d, .J = 8.4 Hz), 13.33 (1H,
0 \--CH, br s). .
1, IV 1H-NMR (DMSO-D6) 6: 0.91 (3H, t, J = 7.3
CI
Hz), 1.37 (6H, s), 1.60-1.67 (2H, m), 2.33
3-16 's---N CH,
H F F (3H, s), 2.62 (2H, t, J = 7.6
Hz), 4.31 (2H, d, J 507 505
HO NI, F = 5.7 Hz), 7.30-7.38 (3H, m), 7.52 (1H, s),
(--c-#3 8 10 8 15 (2H, m), 8.48 (1H, t, J = 5.7 Hz).
254
CA 02936408 2016-06-29
[0801]
[Table 3-3]
<1 _ el 1H-NMR (DMS0-06) 0: 0.35 (2H, dt, J = 8.0,
2.9 Hz), 0.59 (2H, ddd, J = 9.1, 5.0, 2.9 Hz),
1.20-1.29 (1H, m), 1.38 (6H, s), 2.35 (3H, s),
3-17 ,i,, N, .CH, 3.93 (2H, d, J = 7.0 Hz),
4.32 (2H, d, J = 5.6 535 533
..
HO
W CH, Hz), 7.05 (2H, d, J = 8.8 Hz), 7.44 (1H, s),
)/ VE,-,= 7.56 (1H, s), 8.29 (2H, d, J = 8.8 Hz), 8.49
0
F F (1H, t, J = 5.6 Hz), 13.08 (1H, br s).
CH,
1H-NMR (DMSO-06) b: 0.99 (6H, d, J = 6.6
Hz), 1.41 (6H, s), 1.98-2.10 (1H, m), 2.18
C_,4 c, (3H, s), 3.85 (2H, d, J = 6.6 Hz), 4.32 (2H, d,
3-18 N' , *
)--. J = 5.7 Hz), 7.06(2K, d, J = 8.4 Hz), 7.30 537
535
H
(1H, d, J= 8.2 Hz), 7.44 (1H, d, J = 8.2 Hz),
HO H,C N CH , ......,,,
) e ts.zi (2H, d, J = 8.4 Hz), 8.52-8.59 (1H, m),
0 )c: F 13.23 (1H, br s).
F F
,
<F7en
a 1H-NMR (DM60-D6) 0:0.35 (2H, td, J = 5.2,
4.1 Hz), 0.57-0.62 (2H, m), 1.24-1.27 (1H, m),
3-19 N,
CH, 2.61 (3H, s), 3.94 (2H, d, J = 7.2 Hz), 7.09 412
410
N)=N
(2H, d, J = 8.8 Hz), 7.64 (1H, s), 8.27 (1H, s),
HO OH 8.30 (2H, d, J = 8.8 Hz), 13.20 (2H, br s).
0
<Clip
e¨N,
a 1H-NMR (DIVISO-D6) b: 0.35 (2H, td, J = 5.1,
4.1 Hz), 0.58-0.60 (2H, m), 1.22-1.30 (1H, m),
2.45 (3H, s), 3.94 (2H, d, J = 7.2 Hz), 7.09
3-20 (2H, d, J = 9.1 Hz), 7.56 (2H, s), 7.81 (1H, s),
411 409
)=N ,
7.85 (1H, s), 8.32 (2H, d, J = 8.8 Hz), 13.06
CH 1-10 NH,
O (1H, br s).
(-1E?
Cl_ 1H-NMR (DMSO-D6) 6: 0.35(2H, td, J = 5.2,
4.0 Hz), 0.57-0.62 (2H, m), 1.22-1.27 (1H, m),
2.42 (3H, s), 2.77 (3H, d, J = 4.7 Hz), 3.94
3-21 )/--", ¨ 425 423
CH,
H (2H, d, J = 7.0 Hz), 7.09 (2H, d, J = 9.1 Hz),
7.56 (1H, s), 7.77 (1H, s), 8.31 (2H, d, J = 9.1
HO 14,
0 CH3 Hz), 8.32 (1H, s), 13.09 (1H, br s).
<7-00
a 1H-NMR (DMSO-D6) b: 0.35(2K, td, J = 5.6,
4.4 Hz), 0.57-0.61 (2H, m), 1.21-1.29 (1H, m),
3-22 )¨N
i \
CH3 2.28 (3H, s), 2.81 (3H, s), 3.02 (3H, s), 3.93
(2H, d, J = 7.2 Hz), 7.08 (2H, d, J = 9.1 Hz), 439 437
Isl=-N Plt 7.59 (1H, s), 7.62(11-I, s), 8.30 (214, d, J =
9.1
N,
0 CH, Hz), 13.10 (1H, br s).
= 1H-NMR (DMSO-D6) 6: 0.35 (2H, td, J = 5.3,
4 . 4.0 Hz), 0.57-0.61 (21-1, m), 0.90 (3H, t, J =
7.3 Hz), 1.20-1.30 (2H, m), 1.30-1.40 (2H, m),
ci
N 1.46-1.53 (2H, m), 2.41 (3H, s), 3.24 (2H, q, J
3-23 N \ 465
=
6.9 Hz), 3.94 (2H, d, J = 7.2 Hz), 7.09 (2H, 467
HO N
" d, J= 9.1 Hz), 7.56(1K, s), 7.74 (1H, s), 8.31
0
(2H, d, J = 9.1 Hz), 8.37 (1H, t, J = 5.5 Hz),
13.09(1H, br s).
[0802]
Experimental Example 1: Evaluation of human mPGES -1 enzyme
inhibitory activity
The human mPGES -1 enzyme inhibitory activity of a test
article was evaluated according to the report of Xu et al. (XU,
D et al. MF63 [2 -(6 -chloro -1H -phenanthro[9,10 -d]imidazol -2 -yl) -
isophthalonitrile], a selective microsomal prostaglandin E
255
CA 02936408 2016-06-29
synthase-1 inhibitor, relieves pyresis and pain in preclinical
models of inflammation. J Pharmacol Exp Ther. Sep 2008, Vol.326,
No.3, pages 754-763). That is, the amount of PGE2 produced by
human mPGES-1 in the presence of a test article was measured by
the HTRF (homogeneous time resolved fluorescence) method, based
on which the human mPGES-1 enzyme inhibitory activity of the
test article was determined.
[0803]
1) Preparation of human mPGES-1 expressing cell microsome
/o fraction
A DNA fragment containing human mPGES-1, which is added
with a BamHI recognition cleavage sequence immediately before
the translation initiation codon and an EcoRI recognition
cleavage sequence immediately after the translation termination
codon was amplified by the PCR (Polymerase Chain Reaction)
method using a human mPGES-1 expression plasmid DNA (pME-
185/iPGES-1) prepared in-house as a template. The purified DNA
fragment was digested with BamHI and EcoRI, and ligated to
pcDNA3.1(+) (Invitrogen, model number V790-20), similarly
digested with BamHI and EcoRI, by using a DNA Ligation kit
ver.2.1 (Takara Bio, model number 6022). The human mPGES-1
expression plasmid DNA was isolated from Escherichia coli DH5a
(TOYOBO, model number DNA-903) transformed with the obtained
ligation product. The base sequence of human mPGES-1 cloned to
a vector was determined by the Dye Terminator method by using
BigDye Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems,
#4337455). The determined sequence was identical with the
sequence of the protein translational region of human mPGES-1
(Accession number NM 004878) registered in the NCBI Reference
Database.
Human mPGES-1 expression plasmid DNA was transfected into
Chinese hamster ovary-derived cells (Freestyle CHO-S Cell,
Invitrogen, #R800-07) by using a transgene reagent (FreeStyle
MAX Reagent (Invitrogen, #16447-100)), and cultured with
shaking (8% CO2, 37 C) in a medium containing 8 mmol/L L-
256
CA 02936408 2016-06-29
glutamine (GIBCO FreeStyle CHO Expression Medium, Invitrogen,
#12651-022) for 48 hr.
The CHO-S cells were suspended in Homogenate Buffer (100
mmol/L potassium phosphate (pH 7.4), 250 mmol/L Sucrose, 100
mmol/L EDTA, complete EDTA free (Roche, #1873580)). Using an
ultrasonic disruptor UD-201 (Tomy Seiko), the suspended cells
were disrupted at output:3, duty cycle:50 for 30 seconds. The
precipitate was removed by centrifugation (1,000xg, 5 min, 4 C),
and the supernatant was centrifuged (5,000xg, 10 min, 4 C)
/o The supernatant was further centrifuged (105,000xg, 60 min,
4 C). The obtained precipitate was suspended in Resuspension
Buffer (100 mmol/L potassium phosphate (pH 7.4), 250 mmol/L
sucrose, 100 mmol/L EDTA, 10% glycerol) to give a microsome
fraction.
The protein concentration of the microsome fraction was
measured by the Bradford method (Protein Assay Kit, Bio-Rad).
The microsome fraction was rapidly frozen in liquid nitrogen
and preserved at -80 C. Human mPGES-1 in the microsome
fraction was detected by Western Blot using rabbit anti-mPGES-1
polyclonal antibody (ThermoFisher Scientific, #PA1-10264).
[0804]
2) Evaluation of human mPGES-1 enzyme inhibitory activity
A test article solution diluted with 0.1 mol/L potassium
phosphate, pH 7.4 (hereinafter to be referred to as KPB) or
DMS0 (Nacalai Tesque, #13407-45) was added at 5 pL/well to 96
well V-bottom plate (Corning, #3363). The final DMSO
concentration during the reaction was set to 2%(v/v).
Furthermore, a microsome fraction of CHO-S cells expressing
human mPGES-1, which was diluted with reduced GSH (12.5 mmol/L
KPB solution, SIGMA, #G6529-25G) such that the protein
concentration was 5 pg/mL, was added at 20 pL/well. The amount
of the microsome fraction used is the amount of microsome
fraction within a range where the amount of PGE2 produced under
the reaction conditions shown below and the amount of microsome
fraction used show linearity. To the blank was added reduced
257
CA 02936408 2016-06-29
GSH (12.5 mmol/L KPB solution) at 20 pL/well. After stirring
at room temperature for 10 min, PGH2 (PGH2 dissolved in cold
acetone to 100 pg/mL and diluted with D-PBS(-) (Nikken
biomedical laboratory, #CM6201) to 10 pg/mL, Cayman Chemical,
#17020) was added at 25 pL/well, and the mixture was stood at
room temperature for 45 seconds. Tin(II) chloride dihydrate (2
mg/mL 10 mmol/L citric acid solution, Wako Pure Chemical
Industries, Ltd., #204-01562) was added at 50 pL/well, and the
plate was gently shaken to discontinue the enzyme reaction.
The concentration of PGE2 in the above-mentioned enzyme
reaction mixture was measured using Prostaglandin E2 assay
(CISbio Bioassays, #62P2APEC) according to the manual. As the
reference standard for analytical curve, PGE2 (Cayman Chemical,
#14010) was used. Using RUBYstar (BMG Labtech), the time-
resolved fluorescence at 620 nm and 665 nm relative to the
excitation light at 337 nm was measured. PGE2 concentration
was extrapolated from the PGE2 analytical curve. Average of
the PGE2 concentrations of the respectively-treated wells was
used as the data.
The mPGES-1 enzyme inhibitory activity (%) of the test
article was calculated according to the following formula 1.
[formula 1]
mPGES-1 enzyme inhibitory activity (%) = (PGE2A - PGE2x)/(PGE2A
- PGE23) x 100
PGE2A: PGE2 concentration of vehicle-treated well
PGE2B: PGE2 concentration of blank well
PGE2x: PGE2 concentration of test article-treated well
The I050 value (50% inhibitory concentration) of the test
article was calculated according to the following formula 2.
[formula 2]
IC50 value = 10 {log10 (D / E) (50 - G) / (F - G) + log10 (E)
D: concentration of test article that shows activity of not
less than 50% inhibition between two points across 50%
inhibition
E: concentration of test article that shows activity of not
258
CA 02936408 2016-06-29
more than 50% inhibition between two points across 50%
inhibition
F: mPGES-1 enzyme inhibitory activity (%) when concentration of
test article is D
G: mPGES-1 enzyme inhibitory activity (%) when concentration of
test article is E
The results are shown in Table 4-1 to Table 4-9.
259
CA 02936408 2016-06-29
[0805]
[Table 4-1]
Human mPGES-1 Human mPGES-1 Human m PGES-1
Example enzyme inhibitory Example enzyme inhibitory Example enzyme inhibitory
activity (pM) activity (pM) activity (pM)
1-1 0.813 1-18 0.114 1-35 0.022
1-2 0.138 1-19 0.411 1-36 0.0007
1-3 0.164 1-20 0.0016 1-37 0.0008
1-4 0.025 1-21 0.988 1-38 0.0015
1-5 0.672 1-22 0.0027 1-39 0.0019
1-6 0.163 1-23 0.134 1-40 2.231
1-7 0.652 1-24 0.0006 1-41 0.0023
1-8 27.0 1-25 0.108 1-42 0.0010
-9 0.601 1-26 0.018 1-43 0.0020
5% inhibition
-10 1-27 0.0010 1-44 0.0006
(at 30 pM)
42% inhibition
-11 1-28 0.0006 1-45 0.138
(at 30 pM)
-12 0.015 1-29 0.0011 1-46 0.0007
-13 0.397 1-30 0.0006 1-47 0.043
-14 1.413 1-31 0.0010 1-48 0.0009
-15 0.0074 1-32 0.0007 1-49 0.0009
-16 0.010 1-33 0.0008 1-50 0.0009
-17 0.735 1-34 0.0059 1-51 0.0010
260
CA 02936408 2016-06-29
[0806]
[Table 4-2]
Human m PGES-1 Human m PGES-1 Human mPGES-1
Example enzyme inhibitory Example enzyme inhibitory Example enzyme inhibitory
activity (OA) activity (pM) activity (pM)
1-52 0.0006 1-69 0.0003 1-86 0.0058
1-53 0.0045 1-70 0.0007 1-87 0.0008
1-54 0.0009 1-71 0.0025 1-88 0.0012
1-55 0.0011 1-72 0.0013 1-89 0.0009
1-56 0.0006 1-73 0.0006 1-90 0.0004
1-57 0.0005 1-74 0.0006 1-91 0.0004
1-58 0.0005 1-75 0.0067 1-92 0.0005
1-59 0.0006 1-76 0.0017 1-93 0.0007
1-60 0.0004 1-77 0.0009 1-94 0.0046
,
1-61 0.0007 1-78 0.0022 1-95 0.0021
1-62 0.0010 1-79 0.0012 1-96 0.081
. .
1-63 0.0005 1-80 0.0031 1-97 0.0091
1-64 0.0019 1-81 0.0006 1-98 0.0009
1-65 0.0086 1-82 0.0008 1-99 0.0007
1-66 0.0041 1-83 0.011 1-100 0.0009
1-67 0.0010 1-84 0.0006 1-101 0.0058
1-68 0.0003 1-85 0.0005 1-102 0.0009
261
CA 02936408 2016-06-29
[0801
[Table 4-3]
Human mPGES-1 Human mPGES-1 Human m PGES-1
Example enzyme inhibitory Example enzyme inhibitory Example enzyme inhibitory
activity (pM) activity (pM) activity (AA)
1-103 0.0013 1-120 0.048 1-137 0.0005
1-104 0.0015 1-121 0.0012 1-138 0.0005
1-105 0.0007 1-122 0.0013 1-139 0.0006
1-106 0.0007 1-123 0.0023 1-140 0.0005
1-107 0.0012 1-124 0.0009 1-141 0.0011
, 1-108 0.0006 1-125 0.0008 1-142 0.0005
1-109 0.0025 " 1-126 0.0008 1-143 0.0010
1-110 0.0009 1-127 0.0008 1-144 0.0009
1-111 0.0012 1-128 0.0013 1-145 0.0005
1-112 0.0009 1-129 0.0006 1-146 0.0004
1-113 0.0009 1-130 0.009 1-147 0.0008
1-114 0.0059 1-131 0.0009 1-148 0.0017
1-115 0.0006 1-132 0.0003 1-149 0.0008
1-116 0.0020 1-133 0.0005 1-150 0.0004
1-117 0.0016 1-134 0.004 1-151 0.0004
1-118 0.0019 1-135 0.0005 1-152 0.0004
1-119 0.0010 1-136 0.0005 1-153 0.0005
262
CA 02936408 2016-06-29
[0808]
[Table 4-4]
Human m PGES-1 Human mPGES-1 Human m PGES-1
Example enzyme inhibitory Example enzyme inhibitory Example enzyme inhibitory
activity (pM) activity (pM) activity (pM)
1-154 0.0005 1-171 0.0005 1-188 0.0016
1-155 0.0035 1-172 0.017 1-189 1.1
1-156 0.0041 1-173 0.0054 1-190 0.047
1-157 0.0007 1-174 0.0031 1-191 0.015
41% inhibition
1-158 0.012 1-175 0.0013 1-192
(at 30 pM)
1-159 0.0007 1-176 0.0018 1-193 8.7
1-160 0.0014 1-177 0.0013 1-194 10.5
1-161 0.0013 1-178 0.0014 1-195 6.0
1-162 0.0012 1-179 0.016 1-196 0.042
1-163 0.0010 1-180 0.0041 1-197 0.289
1-164 0.0037 1-181 0.0024 1-198 0.014
- _
1-165 0.0009 1-182 0.0016 1-199 0.031
1-166 0.0011 1-183 0.0013 1-200 0.010
-
1-167 0.0019 1-184 0.0019 1-201 0.306
1-168 0.0021 1-185 0.0017 1-202 0.0082
1-169 0.0020 1-186 0.0014 1-203 0.020
-
1-170 0.0015 1-187 0.0053 1-204 0.034
263
CA 02936408 2016-06-29
[0809]
[Table 4-5]
Human mPGES-1 Human mPGES-1 Human m PGES-1
Example enzyme inhibitory Example enzyme inhibitory Example enzyme inhibitory
activity (pM) activity (pM) activity (pM)
1-205 0.367 1-222 0.165 1-239 0.428
1-206 0.014 1-223 0.007 1-240 0.428
1-207 0.0043 1-224 5.8 1-241 0.278
1-208 0.016 1-225 4.2 1-242 0.082
1-209 0.059 1-226 2.2 1-243 0.120
1-210 0.288 1-227 0.050 1-244 0.021
1-211 0.063 1-228 0.672 1-245 0.108
1-212 0.032 1-229 0.532 1-246 0.307
1-213 0.088 1-230 0.750 1-247 0.011
1-214 0.024 1-231 0.045 1-248 0.016
1-215 0.452 1-232 0.521 1-249 0.226
1-216 0.039 1-233 0.848 1-250 0.012
1-217 0.126 1-234 1.0 1-251 0.018
_ -
1-218 0.070 1-235 0.070 1-252 0.511
1-219 0.041 1-236 0.263 1-253 0.791
1-220 0.016 1-237 1.3 1-254 0.030
1-221 0.079 1-238 0.0074 1-255 0.045
264
CA 02936408 2016-06-29
[0810]
[Table 4-6]
Human mPGES-1 Human m PGES-1 Human m PGES-1
Example enzyme inhibitory Example enzyme inhibitory Example enzyme inhibitory
activity (pM) activity (pM) activity (pM)
1-256 0.098 2-6 28% inhion 2-23 0.155
(at 30 pM)
1-257 0.017 2-7 3.5 2-24 2.4
,
1-258 1.9 2-8 1.9 2-25 0.249
1-259 0.176 2-9 6.4 2-26 2.7
1-260 0.147 2-10 0.073 2-27 7.7
.
44% inhibition
1-261 2-11 0.0060 2-28 3.7
(at 30 pM)
1-262 0.007 2-12 0.141 2-29 0.503
,
43% inhibition
1-263 0.702 2-13 23.1 2-30
(at 30 pM)
,
1-264 0.163 2-14 14.3 2-31 0.031
1-265 0.056 2-15 16.4 2-32 0.014
1-266 0.011 2-16 0.412 2-33 0.102
1-267 0.150 2-17 0.039 2-34 0.163
2-1 0.283 2-18 0.0080 2-35 0.017
2-2 21.3 2-19 0.211 2-36 0.053
,
2-3 14.7 2-20 0.052 2-37 0.041
2-4 0.066 2-21 0.341 2-38 1.0
2-5 0.101 2-22 0.219 2-39 0.450
265
CA 02936408 2016-06-29
[ 0 8 1 1 ]
[Table 4-7]
Human mPGES-1 Human mPGES-1 Human mPGES-1
Example enzyme inhibitory Example enzyme inhibitory Example enzyme inhibitory
activity (pM) activity (pM) activity (pM)
2-40 1.3 2-57 0.025 2-74 0.424
2-41 0.429 2-58 0.145 2-75 0.0037
2-42 0.239 2-59 0.095 2-76 0.0058
2-43 0.570 2-60 0.121 2-77 0.0037
2-44 0.563 2-61 0.092 2-78 0.0068
2-45 0.012 2-62 0.0093 2-79 0.0037
,
2-46 0.494 2-63 0.259 2-80 0.0016
2-47 0.295 2-64 0.012 2-81 0.0027
2-48 0.019 2-65 0.151 2-82 0.0017
2-49 0.014 2-66 0.016 2-83 0.051
2-50 0.061 2-67 0.027 2-84 0.017
2-51 0.090 2-68 0.672 2-85 0.0016
2-52 0.100 2-69 0.084 2-86 0.0022
2-53 0.011 2-70 0.158 2-87 0.0018
2-54 0.170 2-71 0.172 2-88 0.0020
2-55 0.010 2-72 0.283 2-89 0.018
2-56 0.018 2-73 0.402 2-90 2.1
266
CA 02936408 2016-06-29
[0812]
[Table 4-8]
Human m PGES-1 Human m PGES-1 Human m PGES-1
Example enzym e inhibitory Example enzym e inhibitory Example enzyme
inhibitory
activity (pM) activity (pM) activity (pM)
2-91 0.0016 2-108 0.0064 2-125 0.0043
2-92 0.0044 2-109 0.0028 2-126 0.0046
2-93 0.038 2-110 0.0074 2-127 0.0062
2-94 0.0041 2-111 0.0044 2-128 0.013
2-95 0.0050 2-112 0.0059 2-129 0.032
2-96 0.021 2-113 0.0051 2-130 0.035
2-97 0.0089 2-114 0.0049 3-1 0.484
2-98 0.0037 2-115 0.0030 3-2 0.148
2-99 0.0017 2-116 0.0055 3-3 0.141
2-100 0.0056 2-117 0.0047 3-4 0.202
2-101 0.0065 2-118 0.0071 3-5 0.341
2-102 0.0059 2-119 0.0018 3-6 0.056
,
2-103 0.010 2-120 0.0041 3-7 0.019
2-104 0.018 2-121 0.014 3-8 0.0010
,
2-105 0.018 2-122 0.015 3-9 0.776
, ,
2-106 0.0050 2-123 0.012 3-10 0.016
,
2-107 0.0038 2-124 0.012 3-11 0.093
267
CA 02936408 2016-06-29
[0813]
[Table 4-9]
Human m PGES-1 Human m PGES-1 Human m PGES-1
Example enzyrne inhibitory Example enzyme inhibitory Example enzyrne
inhibitory
activity (1.1M) activity (pA) activity (pM)
3-12 0.028 3-16 0.0021 3-20 11
3-13 0.034 3-17 0.0008 3-21 0.611
3-14 0.002 3-18 0.0012 3-22 6.9
3-15 0.0051 3-19 24.6 3-23 0.041
[0814]
Experimental Example 2: Evaluation of action of mPGES-1
inhibitor on normal intraocular pressure of Macaca fascicularis
This test was performed using male Macaca fascicularis.
To eliminate interindividual difference and an influence of the
difference in administration days, a crossover test was used
lo for the evaluation as shown in Table 5.
[0815]
[Table 5]
Animal No. First course Second course Third course
test article
SX1M01 reference article vehicle
mg/kg
test article
SX1M02 reference article vehicle
30 mg/kg
test article
SX1M03 reference article vehicle
30 mg/kg
test article
SX1M04 vehicle reference article
30 mg/kg
test article
SX1M05 vehicle reference article
30 mg/kg
[0816]
To exclude the influence of the remaining test article, a
1-week washout period was set between tests. On the day of
test, the monkeys were fed after the final measurement.
The test article (compound of Examples 2-98) was
suspended in 0.5% methylcellulose (Wako Pure Chemical
268
CA 02936408 2016-06-29
Industries, Ltd.), and administered by gavage by using a
polypropylene syringe (sterilized disposable product, Nipro
Corporation) and a stomach catheter (nelaton type A No. 9,
Izumo health). The dose was set to 10 mg/kg/5 mL (N=1) or 30
mg/kg/5 mL (N=4) based on the body weight of each individual
the day before the administration. To the vehicle group was
administered the vehicle (0.5% methylcellulose (MC)) by a
method similar to that for the test article. As a reference
article, Xalatan (registered trade mark) ophthalmic solution
lo 0.005% (Pfizer Inc., general name: latanoprost) was used. The
reference article was administered by instillation of 20 pL
thereof to one eye by using a micropipette. After instillation,
the lacrimal part was lightly fixed by gently pressing the
lower eyelid for about 15 seconds. The opposite eye was
treated in the same manner. The intraocular pressure was
measured immediately before administration, and 2, 4, 8, 12 and
24 hr after administration. Before measurement of the
intraocular pressure, the animal was fixed on a monkey chair,
and topically anesthetized by instillation of an ophthalmic
surface anesthetic (Benoxyl (registered trade mark) ophthalmic
solution 0.4%, Santen Pharmaceutical Co., Ltd., general name:
oxybuprocaine hydrochloride). A lid rectactor (Handaya Co.,
Ltd.) was set, and the intraocular pressure of the both eyes
was measured using a pneumatic applanation tonometer (Mode130
Classic, Reichert Inc.).
To confirm disappearance of the test article, after an
intraocular pressure measurement at 24 hr after the third
course administration, blood samples (1 mL) were collected from
the femoral vein under unanesthetized condition by using
polypropylene syringe and 23 gauge injection needle (both
sterilized disposable products) treated with heparin sodium,
and the concentration of unaltered compound in the plasma
containing the test article was measured.
An intraocular pressure difference (AmmHg; in first
decimal place) from the value immediately before administration
269
CA 02936408 2016-06-29
was determined for each measurement eye at each measurement
time point, an average of the both eyes was calculated and
taken as the evaluation data of the individual. The mean and
standard deviation (in second decimal place) of the intraocular
pressure difference was calculated for each group, and the test
article administration group or reference article
administration group was subjected to a homoscedasticity test
(significance level 5%) based on F-test with the vehicle group.
When the dispersion was equal, Student's t-test was performed
and, when the dispersion was not equal, Aspin-Welch's t-test
was performed. In addition, the maximum ocular hypotensive
effect (Ammlig; maximum descent value from value immediately
before administration, in first decimal place) was determined
for each group, and the groups were compared in the same manner.
/5 The two-sided test was performed. It is a significant
variation when a difference from the vehicle group was found at
a 5% significance level and shown in Fig. 1 separately as 5%
and 1%. Since the test article 10 mg/kg administration group
contained only one animal, it was excluded from the statistical
analysis.
[0817]
The intraocular pressure of Macaca fascicularis used for
this test before administration of a test article was 19.6 1.7
mmHg. After the measurement of intraocular pressure at 24 hr
after the third course administration, the concentration of an
unaltered test article in the plasma of the vehicle group and
the reference article administration group was less than the
lower detection limit. The results are shown in Fig. 1.
[0818]
Experimental Example 3: Evaluation of effect on prostaglandin
composition in guinea pig aqueous humor
A test article was dissolved in saline containing 0.5%
polysorbate80 (Fluka) and 0.003% ophthalmic solution (pH 7.0 -
8.0) was prepared. The test article was administered to
Hartley male guinea pig by instillation of 20 pL thereof to one
270
CA 02936408 2016-06-29
eye by using a micropipette. After instillation, the lacrimal
part was lightly fixed by gently pressing the lower eyelid for
about 15 seconds. The opposite eye was treated in the same
manner. To the vehicle group was administered the medium (0.5%
polysorbate-containing saline) by a method similar to that for
the test article. After 23 hr from the instillation, Mydrin P
(registered trade mark) 0.5% ophthalmic solution (Santen
Pharmaceutical Co., Ltd., general name:
tropicamide/phenylephrine hydrochloride) was dropwisely added
by one drop to the both eyes of a guinea pig to cause mydriasis.
The guinea pig was anesthetized with Escain (registered trade
mark) inhalation anesthetics (Pfizer Inc., general name:
isoflurane), the cornea of the both eyes was tapped with a 30G
injection needle, and the leaked aqueous humor (primary aqueous
humor) was collected. One hour later (24 hr after
instillation), the guinea pig was anesthetized again with
isoflurane, and the secondary aqueous humor was collected in
the same manner. The concentration of prostaglandins in the
secondary aqueous humor obtained from each group (4 guinea pigs,
8 eyes) was measured by the LC/MS/MS system (Ultra high
performance liquid chromatography: Nexera (registered
trademark) manufactured by Shimadzu Corporation, mass
spectrometer: AB SCIEX manufactured by QTRAP (registered
trademark) 5500), and the concentration ratio of each
prostaglandin concentration relative to the total of all
prostaglandin concentrations was calculated. The results are
shown in Table 6.
[0819]
[Table 6]
271
CA 02936408 2016-06-29
6- keto-
Example PGE2 (%) PGF2a (%) PGF1 )
PG D2 (%) TXB2 (%)
vehicle 80.8 7 6.8 4.7 0.7
1-51 50.7 14 21.7 13.2 0.4
1-81 60 9.8 15.7 13.2 1.3
1-98 38 14.2 31.2 16.3 0.3
1-109 29.5 14.1 37.5 18.9 0.1
1-122 37.3 11.7 27.7 23 0.2
1-128 36.2 13.9 29.7 19.3 0.8
1-129 62.5 10.2 18.1 9.2 0
1-130 73.6 8 11.2 6.2 1
1-131 42.9 9.8 27.9 18.8 0.6
1-135 56.1 12.7 19.4 10.9 0.9
1-136 66.7 7.9 17.3 7.4 0.7
1-137 49.5 11.3 24.8 14.1 0.3
1-150 69 8.9 14 8 0.2
1-169 28.7 13.5 40.3 17 0.5
1-178 30 13 36.6 20.1 0.3
1-184 57 10.3 21.2 10.7 0.8
1-185 50 11 25.4 12.1 1.6
2-98 37.8 14.8 27.3 20.1 0
[0820]
Experimental Example 4: Evaluation of action of mPGES-1
inhibitor on normal intraocular pressure of Macaca fascicularis
This test is performed using male Macaca fascicularis.
To eliminate interindividual difference and an influence of the
difference in administration days, a crossover test is used for
the evaluation as shown in Table 7.
[0821]
lo [Table 7]
272
CA 02936408 2016-06-29
Animal W. First course Second course Third course
Fourth course
test article +
SX1M01 vehicle test article reference article
reference article
test article +
SX1M02 test article vehicle reference article
reference article
test article +
SX1M03 reference article test article vehicle
reference article
=
test article +
SX1M04 test article vehicle reference article
reference article
test article +
SX1M05 vehicle reference article test article
reference article
test article +
SX1M06 test article vehicle reference article
reference article
[0822]
To exclude the influence of the remaining test article, a
1-week washout period is set between tests. On the day of test,
the monkeys are fed after the final measurement.
A test article is dissolved in saline containing 0.5%
p01y50rbate80 (Fluka) and 0.1% ophthalmic solution (pH 7.9 -
8.1) is prepared. To the vehicle group is administered the
medium (0.5% polysorbate-containing saline) by a method similar
io to that for the test article. As a reference article, Xalatan
(registered trademark) ophthalmic solution 0.005% (Pfizer Inc.,
general name: latanoprost) is used. The test article is
administered by instillation of 30 pL thereof to one eye 5
times and 1 time of vehicle at 5-min intervals by using a
micropipette (total 6 times instillation for each eye). Each
of vehicle and reference article is adiministered 1 time and
then vehicle is instilled 5 times (total 6 times instillation
for each eye). In the test article+reference article
combination group, the test article is instilled 5 times after
instillation of the reference article (total 6 times
instillation for each eye). After instillation at each time,
the lacrimal part is lightly fixed by gently pressing the lower
eyelid for about 15 seconds. The intraocular pressure is
measured immediately before administration, and 2, 4, 8, 12 and
24 hr after administration. Before measurement of the
intraocular pressure, the animal is fixed on a monkey chair,
273
CA 02936408 2016-06-29
and topically anesthetized by instillation of an ophthalmic
surface anesthetic (Benoxyl (registered trademark) ophthalmic
solution 0.4%, Santen Pharmaceutical Co., Ltd., general name:
oxybuprocaine hydrochloride). A lid rectactor (Handaya Co.,
Ltd.) is set, and the intraocular pressure of the both eyes is
measured using a pneumatic applanation tonometer (Mode130
Classic, Reichert Inc.).
An intraocular pressure difference (AmmHg; in first
decimal place) from the value immediately before administration
/0 is determined for each measurement eye at each measurement time
point, an average of the both eyes is calculated and taken as
the evaluation data of the individual. The mean and standard
deviation (in second decimal place) of the intraocular pressure
difference is calculated for each group, and the test article
administration group or reference article administration group
is subjected to a homoscedasticity test (significance level 5%)
based on F-test with the vehicle group. When the dispersion is
equal, Student's t-test is performed and, when the dispersion
is not equal, Aspin-Welch's t-test is performed. In addition,
the maximum ocular hypotensive effect (AmmHg; maximum descent
value from value immediately before administration, in first
decimal place) is determined for each group, and the groups are
compared in the same manner. The two-sided test is performed.
It is a significant variation when a difference from the
vehicle group is found at a 5% significance level.
[0823]
The Formulation Examples of the present invention include
the following formulations. However, the present invention is
not limited by such Formulation Examples.
Formulation Example 1 (Production of capsule)
1) compound of Example 1-86 30 mg
2) microcrystalline cellulose 10 mg
3) lactose 19 mg
4) magnesium stearate 1 mg
1), 2), 3) and 4) are mixed and filled in a gelatin
274
CA 02936408 2016-06-29
capsule.
Formulation Example 2 (Production of tablet)
1) compound of Example 86 10 g
2) lactose 50 g
3) cornstarch 15 g
4) carmellose calcium 44 g
5) magnesium stearate 1 g
The total amount of 1), 2), 3) and 30 g of 4) are kneaded
with water, vacuum dried and sieved. The sieved powder is mixed
io with 14 g of 4) and 1 g of 5), and the mixture is tableted by a
tableting machine. In this way, 1000 tablets containing 10 mg of
the compound of Example 1-86 per tablet are obtained.
Formulation Example 3 (production of eye drop)
in 100 mL of eye drop
1) compound of Example 1-86 100 mg
2) po1ysorbate80 500 mg
3) sodium chloride 900 mg
4) sodium hydroxide q.s.
5) sterilized purified water q.s.
The above components are aseptically blended to pH 7.9 -
8.1 to give an eye drop.
Formulation Example 4 (production of eye drop)
in 100 mL of eye drop
1) compound of Example 1-86 100 mg
2) po1ysorbate80 100 mg
3) sodium dihydrogen phosphate dehydrate 100 mg
4) sodium chloride 900 mg
5) benzalkonium chloride 5 mg
6) sodium hydroxide q.s.
7) sterilized purified water q.s.
The above components are aseptically blended to pH 7.9 -
8.1 to give an eye drop.
Formulation Example 5 (production of eye drop)
in 100 mL of eye drop
1) compound of Example 1-86 100 mg
275
85406584
2) boric acid 700 mg
3) borax q.s.
4) sodium chloride 500 mg
5) sodium edetate 0.05 mg
6) benzalkonium chloride 0.0005 mg
7) sterilized purified water q.s.
The above components are aseptically blended to pH 7.9 -
8.1 to give an eye drop.
lo INDUSTRIAL APPLICABILITY
[0824]
Since the compound of the present invention and a
pharmaceutically acceptable salt thereof have an mPGES-1
inhibitory activity, they can afford a medicament effective for
the prophylaxis or treatment of pain, rheumatism,
osteoarthritis, fever, Alzheimer's disease, multiple sclerosis,
arteriosclerosis, glaucoma, ocular hypertension, ischemic
retinal disease, systemic scleroderma, cancer including
colorectal cancer and diseases for which suppression of PGE2
production is effective.
This application is based on a patent application No.
2014-031035 filed in Japan on February 20, 2014.
276
Date Recue/Date Received 2021-08-05
